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Toxicology	  –	  much	  like	  the	  rest	  of	  biology	  –	  is	  undergoing	  a	  profound	  
change	  as	  new	  technologies	  begin	  to	  offer	  a	  more	  systems	  oriented	  view	  of	  
cellular	  physiology.	  	  For	  toxicology	  in	  particular,	  this	  means	  moving	  away	  
from	  black-­‐box	  animal	  models	  that	  provide	  limited	  information	  about	  
mechanisms	  of	  toxicity	  towards	  the	  use	  of	  in	  vitro	  approaches	  which	  can	  both	  
expedite	  hazard	  assessment	  while	  at	  the	  same	  time	  providing	  a	  more	  data	  –
rich	  insight	  into	  toxic	  effects	  at	  the	  molecular	  level.	  One	  motivator	  of	  this	  
shift	  is	  Green	  Toxciology,	  which	  seeks	  to	  support	  the	  Green	  Chemistry	  
movement.	  
	   In	  order	  for	  this	  approach	  to	  succeed,	  it	  will	  require	  two	  separate	  but	  
parallel	  efforts.	  The	  first	  is	  an	  Integrated	  Testing	  Strategy	  which	  seeks	  to	  use	  
machine	  learning	  and	  data	  mining	  techniques	  to	  combine	  QSARs	  and	  in	  vitro	  
tests	  in	  the	  most	  efficient	  way	  possible	  to	  accurately	  estimate	  hazard,	  which	  
is	  discussed	  both	  theoretically	  and	  demonstrated	  practically	  with	  the	  
example	  of	  skin	  sensitization.	  Secondly,	  toxicology	  will	  require	  new	  
approaches	  that	  exploit	  the	  insights	  of	  network	  biology	  to	  look	  at	  toxic	  
mechanisms	  from	  a	  systems	  perspective.	  The	  theoretical	  concept	  of	  a	  
Pathway	  of	  Toxicity	  is	  outlined,	  and	  an	  example	  of	  how	  to	  extract	  a	  suggested	  
Pathway	  of	  Toxicity	  is	  given,	  using	  a	  Weighted	  Gene	  Correlation	  Network	  
Analysis	  of	  a	  small	  microarray	  study	  of	  MPTP	  toxicity	  combined	  with	  text-­‐
mining	  and	  other	  high-­‐throughput	  data	  to	  suggest	  novel	  candidate	  
transcription	  factors	  and	  proteins.	  In	  conclusion,	  it	  discusses	  some	  of	  the	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CHAPTER	  I	  –	  Introduction:	  Green	  Toxicology	  as	  a	  Motivator	  for	  
Systems	  Toxicology	  	  
	  
	  
	  “Complexity	  is	  a	  term	  that	  is	  inversely	  related	  to	  the	  degree	  of	  
understanding.”	  —Y.	  Lazebnik	  (Lazebnik,	  2004)	  
	  
	  
One	  common	  argument	  against	  the	  use	  of	  models	  in	  biology	  (and	  specifically,	  
the	  use	  of	  computational	  or	  in	  vitro	  models	  in	  toxicology)	  is	  the	  argument	  of	  
complexity—that	  cells	  (and	  if	  not	  cells,	  certainly	  organisms)	  are	  too	  complex	  to	  be	  
captured	  by	  any	  abstract	  approach.	  But	  a	  system	  that	  seems	  complex	  is	  merely	  a	  
system	  that	  is	  operating	  according	  to	  laws	  not	  yet	  fully	  understood,	  not	  laws	  that	  
are	  impossible	  to	  learn.	  The	  counter	  argument,	  then,	  is	  that	  in	  order	  to	  understand	  
the	  system,	  one	  must	  be	  able	  to	  model	  it—that	  is,	  one	  must	  be	  able	  to	  capture	  
enough	  of	  the	  system	  to	  describe	  and	  predict	  its	  behavior.	  	  Given	  both	  the	  
technological	  revolutions	  that	  have	  dramatically	  changed	  the	  life	  sciences	  in	  the	  last	  
few	  decades,	  and	  the	  concomitant	  computational	  advances,	  complexity	  is	  no	  longer	  
an	  acceptable	  excuse	  for	  using	  a	  black-­‐box	  model.	  	  
While	  the	  push	  towards	  computational	  and	  in	  vitro	  testing	  comes	  partially	  
from	  humane	  concerns	  regarding	  animal	  welfare,	  there	  is	  a	  parallel	  motivation	  for	  
more	  efficient	  toxicology	  coming	  from	  the	  world	  of	  hazard	  assessment—in	  
particular,	  as	  the	  pace	  of	  innovation	  in	  the	  chemical	  industry	  increases,	  there	  needs	  
to	  be	  a	  corresponding	  increase	  in	  the	  ability	  of	  toxicology	  to	  estimate	  the	  hazard	  of	  
novel	  chemicals	  (discussed	  more	  extensively	  in	  Appendix	  I).	  The	  field	  of	  chemistry	  
has	  been	  undergoing	  a	  slow	  revolution	  to	  a	  more	  sustainable,	  and	  environmentally	  
efficient	  “green”	  chemistry;	  for	  toxicologist	  to	  be	  able	  to	  keep	  pace,	  it	  is	  necessary	  to	  
have	  a	  “green”	  toxicology.	  Lengthy	  chemical	  tests	  that	  require	  years	  cannot	  be	  
effectively	  be	  used	  for	  front-­‐loading	  toxicity	  testing	  at	  the	  beginning	  of	  the	  R&D	  
process,	  and	  the	  current	  regulatory	  testing	  paradigm,	  which	  relies	  largely	  on	  “black-­‐
box”	  animal	  models,	  provides	  little	  to	  no	  information	  that	  can	  be	  useful	  to	  a	  chemist	  
seeking	  to	  design	  a	  less	  toxic	  chemical	  replacement.	  	  For	  toxicologists	  to	  be	  able	  to	  
offer	  some	  guidance	  to	  chemists	  seeking	  to	  design	  more	  benign	  alternatives,	  it	  is	  
	  
	   2	  
necessary	  to	  specify,	  as	  completely	  as	  possible,	  the	  molecular	  mechanisms	  of	  
toxicity.	  	  	  
As	  it	  stands	  now,	  the	  knowledge	  is	  not	  often	  available,	  and	  when	  it	  is	  
available,	  it	  is	  often	  not	  accessible,	  as	  no	  database	  effectively	  catalogs	  the	  known	  
molecular	  mechanisms	  of	  toxicity.	  Consider,	  for	  a	  moment,	  a	  chemist	  seeking	  to	  
design	  an	  alternative	  to	  BPA	  –	  an	  endocrine	  disruptor	  that	  has	  been	  the	  subject	  of	  
much	  dispute	  in	  toxicology.	  If	  she	  started	  with	  two	  of	  the	  more	  common	  databases	  –	  
Chemicals	  of	  Biological	  Interest	  (CheBi)	  (Degtyarenko	  et	  al.,	  2008)	  or	  Toxin	  and	  
Toxin	  Target	  (T3)	  database	  (Lim	  et	  al.,	  2010)	  she	  would	  find	  information	  that	  was	  
either	  unspecific	  or	  poorly	  documented;	  Pubchem	  would	  have	  a	  list	  of	  molecular	  
targets	  and	  potencies	  from	  Toxcast	  screens,	  and	  this	  (as	  well	  as	  the	  literature)	  
would	  seem	  to	  indicate	  that	  the	  Estrogen	  Receptor	  Alpha	  (ER-­‐Alpha)	  is	  the	  likely	  
molecular	  target	  for	  BPA.	  On	  this	  basis,	  she	  might	  design	  an	  alternative	  –	  for	  
example,	  BPS	  (bisphenol	  sulfate)	  that	  does	  not	  bind	  to	  the	  ER-­‐Alpha	  receptor.	  
Unfortunately,	  at	  least	  some	  of	  BPA’s	  toxicity	  is	  thought	  to	  be	  mediated	  by	  bind	  to	  
the	  Estrogen	  Receptor	  –	  Gamma	  (ER-­‐Gamma)	  (Okada	  et	  al.,	  2008)	  and	  BPS	  has	  a	  
higher	  binding	  affinity	  to	  ER-­‐Gamma	  than	  BPA	  (Okada	  et	  al.,	  2008).	  However,	  this	  
would	  only	  be	  clear	  after	  a	  copious	  search	  of	  the	  literature,	  and	  would	  be	  invisible	  in	  
the	  Toxcast	  screens.	  	  
	  Furthermore,	  even	  if	  it	  were	  desirable	  to	  test	  every	  novel	  chemical	  with	  
rigorous	  animal	  testing,	  the	  capacity	  is	  simply	  not	  available	  (Rovida	  &	  Hartung,	  
2009).	  The	  costs	  would	  not	  only	  be	  enormous	  (Bottini	  &	  Hartung,	  2010)	  but	  would	  
stifle	  the	  development	  of	  greener	  alternatives	  to	  known	  toxic	  compounds.	  
Therefore,	  moving	  away	  from	  animal	  models	  towards	  an	  approach	  that	  both	  makes	  
better	  use	  of	  computational	  approaches	  and	  more	  precisely	  specifies	  toxicity	  at	  the	  
molecular	  and	  cellular	  level	  can	  both	  expedite	  hazard	  assessment	  but	  can	  also	  
facilitate	  the	  development	  of	  chemicals	  that	  are	  “benign	  by	  design”	  (a	  concept	  
discussed	  more	  extensively	  in	  Appendix	  I).	  	  
Currently,	  the	  most	  common	  computational	  approach	  to	  hazard	  assessment	  
is	  a	  Quantitative	  Structure	  Active	  Relationship	  model	  (QSARs).	  While	  QSARs	  have	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certainly	  proven	  their	  worth	  in	  some	  limited	  domains	  –	  for	  example,	  in	  aquatic	  
toxicity	  (Voutchkova	  et	  al.,	  2011)	  and	  the	  Lipinski	  rules,	  which	  identifies	  drug-­‐like	  
compounds	  (Lipinski,	  2004).	  However,	  QSARs	  typically	  only	  perform	  well	  when	  the	  
molecular	  basis	  of	  toxicity	  is	  both	  simple	  and	  well	  understood.	  QSARs	  have	  limited	  
usefulness	  for	  even	  a	  relatively	  simple	  toxicity	  mechanism	  such	  as	  skin	  
sensitization,	  and	  they	  would	  almost	  certainly	  be	  inadequate	  for	  more	  complicated	  
endpoints	  such	  as	  developmental	  neurotoxicity	  or	  endocrine	  disruption.	  	  
Just	  as	  QSARs	  have	  a	  useful	  domain	  so	  long	  as	  one	  is	  realistic	  about	  their	  
limitations,	  at	  the	  same	  time,	  it	  is	  necessary	  to	  be	  realistic	  about	  the	  limited	  
information	  an	  in	  vitro	  test	  can	  provide.	  No	  single	  in	  vitro	  test	  is	  likely	  to	  effectively	  
replace	  an	  in	  vivo	  assay.	  Toxicity	  is	  often	  an	  emergent	  property	  of	  a	  complex	  system	  
–	  often	  of	  multiple	  tissue	  types	  –	  and	  while	  an	  in	  vitro	  assay	  can	  perhaps	  mimic	  
aspects	  of	  specific	  organs	  (e.g.	  skin	  permeability	  assays)	  or	  provide	  a	  read-­‐out	  of	  a	  
known	  molecular	  pathway	  (e.g.	  receptor	  binding	  assays),	  it	  cannot	  hope	  to	  
effectively	  capture	  the	  complexity	  of	  a	  living	  system.	  Therefore,	  for	  computational	  
toxicology	  to	  truly	  become	  a	  part	  of	  hazard	  assessment,	  it	  will	  require	  two	  separate,	  
but	  parallel	  efforts.	  One,	  an	  Integrated	  Testing	  Strategy	  (discussed	  more	  fully	  in	  
Appendix	  II)	  is	  needed	  to	  optimize	  the	  use	  of	  in	  vitro	  (and	  other)	  sources	  of	  
information	  to	  predict	  hazard	  as	  accurately	  as	  possible	  while	  simultaneously	  
respecting	  the	  probabilistic	  nature	  of	  the	  prediction	  and	  the	  possibility	  that	  a	  hazard	  
estimation	  could	  be	  updated	  with	  additional	  information.	  Two,	  it	  is	  necessary	  for	  
toxicology	  to	  adopt	  a	  more	  “systems	  biology”	  oriented	  approach	  to	  characterizing	  
the	  molecular	  mechanisms	  that	  lead	  to	  adverse	  outcomes.	  In	  essence,	  this	  requires	  
mapping	  the	  Human	  Toxome,	  or	  to	  put	  it	  another	  way,	  producing	  a	  model	  of	  cellular	  
circuitry	  with	  sufficient	  accuracy	  that	  we	  can	  predict,	  with	  some	  confidence,	  where	  
and	  how	  perturbations	  become	  severe	  enough	  to	  cause	  an	  altered	  phenotype.	  	  	  
The	  first	  goal,	  an	  ITS,	  is	  motivated	  by	  the	  clear	  need	  to	  move	  away	  from	  the	  
commonly-­‐used	  weight-­‐of-­‐evidence	  approach	  towards	  a	  more	  systematic	  
methodology	  that	  uses	  machine	  learning	  and	  data-­‐mining	  techniques	  to	  combine	  
multiple	  sources	  of	  information	  (chemoinformatics,	  in	  vitro	  screening	  assays,	  and	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potentially	  –omics	  technologies)	  in	  the	  most	  efficient	  way	  possible	  to	  accurately	  
predict	  hazard	  while	  at	  the	  same	  time	  developing	  a	  framework	  that	  can	  quickly	  
integrate	  new	  information.	  	  This	  is	  true	  not	  only	  because	  such	  an	  approach	  avoids	  
the	  subjectivity	  and	  lack	  of	  precision	  endemic	  to	  a	  weight-­‐of-­‐evidence	  evaluation,	  
but	  also	  because	  the	  shear	  explosion	  of	  newly	  available	  sources	  of	  information	  –	  e.g.	  
from	  initiatives	  such	  as	  Toxcast	  (Dix	  et	  al.,	  2007)–	  produces	  a	  surfeit	  of	  data	  and	  
cannot	  possible	  be	  processed	  by	  experts	  sitting	  around	  together	  in	  a	  room.	  	  
This	  abundance	  of	  data	  has	  its	  downside.	  Given	  the	  potentially	  large	  number	  
of	  false	  positives	  in	  many	  high-­‐throughput	  in	  vitro	  screens,	  it	  risks	  bringing	  the	  field	  
of	  in	  vitro	  assays	  into	  disrepute.	  If	  each	  positive	  in	  a	  screening	  assay	  is	  misconstrued	  
as	  a	  real	  hazard	  –	  even	  if	  only	  by	  consumers	  –	  it	  will	  create	  a	  perverse	  disincentive	  
to	  avoid	  producing	  more	  data.	  Lastly,	  too	  much	  data	  can	  potentially	  result	  in	  an	  
over-­‐fitted	  model,	  giving	  an	  illusion	  of	  accuracy	  (which	  is	  in	  some	  respects	  worse	  
than	  no	  knowledge	  at	  all).	  	  In	  other	  words,	  data	  is	  not	  knowledge,	  and	  as	  data	  grows	  
in	  size	  and	  complexity,	  the	  task	  of	  transforming	  it	  into	  knowledge	  grows	  more	  
difficult.	  	  
As	  an	  example	  of	  this,	  we	  show	  in	  Chapter	  2	  a	  practical	  application	  by	  
demonstrating	  that	  a	  machine	  learning	  approach	  to	  skin	  sensitization	  benefits	  from	  
pruning	  the	  data	  rather	  than	  using	  all	  available	  descriptors,	  and	  that	  combining	  
chemoinformatic	  descriptors	  with	  in	  vitro	  assays	  outperforms	  a	  system	  based	  
exclusively	  on	  descriptors	  of	  chemical	  structures.	  Lastly,	  we	  demonstrate	  that	  using	  
domain-­‐specific	  knowledge	  (in	  this	  case,	  the	  monotonic	  dose-­‐response	  nature	  of	  
skin	  sensitization)	  will	  improve	  the	  results.	  An	  obvious	  extension	  of	  this	  is	  that	  
machine	  learning	  approaches	  to	  hazard	  prediction	  (and,	  in	  vitro	  tests	  generally)	  will	  
improve	  in	  accuracy	  when	  they	  can	  be	  structured	  around	  existing	  knowledge	  of	  the	  
mechanism	  of	  toxicity,	  either	  by	  taking	  advantage	  of	  an	  Adverse	  Outcome	  Pathways	  
(AOP)	  –	  which	  specifies	  the	  toxic	  mechanisms	  at	  the	  organismal	  and	  population	  
level	  	  -­‐	  or,	  at	  the	  cellular	  level,	  a	  Pathway	  of	  Toxicity	  (PoT).	  A	  Pathway	  of	  Toxicity	  
(discussed	  more	  extensively	  in	  Appendix	  III)	  represents	  “a	  molecular	  definition	  of	  
the	  cellular	  processes	  shown	  to	  mediate	  adverse	  outcomes	  of	  toxicants”.	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Therefore,	  the	  second	  parallel	  development	  needed	  to	  make	  computational	  
toxicology	  truly	  revolutionary	  for	  hazard	  assessment	  is	  an	  improved	  ability	  to	  
efficiently	  extract	  Pathways	  of	  Toxicity	  from	  in	  vitro	  data	  –	  to	  take	  advantage	  of	  our	  
newfound	  ability	  to	  survey	  and	  quantify	  subtle	  molecular	  changes	  at	  the	  cellular	  
level.	  
	  Certainly,	  toxicology	  is	  not	  alone	  in	  this	  transformation,	  as	  a	  similar	  project	  
is	  underway	  throughout	  biology	  as	  a	  whole,	  both	  because	  the	  limitations	  of	  the	  
reductionist	  approach	  have	  become	  apparent	  and	  the	  advent	  of	  new	  technologies	  
has	  allowed	  for	  a	  systems	  level	  view.	  Just	  as	  traffic	  congestion	  cannot	  be	  explained	  
by	  the	  physics	  of	  automobiles	  or	  the	  combustion	  of	  gasoline	  but	  instead	  requires	  an	  
understanding	  of	  both	  the	  macro	  level	  (the	  network	  of	  roads)	  and	  the	  micro-­‐level	  
(the	  cars	  and	  drivers),	  toxicological	  effects	  can	  rarely	  be	  explained	  in	  their	  entirety	  
by	  the	  simple	  activation	  of	  one	  receptor	  or	  inhibition	  of	  an	  enzyme,	  but	  instead	  
represent	  a	  disturbance	  of	  homeostasis	  within	  a	  complex	  system	  that	  must	  be	  
appreciated	  at	  a	  systems-­‐level.	  	  	  
Understanding	  such	  networks	  and	  pathways	  requires	  quantitative,	  systems-­‐
level	  measurements	  of	  the	  transcriptomic,	  proteomic,	  and	  metabolomics	  responses	  
of	  a	  cell	  to	  a	  toxicological	  challenge.	  However,	  these	  “-­‐omics”	  approaches	  come	  with	  
some	  significant	  data	  analysis	  challenges.	  	  	  
All	  such	  –omic	  approaches	  can	  be	  noisy,	  and	  the	  large	  quantity	  of	  highly	  
variable	  data	  creates	  a	  dilemma	  for	  data	  analysis	  –	  too	  stringent	  a	  statistical	  test,	  
and	  one	  gets	  a	  handful	  of	  up-­‐	  or	  down-­‐	  regulated	  genes	  or	  a	  few	  obvious	  
metabolites;	  too	  lenient,	  and	  you	  run	  the	  risk	  that	  of	  being	  misled	  by	  false-­‐positives	  
(Shi	  et	  al.,	  2008).	  Therefore,	  -­‐omics	  approaches	  that	  depend	  exclusively	  on	  
inferential	  statistics	  for	  data	  analysis	  are	  likely	  missing	  the	  very	  systems-­‐level	  
insights	  they	  promise	  to	  offer.	  	  
One	  way	  out	  of	  this	  dilemma	  is	  to	  use	  a	  pathway	  based	  approach,	  which	  both	  
minimizes	  the	  need	  to	  correct	  for	  multiple	  hypothesis	  testing	  and	  is	  more	  robust	  to	  
biological	  variability.	  Pathway	  based	  approaches	  can	  be	  either	  supervised,	  and	  
depend	  on	  know	  annotations	  –	  e.g.	  using	  DAVID	  to	  look	  for	  enriched	  GO	  terms	  in	  a	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list	  of	  genes	  (Dennis	  Jr	  et	  al.,	  2003),	  or	  they	  can	  be	  unsupervised,	  	  and	  attempt	  to	  
reconstruct	  pathways	  or	  networks	  de	  novo	  based	  on	  the	  data,	  as	  is	  done	  with	  
correlation-­‐based	  networks	  (Quackenbush,	  2003).	  The	  former	  has	  the	  disadvantage	  
of	  restricting	  data	  analysis	  to	  confirm	  existing,	  known	  pathways.	  The	  latter	  can	  be	  a	  
powerful	  approach	  to	  discovering	  novel	  connections,	  but	  is	  highly	  prone	  to	  spurious	  
results	  and	  requires	  other	  data	  to	  validate	  any	  hypothesis	  generated.	  Furthermore,	  
the	  networks	  produced	  from	  high-­‐throughput	  data	  -­‐	  often	  derisively	  referred	  to	  as	  
“hairball	  diagrams”	  -­‐	  essentially	  tell	  only	  a	  limited	  story	  of	  vague,	  putative	  gene	  
interactions.	  In	  other	  words,	  it	  may	  provide	  an	  integrated	  view	  at	  the	  genomic	  level,	  
but	  it	  provides	  few	  instead	  into	  the	  logic	  of	  the	  genetic	  circuitry	  and	  a	  somewhat	  
limited	  knowledge	  of	  what	  is	  happening	  at	  the	  dynamic	  level.	  	  
In	  Chapter	  3,	  we	  demonstrate	  the	  advantage	  of	  using	  a	  correlation	  and	  
graph-­‐theoretical	  approach	  for	  deriving	  a	  putative	  Pathway	  of	  Toxicity	  de	  novo	  from	  
transcriptomic	  data,	  based	  on	  a	  small	  study	  of	  MPTP	  toxicity	  in	  mice.	  We	  also	  show	  
that	  any	  analysis	  limited	  to	  known	  annotations	  may	  miss	  much	  that	  is	  of	  interest	  to	  
a	  toxicologist;	  toxicological	  processes	  often	  a	  combination	  of	  physiological	  
responses	  that	  are	  repurposed	  from	  inflammatory	  or	  developmental	  pathways,	  and	  
dependence	  on	  the	  canonical	  pathways	  may	  be	  misleading	  or	  incomplete.	  
Furthermore,	  in	  order	  to	  provide	  a	  model	  that	  offers	  more	  insight	  into	  the	  dynamics	  
of	  the	  toxic	  process,	  we	  combined	  the	  transcriptomic	  network	  with	  an	  analysis	  of	  
transcription	  factor	  binding	  sites	  and	  ChiP	  data	  to	  produce	  a	  rudimentary	  Genetic	  
Regulatory	  Network	  (GRN).	  	  
While	  Chapter	  3	  shows	  both	  the	  potential	  insights	  that	  –omics	  technology	  
can	  provide,	  as	  well	  as	  the	  disadvantages	  of	  depending	  exclusively	  on	  annotations	  
for	  a	  data	  analysis,	  Chapter	  4	  details	  the	  problems	  that	  arise	  in	  a	  relatively	  new	  -­‐
omics	  technology	  	  -­‐	  metabolomics-­‐	  	  when	  the	  noise	  simply	  overwhelms	  the	  signal,	  
and	  when	  annotations	  (and	  the	  database	  infrastructure	  that	  supports	  them)	  are	  
largely	  inadequate	  for	  a	  pathway-­‐level	  data	  analysis.	  Metabolomics	  has	  many	  of	  the	  
same	  problems	  as	  transcriptomics,	  while	  at	  the	  same	  time	  it	  has	  both	  analytical	  and	  
computational	  challenges	  that	  are	  unique.	  Some	  of	  the	  cautionary	  message	  of	  this	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chapter	  is	  likely	  applicable	  to	  other	  –omics	  technologies,	  such	  as	  
phosphoproteomics	  that	  are	  similarly	  immature.	  	  All	  –omics	  technologies	  typically	  
come	  with	  high	  expectations	  and	  even	  a	  certain	  degree	  of	  hype	  –	  it	  is	  important	  to	  
be	  realistic	  about	  the	  limitations	  to	  avoid	  being	  led	  astray	  by	  artifacts,	  but	  also	  to	  
avoid	  a	  backlash	  when	  such	  technologies	  are	  inevitably	  shown	  to	  have	  pitfalls.	  
There	  are,	  therefore,	  many	  obstacles	  that	  remain	  before	  a	  comprehensive	  
map	  of	  the	  Human	  Toxome	  can	  be	  said	  to	  be	  complete	  and	  a	  PoT-­‐based	  toxicology	  
can	  be	  realized.	  Some	  of	  them	  are	  technological,	  some	  of	  are	  computational,	  and	  
some	  require	  the	  decidedly	  unglamorous	  but	  necessary	  work	  of	  creating	  databases,	  
annotations	  and	  ontologies,	  all	  of	  which	  are	  necessary	  for	  the	  data	  to	  be	  more	  than	  
the	  sum	  of	  its	  parts.	  Nonetheless,	  however	  complex	  the	  task	  may	  be,	  it	  is	  certainly	  
not	  impossible.	  The	  number	  of	  cellular	  targets	  and	  metabolic	  pathways	  is	  finite,	  and	  
thus	  the	  number	  of	  PoT	  should	  be,	  too.	  
	  Our	  understanding	  of	  the	  Human	  Toxome	  is,	  in	  some	  respects,	  much	  like	  
cartography	  before	  the	  development	  of	  satellites—islands	  of	  well-­‐described	  
territory	  alongside	  vast	  oceans	  about	  which	  little	  is	  known;	  it	  could	  be	  said	  that	  
even	  the	  extent	  of	  the	  unmapped	  territory	  is	  unknown.	  But	  the	  terra	  incognita	  
should	  not	  frighten	  us;	  instead,	  it	  should	  beckon	  us	  towards	  it.	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CHAPTER	  II	  –	  Probabilistic	  Hazard	  Assessment	  for	  Skin	  
Sensitization	  Potency	  using	  Machine	  Learning	  to	  Design	  Integrated	  
Testing	  Strategies	  
	  
This	  project	  was	  performed	  with	  Tom	  Luechtefeld	  and	  Dr.	  Vanessa	  sa’Rocha.	  The	  
author	  was	  responsible	  for	  the	  chemoinformatics,	  chemical	  similarity	  graph,	  
developing	  and	  refining	  different	  approaches	  for	  machine	  learning,	  and	  writing	  the	  
final	  draft.	  Tom	  Luechtefeld	  was	  responsible	  for	  developing	  and	  describing	  the	  
machine	  learning	  approach	  and	  all	  coding	  and	  implementation	  of	  the	  algorithms.	  Dr.	  
Vanessa	  sa’Rocha	  was	  responsible	  for	  acquiring	  and	  organizing	  the	  data	  as	  well	  as	  
writing	  the	  final	  draft.	  	  	  	  
Abstract	  
Integrated	  Testing	  Strategies	  (ITS)	  aim	  to	  combine	  various	  information	  streams	  to	  
hazard	  prediction.	  They	  are	  fueled	  by	  the	  increasing	  understanding	  of	  Adverse	  
Outcome	  Pathways	  (AOP),	  i.e.	  mechanistic	  understanding	  and	  the	  development	  of	  
tests	  reflecting	  these	  mechanisms.	  However,	  simple	  addition	  of	  further	  information	  
bears	  the	  danger	  of	  adding	  noise	  and	  over-­‐fitting.	  The	  problem	  is	  further	  amplified	  
when	  potency	  information	  (dose/response)	  of	  hazard	  shall	  be	  estimated	  by	  these	  
ITS.	  	  
Skin	  sensitization	  currently	  serves	  as	  the	  foster	  child	  for	  AOP	  and	  ITS	  development	  
as	  legislative	  pressures	  combined	  with	  a	  very	  good	  mechanistic	  understanding	  of	  
contact	  dermatitis,	  have	  led	  to	  test	  development	  and	  relatively	  large	  high-­‐quality	  
datasets.	  We	  curated	  such	  a	  dataset	  and	  combined	  a	  recursive	  variable	  selection	  
algorithm	  to	  evaluate	  the	  information	  available	  through	  in	  silico,	  in	  chemico,	  and	  in	  
vitro	  assays.	  Chemical	  similarity	  alone	  could	  not	  cluster	  chemical’s	  sensitizing	  
potency,	  and	  in	  vitro	  assays	  consistently	  ranked	  high	  in	  recursive	  feature	  
elimination	  approaches.	  This	  allows	  for	  a	  reduction	  in	  the	  number	  of	  tests	  included	  
in	  an	  ITS.	  Next	  we	  performed	  analysis	  with	  a	  Hidden	  Markov	  model	  that	  takes	  
advantage	  of	  an	  intrinsic	  inter-­‐relationship	  amongst	  the	  LLNA	  classes—that	  is,	  the	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monotonous	  connection	  between	  LLNA	  and	  dose.	  The	  Dose-­‐informed	  Random	  
Forest/Hidden	  Markov	  Model	  was	  superior	  to	  the	  Dose-­‐naive	  Random	  Forest	  model	  
on	  all	  data	  sets.	  Although	  from	  the	  standpoint	  of	  balanced	  accuracy	  the	  
improvement	  may	  seem	  small,	  this	  obscures	  the	  actual	  improvement	  in	  mis-­‐
classifications	  as	  the	  dose-­‐informed	  Hidden	  Markov	  model	  had	  fewer	  “false-­‐
negatives”	  (i.e.	  extreme	  sensitizers	  as	  non-­‐sensitizer)	  on	  all	  data	  sets.	  
Abbreviations:	  LLNA	  (Local	  Lymph	  Node	  Assay),	  HMM	  (Hiddem	  Markov	  Model),	  ITS	  
(Integrated	  Testing	  Stretgy),	  AOP	  (Adverse	  Outcome	  Pathway)	  
	  
1. Introduction	  
Skin	  sensitization,	  which	  clinically	  manifests	  in	  humans	  as	  allergic	  contact	  
dermatitis	  (ACD),	  is	  an	  increasingly	  common	  concern	  among	  both	  regulators	  and	  
the	  general	  population.	  Epidemiologic	  data	  indicate	  that	  an	  estimated	  15-­‐20%	  of	  the	  
general	  population	  suffers	  from	  contact	  allergy	  (Thyssen,	  Johansen,	  &	  Menne,	  2007).	  
Most	  common	  are	  allergies	  to	  nickel,	  preservatives	  and	  fragrances	  (Peiser	  et	  al.,	  
2012).	  In	  the	  particular	  case	  of	  fragrance	  allergy,	  prevalence	  estimates	  are	  ranging	  
from	  1.0-­‐4.2%	  (Thyssen,	  Linneberg,	  Menne,	  &	  Johansen,	  2007).	  Occupational	  
contact	  dermatitis	  is	  particularly	  prevalent	  in	  the	  personal	  services	  industry,	  with	  
an	  estimated	  prevalence	  of	  1.2	  percent	  in	  the	  beauty/haircare	  industry	  (Warshaw	  et	  
al.,	  2012),	  as	  well	  as	  the	  petrochemical,	  rubber,	  plastic,	  metal	  and	  automotive	  
industries	  (McDonald,	  Beck,	  Chen,	  &	  Cherry,	  2006).	  For	  several	  decades,	  animal	  
testing	  has	  been	  used	  as	  predictive	  tool	  to	  identify	  and	  characterize	  skin	  sensitizers,	  
with	  the	  guinea	  pig	  as	  the	  initial	  animal	  of	  choice,	  which	  over	  the	  last	  15	  years	  has	  
increasingly	  been	  replaced	  by	  the	  mouse	  local	  lymph	  node	  assay	  (LLNA),	  which	  has	  
also	  been	  validated	  as	  a	  stand-­‐alone	  (OECD).	  The	  assay	  uses	  slightly	  fewer	  animals	  
(16	  instead	  of	  20),	  reduces	  time	  and	  suffering	  as	  it	  stops	  at	  the	  stage	  of	  lymph	  node	  
swelling,	  and	  is	  thus	  considered	  a	  refinement	  alternative,	  and	  also	  provides	  a	  
sensitization	  potency	  estimate,	  in	  contrast	  to	  the	  guinea	  pig	  assay.	  However,	  during	  
the	  last	  few	  decades,	  there	  has	  been	  a	  growing	  concern	  about	  using	  animals	  for	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product	  development	  and	  regulatory	  testing,	  especially	  for	  cosmetic	  products	  and	  
ingredients.	  The	  drive	  for	  this	  change	  resulted	  first	  in	  the	  implementation	  in	  Europe	  
of	  Cosmetic	  Directive	  (76/768/EEC),	  now	  Cosmetics	  Regulation	  (European	  Union,	  
2009),	  which	  stipulates	  a	  progressive	  phasing	  out	  of	  animal	  tests	  for	  the	  purpose	  of	  
assessing	  the	  safety	  of	  cosmetics	  and	  their	  ingredients,	  and	  ultimately,	  a	  complete	  
testing	  ban,	  enforced	  with	  a	  marketing	  ban	  with	  deadline	  in	  2013.	  The	  European	  
chemicals	  legislation	  on	  the	  Registration,	  Evaluation,	  Authorization	  and	  Restriction	  
of	  Chemicals	  (REACH;	  Regulation	  EU	  No	  1907/2006)	  requires	  that	  animal	  testing	  
for	  hazard	  assessment	  should	  be	  conducted	  only	  as	  a	  last	  resort	  and	  authorize	  the	  
usage	  of	  validated	  in	  vitro	  methods.	  In	  2007	  the	  US	  National	  Academy	  of	  Sciences	  
released	  a	  report	  called	  “Toxicity	  Testing	  in	  the	  21st	  Century:	  A	  Vision	  and	  a	  
Strategy”	  outlining	  a	  strategy	  for	  toxicity	  testing	  that	  would	  be	  based	  on	  human	  
rather	  than	  animal	  biology	  and	  suggests	  moving	  regulatory	  toxicology	  to	  a	  more	  
mechanistic	  approach	  requiring	  substantially	  fewer	  or	  no	  animals	  (National	  
Research	  Council,	  2007).	  Furthermore,	  as	  knowledge	  of	  the	  molecular	  key	  steps	  of	  
skin	  sensitization	  becomes	  more	  detailed,	  this	  presents	  both	  an	  opportunity	  and	  a	  
challenge	  to	  improve	  the	  availability	  of	  alternative	  methods.	  	  
	   Newer	  alternative	  methods	  developed	  for	  skin	  sensitization	  are	  based	  on	  the	  
specific,	  key	  mechanistic	  steps:	  the	  chemical’s	  ability	  to	  penetrate	  the	  skin,	  its	  
capacity	  to	  bind	  with	  proteins	  present	  in	  the	  skin,	  as	  well	  as	  the	  recognition	  of	  this	  
protein	  complex	  by	  immune	  cells	  (Adler	  et	  al.,	  2011).	  The	  Direct	  Peptide	  Reactivity	  
Assay	  (DPRA)	  is	  the	  first	  non-­‐animal	  test	  method	  formally	  recommended	  by	  the	  
European	  Centre	  for	  the	  Validation	  of	  Alternative	  Methods	  (ECVAM)	  for	  skin	  
sensitization	  (European	  Commission	  Joint	  Research	  Centre,	  2013)—and	  addresses	  
the	  chemical’s	  reactivity	  to	  proteins	  by	  measuring	  depletion	  of	  synthetic	  peptides	  
containing	  either	  cysteine	  or	  lysine	  (Gerberick	  et	  al.,	  2004;	  Gerberick	  et	  al.,	  2007).	  
The	  accuracy	  of	  the	  DPRA	  for	  distinguishing	  sensitizers	  from	  non-­‐sensitizers	  was	  
82%	  (sensitivity	  of	  76%,	  specificity	  of	  92%),	  excluding	  metal	  compounds	  for	  which	  
the	  test	  is	  not	  applicable	  (Gerberick	  et	  al.,	  2007).	  More	  recently,	  ECVAM	  also	  
published	  a	  recommendation	  indicating	  the	  usefulness	  of	  the	  KeratinoSens™	  assay	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(European	  Commission	  Joint	  Research	  Centre,	  2014).	  The	  assay	  addresses	  the	  
activation	  of	  the	  Keap1-­‐Nrf2	  ARE	  pathway	  in	  human	  keratinocytes	  (HaCaT)	  which	  is	  
considered	  a	  major	  regulator	  of	  cyto-­‐protective	  responses	  to	  electrophile	  and	  
oxidative	  stress	  by	  controlling	  the	  expression	  of	  detoxification,	  antioxidant	  and	  
stress	  response	  enzymes	  and	  proteins	  (Emter,	  Ellis,	  &	  Natsch,	  2010).	  The	  accuracy	  
was	  77%	  based	  on	  testing	  of	  about	  145	  chemicals	  with	  79%	  of	  sensitivity	  and	  72%	  
of	  specificity	  (Natsch	  et	  al.,	  2013).	  According	  to	  ECVAM,	  none	  of	  these	  assays	  can	  be	  
used	  as	  stand-­‐alone	  method	  and	  data	  should	  be	  considered	  in	  combination	  with	  
other	  information.	  A	  similar	  assay	  using	  the	  same	  cell	  system	  including	  a	  
combination	  of	  glutathione	  (GSH)	  depletion	  and	  gene	  expression	  known	  to	  be	  
activated	  by	  sensitizing	  agents	  (Keap	  1/Nrf	  2/ARE/EpRE,	  ARNT/AhR/XRE	  and	  
Nrf1/MTF/MRE)	  shown	  an	  accuracy	  of	  84%,	  with	  a	  sensitivity	  of	  81%	  and	  
specificity	  of	  92%	  based	  of	  102	  chemicals	  (McKim,	  Keller,	  &	  Gorski,	  2010).	  Other	  
assays	  have	  shown	  promising	  results	  to	  test	  the	  induction	  of	  dendritic	  cell	  (DC),	  
which	  includes	  cell	  line	  surrogates	  (THP-­‐1	  a	  human	  monocytic	  leukemia	  cell	  line)	  
and	  U937	  (a	  human	  histiocytic	  lymphoma	  cell	  line)	  with	  DC-­‐like	  characteristics	  for	  
phenotypic	  markers	  of	  activated	  DC	  (eg.	  CD86	  and	  CD54)	  (Ashikaga	  et	  al.,	  2010;	  
Sakaguchi	  et	  al.,	  2006).	  In	  addition,	  some	  commercially	  available	  in	  silico	  models	  
such	  as	  TIMES	  (Dimitrov	  et	  al.,	  2005)	  and	  DEREK	  (Sanderson	  &	  Earnshaw,	  1991)	  
have	  been	  developed	  based	  on	  Structure	  Activity	  Relationships	  (SAR).	  	  
As	  skin	  sensitization	  is	  a	  complex	  endpoint	  that	  needs	  more	  than	  one	  
alternative	  assay	  to	  replace	  animal	  test,	  the	  open	  question	  remains	  on	  how	  to	  
integrate	  available	  information	  for	  predicting	  the	  skin	  sensitization	  hazard,	  and	  
more	  specifically	  how	  to	  make	  the	  best	  use	  of	  the	  cumulative	  information	  in	  the	  
most	  efficient	  way	  possible	  as	  well	  as	  guide	  for	  future	  testing	  in	  such	  a	  way	  that	  the	  
information	  gain	  is	  maximized	  and	  accomplished	  with	  fewest	  possible	  tests	  
(Jaworska,	  Harol,	  Kern,	  &	  Gerberick,	  2011).	  Recently,	  the	  use	  of	  an	  Integrated	  
Testing	  Strategy	  (ITS)	  of	  batteries	  of	  in	  vitro	  tests	  combined	  with	  in	  silico	  models	  
have	  been	  proposed	  for	  the	  replacement	  of	  LLNA	  (Bauch	  et	  al.,	  2012;	  Hartung,	  
Luechtefeld,	  Maertens,	  &	  Kleensang,	  2013;	  Hirota	  et	  al.,	  2013;	  Jaworska,	  Dancik,	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Kern,	  Gerberick,	  &	  Natsch,	  2013;	  Jaworska	  et	  al.,	  2011;	  Maxwell	  et	  al.,	  2014;	  McKim	  
et	  al.,	  2010;	  McKim,	  Keller,	  &	  Gorski,	  2012;	  Nukada,	  Miyazawa,	  Kazutoshi,	  Sakaguchi,	  
&	  Nishiyama,	  2013).	  	  
ITS	  provides	  a	  more	  formal,	  systematic,	  and	  quantitative	  approach	  to	  risk	  
estimation	  (as	  distinct	  from	  a	  Weight	  of	  Evidence	  approach)	  than	  a	  fixed	  battery	  of	  
tests.	  As	  suggested	  earlier,	  an	  ITS	  is	  “an	  algorithm	  to	  combine	  (different)	  test	  result(s)	  
and,	  possibly,	  non-­‐test	  information	  (existing	  data,	  in	  silico	  extrapolations	  from	  existing	  
data	  or	  modeling)	  to	  give	  a	  combined	  test	  result.	  They	  often	  will	  have	  interim	  decision	  
points	  at	  which	  further	  building	  blocks	  may	  be	  considered"	  (Hartung	  et	  al.,	  2013).	  	  
Since	  the	  volume	  of	  data—in	  silico,	  in	  chemico	  and	  in	  vitro—to	  be	  considered	  
increases	  at	  a	  rapid	  rate	  and	  is	  becoming	  more	  heterogeneous	  in	  nature,	  there	  is	  a	  
keen	  need	  for	  a	  new	  ways	  to	  combine	  them	  that	  offers	  both	  a	  robust	  and	  powerful	  
approach	  to	  estimate	  hazard	  and	  support	  a	  risk	  decision.	  Likely	  this	  has	  to	  be	  done	  
in	  a	  probabilistic	  way,	  where	  the	  different	  input	  parameters	  are	  combined	  to	  
generate	  an	  overall	  probability	  of	  hazard	  and	  risk.	  Furthermore,	  understanding	  the	  
effects	  of	  test	  substances	  at	  different	  doses	  is	  an	  essential	  aspect	  of	  safety	  testing	  
that	  is	  not	  being	  addressed	  by	  the	  current	  proposals.	  We	  believe	  that	  an	  ITS	  based	  
on	  a	  machine	  learning	  approach	  offers	  the	  best	  possibility	  to	  combine	  data	  for	  the	  
optimal	  estimate	  of	  hazard	  given	  the	  information	  available.	  To	  this	  end,	  we	  
combined	  a	  variable	  selection	  algorithm	  to	  evaluate	  the	  information	  available	  
through	  both	  in	  silico,	  in	  chemico,	  and	  in	  vitro	  assays	  with	  a	  Hidden	  Markov	  model	  
that	  takes	  advantage	  of	  an	  intrinsic	  inter-­‐relationship	  amongst	  the	  LLNA	  classes—
that	  is,	  the	  connection	  between	  LLNA	  and	  dose.	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2.	   Material	  and	  methods	  
2.1 Dataset	  
The	  data	  set	  included	  a	  total	  of	  145	  distinct	  chemicals	  with	  in	  vitro	  assays	  from	  
(Jaworska	  et	  al.,	  2013),	  which	  included	  the	  chemicals	  of	  the	  LLNA	  dataset	  (Gerberick	  
et	  al.,	  2005).	  In	  addition,	  we	  obtained	  a	  subset	  of	  the	  original	  chemicals	  from	  
(McKim	  et	  al.,	  2010)	  and	  (Natsch,	  Emter,	  &	  Ellis,	  2009)	  additional	  in	  vitro	  assays.	  
The	  total	  number	  of	  descriptors:	  7,	  9	  and	  10	  in	  vitro/in	  chemico	  for	  datasets	  1,	  2	  and	  
3,	  respectively,	  and	  1666	  chemoinformatic	  molecular	  descriptors	  available	  from	  
DRAGON	  software.	  For	  all	  distinct	  145	  chemicals	  LLNA	  classifications	  were	  available	  
as	  reference	  classification.	  Simplified	  molecular	  input	  line	  entry	  system	  (SMILES)	  
strings	  were	  obtained	  via	  Pubchem	  (Bolton,	  Wang,	  Thiessen,	  &	  Bryant,	  2010).	  
DRAGON	  features	  were	  calculated	  with	  VCLABS	  E-­‐DRAGON	  software	  (Tetko	  et	  al.,	  
2005;	  Todeschini,	  Consonni,	  &	  Todeschini,	  2009)..	  
The	  initial	  data	  set	  (Data	  Set	  1,	  145	  distinct	  chemicals)	  was	  based	  on	  the	  work	  
of	  Jaworwska	  (2013),	  which	  included	  TIMES	  predictions	  (Dimitrov	  et	  al.,	  2005),	  
combined	  with	  Dragon	  descriptors.	  Data	  Set	  1	  was	  subdivided	  into	  smaller	  data	  sets	  
based	  on	  additional	  available	  in	  vitro	  results	  as	  follows:	  Data	  Set	  2	  included	  values	  
for	  ARE	  EC	  1.5,	  ARE	  Cmax	  (defined	  as	  the	  concentration	  that	  causes	  as	  1.5	  fold	  
increase	  and	  maximal	  increase	  in	  the	  Antioxidant	  Response	  Element	  induction)	  and	  
Imax	  (the	  maximum	  fold-­‐induction	  achieved)	  for	  84	  chemicals	  from	  Natsch	  et	  al.	  
(2009),	  and	  Data	  Set	  3	  included	  glutathione	  depletion	  from	  McKim	  et	  al.	  (2010)	  for	  a	  
subset	  of	  65	  chemicals.	  Data	  sets	  are	  available	  in	  Supplement	  1.	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Chemicals Descriptors Source
Data	  Set	  1 145 TIMES,	  Dragon	  Descriptors,	  
keratinoSens	  KEC	  1.5	  and	  KEC	  3.0,	  
Cytotoxicic_	  IC50,	  DPRACys,	  
DPRALys,	  CDFree,	  CD86
(Jaworska	  et	  al.,	  2013)
Data	  Set	  2 84 Dragon	  Descriptors,	  keratinoSens	  
KEC	  1.5	  and	  KEC	  3.0,	  Cytotoxicic_	  
IC50,	  DPRACys,	  DPRALys,	  CDFree,	  
CD86,	  ARE	  EC	  1.5,	  Imax,	  ARE	  Cmax
(Jaworska	  et	  al.,	  2013)	  
(Natsch	  et	  al.,	  2009)
Data	  Set	  3 65 Subset	  of	  Data	  Set	  1	  with	  
additional	  Glutathione	  depletion	  
data	  available
(Jaworska	  et	  al.,	  2013)	  
(McKim	  et	  al.,	  2010)	  
(Natsch	  et	  al.,	  2009) 	  
Chapter	  II,	  Table	  1:	  Overview	  on	  dataset	  1	  to	  3	  as	  described	  the	  section	  
dataset.	  
	  
2.3 Chemical	  Similarity	  generation	  
A	  chemical	  similarity	  map	  was	  generated	  by	  the	  ChemViz	  plug-­‐in	  and	  
Cytoscape	  2.8.3	  (http://www.cgl.ucsf.edu/cytoscape/chemViz/	  ).	  Tanimoto	  
distances	  were	  calculated	  based	  on	  SMILES	  strings	  using	  the	  Klekota	  and	  Roth	  
fingerprint	  algorithm	  (Klekota	  &	  Roth,	  2008),	  and	  any	  chemical	  with	  a	  Tanimoto	  
similarity	  of	  greater	  than	  0.70	  was	  considered	  as	  link.	  	  
2.4 Random	  Forest	  
We	  used	  the	  scikit-­‐learn	  Random	  Forest	  (Pedregosa	  et	  al.,	  2011)	  version	  0.14	  
implementation	  in	  these	  analyses.	  Random	  Forest	  is	  an	  ensemble	  supervised	  
learning	  model.	  Briefly,	  a	  Random	  Forest	  model	  (Breiman,	  2003)	  is	  trained	  on	  a	  
subset	  of	  all	  the	  data;	  during	  training	  we	  construct	  100	  random	  trees.	  Each	  tree	  is	  
constructed	  via	  recursively	  splitting	  training	  data	  using	  a	  random	  selection	  of	  the	  
available	  features	  with	  each	  permitted	  up	  to	  log_2	  of	  the	  available	  features	  and	  
splitting	  continued	  until	  the	  split	  data	  contains	  only	  one	  chemical	  (tree	  split	  
criterion:	  entropy;	  min-­‐samples-­‐leaf:	  1).	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During	  each	  chemical	  prediction	  the	  class	  is	  passed	  down	  each	  random	  tree	  
(using	  the	  feature	  values	  for	  that	  test	  chemical).	  Each	  tree	  reports	  the	  class	  of	  the	  
chemical	  in	  the	  leaf	  node	  most	  closely	  matching	  that	  of	  the	  test	  chemical.	  The	  
Random	  Forest	  then	  makes	  a	  prediction	  by	  picking	  the	  class	  most	  voted	  for	  (so	  
called	  ensemble	  method).	  
	  
2.5 Recursive	  Feature	  Elimination	  
Recursive	  feature	  elimination	  involves	  first	  evaluating	  feature	  importance	  and	  
then	  eliminating	  low	  importance	  features.	  Feature	  importance	  was	  calculated	  with	  
the	  scikit-­‐learns	  implementation	  of	  the	  Breiman	  Random	  Forest	  Variable	  
Importance	  algorithm	  (Breiman,	  2003).	  This	  algorithm	  evaluates	  a	  given	  feature’s	  
importance	  in	  a	  trained	  model	  by	  randomly	  permuting	  all	  available	  values	  and	  
recording	  the	  subsequent	  loss	  in	  model	  accuracy	  and	  the	  permutation	  that	  results	  in	  
the	  greatest	  loss	  is	  given	  greater	  accuracy.	  Variable	  importance	  was	  normalized	  by	  
dividing	  each	  feature	  importance	  value	  by	  that	  of	  the	  maximally	  important	  feature,	  
which	  was	  thereby	  assigned	  a	  value	  of	  1.	  	  
	  
	  
2.6 Dose	  transformation	  
To	  encode	  the	  data	  using	  LLNA	  classes	  we	  transformed	  the	  LLNA	  classification	  
into	  a	  binary	  classification	  as	  follows:	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This	  transformation	  allows	  us	  to	  train	  a	  dose	  informed	  Random	  Forest	  that	  
can	  classify	  chemicals	  combined	  with	  categories	  as	  toxic	  or	  non-­‐toxic.	  Thus	  for	  a	  
given	  chemical	  our	  new	  model	  can	  make	  3	  predictions:	  
	  
Chemical	  
1-­‐bromobutane	   LLNA	  reference	  classification:	  non-­‐sensitizer	  
	  
Transformed	  LLNA	  classification	  
LLNA	  Low	  Dose	   LLNA	  Medium	  Dose	   LLNA	  High	  Dose	  
Nontoxic	   Nontoxic	   Nontoxic	  
	  
This	  transformation	  allows	  us	  to	  use	  the	  predictions	  made	  by	  the	  Random	  
Forest	  to	  build	  a	  Hidden	  Markov	  model.	  It	  should	  be	  noted	  that	  a	  supervised	  model	  
trained	  with	  this	  dose	  transformation	  may	  very	  well	  predict/classify	  a	  chemical	  as	  
follows:	  
	  
Prediction	  Series	  of	  the	  Hidden	  Markov	  model	  
LLNA	  Low	  Dose	   LLNA	  Medium	  Dose	   LLNA	  High	  Dose	  
Nontoxic	   Toxic	   Nontoxic	  
	  
This	  prediction	  series	  is	  concerning	  because	  our	  prior	  knowledge	  tells	  us	  that	  
if	  a	  chemical	  is	  toxic	  at	  low	  dose	  it	  will	  remain	  toxic	  at	  higher	  doses;	  in	  order	  to	  
avoid	  this	  we	  constrained	  the	  model	  so	  that	  a	  chemical	  that	  was	  predicted	  as	  toxic	  at	  
a	  low	  dose	  would	  remain	  automatically	  be	  considered	  toxic	  at	  higher	  doses	  (see	  as	  
well	  section	  2.7	  Hidden	  Markov	  Model	  transition	  probabilities).	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2.7 Hidden	  Markov	  Model	  
A	  Hidden	  Markov	  model	  allows	  us	  to	  enforce	  proper	  prediction	  series	  by	  
encoding	  our	  knowledge	  of	  allowable	  toxicity	  transformations.	  For	  example,	  a	  
chemical	  that	  is	  toxic	  at	  low	  does	  cannot	  become	  non-­‐toxic	  at	  higher	  dose.	  Namely	  
that	  a	  chemical	  that	  is	  toxic	  at	  low	  dose	  will	  be	  as	  well	  toxic	  at	  higher	  doses,	  and	  that	  
a	  chemical	  that	  is	  non-­‐toxic	  at	  high	  dose	  must	  be	  non-­‐toxic	  at	  lower	  doses.	  
A	  Hidden	  Markov	  model	  contains	  several	  important	  properties:	  
• Hidden	  States:	  These	  are	  states	  that	  cannot	  be	  directly	  observed.	  In	  our	  case	  
a	  given	  chemical	  contains	  6	  hidden	  states,	  one	  for	  toxic	  or	  non-­‐toxic	  at	  each	  
of	  the	  three	  dose	  categories.	  
• Transition	  Probabilities:	  Transition	  probabilities	  tell	  us	  the	  probability	  for	  
transitioning	  from	  one	  hidden	  state	  to	  another.	  Transition	  probabilities	  allow	  
us	   to	   encode	  our	  prior	   knowledge	   about	   toxicity	   changes.	  By	  disallowing	   a	  
transformation	  from	  the	  hidden	  state	  corresponding	  to	  low	  dose-­‐toxic	  to	  the	  
hidden	  state	  corresponding	  to	  moderate	  dose-­‐non-­‐toxic	  we	  can	  ensure	  that	  
no	  prediction	  sequences	  will	  contain	  this	  transition.	  
• Empirically	  speaking,	  transition	  probabilities	  can	  be	  obtained	  from	  the	  data	  
by	  counting	  how	  often	  a	  chemical	  transition	  from	  one	  hidden	  state	  to	  another	  
takes	   place.	   Thus	   no	   special	   treatment	   is	   needed	   to	   encode	   our	   prior	  
knowledge	  about	  chemical	   transformations	  since,	   for	   instance,	   the	  chemical	  
data	  will	  contain	  no	  instances	  where	  a	  chemical	  transitions	  from	  toxic	  at	  low	  
dose	  to	  non-­‐toxic	  at	  higher	  dose	  occurs.	  	  
• Emission	  Probabilities:	  In	  our	  case,	  emission	  probabilities	  inform	  about	  the	  
probability	   that	   a	   given	   hidden	   state	  will	   emit	   the	   prediction	   given	   by	   our	  
dose-­‐informed	  supervised	  model.	  This	  emission	  probability	  can	  be	  obtained	  
empirically	   by	   counting	  how	  often	   a	   given	  prediction	   aligns	  with	   the	   given	  
hidden	  state	  divided	  by	  the	  number	  of	  predictions.	  
	  
The	  Hidden	  Markov	  Model	  was	  built	  using	  the	  scikit-­‐learn	  HMM-­‐module	  (Pedregosa	  
et	  al.,	  2011).	  Transmission	  probabilities	  were	  built	  by	  enumeration	  from	  data	  and	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emission	  probabilities	  by	  counting	  classifier	  outputs	  matched	  with	  actual	  toxicity	  
class	  (10	  iterations,	  0.01	  threshold).	  The	  trained	  Markov	  model	  chemical	  
predictions	  were	  obtained	  using	  the	  Viterbi	  algorithm	  (Viterbi,	  1967)	  scikit-­‐learn	  
implementation.	  For	  an	  introduction	  to	  HMM	  please	  see	  e.g.	  (Baum	  &	  Petrie,	  1966).	  
2.8 Cross	  Validation	  
In	  order	  to	  ensure	  a	  training	  data	  set	  that	  closely	  resembled	  the	  testing	  data	  
set,	  we	  used	  100	  iterations	  of	  train/test	  set	  splits	  created	  via	  scikit-­‐learn’s	  stratified	  
shuffle	  split-­‐cross	  validation	  approach	  (Pedregosa	  et	  al.,	  2011).	  In	  testing	  both	  the	  
dose	  informed	  and	  dose-­‐naive	  approaches	  to	  skin-­‐sensitization	  classification	  we	  
allowed	  training	  on	  90%	  of	  the	  available	  data	  and	  testing	  on	  the	  remaining	  unseen	  
10%	  of	  the	  data	  separately	  for	  each	  dataset,	  avoiding	  peeking	  by	  insuring	  that	  no	  
model	  was	  trained	  on	  data	  it	  would	  later	  be	  tested	  on	  except	  unavoidably	  in	  the	  case	  
of	  the	  comparison	  of	  Dataset	  1	  with	  and	  without	  the	  TIMES	  as	  the	  TIMES	  was	  
trained	  on	  a	  number	  of	  chemicals	  that	  are	  included	  in	  the	  dataset.	  
	  
3.	   Results	  
3.1	  Chemical	  diversity	  of	  dataset	  
The	  chemical	  similarity	  map	  (Figure	  1)	  indicates	  that	  many	  of	  the	  chemicals	  
were	  highly	  similar	  compounds,	  but	  that	  clusters	  of	  similar	  chemicals	  did	  not	  
necessarily	  share	  LLNA	  status—skin	  sensitization	  is	  therefore	  difficult	  to	  predict	  
using	  chemicals	  descriptors	  alone.	  Furthermore,	  the	  data	  set	  included	  several	  
chemicals	  (35)	  that	  were	  chemically	  dissimilar—meaning	  they	  had	  a	  Tanimoto	  
similarity	  of	  less	  than	  .70—from	  all	  other	  chemicals	  in	  the	  data	  set.	  Interestingly,	  the	  
largest	  cluster	  of	  similar	  chemicals	  contained	  several	  instances	  of	  chemicals	  from	  all	  
four	  LLNA	  classes	  (non-­‐weak,	  moderate,	  strong,	  extreme),	  but	  had	  only	  one	  
chemical	  with	  a	  class	  error	  greater	  than	  1,	  indicating	  that	  the	  model	  performed	  well	  
in	  differentiating	  LLNA	  class	  amongst	  structurally	  similar	  chemicals.	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Chapter	  II,	  Figure	  1:	  Chemical	  similarity	  map:	  Chemicals	  are	  colored	  according	  
to	  LLNA	  status.	  
Figure	  1,	  Legend:	  (Red	  =	  Extreme	  sensitizer;	  Orange	  =	  Strong,	  Yellow	  =	  Moderate,	  
Green	  =	  Weak/Non).	  Chemicals	  with	  a	  Tanimoto	  index	  >	  .70	  are	  linked;	  distance	  is	  
proportional	  to	  Tanimoto	  similarity.	  	  Although	  there	  was	  a	  large	  cluster	  of	  highly	  
similar	  chemicals,	  35	  chemicals	  had	  no	  similarity	  to	  any	  other	  chemical	  in	  the	  data	  
set	  and	  an	  additional	  8	  had	  only	  one	  similar	  chemical.	  The	  difference	  between	  
predicted	  and	  actual	  class	  are	  denoted	  by	  shape:	  No	  difference	  between	  predicted	  
and	  actual	  are	  indicated	  by	  circles,	  one	  class	  difference	  by	  squares,	  and	  two	  class	  
difference	  by	  triangles.	  	  
	  
3.2 	  Feature	  Selection	  and	  Variable	  Importance	  
As	  skin	  sensitization	  is	  difficult	  to	  predict	  from	  chemoinformatics	  
methods/QSARs	  alone,	  it	  is	  therefore	  desirable	  to	  combine	  in	  silico	  data	  with	  in	  vitro	  
and	  in	  chemico	  assays.	  Feature	  selection	  methods	  typically	  improve	  predictive	  
models	  by	  avoiding	  the	  over-­‐fitting	  that	  comes	  from	  using	  statistically	  independent	  
features	  in	  the	  prediction	  model	  generation	  (training	  phase),	  shortens	  
computational	  time,	  and	  makes	  the	  model	  easier	  to	  understand.	  Recursive	  feature	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elimination	  can	  be	  used	  to	  trim	  a	  dataset	  with	  a	  large	  number	  of	  features—in	  
essence,	  a	  Random	  Forest	  is	  trained	  on	  the	  dataset	  and	  the	  resulting	  features	  are	  
ranked	  according	  to	  the	  Breiman	  feature	  importance	  test	  (Breiman,	  2003).	  After	  
ranking	  the	  dataset	  it	  is	  modified	  by	  the	  removal	  of	  the	  least	  valuable	  feature.	  The	  
process	  is	  then	  repeated	  until	  the	  number	  of	  features	  in	  the	  dataset	  is	  reduced	  to	  the	  
20	  most	  informative	  variables	  that	  were	  subsequently	  selected	  for	  building	  the	  
prediction	  model.	  	  
Recursive	  feature	  selection	  indicated	  that	  the	  available	  in	  vitro	  tests	  were	  
providing	  substantial	  information	  compared	  to	  the	  chemical	  descriptors	  alone	  as	  
they	  were	  consistently	  ranked	  within	  the	  top	  20	  descriptors	  (see	  Figure	  2).	  As	  data	  
accumulates,	  recursive	  feature	  elimination	  will	  likely	  allow	  for	  a	  more	  informed	  
ranking	  of	  in	  vitro	  assays	  and	  a	  better	  choice	  in	  terms	  of	  what	  test	  to	  perform	  next	  
when	  presented	  with	  a	  chemical	  with	  limited	  available	  in	  vitro	  data,	  or	  in	  cases	  
where	  a	  QSAR	  has	  predicted	  the	  potential	  for	  skin	  sensitization	  either	  on	  the	  basis	  
of	  skin	  permeability	  or	  electrophilicity.	  
	  
Chapter	  III,	  Figure	  3:	  Balanced	  accuracy	  (four	  class	  problem)	  of	  data	  with	  
feature	  selection	  (20	  most	  informative	  features)	  and	  without.	  
Legend,	  Figure	  3:	  Feature	  selection	  consistently	  improved	  the	  balanced	  accuracy	  
compared	  to	  a	  non-­‐balanced	  accuracy.	  Error	  bars	  indicate	  standard	  deviation	  of	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  Figure	  3	  shows	  that	  that	  the	  balanced	  accuracy	  of	  data	  with	  feature	  (20	  most	  
informative	  features)	  and	  without	  feature	  selection	  consistently	  improved	  the	  
balanced	  accuracy	  compared	  to	  a	  non-­‐balanced	  accuracy	  for	  all	  three	  datasets.	  
Chemical	  descriptors	  alone	  showed	  very	  poor	  overall	  accuracy	  for	  prediction.	  
Combining	  in	  vitro	  assays	  with	  the	  chemical	  descriptors	  selected	  by	  the	  recursive	  
feature	  elimination	  algorithm	  performed	  seemingly	  as	  well	  as	  the	  in	  vitro	  models	  
with	  TIMES	  (see	  Figure	  4)	  	  -­‐but	  without	  the	  same	  restriction	  on	  applicability	  domain	  
as	  TIMES.	  Furthermore,	  TIMES	  performance	  is	  likely	  overstated	  in	  this	  case	  by	  
“peeking”—that	  is,	  this	  data	  set	  includes	  chemicals	  that	  were	  part	  of	  the	  TIMES	  
training	  set.	  	  
	  
	  
Chapter	  III,	  Figure	  2:	  Variable	  importance:	  20	  most	  informative	  features	  were	  
selected	  by	  recursive	  feature	  elimination	  algorithm.	  	  
Legend,	  Figure	  2:	  In	  vitro/in	  chemico	  assays	  are	  shown	  in	  gray	  and	  DRAGON	  
descriptors	  are	  shown	  in	  black.	  In	  vitro	  assays	  consistently	  ranked	  amongst	  the	  top	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Chapter	  III,	  Figure	  3:	  Balanced	  accuracy	  (four	  class	  problem)	  of	  data	  with	  
feature	  selection	  (20	  most	  informative	  features)	  and	  without.	  
Legend,	  Figure	  3:	  Feature	  selection	  consistently	  improved	  the	  balanced	  accuracy	  
compared	  to	  a	  non-­‐balanced	  accuracy.	  Error	  bars	  indicate	  standard	  deviation	  of	  
balanced	  accuracy	  estimates	  calculated	  from	  cross	  validation.	  
	  
Chapter	  III,	  Figure	  4:	  Balanced	  accuracies	  for	  different	  feature	  subsets	  of	  
dataset	  1.	  
	  
3.3 Hidden	  Markov	  Model	  Generation	  and	  Validation	  
Hidden	  Markov	  Models	  (HMMs)	  are	  a	  formal	  methods	  for	  making	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states	  and	  T	  discrete	  time-­‐steps;	  in	  this	  case,	  however,	  instead	  of	  time	  the	  Markov	  
chain	  is	  based	  on	  dose.	  This	  required	  transforming	  our	  data	  from	  pairs	  of	  
chemicals/LLNA	  class	  into	  chemical-­‐dose	  pairs.	  In	  other	  words,	  each	  chemical	  was	  
classified	  as	  toxic/non-­‐toxic	  at	  a	  low	  dose,	  medium	  dose,	  or	  high	  dose	  (see	  figure	  5)	  
corresponding	  to	  LLNA	  which	  meant	  that	  the	  model	  in	  essence	  predicted	  a	  binary	  
question—that	  is,	  whether	  the	  chemical	  was	  toxic	  or	  non-­‐toxic	  at	  a	  given	  dose	  
increment—instead	  of	  trying	  to	  predict	  a	  four-­‐class	  problem.	  In	  principle,	  a	  model	  
that	  uses	  this	  extra	  information—a	  “a	  dose-­‐informed”	  Hidden	  Markov/Random	  
Forest	  approach—should	  perform	  better	  than	  a	  “dose-­‐naïve”	  Random	  Forest.	  
Emission	  probabilities	  of	  a	  Hidden	  Markov	  model	  help	  us	  to	  encode	  and	  exploit	  this	  
variable	  supervised	  model	  performance.	  
Figure	  5	  shows	  how	  HMM	  has	  been	  implemented	  to	  build	  the	  dose	  informed	  
Hidden	  Markov/Random	  Forest	  approach.	  
	  
Chapter	  III,	  Figure	  5:	  Visual	  description	  of	  dose	  transformation	  use	  in	  a	  
Hidden	  Markov	  Model.	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3.4 Average	  Class	  Error	  	  
With	  the	  addition	  of	  the	  DRAGON	  descriptors,	  the	  total	  number	  of	  features	  
available	  for	  data	  sets	  was	  quite	  large.	  In	  this	  case,	  a	  comparison	  of	  both	  dose-­‐
informed	  and	  dose-­‐naïve	  models	  by	  average	  class	  error	  using	  all	  available	  chemical	  
descriptors	  from	  DRAGON	  and	  all	  in	  vitro	  assays	  performed	  seemingly	  worse	  than	  
using	  only	  the	  20	  most	  informative	  features	  selected	  by	  recursive	  feature	  selection	  	  
(Figure	  6).	  	  Significantly,	  average	  class	  error	  for	  Dose-­‐informed	  Random	  
Forest/Hidden	  Markov	  Models	  was	  lower	  than	  average	  class	  error	  in	  the	  Dose-­‐naive	  
Random	  Forest	  models	  on	  all	  data	  sets.	  Although	  from	  the	  standpoint	  of	  balanced	  
accuracy	  the	  improvement	  is	  not	  apparent,	  this	  obscures	  the	  actual	  improvement	  in	  
mis-­‐classifications.	  
The	  best	  performing	  dose-­‐informed	  models	  (Data	  Set	  1	  and	  2)	  had	  no	  
misclassifications	  greater	  than	  2	  classes,	  i.e.	  no	  extreme	  sensitizers	  classified	  as	  non-­‐
sensitizers	  and	  no	  non-­‐sensitizers	  classified	  as	  extreme	  sensitizers,	  indicating	  
overall	  a	  very	  small	  rate	  of	  extreme	  false-­‐negatives	  (an	  extreme	  sensitizer	  classified	  
as	  having	  no	  sensitization)	  and	  no	  extreme	  false-­‐positives	  (non-­‐sensitizers	  classified	  
as	  extreme	  sensitizers)	  in	  any	  data-­‐set	  (Table	  2)	  	  Interestingly,	  the	  extreme	  
sensitizer	  misclassified	  (phthalic	  anhydride	  [CAS	  85-­‐44-­‐9]	  in	  Data	  Set	  3)	  hydrolyzes	  
in	  water	  at	  pH	  6.8-­‐7.24	  with	  half-­‐lives	  of	  0.5-­‐1	  min	  at	  25	  °C,	  forming	  phthalic	  acid	  
and	  is	  therefore	  not	  within	  the	  applicability	  domain	  of	  in	  vitro	  assays	  (OECD	  SIDS	  
Initial	  Assessment	  Report	  2005).	  Phthalic	  acid	  [CAS	  88-­‐99-­‐3]	  is	  classified	  on	  a	  non-­‐
sensitizer	  by	  a	  modification	  of	  the	  Maguire	  method	  and	  the	  LLNA	  (ECHA	  database	  
on	  registered	  substances,	  searched	  on	  25.07.2014),	  which	  explains	  the	  classification	  
as	  non-­‐sensitizer	  by	  our	  approach.	  
Looking	  at	  it	  another	  way,	  using	  the	  dose-­‐informed	  Hidden	  Markov	  model	  had	  
95.8%,	  92.6%	  and	  92.1%	  accuracy	  predicting	  the	  LLNA	  class	  +/-­‐	  1	  one	  class,	  versus	  
just	  90.4%,	  88.6%	  and	  90.6%	  balanced	  accuracy	  for	  the	  dose-­‐naive	  model	  for	  
dataset	  1,	  2	  and	  3,	  respectively.	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Chapter	  II,	  Figure	  6:	  Average	  Class	  Error	  and	  standard	  deviation	  from	  cross	  
validation:	  	  
Legend,	  Figure	  6:	  For	  all	  comparisons	  the	  dose-­‐informed	  model	  gave	  smaller	  
average	  class	  errors	  compared	  to	  the	  dose-­‐naive	  model.	  Furthermore,	  feature	  
selection	  improved	  the	  results—using	  all	  chemical	  descriptors	  significantly	  





Dataset 1 Feature Elimination Dataset 1 No Feature Elimination Dataset 2 Feature Elimination Dataset 3 Feature Elimination
Dose Informed Random Forest
Dose Naive Random Forest
Average Class Error
	  




Predicted Non Moderate Strong Extreme
Sum	  of	  




Non 35 5 3 0 43 36 6 5 3 50
Moderate 6 18 5 2 31 2 18 5 1 26
Strong 1 10 25 10 46 0.65 4 8 22 9 43 0.63
Extreme 0 0 7 18 25 0 1 8 17 26
Occurrences 42 33 40 30 145 42 33 40 30 145




0.19 0.45 0.45 0.47 0.39 0.24 0.48 0.58 0.67 0.49
Data	  Set	  II
Non 13 3 4 0 20 14 1 5 2 22
Moderate 5 10 2 1 18 5 11 2 2 20
Strong 2 4 19 6 31 0.62 1 5 20 5 31 0.63
Extreme 0 0 4 10 14 0 0 2 8 10
Occurrences 20 17 29 17 83 20 17 29 17 83




0.45 0.41 0.48 0.47 0.45 0.35 0.35 0.48 0.88 0.52
Data	  Set	  III
Non 11 1 2 1 15 12 1 2 1 16
Moderate 4 9 3 1 17 1 9 2 1 13
Strong 0 2 15 4 21 0.65 2 3 16 5 26 0.66
Extreme 0 1 3 7 11 0 0 3 6 9
Occurrences 15 13 23 13 64 15 13 23 13 64

































Chapter	  III,	  Table	  2:	  Confusion	  matrix	  of	  predicted	  chemical’s	  sensitizing	  
potency	  vs.	  LLNA	  Reference	  classification	  for	  datasets	  1	  to	  3	  including	  
balanced	  accuracy	  and	  balanced	  error.	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4.	   Discussion	  
Although	  toxicology	  has	  a	  handful	  of	  in	  vitro	  test	  batteries	  that	  are	  well-­‐
established	  (e.g.	  mutagenicity),	  such	  approaches	  have	  not	  kept	  up	  to	  date	  with	  the	  
ability	  to	  produce	  high-­‐throughput	  in	  vitro	  datasets.	  As	  in	  vitro	  assays	  grow	  in	  
importance	  and	  availability,	  a	  more	  objective	  way	  of	  evaluating	  them	  becomes	  
necessary,	  otherwise	  every	  positive	  result	  is	  a	  liability	  for	  the	  risk	  assessment	  of	  a	  
given	  substance,	  and	  eventually	  this	  leads	  to	  an	  accumulation	  of	  false-­‐positives	  and	  
ultimately,	  inaccurate	  risk	  assessment	  and	  a	  lack	  of	  faith	  in	  in	  vitro	  method.	  	  
While	  skin	  sensitization	  provides	  a	  strong	  domain	  for	  the	  use	  of	  modern	  
machine	  learning	  techniques,	  it	  also	  presents	  some	  challenges:	  since	  the	  models	  will	  
be	  applied	  for	  regulatory	  purposes,	  we	  need	  hazard	  estimation	  models	  that	  are	  
easily	  understood	  and	  visualized,	  which	  precludes	  black-­‐box	  approaches	  such	  as	  
Bayesian	  networks.	  However,	  the	  existing	  datasets	  have	  several	  traits	  that	  make	  
more	  straightforward	  approaches,	  such	  as	  decision	  trees,	  impractical.	  To	  begin	  with,	  
the	  datasets	  typically	  has	  more	  descriptors	  than	  samples	  and	  requires	  combining	  
datasets.	  This	  means	  employing	  a	  methodology	  that	  is	  robust	  to	  both	  missing	  
information,	  as	  well	  as	  highly	  correlated	  data	  since	  each	  dataset	  will	  likely	  contain	  
redundant	  or	  overlapping	  data	  –	  for	  example,	  DRAGON	  chemical	  descriptors	  which	  
attempt	  to	  calculate	  electrophilicity	  will	  likely	  show	  a	  high	  level	  of	  correlation	  with	  
ARE	  (Antioxidant	  Response	  Element)	  induction.	  Here,	  we	  show	  that	  in	  vitro	  tests	  
contribute	  substantial	  predictive	  information	  compared	  to	  the	  chemical	  descriptors	  
alone.	  Furthermore,	  we	  show	  that	  given	  the	  expansion	  of	  chemical	  descriptors,	  in	  
vitro	  tests,	  in	  chemico	  tests,	  etc.	  machine	  learning	  techniques	  likely	  require	  pruning	  
the	  information	  used	  in	  a	  model—something	  that	  will	  become	  even	  more	  important	  
as	  Toxcast	  and	  other	  high	  throughput	  data	  become	  available;	  at	  some	  point,	  
additional	  data	  is	  merely	  adding	  noise	  or	  causing	  model	  over-­‐fitting.	  It	  is	  always	  a	  
temptation	  to	  assume	  that	  using	  all	  available	  data	  will	  improve	  accuracy;	  however,	  
the	  reality	  is	  that	  more	  descriptors	  may	  simply	  be	  adding	  more	  noise	  and	  not	  
offering	  additional	  information.	  In	  toxicology,	  we	  have	  the	  prominent	  example	  of	  the	  
accumulation	  of	  false-­‐positives	  that	  have	  made	  the	  battery	  of	  tests	  for	  mutagenicity	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cumbersome	  (Kirkland,	  Aardema,	  Henderson,	  &	  Muller,	  2005;	  D.	  J.	  Kirkland	  et	  al.,	  
2005).	  
Furthermore,	  it	  has	  become	  increasingly	  evident	  that	  characterizing	  the	  
dose-­‐response	  relationship	  in	  in	  vitro	  assays	  is	  key	  to	  using	  them	  effectively	  in	  
machine	  learning	  techniques.	  Typically,	  predicting	  LLNA	  is	  a	  four-­‐class	  problem	  
(predicting	  non-­‐sensitizer-­‐weak,	  moderate,	  strong	  and	  extreme),	  which	  presents	  a	  
significant	  challenge	  to	  most	  machine	  learning	  techniques.	  While	  some	  approaches	  
try	  to	  solve	  this	  problem	  by	  predicting	  sensitizer	  vs	  non-­‐sensitizer	  only,	  this	  model	  
seeks	  to	  exploit	  the	  fact	  that	  LLNA	  follows	  a	  monotonic	  dose-­‐response	  curve:	  that	  is,	  
if	  a	  chemical	  is	  a	  sensitizer	  at	  a	  low	  dose,	  it	  will	  also	  be	  a	  sensitizer	  at	  a	  high	  dose.	  By	  
redefining	  the	  problem	  as	  predicting	  whether	  a	  chemical	  is	  a	  skin	  sensitizer	  at	  a	  
given	  dose-­‐increment,	  the	  prediction	  becomes	  a	  binary	  problem.	  From	  a	  theoretical	  
perspective,	  it	  is	  clear	  that	  a	  Hidden	  Markov	  Model	  will	  lessen	  extreme	  mis-­‐
classifications;	  this	  is	  borne	  out	  in	  our	  datasets	  by	  the	  fairly	  small	  average	  class	  
distance	  between	  predicted	  vs.	  actual	  for	  the	  Dose-­‐Informed	  vs.	  Dose-­‐Naïve.	  From	  a	  
practical	  stand	  point,	  this	  can	  give	  users	  of	  the	  model	  some	  confidence	  that	  while	  
the	  actual	  predicted	  class	  may	  not	  be	  accurate,	  a	  predicted	  non-­‐sensitizer	  is	  unlikely	  
to	  be	  an	  extreme	  sensitizer	  and	  vice	  versa.	  Our	  dose-­‐informed	  Hidden	  Markov	  
Model	  generally	  outperformed	  the	  dose-­‐naïve	  4-­‐class	  Random	  Forest	  prediction	  
models	  and	  minimized	  miss-­‐classifications	  of	  a	  more	  than	  two-­‐class	  distance.	  
Furthermore,	  a	  dose-­‐informed	  Hidden	  Markov	  Model	  could	  potentially	  be	  extended	  
when	  used	  with	  attributes	  that	  show	  a	  dose-­‐response	  curve	  as	  opposed	  to	  the	  
single-­‐value	  assays	  used	  here.	  This	  approach	  can	  likely	  be	  extended	  with	  the	  
increasing	  availability	  of	  descriptors	  such	  as	  those	  from	  Toxcast,	  which	  capture	  the	  
dose-­‐response	  curve	  of	  the	  mechanistic	  steps	  involved	  in	  an	  adverse	  outcome.	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CHAPTER	  III	  –	  MPTP’s	  Pathway	  of	  Toxicity	  Indicates	  Central	  Role	  of	  
Transcription	  Factor	  SP1	  
	  
	  
Abstract:	  Deriving	  a	  Pathway	  of	  Toxicity	  from	  transcriptomic	  data	  remains	  a	  
challenging	  task.	  In	  this	  paper,	  we	  explore	  the	  use	  of	  weighted	  gene	  correction	  
network	  analysis	  (WGCNA)	  to	  extract	  an	  initial	  network	  from	  a	  small	  microarray	  
study	  of	  MPTP	  toxicity.	  	  The	  resulting	  network	  was	  analyzed	  for	  transcription	  factor	  
candidates,	  which	  were	  narrowed	  down	  via	  text-­‐mining	  for	  relevance	  to	  the	  disease	  
model,	  and	  then	  combined	  with	  the	  FANTOM4	  database	  to	  generate	  a	  Genetic	  
Regulatory	  Network.	  	  This	  analysis	  demonstrated	  that	  a	  small	  microarray	  study	  can	  
capture	  much	  of	  the	  known	  biology	  of	  MPTP	  toxicity	  and	  suggests	  several	  
candidates	  for	  further	  study.	  Furthermore,	  the	  analysis	  strongly	  suggests	  that	  SP1	  
plays	  a	  central	  role	  in	  co-­‐ordinating	  the	  cellular	  response	  to	  MPTP	  toxicity.	  	  	  
	  
	   Abbreviations:	  MPTP	  (1-­‐methyl-­‐4-­‐phenyl-­‐1,2,3,6-­‐tetrahydropyridine),	  PD	  	  
(Parkinson’s	  Disease),	  MT	  (microtubules),	  ETC	  (electronic	  transport	  chain),	  WGCNA	  
(Weighted	  Gene	  Correlation	  Network),	  GRN	  (Genetic	  Regulatory	  Network),	  POT	  
(Pathway	  of	  Toxicity),	  TOM	  (Topological	  Overlap	  Metric),	  	  
	  
1.	   Introduction	  	  
In	  order	  to	  bring	  toxicology	  into	  the	  21st	  century,	  toxicology	  is	  undergoing	  a	  
profound	  paradigm	  change:	  away	  from	  animal-­‐based	  black-­‐box	  models	  towards	  a	  
systems	  toxicology	  approach	  based	  on	  higher	  throughput	  testing.	  The	  necessary	  
mapping	  of	  	  the	  pathways	  of	  toxicity	  often	  involves	  using	  high	  dimensional	  data	  sets,	  
which	  are	  traditionally	  analyzed	  by	  looking	  for	  a	  few	  differentially	  expressed	  genes.	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However,	  cellular	  pathways	  leading	  to	  toxicity	  may	  involve	  subtle	  perturbations	  in	  
many	  genes	  rather	  than	  drastic	  alterations	  in	  a	  few.	  In	  addition,	  microarrays	  can	  
often	  be	  noisy	  and	  can	  show	  poor	  reproducibility,	  which	  only	  increases	  the	  difficulty	  
of	  extracting	  meaningful,	  systems-­‐level	  insights	  into	  biology	  from	  the	  data.	  
	   Here,	  we	  used	  an	  approach	  that	  derives	  a	  de	  novo	  network	  from	  a	  small	  data	  
set	  by	  using	  a	  weighted	  approach,	  clusters	  by	  network	  topology,	  and	  uses	  the	  
resulting	  clusters	  for	  further	  analysis	  with	  text-­‐mining	  and	  other	  sources	  of	  high	  
throughput	  data	  (ChIP	  experiments	  and	  siRNA	  perturbation	  studies),	  ultimately	  
producing	  a	  more	  specific	  genetic	  regulatory	  network	  (GRN).	  Using	  a	  WGCNA	  
approach	  offers,	  in	  essence,	  a	  dimensionality	  reduction	  technique	  that	  can	  be	  used	  
to	  produce	  a	  more	  detailed	  genetic	  regulatory	  network	  based	  on	  known	  and	  
predicted	  transcription	  factor	  interactions,	  and	  brings	  us	  a	  small	  step	  closer	  to	  a	  
wiring	  diagram	  of	  the	  cell.	  	  	  
	   MPTP	  (methyl-­‐4-­‐phenyl-­‐1,2,3,6-­‐tetrahydropyridine)	  toxicity	  offers	  an	  
excellent	  “proof-­‐of-­‐concept”	  for	  the	  ability	  to	  derive	  a	  Pathway	  of	  Toxicity	  from	  
high-­‐throughput	  data,	  since	  the	  broad	  outlines	  of	  the	  Pathway	  of	  Toxicity	  are	  
understood.	  It	  is	  used	  widely	  as	  an	  animal	  model	  for	  a	  relatively	  data-­‐rich	  disease	  
(Parkinson’s	  disease)	  (Schober,	  2004),	  since	  MPTP	  poisoning,	  like	  Parkinson’s,	  is	  
highly	  selective	  for	  dopaminergic	  neurons	  in	  the	  substantia	  nigra	  and	  the	  clinical	  
symptoms	  are	  highly	  similar	  to	  Parkinson’s	  (Snyder	  &	  D'Amato,	  1986).	  
	  	   MPTP	  is	  not	  itself	  toxic,	  but	  owing	  to	  its	  high	  lipophilicity	  it	  is	  able	  to	  cross	  
the	  blood	  brain	  barrier,	  where	  it	  is	  metabolized	  in	  astrocytes	  by	  Monoamine	  
Oxidase	  B	  (MOA-­‐B)	  to	  MPP+.	  MPP+	  is	  then	  transported	  selectively	  by	  the	  dopamine	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transporter	  into	  neurons.	  Once	  inside	  the	  neuron,	  it	  is	  thought	  to	  exert	  its	  primary	  
action	  through	  targeting	  Complex	  I	  in	  the	  mitochondria,	  which	  results	  in	  disruption	  
of	  the	  electron	  transport	  chain	  (ETC).	  While	  MPTP	  disruption	  of	  the	  ETC	  causes	  a	  
loss	  of	  ATP,	  it	  is	  not	  a	  critical	  failure	  of	  Complex	  I	  and	  oxidative	  phosphorylation	  
that	  causes	  pathology,	  as	  MPTP	  typically	  only	  causes	  a	  mild	  decrease	  in	  ATP	  levels	  
and	  falls	  short	  of	  levels	  required	  to	  cause	  significant	  energy	  depletion	  (Perier	  &	  Vila,	  
2012)	  and	  deficiency	  in	  a	  component	  of	  Complex	  I	  does	  not	  lead	  to	  selective	  
dopaminergic	  neural	  death	  (Sterky	  et	  al.,	  2012).	  Therefore,	  MPTP	  
neurodegeneration	  is	  not	  necessarily	  caused	  by	  energy	  depletion.	  More	  likely,	  a	  shift	  
in	  energy	  balance	  is	  a	  contributing	  factor	  (Krug	  et	  al.,	  2014).	  
	   Another	  consequence	  of	  the	  ETC	  disruption	  is	  increased	  ROS	  generated	  by	  
impaired	  mitochondria.	  This	  may	  in	  turn	  cause	  oxidative	  damage	  to	  Complex	  I,	  
initiating	  a	  spiral	  of	  decreased	  mitochondrial	  efficiency	  and	  increased	  ROS.	  ROS	  can	  
cause	  peroxidation	  of	  the	  lipids,	  which	  disrupts	  the	  normal	  binding	  of	  
cytochrome	  c	  to	  the	  mitochondrial	  membrane	  and	  facilitates	  the	  pro-­‐apoptotic	  
release	  of	  cytochrome	  c	  to	  the	  cytosol	  (Perier	  &	  Vila,	  2012).	  Mitochondria-­‐derived	  
ROS	  have	  also	  been	  shown	  to	  damage	  lysosomal	  membranes	  in	  MPTP-­‐intoxicated	  
mice,	  leading	  to	  an	  impairment	  of	  lysosomal	  function	  and	  defective	  autophagic	  
activity	  (Dehay	  et	  al.,	  2010),	  including	  mitochondrial	  autophagy	  (Ivatt	  &	  Whitworth,	  
2014).	  In	  addition	  to	  proteins	  and	  lipids,	  MPTP-­‐intoxicated	  mice	  also	  exhibit	  
oxidative	  damage	  to	  nuclear	  and	  mitochondrial	  DNA	  (Hoang	  et	  al.,	  2009).	  Despite	  
the	  centrality	  of	  the	  intracellular,	  mitochondrial-­‐generated	  ROS,	  there	  may	  be	  other	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contributors	  to	  ROS	  in	  the	  context	  of	  PD/MPTP	  toxicity	  —for	  example,	  astrocytes	  or	  
microglia.	  	  
	   Another	  key	  component	  of	  MPTP	  toxicity	  is	  microtubule	  	  (MT)	  disruption.	  
MPP+	  is	  believed	  to	  lead	  to	  hyperphosphorylation	  of	  Microtubule	  Associated	  
Protein	  Tau	  (MAPT),	  which	  leads	  to	  microtubule	  instability	  (Cappelletti,	  Pedrotti,	  
Maggioni,	  &	  Maci,	  2001).	  Depolymerization	  of	  MTs	  is	  one	  suggested	  reason	  for	  the	  
selective	  vulnerability	  of	  dopaminergic	  (DA)	  neurons	  by	  toxins	  such	  as	  MPTP,	  
paraquat	  and	  rotenone,	  as	  dopaminergic	  neurons	  require	  axonal	  transport	  of	  
neurotransmitters	  to	  the	  striatum	  for	  dopamine	  release	  (Ren,	  Liu,	  Jiang,	  Jiang,	  &	  
Feng,	  2005).	  The	  traffic	  along	  the	  axonal	  length	  of	  DA	  neurons	  requires	  intricate	  
coordination	  between	  MTs	  and	  the	  motor	  proteins	  to	  ensure	  dopamine	  is	  
transported	  successfully	  through	  vesicle	  transport.	  Depolymerization—or,	  less	  
acutely,	  an	  impairment	  of	  coordinated	  traffic—can	  lead	  to	  an	  impairment	  of	  neural	  
function.	  Furthermore,	  in	  neurons,	  mitochondria	  are	  actively	  transported	  
throughout	  the	  cell	  body;	  the	  combination	  of	  impaired	  mitochondrial	  activity	  and	  
impaired	  transport	  is	  likely	  key	  to	  the	  toxic	  outcome	  (Sterky	  et	  al.,	  2012).	  
	   The	  final	  step	  of	  MPTP	  toxicity,	  apoptosis,	  is	  likely	  the	  result	  of	  several	  
pathways	  that	  combine	  to	  produce	  cell	  death.	  Apoptosis	  is	  thought	  to	  be	  generated	  
through	  a	  mitochondrial-­‐initiated,	  BAX-­‐dependent	  process.	  Complex	  I	  inhibition	  
does	  not	  directly	  trigger	  mitochondrial	  cytochrome	  c	  release	  but	  instead	  increases	  
the	  “releasable”	  pool	  of	  cytochrome	  c	  in	  the	  mitochondrial	  membrane—increasing	  
the	  magnitude	  of	  the	  signal	  that	  can	  be	  released	  when	  activated	  by	  BAX	  (Perier	  &	  
Vila,	  2012).	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   In	  summary,	  while	  MPTP	  toxicity	  has	  an	  agreed-­‐upon	  origin	  (mitochondrial	  
disruption),	  there	  is	  still	  much	  to	  be	  learned	  about	  the	  exact	  Pathway	  of	  Toxicity,	  
and	  the	  toxicity	  mechanism	  likely	  involves	  alterations	  of	  several	  pathways	  along	  key	  
points	  (Krug	  et	  al.,	  2014).	  
2.	   Materials	  and	  Methods	  
2.1:	  Data:	  Dataset	  GDS2053,	  which	  represented	  a	  small	  study	  of	  12	  samples	  
based	  on	  the	  Affymetrix	  Murine	  Genome	  U74A	  Array	  (normalized	  via	  RMA	  and	  RAS	  
5)	  from	  MPTP-­‐treated	  mice,	  was	  downloaded	  from	  GEO	  with	  GEOQuery	  (Davis	  &	  
Meltzer,	  2007)	  and	  checked	  for	  outliers	  via	  the	  IAC	  function	  in	  WGCNA	  (Langfelder	  
&	  Horvath,	  2008).	  The	  top	  5000	  genes	  were	  filtered	  using	  the	  rankmeans	  function	  in	  
WGCNA.	  	  	  
	   WGCNA	  uses	  the	  strength	  of	  the	  correlation	  to	  determine	  the	  strength	  of	  the	  
network	  connection—typically,	  β	  can	  be	  chosen	  to	  fit	  the	  network	  to	  a	  scale-­‐free	  
topology	  A=[aij]=[|cor(xi,xj)|β.	  Here,	  β	  was	  chosen	  as	  7	  based	  on	  the	  lowest	  value	  
that	  produced	  a	  scale-­‐free	  topology	  in	  the	  network.	  A	  Toplogical	  Overlap	  Metric	  
(TOM)	  was	  calculated	  as	  described	  in	  (Yip	  &	  Horvath,	  2007)	  and	  probes	  were	  
clustered	  and	  assigned	  to	  modules	  using	  the	  “blockwisemodule”	  function	  with	  a	  
signed	  Spearman	  rank	  correlation	  with	  β=7,	  and	  a	  deepsplit	  level	  of	  2	  (which	  
represents	  a	  medium	  level	  of	  sensitivity	  in	  terms	  of	  how	  modules	  are	  detected),	  a	  
minimum	  module	  size	  of	  40,	  and	  clustering	  based	  on	  the	  Dynamic	  Treecut	  algorithm	  
(Langfelder,	  Zhang,	  &	  Horvath,	  2008).	  Eigengenes	  were	  calculated	  from	  each	  
module	  and	  p-­‐values	  calculated	  based	  on	  the	  functions	  in	  the	  WGCNA	  package	  
(Langfelder	  &	  Horvath,	  2007).	  The	  network	  was	  based	  on	  the	  TOM	  calculated	  from	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3.	   Results	  
3.1	  WGCNA	  Clustered	  Probes	  by	  Function	  and	  Captured	  the	  Relevant	  
Pathways:	  While	  correlation	  networks—often	  referred	  to	  as	  “guilt-­‐by-­‐association”	  
analysis	  (Quackenbush,	  2003)—are	  commonly	  used	  to	  derive	  networks	  de	  novo	  
from	  microarray	  data,	  Weighted	  Gene	  Correlation	  Network	  Analysis	  (WGCNA)	  
offers	  several	  advantages.	  Unweighted	  correlation	  networks	  typically	  establish	  a	  
hard	  cut-­‐off	  for	  a	  link,	  but	  WGCNA	  links	  each	  gene	  by	  a	  weight,	  and	  this	  network	  is	  
used	  to	  derive	  a	  Topological	  Overlap	  Metric,	  which	  is	  most	  simply	  thought	  of	  as	  a	  
measurement	  of	  gene	  interconnectivity.	  This	  combines	  the	  advantages	  of	  a	  
correlation	  network	  with	  the	  insights	  that	  can	  be	  gleaned	  from	  a	  graph-­‐theoretical	  
approach;	  it	  is	  typically	  more	  sensitive	  to	  “weaker”	  connections	  amongst	  genes	  that	  
may	  be	  significant,	  while	  at	  the	  same	  time	  it	  is	  somewhat	  more	  robust	  to	  noise	  
(Langfelder	  and	  Hovarth,	  2008).	  We	  chose	  MPTP	  toxicity,	  a	  commonly-­‐used	  toxicity	  
model	  for	  Parkinson’s	  disease,	  and	  located	  a	  publicly	  available	  GEO	  Data	  Set	  
produced	  from	  tissue	  isolated	  from	  the	  substania	  nigra	  of	  male	  C57BL/6J	  mice	  
dosed	  at	  10	  weeks	  of	  age	  with	  a	  total	  of	  three	  doses	  of	  30	  mg/kg	  MPTP	  dosed	  via	  i.p.	  
or	  saline	  control	  and	  killed	  either	  24	  hours	  or	  7	  days	  after	  the	  final	  dose	  of	  
neurotoxin.	  Biological	  replicates	  were	  pooled	  and	  twelve	  arrays	  total	  were	  used	  
with	  four	  arrays	  per	  group;	  the	  control	  group	  were	  un-­‐dosed	  and	  sacrificed	  at	  10	  
weeks.	  The	  initial	  data	  set	  was	  downloaded	  as	  RMA	  normalized	  data,	  filtered	  for	  the	  
top	  5000	  probes	  by	  ranked	  mean	  differential	  expression,	  and	  used	  to	  produce	  the	  
initial	  network	  which	  was	  divided	  into	  modules	  based	  on	  the	  Topological	  Overlap	  
Metric	  as	  clustered	  by	  the	  Dynamic	  Tree	  Cut	  algorithm	  (Figure	  1).	  	  The	  modules	  
	  
	   37	  
were	  summarized	  as	  “eigengenes”—essentially,	  the	  first	  principal	  component	  of	  all	  
genes’	  expression	  for	  that	  module,	  which	  represents	  an	  “expression	  signature.”	  The	  
eigengenes	  are	  then	  correlated	  with	  the	  phenotypic	  label,	  in	  this	  case	  time	  (Control,	  
Day	  1,	  and	  Day	  7).	  Five	  modules	  were	  statistically	  significant	  (shown	  in	  figure	  1)	  
with	  the	  Midnight	  Blue	  module	  having	  the	  highest	  correlation	  (Table	  1).	  Unassigned	  
genes	  had	  no	  significant	  correlation,	  as	  would	  be	  expected.	  Therefore,	  WGCNA	  
identified	  in	  an	  untargeted	  approach	  a	  total	  of	  1,247	  genes	  in	  five	  clusters	  that	  were	  
significantly	  correlated	  to	  the	  phenotype	  label.	  	  
	   One	  of	  the	  underlying	  ideas	  of	  WGCNA	  is	  that	  genes	  with	  a	  similar	  function	  
will	  cluster	  together.	  In	  order	  to	  both	  ensure	  that	  the	  clusters	  produced	  were	  
biologically	  meaningful	  and	  that	  they	  captured	  the	  known	  biological	  processes	  
involved	  in	  MPTP	  toxicity,	  we	  analyzed	  the	  modules	  using	  DAVID	  for	  over-­‐
represented	  annotations.	  All	  significant	  modules	  except	  one,	  the	  Midnight	  Blue	  
module,	  were	  significantly	  enriched	  for	  terms	  when	  investigated	  by	  DAVID,	  and	  the	  
DAVID	  Enrichment	  clusters	  captured	  the	  known	  biology	  of	  MPTP	  toxicity	  (e.g.	  
apoptosis	  -­‐	  Magenta	  module;	  oxidative	  phosphorylation/Parkinson’s	  disease	  -­‐	  
Brown	  module)	  (Table	  2).	  The	  resulting	  network	  was	  visualized	  in	  Cytoscape	  
(Figure	  2).	  One	  advantage	  of	  WGCNA	  is	  that	  it	  is	  a	  dimensionality	  reduction	  
technique	  that	  allows	  for	  some	  insight	  into	  the	  interrelationship	  amongst	  the	  
modules.	  As	  can	  be	  seen	  from	  the	  network	  (Figure	  2),	  three	  modules	  (Brown,	  
Salmon,	  and	  Magenta)	  were	  fairly	  tightly	  interconnected,	  while	  the	  Midnight	  Blue	  
module	  appeared	  as	  a	  sparse	  module,	  which	  connected	  the	  Cyan	  module	  with	  the	  
other	  three.	  This	  suggests	  that	  the	  Midnight	  Blue	  module	  may	  act	  to	  coordinate	  the	  
distinct	  functions	  of	  the	  other	  three	  modules,	  which	  may	  be	  mediated	  by	  
transcription	  factor	  TCF3	  (see	  discussion	  below).	  

	  




Module	   Correlation	   p-­‐Value	   Genes	  
Magenta	   0.7996246	   1.80E-­‐03	   212	  
Salmon	   0.76605824	   3.67E-­‐03	   184	  
Brown	   0.58916781	   4.38E-­‐02	   560	  
Cyan	   0.69331419	   1.24E-­‐02	   177	  
Midnight	  Blue	   0.94604195	   3.29E-­‐06	   125	  
Unassigned	   0.13829676	   6.68E-­‐01	   68	  
Chapter	  III,	  Table	  1:	  Modules	  Correlated	  with	  Time.	  	  
Legend,	  Table	  1:	  Five	  of	  the	  modules	  produced	  were	  significantly	  correlated;	  
significance	  is	  calculated	  via	  a	  permutation	  test.	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Chapter	  III,	  Table	  2:	  Modules	  annotated	  by	  DAVID.	  	  
Legend,	  Table	  2:	  All	  modules	  except	  the	  Midnight	  Blue	  module	  were	  significantly	  
enriched	  for	  annotation	  terms,	  reflecting	  that	  WGCNA	  had	  clustered	  probes	  by	  
function	  and	  identified	  physiologically	  relevant	  functions,	  and	  the	  presence	  of	  
apoptosis	  and	  the	  KEGG	  Pathway	  for	  Parkinson’s	  disease	  indicates	  that	  the	  known	  
physiology	  of	  MPTP	  toxicity	  was	  captured	  by	  the	  modules.	  
BROWN
Annotation	  Cluster	  1 Enrichment	  Score:	  9.1
GO	  Term structural	  constituent	  of	  ribosome
KEGG	  Pathway ribosome
Annotation	  Cluster	  2 Enrichment	  Score:	  6.31
GO	  TERM	  MF mitochondrion
GO	  TERM	  MF generation	  of	  precursor	  metabolites	  and	  energy
KEGG	  Pathway Oxidative	  phosphorylation
KEGG	  Pathway Parkinson's	  disease
SALMON
Annotation	  Cluster	  1 Enrichment	  Score:	  2.37
GOTERM	  CC vacuole
GOTERM	  CC lysosome
Annotation	  Cluster	  2 Enrichment	  Score:	  2.18
GOTERM	  BP positive	  regulation	  of	  transcription
GOTERM	  BP positive	  regulation	  of	  gene	  expression
GOTERM	  BP positive	  regulation	  of	  nucleobase,	  nucleoside,	  
nucleotide	  and	  nucleic	  acid	  metabolic	  process
CYAN
Annotation	  Cluster	  1 Enrichment	  Score:	  3.75
SIR	  Protein	  Keywordsnucleotide-­‐binding
GO	  TERM	  MF purine	  nucleotide	  binding
GO	  TERM	  MF ribonucleotide	  binding
Annotation	  Cluster	  2 Enrichment	  Score:	  2.67
GOTERM	  BP intracellular	  protein	  transport
GOTERM	  BP cellular	  protein	  localization
GOTERM	  BP cellular	  macromolecule	  localization
GOTERM	  BP protein	  transport
MAGENTA
Annotation	  Cluster	  1 Enrichment	  Score:	  2.71
GOTERM	  BP regulation	  of	  protein	  kinase	  activity
GOTERM	  BP regulation	  of	  transferase	  activity
GOTERM	  BP regulation	  of	  phosphorus	  metabolic	  process
Annotation	  Cluster	  2 Enrichment	  Score:	  2.16
GO	  TERM	  BP negative	  regulation	  of	  apoptosis
GO	  TERM	  BP negative	  regulation	  of	  programmed	  cell	  death
MIDNIGHT	  BLUE
Annotation	  Cluster	  1 Enrichment	  Score:	  1.4
GO	  TERM	  -­‐	  BP hexose	  metabolic	  process
GO	  TERM	  -­‐	  BP monosaccharide	  metabolic	  process
GO	  TERM	  -­‐	  BP glucose	  metabolic	  process
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Correlation	  networks	  typically	  have	  both	  a	  high	  rate	  of	  false	  positives	  and	  
provide	  no	  insight	  into	  the	  regulatory	  mechanisms.	  Therefore,	  to	  bring	  this	  	  
approach	  closer	  to	  a	  mechanistically	  specified	  network	  and	  to	  better	  characterize	  
the	  underlying	  biology,	  each	  module	  was	  analyzed	  for	  gene	  signatures	  in	  the	  
Chemical	  and	  Genetic	  Perturbation	  subset	  of	  MSigDB	  as	  well	  as	  for	  over-­‐represented	  
transcription	  factor	  binding	  sites.	  Each	  module,	  except	  for	  the	  Magenta	  module,	  was	  
substantially	  enriched	  for	  genes	  involved	  in	  Alzheimer’s	  disease	  (Table	  3),	  and	  while	  
Alzheimer’s	  has	  a	  different	  mechanism	  of	  neuronal	  degeneration	  compared	  to	  
Parkinson’s,	  this	  does	  indicate	  that	  the	  approach	  selected	  genes	  that	  are	  involve	  in	  
neurodegenerative	  disease.	  Furthermore,	  it	  indicates	  that	  while	  the	  Midnight	  Blue	  
module	  had	  no	  annotations	  to	  establish	  the	  functional	  significance	  of	  the	  cluster,	  the	  
genes	  identified	  are	  related	  to	  neurodegeneration.	  	  
	  
MODULE	   Curated	  Gene	  Set	   FDR	  corrected	  q-­‐value	  
BROWN	   Genes	  down-­‐regulated	  




CYAN	   Genes	  up-­‐regulated	  in	  





MIDNIGHT	  BLUE	   Genes	  up-­‐regulated	  in	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SALMON	   Genes	  up-­‐regulated	  in	  





Chapter	  III,	  Table	  3:	  Overlap	  of	  the	  modules	  with	  Alzheimer’s	  genes,	  from	  
MSigDB	  C2	  gene	  sets.	  Alzheimer’s	  genes	  are	  based	  on	  the	  Blalock	  dataset	  
(Blalock	  et	  al.,	  2004).	  
	  
	  
3.2	  Modules	  Were	  Enriched	  For	  Transcription	  Factors	  Relevant	  To	  
Parkinson’s	  Disease:	  One	  biological	  reason	  for	  correlation	  of	  gene	  expression	  is	  
common	  transcription	  factors	  or	  microRNAs.	  Therefore,	  each	  module	  was	  also	  
analyzed	  in	  MSigDB	  for	  enriched	  transcription	  factor	  binding	  sites	  with	  an	  FDR	  
corrected	  p-­‐value	  of	  less	  than	  .01.	  This	  generated	  a	  list	  of	  114	  candidate	  
transcription	  factor	  binding	  sites	  that	  were	  enriched	  in	  the	  modules	  (of	  which	  25	  
had	  no	  known	  transcription	  factor)	  and	  23	  microRNA	  binding	  sites.	  All	  modules	  had	  
more	  than	  10	  predicted	  enriched	  motifs,	  and	  there	  was	  substantial	  overlap	  between	  
enriched	  motifs	  amongst	  the	  modules.	  Candidate	  transcription	  factors	  and	  
microRNA	  were	  text-­‐mined	  for	  association	  with	  either	  Parkinson’s	  disease	  or	  MPTP	  
toxicity,	  and	  any	  transcription	  factor	  with	  more	  than	  two	  articles	  for	  Parkinson’s	  
and/or	  MPTP	  toxicity	  (one	  article	  for	  microRNA,	  owing	  to	  the	  smaller	  literature	  
base)	  were	  considered	  relevant	  for	  building	  a	  genetic	  regulatory	  network	  (Table	  4).	  
This	  methodology	  found	  transcription	  factors	  that	  were	  well	  known	  for	  
Parkinson’s—JUN	  and	  NRF2,	  as	  well	  as	  ELK1,	  which	  had	  both	  literature	  evidence	  for	  
Parkinson’s	  and	  were	  in	  the	  Parkinson’s	  Pathway	  in	  the	  PANTHER	  Database	  (Mi,	  
Muruganujan,	  Casagrande,	  &	  Thomas,	  2013).	  Additionally,	  one	  of	  the	  transcription	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factor	  binding	  sites—SP1—had	  relatively	  few	  articles	  for	  Parkinson’s	  disease,	  but	  
did	  have	  binding	  motifs	  enriched	  in	  each	  of	  the	  modules	  (Table	  4).	  SP1	  was	  the	  only	  
transcription	  factor	  with	  annotations	  for	  Parkinson’s	  that	  was	  identified	  by	  MSigDB	  
as	  relevant	  for	  Midnight	  Blue;	  the	  Cyan	  module	  had	  many	  transcription	  factors	  that	  
were	  not	  shared	  with	  other	  modules,	  while	  the	  Brown	  module,	  in	  keeping	  with	  its	  







MPTP/MPP+	   Module	   FDR	  
Corrected	  
P-­‐Value	  
JUN	   4451	   729	   BROWN	   3.44E-­‐08	  
NRFR2	   59	   25	   SALMON	   6.23E-­‐03	  
FOXF2	   21	   1	   BROWN	   1.69E-­‐07	  
SP1	   12	   2	   BROWN	   4.25E-­‐26	  
	   	   	   CYAN	   2.51E-­‐06	  
	   	   	   MAGENTA	   8.08E-­‐05	  
	   	   	   MIDNIGHT	  
BLUE	  
2.53E-­‐03	  
	   	   	   SALMON	   7.85E-­‐05	  
ATF4	   12	   2	   BROWN	   9.14E-­‐07	  
TCF3	   11	   6	   BROWN	   9.20E-­‐07	  
	   	   	   CYAN	   5.82E-­‐04	  
	   	   	   SALMON	   2.52E-­‐02	  
ELK1	   3	   	   BROWN	   3.14E-­‐15	  
	   	   	   MAGENTA	   8.08E-­‐05	  
AP1	   3	   1	   BROWN	   3.44E-­‐08	  
	   	   	   SALMON	   2.52E-­‐02	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STAT1	  	   7	   2	   BROWN	   3.76E-­‐06	  
NRF1	   6	   3	   BROWN	   2.34E-­‐06	  
	   	   	   CYAN	   7.59E-­‐04	  
SRY	   6	   	   CYAN	   4.84E-­‐03	  
MIR-­‐132	   5	   	   BROWN	   3.76E-­‐06	  
SREBF1	   5	   	   CYAN	   7.59E-­‐04	  
ATF3	   4	   1	   CYAN	   4.84E-­‐03	  
MIR30C	   1	   	   CYAN	   4.84E-­‐03	  
SRY	   6	   	   CYAN	   4.84E-­‐03	  
MIR221	   2	   	   CYAN	   4.95E-­‐03	  
MEF2A	   2	   	   CYAN	   9.52E-­‐03	  
	   	   	   MAGENTA	   0.000809	  
ELK1	   2	   	   MAGENTA	   8.08E-­‐05	  
	   	   	   BROWN	   3.14E-­‐15	  
Chapter	  III,	  Table	  4:	  Candidate	  transcription	  factors	  associated	  with	  
Parkinson’s	  and	  MPTP	  via	  text-­‐mining;	  p-­‐values	  based	  on	  enrichment	  in	  
MSigDB	  C3	  gene	  sets.	  	  
	  
3.3	  Transcription	  Factors	  Significantly	  Improved	  The	  Number	  Of	  Genes	  
That	  Could	  Be	  Connected	  In	  A	  Component:	  For	  each	  module,	  all	  of	  the	  genes	  that	  
could	  be	  located	  in	  the	  FANTOM4	  database	  were	  analyzed	  with	  and	  without	  the	  
subset	  of	  transcription	  factors	  both	  significant	  for	  that	  module	  and	  identified	  as	  
being	  relevant	  to	  Parkinson’s	  disease	  to	  form	  the	  basis	  of	  a	  genetic	  regulatory	  
network	  for	  that	  module.	  All	  modules	  but	  one—the	  Midnight	  Blue	  module—
contained	  a	  subset	  of	  genes	  that	  were	  connected	  by	  experimentally	  verified	  
regulatory	  interactions	  in	  FANTOM4	  (ChIP	  data,	  siRNA,	  or	  published	  interactions),	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indicating	  that	  the	  modules	  consisted	  of	  genes	  that	  could	  be	  connected	  to	  each	  other	  
with	  experimental	  data	  (Table	  5).	  
	   However,	  the	  “connected	  component”—that	  is	  to	  say,	  the	  largest	  subset	  of	  
genes	  and	  proteins	  that	  were	  interconnected	  with	  each	  other—grew	  substantially	  
with	  the	  addition	  of	  the	  predicted	  transcription	  factors	  as	  identified	  by	  MSigDB	  and	  
text-­‐mining,	  even	  when	  restricting	  to	  experimental	  evidence;	  the	  percent	  of	  the	  
module	  connected	  by	  experimentally	  verified	  interactions	  ranged	  from	  a	  low	  of	  70-­‐
80	  percent	  for	  each	  module,	  and	  was	  100	  percent	  for	  the	  Midnight	  Blue	  module	  
(Table	  5).	  For	  each	  module,	  the	  transcription	  factor	  that	  had,	  by	  far,	  the	  highest	  
number	  of	  interactions	  was	  SP1	  and	  it	  also	  had	  substantial	  experimental	  evidence	  of	  
interactions	  (see	  Fig	  	  3,	  5,6,7,8).	  Within	  the	  Brown	  module,	  a	  subnetwork	  centered	  
around	  SP1	  and	  JUN	  indicated	  that	  it	  not	  only	  activated	  JUN	  but	  was	  connected	  to	  
several	  downstream	  components	  as	  well	  (see	  Fig.	  4).	  Within	  the	  Midnight	  Blue	  
module,	  even	  when	  restricted	  to	  evidence	  of	  4	  ChIP	  experiments,	  SP1	  remained	  a	  
significant	  hub	  (see	  Fig	  8).	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CONNECTED	  COMPONENT	  –	  






EXPERIMENTAL	   PREDICTED	  	  	   EXPERIMENTAL	  
PREDICTED	  
SALMON	   163	   14	   47	  
SP1,	  NRF2,	  
TCF3,	  AP1	  
125	   132	  
MIDNIGHT	  
BLUE	  
105	   0	   14	   SP1	  
75	   105	  





121	   130	  







381	   409	  
MAGENTA	   106	   14	   26	  
SP1,	  ELK1,	  
MEF2A	  
82	   91	  
Chapter	  III,	  Table	  5:	  Addition	  of	  Predicted	  Transcription	  Factors	  Substantially	  
Increased	  Connected	  Component.	  
Table	  5:	  For	  each	  module,	  gene	  symbols	  were	  entered	  into	  FANTOM4	  
EdgeExpressDB	  and	  a	  predicted	  regulatory	  network	  was	  drawn	  based	  on	  
experimental	  evidence	  (ChIP,	  published	  interactions	  and	  siRNA	  experiments),	  with	  
and	  without	  the	  addition	  of	  predicted	  evidence	  (predicted	  transcription	  factor	  
binding	  and	  microRNA).	  Transcription	  factors	  were	  added	  based	  on	  evidence	  of	  
significantly	  over-­‐represented	  motifs	  in	  MSigDB	  and	  textual	  evidence	  of	  
involvement	  in	  Parkinson’s.	  *In	  the	  case	  of	  the	  Brown	  module,	  STAT1	  and	  JUN	  was	  
already	  in	  the	  module.	  “Connected	  component”	  consists	  of	  all	  genes	  that	  were	  not	  
singletons	  in	  the	  predicted	  regulatory	  network.	  	  
	  
SP1	  is	  a	  ubiquitously	  expressed	  transcription	  factor	  that	  regulates	  a	  
sweeping	  number	  of	  genes	  during	  development	  and	  other	  cellular	  functions.	  SP1	  is	  
known	  to	  play	  a	  key	  role	  in	  tissue	  differentiation;	  knock-­‐out	  mice	  are	  embryo-­‐lethal	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and	  have	  multiple	  abnormalities	  (OMIM).	  SP1	  is	  also	  known	  to	  play	  a	  role	  in	  cell-­‐
cycle	  inhibition	  (Deniaud	  et	  al.,	  2009)	  and	  over-­‐expression	  leads	  to	  apoptosis	  
(Chuang,	  Wu,	  Lai,	  Chang,	  &	  Hung,	  2009).	  Furthermore,	  SP1	  is	  known	  to	  regulate	  the	  
dopamine	  transporter	  (J.	  Wang	  &	  Bannon,	  2005),	  and	  is	  involved	  in	  several	  
neurodegenerative	  diseases	  (Qiu	  et	  al.,	  2006)	  (Santpere,	  Nieto,	  Puig,	  &	  Ferrer,	  
2006).	  SP1	  is	  known	  to	  be	  acetylated	  in	  neurons	  in	  response	  to	  oxidative	  stress	  and	  
works	  in	  tandem	  with	  histone	  deactylaces	  to	  prevent	  cell	  death	  (Ryu	  et	  al.,	  2003);	  
acetylation	  is	  but	  one	  of	  many	  post-­‐translational	  modifications	  that	  expand	  SP1’s	  
response	  repertoire.	  
SP1	  was	  not	  present	  in	  the	  modules,	  nor	  was	  it	  amongst	  the	  genes	  
differentially	  expressed,	  even	  with	  the	  most	  generous	  of	  cut-­‐off	  values	  for	  
significance.	  However,	  SP1	  protein	  and	  mRNA	  levels	  have	  been	  shown	  to	  increase	  
following	  MPP+	  dosing	  in	  PC12	  cells	  by	  approximately	  1.5	  fold,	  which	  was	  blocked	  
by	  antioxidant	  treatment	  (Ye,	  Zhang,	  Huang,	  Zhu,	  &	  Chen,	  2013).	  The	  lack	  of	  
appearance	  of	  SP1	  amongst	  the	  genes	  differentially	  expressed	  or	  in	  the	  modules	  
may	  simply	  reflect	  that	  SP1	  mRNA	  rises	  only	  modestly	  or	  perhaps	  briefly,	  or,	  
alternatively,	  it	  is	  regulated	  by	  means	  other	  than	  an	  increase	  in	  mRNA	  levels,	  and	  
the	  signal	  increase	  is	  therefore	  non-­‐linear	  compared	  to	  mRNA	  levels	  (Courey,	  
Holtzman,	  Jackson,	  &	  Tjian,	  1989).	  As	  SP1	  is	  constitutively	  expressed	  rather	  than	  
inducible,	  it	  may	  also	  act	  as	  a	  preliminary	  sensor	  that	  initiates	  the	  cascade.	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Chapter	  V,	  Figure	  3:	  Brown	  Module,	  Identified	  Transcription	  Factors	  in	  Red.	  	  
Figure	  3,	  Legend:	  The	  Brown	  module	  formed	  a	  dense	  of	  network	  of	  regulatory	  
interactions	  centered	  on	  SP1.	  Self-­‐loops	  indicate	  a	  gene	  interacts	  with	  itself.	  	  
7/22/14 1:55 PM
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Chapter	  III,	  Figure	  4:	  SP1,	  JUN,	  and	  STAT1	  subnetwork	  from	  the	  Brown	  
Module.	  	  
Legend:	  Green	  indicates	  ChIP	  data;	  red	  indicates	  perturbation	  experiment;	  yellow,	  
published	  protein-­‐DNA	  interactions,	  and	  purple	  indicates	  protein-­‐protein	  
interaction.	  Node	  size	  is	  proportional	  to	  predicted	  dynamics	  of	  the	  gene,	  and	  darker	  
nodes	  indicate	  higher	  scaled	  expression	  levels.	  Because	  the	  FANTOM4	  database	  
gives	  an	  estimate	  of	  the	  dynamics	  of	  gene	  expression,	  the	  resulting	  gene	  regulatory	  
network	  can	  be	  used	  as	  the	  foundation	  for	  building	  a	  dynamic	  model.	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Genes	  from	  all	  modules	  were	  combined	  into	  a	  genetic	  regulatory	  network	  
based	  on	  FANTOM4	  interactions,	  as	  follows:	  (1)	  evidence	  limited	  to	  published	  
interactions	  and	  siRNA	  perturbation	  data,	  (2)	  published/perturbation	  data	  with	  the	  
addition	  of	  ChIP	  data,	  and	  (3)	  all	  evidence,	  including	  transcription	  factor	  binding	  
sites.	  Even	  when	  restricted	  to	  published	  evidence,	  the	  resulting	  genetic	  regulatory	  
network	  consisted	  of	  a	  connected	  component	  of	  256	  genes	  with	  several	  hubs	  
(Figure	  9).	  Including	  ChIP	  data	  extended	  it	  to	  782	  and	  predicted	  transcription	  factor	  
bind	  sites	  to	  830.	  In	  addition	  to	  SP1,	  the	  network	  hubs	  consist	  of	  some	  candidates	  
well	  known	  for	  their	  role	  in	  Parkinson’s	  (STAT3,	  JUN)	  but	  also	  produced	  other	  
candidates	  that	  have	  been	  implicated	  in	  Parkinson’s.	  SREBF1	  has	  previously	  been	  
identified	  as	  a	  risk	  locus	  for	  sporadic	  Parkinson’s	  disease	  (Do	  et	  al.,	  2011)	  and	  in	  a	  
recent	  RNAi	  screening	  study,	  it	  was	  implicated	  in	  the	  control	  of	  the	  PTEN-­‐induced	  
kinase	  1	  (PINK1)/Parkin	  pathways	  that	  control	  the	  autophagic	  destruction	  of	  
mitochondria	  (Ivatt	  &	  Whitworth,	  2014).	  
	   One	  hub	  identified	  in	  the	  reconstructed	  GRN	  from	  FANTOM4,	  HDAC1,	  has	  
been	  implicated	  in	  cell-­‐survival	  in	  neurotoxicity	  to	  dopaminergic	  neurons	  in	  vitro	  
and	  ischemia	  in	  vivo	  (Kim	  et	  al.,	  2008);	  HDAC1	  was	  also	  a	  hub	  in	  the	  WGCNA	  
network	  and	  many	  of	  the	  first	  neighbors	  of	  HDAC1	  in	  the	  FANTOM4	  network	  were	  
also	  first	  neighbors	  in	  the	  WGCNA	  network	  (Figure	  10,	  11).	  The	  WGCNA	  network	  
also	  suggested	  a	  protein,	  LANCL1,	  that	  was	  connected	  to	  both	  HDAC1	  and	  STAT3	  
(Figure	  11).	  LANCL1	  binds	  glutathione	  and	  is	  believed	  to	  play	  a	  role	  in	  neuronal	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survival	  following	  oxidative	  insult	  (Zhong	  et	  al.,	  2012),	  and	  its	  connection	  to	  HDAC1	  
and	  STAT3	  seems	  plausible.	  	  
	   One	  of	  the	  smaller	  hubs,	  ZNF148,	  a	  zinc-­‐binding	  transcription	  factor,	  had	  
several	  predicted	  connections	  from	  FANTOM4	  within	  the	  Midnight	  Blue	  module;	  of	  
the	  18	  genes	  connected	  to	  ZNF148	  in	  the	  original	  WGCNA	  network,	  four	  were	  also	  
linked	  by	  predicted	  interactions	  in	  FANTOM4.	  ZNF148	  (also	  referred	  to	  as	  ZPB89)	  is	  
not	  present	  on	  any	  pathway	  in	  Panther	  or	  KEGG	  and	  has	  a	  relatively	  sparse	  
literature	  base	  with	  no	  indication	  of	  any	  role	  in	  Parkinson’s.	  However,	  ZNF148	  is	  
known	  to	  play	  a	  role	  in	  apoptosis	  (Zhang,	  Chen,	  &	  Lai,	  2010),	  and	  would	  be	  an	  
interesting	  candidate	  for	  further	  study.	  ATF4,	  which	  has	  recently	  been	  identified	  in	  
other	  high-­‐throughput	  studies	  as	  a	  key	  transcriptional	  factor	  in	  MPTP	  toxicity	  by	  us	  
and	  others	  (Ye	  et	  al.,	  2013),	  (Krug	  et	  al.,	  2014),	  was	  also	  present	  as	  a	  small	  hub	  
containing	  mostly	  protein-­‐protein	  interaction	  connections	  in	  the	  network	  when	  
restricted	  to	  experimentally	  verified	  interactions.	  Similarly,	  TCF3	  had	  relatively	  few	  
experimentally	  verified	  reactions	  and	  is	  thus	  relatively	  small	  in	  the	  graph;	  however,	  
an	  expanded	  subnetwork	  that	  included	  predicted	  transcription	  factor	  binding	  sites,	  
even	  when	  restricted	  to	  a	  high	  stringency	  level,	  would	  have	  been	  substantially	  
larger.	  TCF3	  was	  in	  the	  Midnight	  Blue	  module,	  and	  the	  Cyan,	  Salmon,	  and	  Brown	  
module	  were	  all	  enriched	  for	  TCF3	  binding	  motifs.	  This	  is	  likely	  a	  case	  where	  the	  
relative	  importance	  of	  a	  gene	  is	  underestimated	  based	  on	  the	  lack	  of	  available	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Chapter	  III,	  Figure	  9:	  Genetic	  Regulatory	  Network	  based	  on	  published	  
interactions.	  
Legend,	  Figure	  9:	  Node	  label	  is	  proportionate	  to	  hub	  status	  as	  determined	  by	  edge	  
count.	  Self-­‐interactions	  were	  deleted	  for	  visual	  clarity.	  	  
	  
	  
Chapter	  III,	  Figure	  10:	  HDAC	  Subnetwork	  from	  FANTOM4;	  single	  leaves	  
collapsed	  for	  visual	  clarity	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Chapter	  III,	  Figure	  11:	  HDAC1	  Subnetwork,	  WGCNA.	  
Legend,	  Figure	  11:	  All	  genes	  from	  Figure	  7	  (and	  any	  common	  nearest	  neighbors)	  as	  
seen	  in	  WGCNA.	  The	  connected	  component	  from	  the	  GRN	  was	  present	  in	  WGCNA.	  In	  
addition,	  HDAC1	  was	  not	  only	  directly	  connected	  to	  STAT3	  (as	  it	  was	  in	  the	  
FANTOM4	  GRN)	  but	  was	  also	  connected	  through	  LANCL1.	  
	  
One	  of	  the	  transcription	  factor	  binding	  sites	  that	  was	  consistently	  ranked	  by	  
MSigDB	  across	  all	  modules	  (PAX4),	  had	  no	  textual	  evidence	  for	  involvement	  with	  
Parkinson’s,	  although	  it	  does	  appear	  to	  be	  expressed	  in	  the	  brain.	  However,	  there	  
was	  no	  experimental	  evidence	  in	  FANTOM4	  that	  it	  bound	  to	  any	  of	  the	  targets	  in	  the	  
modules,	  the	  predicted	  targets	  were	  quite	  sparse,	  and	  its	  inclusion	  would	  not	  have	  
fundamentally	  changed	  the	  architecture	  of	  the	  network.	  This	  would	  seem	  to	  indicate	  
that	  the	  resultant	  genetic	  regulatory	  network	  is	  not	  just	  reflecting	  non-­‐specific	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predicted	  transcription	  factor	  binding	  motifs	  that	  are	  enriched	  in	  a	  subset	  of	  genes,	  
but	  is	  instead	  constructing	  a	  genetic	  regulatory	  network	  that	  is	  likely	  enriched	  for	  
biologically	  relevant	  targets.	  	  
4.	   Discussion	  
Current	  analysis	  of	  microarray	  data	  in	  toxicology	  does	  not	  take	  advantage	  of	  the	  
data-­‐mining	  and	  bioinformatics	  tools	  available	  to	  interpret	  the	  underlying	  mechanisms	  
but	  remains	  at	  the	  level	  of	  “biomarker”	  or	  signature	  identification,	  either	  generating	  a	  
relatively	  small	  list	  of	  genes	  differentially	  expressed	  using	  inferential	  statistics,	  or	  over-­‐
representation	  analysis	  which	  is	  highly	  dependent	  on	  pathway	  annotations.	  We	  chose	  
an	  existing	  dataset,	  which	  was	  originally	  used	  to	  identify	  a	  few	  genes	  as	  signatures	  of	  
MPTP	  toxicity	  in	  vivo,	  in	  order	  to	  explore	  an	  alternative	  method	  that	  would	  offer	  more	  
insight	  into	  dynamics	  of	  gene	  expression	  compared	  to	  inferential	  statistics	  and	  would	  
not	  be	  dependent	  on	  pathway	  annotations.	  WGCNA	  offer	  many	  advantages	  for	  
analyzing	  microarray	  data:	  it	  is	  unsupervised,	  and,	  unlike	  correlation	  networks	  that	  are	  
based	  solely	  on	  a	  Pearson	  or	  Spearman	  correlation,	  it	  preserves	  weak	  links—capturing	  
interactions	  that	  may	  be	  small,	  but	  that	  may	  nonetheless	  be	  biologically	  interesting;	  this	  
may	  be	  especially	  relevant	  to	  toxicology,	  as	  the	  effects	  may	  be	  subtle	  and	  distributed	  
amongst	  many	  pathways.	  
	   As	  this	  represented	  a	  fairly	  unsophisticated	  approach	  to	  text-­‐mining	  
transcription	  factor	  candidates,	  it	  is	  quite	  probable	  that	  the	  proposed	  regulatory	  
network	  is	  only	  a	  “10,000-­‐ft”	  view;	  many	  of	  the	  transcription	  factors	  may	  have	  had	  
textual	  evidence	  of	  being	  involved	  in	  physiological	  processes	  that	  are	  relevant	  to	  
MPTP	  toxicity—e.g.	  oxidative	  stress	  or	  apoptosis—although	  extending	  the	  text-­‐
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mining	  in	  such	  a	  way	  would	  likely	  also	  have	  increased	  the	  false-­‐positives,	  it	  could	  
also	  fine-­‐tune	  the	  map	  in	  some	  of	  the	  “neighborhoods.”	  MPTP’s	  Pathway	  of	  Toxicity	  
is	  aided	  markedly	  by	  the	  fact	  it	  serves	  as	  an	  animal	  model	  for	  a	  relatively	  well-­‐
researched	  disease	  such	  as	  Parkinson’s;	  depending	  on	  MPTP/MPP+	  literature	  would	  
have	  produced	  a	  much	  smaller	  subset	  of	  candidate	  transcription	  factors	  and	  no	  
microRNAs,	  perhaps	  reflecting	  the	  relatively	  immature	  literature	  base	  from	  
microRNAs	  compared	  to	  transcription	  factors.	  	  	  
	   Furthermore,	  just	  as	  the	  “connected	  component”	  likely	  contains	  some	  
regulatory	  connections	  that	  are	  artifacts,	  the	  unconnected	  component	  contains	  both	  
genes	  that	  are	  spurious	  correlations	  as	  well	  as	  genes	  that	  are	  unconnected	  due	  to	  
lack	  of	  data	  about	  the	  probable	  regulatory	  mechanism.	  Disappointingly,	  neither	  of	  
the	  two	  microRNAs	  that	  were	  identified	  as	  candidates	  were	  found	  to	  have	  
regulatory	  connections;	  this	  may	  reflect	  the	  fact	  that	  microRNAs	  simply	  have	  an	  
inadequate	  dataset,	  and	  it	  is	  likely	  that	  multiple	  microRNAs	  are	  involved	  but	  are	  
simply	  invisible	  in	  this	  analysis.	  Surprisingly,	  one	  of	  the	  “unconnected”	  genes	  in	  the	  
Brown	  module	  was	  MAO-­‐A	  (Monoamine	  Oxidase	  A).	  Although	  MPTP	  is	  metabolized	  
much	  more	  efficiently	  by	  MAO-­‐B,	  MAO-­‐A	  is	  possibly	  involved	  in	  dopaminergic	  cell	  
death	  in	  neurons	  (Naoi,	  Maruyama,	  &	  Inaba-­‐Hasegawa,	  2012)	  and	  there	  is	  evidence	  
that	  SP1	  binds	  to	  the	  promoter	  of	  MAO-­‐A	  (Zhu,	  Chen,	  &	  Shih,	  1994).	  	  
	   Similarly,	  within	  the	  Midnight	  Blue	  module,	  two	  proteins	  that	  had	  relatively	  
weak	  evidence	  of	  connection	  to	  SP1,	  AQP4	  (Aquaporin-­‐4)	  and	  TUB	  (Tubby	  protein),	  
and	  were	  not	  in	  the	  final	  genetic	  regulatory	  network,	  were	  examined	  for	  evidence	  of	  
involvement	  in	  MPTP	  toxicity	  related	  processes,	  as	  both	  have	  knock-­‐out	  mice	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models.	  Aquaporin-­‐4	  knock-­‐out	  mice	  are	  more	  prone	  to	  MPTP	  toxicity	  (Fan	  et	  al.,	  
2008)	  and	  although	  Aquaporin-­‐4	  may	  or	  may	  not	  be	  regulated	  by	  SP1,	  it	  likely	  does	  
play	  a	  role	  in	  the	  ultimate	  phenotypic	  consequences	  of	  MPTP	  toxicity	  and	  perhaps	  
Parkinson’s	  as	  well.	  Tubby	  protein	  knock-­‐out	  mice	  have	  a	  primary	  phenotype	  of	  
obesity	  but	  also	  display	  neurodegeneration.	  There	  is	  some	  evidence	  that	  TUB	  is	  a	  
regulator	  of	  microglial	  phagocytosis	  through	  the	  MerTK	  receptor.	  However,	  the	  
exact	  nature	  and	  role	  of	  TUB	  in	  MPTP	  toxicity	  remains	  speculative.	  Nonetheless,	  
neither	  the	  genes	  unconnected	  to	  the	  larger	  network	  nor	  the	  weaker	  links	  in	  the	  
network	  that	  lack	  substantial	  experimental	  evidence	  should	  be	  discarded	  wholesale.	  	  	  
	   Mitochondrial	  disruption	  is	  a	  commonality	  for	  a	  variety	  of	  neurotoxins	  and	  
neurodegenerative	  diseases;	  however,	  often	  the	  exact	  route	  between	  mitochondrial	  
disruption	  and	  the	  phenotype	  is	  unclear.	  MPTP,	  like	  other	  toxins,	  may	  work	  
primarily	  to	  disrupt	  the	  mitochondria,	  but	  the	  disruption	  likely	  has	  pleiotropic	  
effects	  that	  differ	  from	  other	  toxins	  and	  disease	  states.	  Depending	  on	  annotations	  to	  
reveal	  physiological	  function	  (or,	  alternatively,	  discarding	  a	  cluster	  because	  of	  lack	  
of	  annotations)	  may	  miss	  useful	  information	  about	  toxic	  processes.	  In	  this	  case,	  the	  
Midnight	  Blue	  module	  contained	  genes	  known	  or	  strongly	  suspected	  to	  be	  involved	  
in	  Parkinson’s	  or	  MPTP	  toxicity	  (MAPT,	  SYNGR1)	  as	  well	  as	  genes	  known	  to	  be	  
involved	  in	  neuropathology	  (THOP1,	  which	  cleaves	  amyloid	  precursor	  protein)	  
(Pollio	  et	  al.,	  2008).	  It	  also	  suggested	  novel	  candidates	  that	  are	  plausibly	  involved	  in	  
the	  degenerative	  process	  (AQP4	  and	  TUB),	  neither	  of	  which	  were	  on	  existing	  
Parkinson’s	  pathways	  (Panther,	  KEGG)	  and	  both	  of	  which	  had	  an	  inadequate	  
literature	  depth	  on	  which	  to	  base	  enrichment	  analysis.	  	  
	  
	   59	  
	   The	  pronounced	  promiscuousness	  of	  SP1	  binding	  sites	  entails	  that	  many,	  if	  
not	  most,	  of	  the	  predicted	  interactions	  are	  spurious	  and	  the	  experimentally	  verified	  
interactions	  may	  be	  irrelevant	  within	  the	  particular	  context	  of	  MPTP	  toxicity	  in	  
dopaminergic	  neurons.	  However,	  given	  the	  statistically	  significant	  over-­‐
representation	  of	  SP1	  motifs	  in	  all	  the	  modules,	  the	  centrality	  of	  SP1	  to	  the	  
predicted	  network,	  the	  literature	  evidence	  of	  involvement	  in	  Parkinson’s,	  dopamine	  
regulation,	  and	  MPTP	  toxicity,	  and	  the	  experimental	  evidence	  of	  interactions	  with	  
known	  signaling	  networks	  (such	  as	  JUN)	  involved	  in	  Parkinson’s	  and	  MPTP,	  SP1	  is	  
likely	  necessary	  (though	  not	  sufficient)	  for	  MPTP	  toxicity	  and	  acts	  to	  integrate	  
multiple	  signaling	  pathways	  in	  a	  combinatorial	  and	  complex	  manner.	  The	  proposed	  
genetic	  regulatory	  network	  offers	  an	  advantage	  compared	  to	  a	  correlation	  network	  
insofar	  as	  it	  offers	  a	  direction	  of	  action,	  an	  estimate	  of	  transcription	  factor	  binding	  
site	  strength,	  multiple	  lines	  of	  evidence,	  and	  an	  estimate	  of	  the	  dynamics	  of	  gene	  
expression.	  Therefore,	  it	  can	  act	  as	  scaffolding,	  which	  further	  experiments,	  both	  in	  
silico	  and	  in	  vitro,	  can	  refine.	  Although	  this	  study	  isolated	  neurons,	  it	  likely	  
benefitted	  from	  capturing	  the	  complex	  interplay	  between	  neurons	  and	  astrocytes,	  
and	  specifically	  the	  inflammatory	  contribution	  of	  astrocytic	  processes.	  	  	  
	   This	  study	  shows	  that	  a	  relatively	  small	  gene	  array	  study	  allows	  for	  the	  
pinpointing	  of	  mechanistic	  information	  by	  a	  combination	  of	  correlative	  and	  data-­‐
mining	  approaches	  and	  can	  suggest	  many	  plausible	  candidates	  for	  further	  study.	  
However,	  any	  data-­‐mining	  approach—especially	  ones	  that	  tend	  to	  generate	  false-­‐
positives—has	  to	  go	  hand-­‐in-­‐hand	  with	  confirmation	  of	  the	  (patho-­‐)physiological	  
sense	  of	  the	  distilled	  information.	  These	  emerging	  approaches	  for	  Pathway	  of	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Toxicity	  identification	  can	  become	  even	  more	  powerful	  when	  several	  orthogonal	  
omics	  technologies	  are	  employed	  and	  different	  experimental	  models	  are	  combined.	  	  	  
Furthermore,	  a	  better	  understanding	  of	  the	  dynamics	  of	  the	  toxic	  process	  can	  
suggest	  a	  better	  experimental	  framework	  to	  investigate	  the	  process	  with	  a	  greater	  
granularity.	  If,	  as	  the	  in	  vitro	  data	  suggested,	  SP1	  is	  an	  early	  sensor	  for	  oxidative	  
stress,	  experiments	  that	  focused	  on	  earlier	  time	  points	  might	  offer	  greater	  insight	  
into	  temporal	  dynamics	  of	  the	  initiating	  events.	  A	  study	  with	  time-­‐matched	  controls	  
(as	  opposed	  to	  this	  study,	  which	  did	  not	  have	  a	  vehicle-­‐treated	  control	  at	  each	  time	  
point)	  might	  offer	  greater	  power	  to	  see	  differences	  of	  treated	  vs	  normal.	  Lastly,	  
using	  a	  complimentary	  technology	  –	  such	  as	  RNA-­‐seq	  –	  would	  offer	  an	  opportunity	  
to	  confirm	  the	  results	  with	  another	  technology,	  and	  at	  the	  same	  time	  would	  have	  the	  
advantage	  of	  offering	  greater	  resolution	  for	  lower	  abundance	  transcripts.	  	  
The	  exploration	  of	  the	  Genetic	  Regulatory	  Network	  was	  aided	  by	  the	  
extensive	  database	  of	  RNAi	  and	  ChIP-­‐seq	  experiments	  that	  target	  SP1,	  and	  building	  
upon	  these	  experiments	  by	  targeting	  other	  candidate	  transcription	  factors	  would	  
likely	  identify	  more	  precisely	  the	  regulatory	  mechanisms	  involved	  downstream	  of	  
SP1,	  especially	  if	  the	  experiments	  were	  performed	  in	  an	  in	  vitro	  neuron	  model.	  
	  If	  nothing	  else,	  this	  study	  has	  indicated	  the	  extant	  to	  which	  our	  knowledge	  of	  
signaling	  networks	  involved	  in	  MPTP	  toxicity	  is	  likely	  limited	  to	  the	  downstream	  
consequences	  of	  damage	  long	  before	  the	  initial	  event	  that	  perturbs	  homeostasis.	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clarity	  in	  the	  data	  can	  result	  in	  a	  profound	  problem	  for	  risk	  assessment	  and	  
regulatory	  toxicology,	  as	  well	  as	  the	  difficulty	  of	  bridging	  experimental	  science	  and	  
traditional,	  regulatory	  toxicology	  testing	  (Borrell,	  2010).	  Endocrine	  disruptors	  
represent	  a	  complex	  physiological	  puzzle	  that	  would	  benefit	  from	  an	  approach	  that	  
uses	  high-­‐content	  data	  on	  a	  human-­‐based	  tissue	  to	  explain	  mechanistically	  precisely	  
how	  endocrine	  disruptors	  cause	  altered	  phenotypes	  (Bouhifd	  et	  al.,	  2014).	  	  
	   At	  the	  same	  time,	  metabolomics	  presents	  many	  challenges.	  The	  fact	  that	  
metabolomics	  is	  ultimately	  very	  close	  to	  the	  phenotype	  turns	  out	  to	  be	  a	  double-­‐
edged	  sword,	  as	  it	  means	  that	  metabolomics	  is	  extraordinarily	  sensitive	  to	  slight	  
changes	  in	  experimental	  parameters,	  and	  it	  requires	  a	  scrupulous	  commitment	  to	  
protocol	  and	  a	  long-­‐term	  commitment	  to	  trouble-­‐shooting	  as	  virtually	  any	  small	  
change—different	  brands	  of	  food	  for	  animals,	  different	  plastic	  plates	  in	  tissue	  
culture—can	  introduce	  artifacts.	  Additionally,	  sample	  preparation	  must	  be	  kept	  to	  a	  
minimum	  as	  every	  step	  has	  the	  potential	  to	  add	  artifacts.	  	  
	   In	  terms	  of	  analytical	  chemistry,	  metabolomics	  presents	  another	  challenge:	  
the	  universe	  of	  metabolites	  consists	  of	  chemicals	  with	  a	  vast	  range	  of	  properties—
there	  are	  approximately	  2,000	  polar	  and	  natural	  lipids,	  500	  class-­‐specific	  
metabolites,	  200	  redox	  metabolites,	  and	  800	  primary	  metabolites—and	  the	  
different	  biochemical	  properties	  precludes	  coverage	  with	  any	  one	  platform,	  e.g.	  
HPLC	  will	  have	  different	  coverage	  than	  gas	  chromatography,	  different	  
chromatography	  columns	  and	  solvent	  gradients	  can	  have	  a	  strong	  ,	  positive	  or	  
negative	  polarity	  will	  ionize	  different	  metabolites,	  etc.	  Therefore,	  while	  untargeted	  
metabolomics	  attempts	  to	  catch	  “all”	  the	  metabolites,	  the	  choice	  of	  platform	  will	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likely	  privilege	  some	  over	  others.	  This	  is	  important	  to	  keep	  in	  mind	  for	  pathway	  
analysis,	  as	  metabolites	  that	  are	  invisible	  to	  a	  specific	  platform	  but	  are	  heavily	  
represented	  on	  a	  pathway	  of	  interest	  may	  skew	  the	  result,	  i.e.	  cells	  treated	  with	  
estrogen	  may	  have	  steroid-­‐specific	  pathways	  up-­‐regulated,	  but	  if	  a	  technology	  does	  
not	  adequately	  capture	  large,	  non-­‐polar	  compounds,	  any	  impact	  on	  that	  pathway	  
may	  be	  difficult	  to	  see.	  	  
	   Furthermore,	  metabolomics,	  unlike	  transcriptomics,	  does	  not	  produce	  a	  list	  
of	  unambiguously	  identified	  “features.”	  Instead,	  it	  depends	  on	  several	  intricate	  steps	  
of	  data	  analysis	  to	  go	  from	  a	  chromatogram	  to	  a	  list	  of	  metabolites	  with	  
concentrations,	  including	  peak	  alignment,	  deconvolution,	  adequate	  identification	  of	  
ions,	  isotopes,	  and	  possible	  adduct	  modifications	  (water,	  sodium,	  or	  other	  small	  
molecules	  that	  may	  be	  bound	  or	  lost	  to/from	  the	  compound	  and	  therefore	  reflected	  
in	  the	  m/z),	  and	  lastly	  (and	  the	  one	  that	  will	  be	  the	  focus	  here),	  accurate	  metabolite	  
identification,	  which	  is	  dependent	  not	  only	  on	  all	  of	  the	  above	  steps,	  but	  also	  on	  the	  
accuracy	  and	  metabolite	  coverage	  provided	  by	  the	  database	  used	  for	  compound	  
identification.	  	  
	   One	  critical	  problem	  for	  metabolomics	  is	  that	  knowledge	  of	  metabolic	  
networks	  is	  still	  relatively	  incomplete,	  the	  databases	  still	  comparatively	  new,	  and	  
the	  data	  infrastructure	  lacking,	  which	  presents	  some	  challenges	  for	  both	  metabolite	  
identification	  and	  pathway	  analysis.	  	  
	   	  Currently,	  there	  are	  several	  public	  databases	  that	  can	  be	  used	  for	  metabolite	  
identification:	  PubChem	  (run	  by	  NCBI),	  ChEBI,	  Metlin,	  and	  HMDB.	  PubChem	  (Y.	  
Wang	  et	  al.,	  2009)	  is	  focused	  on	  acting	  as	  a	  repository	  for	  all	  chemicals	  and	  is	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therefore	  not	  exclusive	  to	  metabolites,	  but	  does	  have	  the	  most	  extensive	  coverage	  of	  
the	  chemical	  universe.	  ChEBI	  (Chemical	  Entities	  of	  Biological	  Interest)	  is	  a	  database	  
of	  ‘small’	  chemical	  compounds	  that	  are	  either	  “products	  of	  nature	  or	  synthetic	  
products	  used	  to	  intervene	  in	  the	  processes	  of	  living	  organisms”	  (Degtyarenko	  et	  al.,	  
2008).	  Metlin	  (Smith	  et	  al.,	  2005)	  is	  exclusively	  focused	  on	  metabolomics	  and	  is	  the	  
only	  database	  to	  match	  precursor	  ions;	  Metlin	  has	  240,493	  metabolites	  and	  is	  the	  
largest	  metabolomics	  database.	  Pubchem,	  Metlin,	  and	  ChEBI	  are	  extensive	  in	  terms	  
of	  coverage	  of	  the	  chemical	  universe,	  but	  may	  match	  too	  many	  compounds	  as	  none	  
of	  them	  are	  exclusive	  to	  humans.	  HMDB	  (Wishart	  et	  al.,	  2013),	  which	  has	  41,828	  
entries,	  is	  focused	  exclusively	  on	  human	  metabolites	  while	  KEGG	  (Kanehisa	  &	  Goto,	  
2000)	  (which	  can	  be	  used	  both	  for	  identification	  and	  pathway-­‐level	  annotations)	  
allows	  filtering	  based	  on	  organism,	  but	  both	  have	  issues	  with	  accuracy	  in	  terms	  of	  
organism	  specificity.	  For	  example,	  both	  Aflatoxin	  G	  (HMDB30474)	  and	  psilocin	  
(HMDB42000)	  are	  identified	  as	  “Endogenous”;	  while	  KEGG	  has	  many	  pathways	  that	  
are	  annotated	  to	  humans	  but	  involve	  metabolites	  not	  endogenous	  (e.g.	  neomyocin	  
and	  byturison	  pathway,	  which	  involve	  bacterial	  synthesis	  of	  antibiotics).	  	  
	   Turning	  to	  the	  sources	  that	  focus	  on	  pathways	  –	  in	  other	  words,	  that	  try	  to	  
place	  metabolites	  into	  known	  reactions,	  -­‐and	  attempt	  to	  provide	  a	  comprehensive	  
map	  (Recon/EHMNM,	  HumanCyc,	  KEGG,	  and	  Reactome),	  here	  is	  remarkably	  little	  
overlap.	  These	  databases	  differ	  in	  size—from	  a	  low	  of	  970	  metabolites	  in	  Recon1	  
(reflecting	  that	  it	  is	  based	  on	  manual	  curation)	  to	  a	  high	  of	  2,676	  metabolites	  for	  the	  
EHMN	  (which	  is	  based	  in	  part	  on	  automated	  annotations)	  (Stobbe	  et	  al.,	  2013).	  
However,	  somewhat	  worryingly,	  there	  is	  a	  striking	  lack	  of	  agreement	  amongst	  the	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databases	  in	  terms	  of	  commonality—the	  five	  main	  databases	  agree	  only	  on	  402	  
metabolites	  (nine	  percent	  of	  the	  total	  metabolites	  in	  the	  different	  databases)	  and	  a	  
full	  3,107	  of	  metabolites	  are	  present	  in	  only	  one	  database	  (See	  Table	  1)	  (Stobbe	  et	  
al.,	  2013).	  	  
	   This	  can	  be	  attributed	  to	  several	  reasons.	  One,	  the	  databases	  may	  have	  
different	  levels	  of	  granularity—for	  example,	  a	  reaction	  may	  include	  all	  associated	  
molecules	  (including	  “currency	  molecules,”	  such	  as	  ATP	  and	  NADH)	  in	  one	  database,	  
but	  another	  database	  may	  focus	  only	  on	  the	  main	  players.	  Two,	  various	  databases	  
were	  started	  with	  different	  aims	  in	  mind	  and	  use	  different	  identifiers—the	  lack	  of	  
database	  interoperability	  makes	  it	  exceedingly	  difficult	  to	  translate	  chemical	  
identifiers	  from	  one	  database	  to	  another,	  because	  of	  the	  lack	  of	  efficient	  ID	  
conversion	  tools,	  the	  complexity	  of	  chemical	  nomenclature,	  and	  the	  difficulty	  in	  
using	  structural-­‐based	  IDs	  such	  as	  InChI	  and	  SMILES	  for	  database	  indexing.	  	  
	  	   Reactions	   Metabolites	  
Union	   6910	   4677	  
Consensus	   206	  (3%)	   402	  (9%)	  
Majority	   1015	  (15%)	   984	  (21%)	  
Unique	   4805	  (70%)	   3107	  (66%)	  
Chapter	  IV,	  Table	  1:	  From	  Consensus	  and	  Conflict	  Database,	  data	  taken	  from	  
http://www.molgenis.org/c2cards/molgenis.do	  
	  
An	  illustration	  of	  the	  different	  perspectives	  is	  provided	  below.	  Both	  estradiol	  
and	  estrone	  were	  present	  in	  all	  databases	  (Tables	  1	  and	  2),	  although	  estradiol	  has	  
three	  different	  names.	  Both	  were	  present	  as	  a	  dead-­‐end	  metabolite	  in	  at	  least	  one	  
database.	  Looking	  at	  the	  reaction	  between	  estrone	  and	  estrone-­‐sulfate	  indicates	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agreement	  on	  the	  EC	  number	  (which	  places	  it	  in	  the	  minority	  of	  relatively	  well	  
documented	  reactions,	  as	  only	  17	  percent	  of	  reactions	  agree	  on	  EC	  number	  in	  all	  
databases),	  with	  slight	  variants	  of	  the	  sulfo-­‐transferase—but	  virtually	  no	  agreement	  
on	  pathway.	  
	  
Metabolite	   Compartment	   Dead-­‐end	  metabolite?	   Database	  
Estradiol	   Null	   No	   KEGG	  
estradiol-­‐
17beta	  
Cytosol	   No	   EHMN	  
estradiol-­‐
17beta	  
ER	   No	   EHMN	  
estradiol-­‐
17beta	  
Uncertain	   No	   EHMN	  
estradiol-­‐
17beta	  
Null	   Yes,	  not	  consumed	   HumanCyc	  
beta-­‐estradiol	   Cytosol	   No	   Reactome	  
Estradiol	   ER	   No	   H.	  sapiens	  
Recon	  1	  
Estradiol	   Cytosol	   No	   H.	  sapiens	  
Recon	  1	  
Estradiol	   Null	   No	   KEGG	  
estradiol-­‐
17beta	  
Cytsosol	   No	   EHMN	  
Chapter	  IV,	  Table	  2:	  Estrogen	  From	  Consensus	  and	  Conflict	  Database,	  ,	  data	  
taken	  from	  http://www.molgenis.org/c2cards/molgenis.do	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Metabolite	   Compartment	   Dead-­‐end	  metabolite?	   Database	  
Estrone	   Null	   No	   KEGG	  
Estrone	   Uncertain	   Yes,	  not	  produced	   EHMN	  
Estrone	   Cytosol	   No	   EHMN	  
Estrone	   ER	   No	   EHMN	  
Estrone	   Golgi	   No	   EHMN	  
Estrone	   Lysosome	   No	   EHMN	  
Estrone	   Null	   No	   HumanCyc	  
Estrone	   Cytosol	   No	   Reactome	  
Estrone	   ER	   No	   H.	  sapiens	  
Recon	  1	  
Estrone	   Cytosol	   No	   H.	  sapiens	  
Recon	  1	  
Chapter	  IV,	  Table	  3:	  Estrone,	  From	  Consensus	  and	  Conflict	  Database,	  data	  
taken	  from	  http://www.molgenis.org/c2cards/molgenis.do	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that	  compounds	  the	  variability	  of	  high-­‐content	  results.	  The	  MCF-­‐7	  cell	  line	  (a	  human	  
breast	  cancer	  epithelial	  derived	  tissue	  line)	  was	  originally	  selected	  as	  it	  is	  a	  fairly	  
well-­‐studied	  in	  vitro	  system,	  and	  has	  multiple	  published	  datasets	  with	  genomic,	  
epigenomic,	  transcriptomic,	  and	  proteomic	  data	  widely	  available.	  However,	  the	  
many	  different	  experimental	  settings	  and	  published	  results	  can	  vary	  significantly,	  
even	  if	  looking	  at	  the	  same	  treatment	  (e.g.	  17β-­‐estradiol)—owing	  to	  different	  
analysis	  and	  normalization	  methods,	  different	  experimental	  aims,	  the	  high	  rate	  of	  
false	  positives	  in	  high-­‐throughput	  data—but	  also,	  the	  intrinsic	  biological	  variability	  
of	  the	  system.	  Nonetheless,	  in	  microarray	  studies,	  while	  the	  specific	  composition	  of	  
gene	  lists	  from	  different	  studies	  shows	  poor	  overlap	  at	  a	  gene-­‐by-­‐gene	  level,	  they	  
often	  coincide	  at	  the	  pathway	  level	  (Beltrame	  et	  al.,	  2009).	  Therefore,	  one	  
expectation	  	  for	  metabolomics	  studies	  was	  that	  inferential	  statistics—looking	  for	  
reproducibility	  at	  the	  level	  of	  fold-­‐change	  for	  individual	  metabolites—might	  not	  be	  
of	  much	  use	  given	  the	  noise	  in	  the	  analytical	  method	  and	  the	  variability	  in	  the	  
biological	  system,	  and	  that	  a	  pathway	  approach	  would	  likely	  be	  necessary	  as	  it	  
should	  in	  theory	  be	  less	  sensitive	  to	  noise,	  although	  this	  is	  assumption	  is	  predicted	  
on	  a	  well-­‐elucidated	  pathways.	  	  
	   In	  summary,	  metabolomics	  lacks	  the	  large-­‐scale,	  integrated	  databases	  that	  
have	  been	  crucial	  to	  the	  analysis	  of	  transcriptomic	  and	  proteomic	  data:	  specifically,	  
it	  lacks	  databases	  such	  as	  Entrez	  and	  Uniprot	  that	  have	  established	  an	  agreed	  upon	  
naming	  scheme,	  a	  high-­‐level	  of	  database	  curation	  such	  as	  that	  provided	  by	  the	  NCBI	  
to	  ensure	  accuracy,	  robust	  web	  services	  to	  translate	  identifiers,	  and	  publicly	  
available	  data	  sets	  (similar	  to	  the	  ones	  provided	  by	  GEO)	  to	  allow	  benchmarking	  of	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data	  analysis	  methodologies,	  since,	  much	  like	  the	  early	  years	  of	  microarrays,	  there	  
are	  still	  no	  established	  methods	  to	  interpret	  data	  (Griffin,	  2006).	  In	  summary,	  while	  
metabolomics	  can	  theoretically	  measure	  everything,	  this	  is	  also	  a	  pitfall,	  especially	  if	  
everything	  cannot	  be	  accurately	  labeled.	  
2.	   Materials	  and	  Methods	  
2.1	  Data:	  This	  analysis	  is	  based	  on	  three	  different	  sets	  of	  experiments	  that	  
were	  performed	  on	  MCF-­‐7	  cells.	  All	  studies	  used	  cells	  with	  a	  limited	  passage	  number	  
(and	  in	  studies	  which	  focused	  on	  inter-­‐	  or	  intra-­‐laboratory	  reproducibility,	  passage	  
number	  was	  harmonized	  as	  far	  as	  possible	  between	  the	  experiments).	  All	  cells	  were	  
serum	  starved	  before	  dosing	  and	  charcoal-­‐stripped	  media	  was	  used	  (See	  Figure	  1	  
for	  Experiment	  Setup).	  
	  
	  
Chapter	  VI,	  Figure	  1:	  Experiment	  Setup.	  Figure	  from	  (Bouhifd	  et	  al.,	  2014)	  
	  
Study	  1:	  A	  time	  and	  dose-­‐response	  curve	  with	  4	  biological	  replicates	  at	  0,	  2,	  
4,	  8,	  and	  24	  hours,	  and	  doses	  of	  0,	  .001,	  .01,	  .1,	  and	  1	  nm	  estrogen	  (17-­‐beta-­‐
estradiol)	  at	  each	  time	  point.	  Metabolites	  were	  extracted	  via	  methanol	  and	  HPLC-­‐MS	  
was	  performed	  on	  an	  Agilent	  QTOF	  6520	  with	  a	  range	  of	  100-­‐1100	  M/z	  and	  
metabolite	  identification	  performed	  via	  a	  recursive	  algorithm	  using	  Agilent	  
Masshunter	  b.05.	  Masshunter	  identifies	  metabolites	  based	  on	  the	  amount	  of	  
isotopes	  and	  ions	  detected	  and	  establishes	  a	  quality	  score	  that	  requires	  70	  out	  of	  
100	  points	  to	  establish	  a	  true	  metabolite.	  Metabolite	  identification	  was	  based	  on	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both	  an	  original	  library	  based	  largely	  on	  KEGG	  metabolites	  annotated	  as	  human	  
(“KEGG	  Library”),	  and	  an	  additional,	  custom-­‐built	  library	  based	  on	  HMDB	  and	  SMPD	  
to	  eliminate	  incorrectly	  identified	  metabolites	  (“HMDB	  Library”).	  	  
	   Studies	  2	  and	  3:	  Same	  time,	  dose-­‐response	  curve,	  and	  biological	  replicates	  as	  
Study	  1,	  and	  performed	  at	  Johns	  Hopkins	  and	  Brown	  University	  to	  study	  inter-­‐
laboratory	  variability.	  Data	  analysis	  was	  done	  using	  Agilent	  Masshunter	  workflow	  
and	  the	  KEGG	  Library.	  
	   Studies	  4	  and	  5:	  Identical	  studies	  were	  both	  performed	  at	  Johns	  Hopkins	  two	  
weeks	  apart	  using	  0	  and	  1	  nm	  estrogen	  at	  4	  and	  24	  hours	  to	  compare	  intra-­‐
laboratory	  reproducibility,	  analyzed	  with	  Agilent	  Masshunter	  workflow.	  The	  same	  
data	  were	  later	  analyzed	  using	  XCMS	  (Gowda	  et	  al.,	  2014)	  for	  comparison	  of	  log-­‐fold	  
changes	  between	  0	  and	  1	  nm	  estrogen	  at	  both	  time	  points	  and	  metabolite	  
identification	  was	  performed	  based	  on	  Mummichog	  (Li	  et	  al.,	  2013).	  	  	  
2.2	  Data	  Analysis:	  	  All	  preprocessing	  was	  done	  using	  Metaboanalyst	  (Xia,	  
Mandal,	  Sinelnikov,	  Broadhurst,	  &	  Wishart,	  2012);	  metabolites	  with	  more	  than	  50	  
percent	  missing	  values	  were	  removed	  and	  missing	  data	  was	  imputed	  using	  k-­‐
nearest	  neighbors.	  Data	  was	  filtered	  using	  interquartile	  range	  and	  normalized	  via	  
log	  transformation	  and	  Pareto	  scaling.	  MSEA	  (Metabolite	  Set	  Enrichment	  Analysis)	  
was	  performed	  using	  Metaboanalyst	  (Xia	  &	  Wishart,	  2010).	  	  
	   In	  addition	  to	  Metaboanalyst/MSEA,	  the	  following	  were	  used	  for	  metabolite	  
enrichment	  analysis:	  IMPaLA	  (Kamburov,	  Cavill,	  Ebbels,	  Herwig,	  &	  Keun,	  2011),	  
which	  analyzes	  based	  on	  pathways	  from	  SMPD,	  KEGG,	  and	  REACTOME,	  and	  MBRole,	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which	  offers	  the	  additional	  option	  of	  analyzing	  for	  chemical	  class	  (Chagoyen	  &	  
Pazos,	  2011).	  	  
	   WGCNA:	  A	  weighted	  correlation	  network	  was	  built	  using	  the	  WGCNA	  
package	  (Langfelder	  &	  Horvath,	  2008)	  based	  on	  an	  unsigned	  Spearman	  rank	  
correlation	  transformed	  via	  a	  weighting	  function	  with	  the	  weight	  set	  to	  7	  (for	  
details,	  see	  Chapter	  Five,	  Materials	  and	  Methods).	  Clustering	  was	  done	  based	  on	  the	  
Dynamic	  Tree	  Cut	  algorithm	  (Langfelder	  et	  al.,	  2008)	  with	  deepsplit	  set	  to	  3	  (based	  
on	  a	  1-­‐4	  scale	  of	  how	  sensitive	  the	  algorithm	  is	  to	  selecting	  modules;	  3	  was	  chosen	  
to	  give	  fairly	  small,	  precise	  modules),	  a	  minimum	  module	  size	  of	  10,	  and	  modules	  
with	  a	  distance	  of	  less	  than	  .25	  merged.	  	  	  
3.	   Results	  and	  Discussion	  
3.1	  QEA	  COMPARED	  TO	  ORA:	  The	  Metaboanalyst	  platform	  for	  Metabolite	  
Set	  Enrichment	  Analysis	  was	  used	  for	  both	  over-­‐representation	  analysis	  (ORA)	  and	  
Quantitative	  Set	  Enrichment	  Analysis	  (QEA)	  (Xia	  &	  Wishart,	  2010).	  ORA	  analyzes	  
whether	  a	  given	  metabolite	  set	  identified	  as	  statistically	  significant	  from	  an	  
experiment	  is	  over-­‐represented	  in	  a	  given	  pathway	  compared	  to	  an	  expected	  value	  
based	  on	  the	  size	  of	  the	  pathway	  and	  assuming	  a	  hypergeometric	  distribution,	  after	  
correcting	  for	  a	  false	  discovery	  rate	  (FDR).	  The	  other	  approach,	  QEA,	  is	  based	  on	  the	  
“global	  test”	  algorithm	  (Goeman,	  van	  de	  Geer,	  de	  Kort,	  &	  van	  Houwelingen,	  2004),	  
commonly	  used	  for	  microarray	  experiments,	  to	  perform	  enrichment	  analysis	  
directly	  from	  normalized	  concentration	  data.	  “Global	  test”	  was	  originally	  created	  to	  
examine	  associations	  between	  gene	  sets	  and	  clinical	  outcomes,	  but	  it	  has	  been	  used	  
extensively	  for	  microarray	  data	  and	  adapted	  for	  multiclass	  and	  continuous	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phenotypes.	  It	  uses	  a	  generalized	  linear	  model	  to	  compute	  a	  ‘Q-­‐stat’	  for	  each	  gene	  
set,	  using	  the	  average	  of	  the	  squared	  covariance	  between	  the	  expression	  level	  of	  the	  
genes	  (or,	  in	  the	  case	  of	  metabolomics,	  concentration)	  and	  the	  label.	  MSEA	  includes	  
appropriate	  methods	  to	  adjust	  for	  the	  multiple	  testing	  problems	  that	  occur	  during	  
enrichment	  analysis	  (e.g.	  Benjamini	  and	  Hochberg	  FDR).	  	  
	   For	  ORA,	  each	  dose-­‐response	  curve	  at	  a	  given	  time	  point	  was	  analyzed	  via	  
one-­‐way	  ANOVA	  and	  all	  metabolites	  identified	  as	  significant	  (p-­‐value	  less	  than	  .05)	  
were	  used	  for	  ORA.	  The	  8-­‐hour	  dose–response	  curve	  had	  the	  most	  significant	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GALACTOSE	  
METABOLISM	   25	   3	   17.884	   4.747	   0.00007521	   0.0038357	   0.00054516	  
RIBOFLAVIN	  
METABOLISM	   9	   2	   26.779	   4.7497	   0.000076513	   0.0038357	   0.00054516	  
CITRIC	  ACID	  CYCLE	   23	   3	   24.227	   4.7516	   0.000088921	   0.0043571	   0.00056316	  
PYRUVATE	  
METABOLISM	   20	   3	   16.02	   4.7251	   0.00011023	   0.005291	   0.00057284	  
ARGININE	  AND	  
PROLINE	  
METABOLISM	   26	   3	   17.719	   4.7436	   0.00011055	   0.005291	   0.00057284	  
TRYPTOPHAN	  
METABOLISM	   34	   4	   14.174	   4.7234	   0.00012847	   0.0059097	   0.00061024	  
GLYCEROL	  
PHOSPHATE	  SHUTTLE	   8	   1	   28.356	   4.7514	   0.00014766	   0.0066449	   0.00064745	  
GLUCONEOGENESIS	   27	   2	   16.178	   4.7221	   0.0001619	   0.0071235	   0.00065915	  
VITAMIN	  B6	  
METABOLISM	   10	   4	   17.59	   4.7417	   0.00018373	   0.0079004	   0.00067927	  
SULFATE/SULFITE	  
METABOLISM	   7	   3	   17.202	   4.7436	   0.00019067	   0.0080082	   0.00067927	  
ANDROGEN	  AND	  
ESTROGEN	  
METABOLISM	   17	   1	   26.767	   4.7501	   0.00024094	   0.0098787	   0.00080787	  
PROTEIN	  
BIOSYNTHESIS	   19	   5	   20.811	   4.745	   0.00026683	   0.010673	   0.00084496	  
PHENYLALANINE	  
AND	  TYROSINE	  
METABOLISM	   13	   1	   23.606	   4.7424	   0.00030036	   0.011714	   0.00090108	  
AMINO	  SUGAR	  
METABOLISM	   15	   2	   21.09	   4.7456	   0.00040019	   0.015207	   0.0010645	  
METHIONINE	  
METABOLISM	   24	   1	   22.913	   4.7419	   0.00041087	   0.015207	   0.0010645	  
BETAINE	  
METABOLISM	   10	   1	   22.913	   4.7419	   0.00041087	   0.015207	   0.0010645	  
BILE	  ACID	  
BIOSYNTHESIS	   49	   5	   16.063	   4.7502	   0.00061413	   0.021494	   0.0014611	  
UREA	  CYCLE	   20	   1	   19.698	   4.7363	   0.00061522	   0.021494	   0.0014611	  
BIOTIN	  METABOLISM	   4	   1	   22.506	   4.745	   0.00074133	   0.024464	   0.0016902	  
ALANINE	  
METABOLISM	   6	   1	   21.589	   4.7404	   0.00090323	   0.028903	   0.0019802	  
PURINE	  METABOLISM	   45	   5	   13.677	   4.7404	   0.0010959	   0.033973	   0.0023136	  
BETA	  OXIDATION	  OF	  
VERY	  LONG	  CHAIN	  
FATTY	  ACIDS	   14	   1	   20.626	   4.7406	   0.0011527	   0.034582	   0.0023466	  
GLYCOLYSIS	   21	   1	   15.358	   4.723	   0.001318	   0.038221	   0.0025042	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RETINOL	  
METABOLISM	   18	   1	   15.358	   4.723	   0.001318	   0.038221	   0.0025042	  
ASPARTATE	  
METABOLISM	   12	   3	   14.097	   4.7467	   0.0015295	   0.041297	   0.0028124	  
STARCH	  AND	  
SUCROSE	  
METABOLISM	   14	   2	   13.909	   4.733	   0.0020946	   0.05446	   0.003731	  
GLYCINE,	  SERINE	  AND	  
THREONINE	  
METABOLISM	   26	   3	   12.683	   4.7479	   0.0025548	   0.063869	   0.0044128	  
UBIQUINONE	  
BIOSYNTHESIS	   10	   1	   19.619	   4.7497	   0.0035558	   0.085338	   0.0059611	  
CYSTEINE	  
METABOLISM	   8	   1	   18.486	   4.7441	   0.0040482	   0.093108	   0.0065927	  
THIAMINE	  
METABOLISM	   4	   1	   16.784	   4.7428	   0.0073103	   0.16083	   0.011575	  
BETA-­‐ALANINE	  
METABOLISM	   13	   5	   10.116	   4.7464	   0.0081177	   0.17047	   0.012506	  
NUCLEOTIDE	  SUGARS	  
METABOLISM	   9	   3	   11.733	   4.7395	   0.0088294	   0.17659	   0.013244	  
LYSINE	  
DEGRADATION	   13	   1	   16.069	   4.7422	   0.0096781	   0.18388	   0.014145	  
PYRIMIDINE	  
METABOLISM	   36	   7	   10.212	   4.7462	   0.010089	   0.18388	   0.014376	  
GLUCOSE-­‐ALANINE	  
CYCLE	   12	   1	   12.951	   4.742	   0.031162	   0.52975	   0.042291	  
MALATE-­‐ASPARTATE	  
SHUTTLE	   8	   1	   12.951	   4.742	   0.031162	   0.52975	   0.042291	  
Chapter	  IV,	  Table	  5:	  Experiment	  1,	  QEA	  24-­‐Hour	  Dose–Response	  Curve.	  	  
	  
On	  the	  one	  hand,	  QEA	  appeared	  to	  have	  identified	  pathways	  at	  each	  time	  
point,	  indicating	  the	  presence	  of	  a	  dose	  response,	  but	  the	  shifts	  in	  pathways	  over	  
time	  do	  not	  tell	  a	  consistent	  biological	  story.	  More	  worrisomely,	  as	  can	  be	  seen	  in	  
Table	  5,	  many	  of	  the	  most	  significant	  pathways	  had	  relatively	  few	  metabolites	  
mapped	  to	  the	  pathway,	  and	  in	  some	  cases	  only	  one—meaning	  that	  a	  single	  
misidentified	  metabolite	  could	  be	  significantly	  skewing	  the	  results,	  and	  the	  pathway	  
with	  the	  largest	  hits	  (caffeine	  metabolism,	  with	  four	  metabolites)	  represents	  a	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pathway	  not	  informative	  for	  this	  study	  and	  probably	  contains	  misidentified	  
metabolites.	  	  
ORA	  and	  QEA	  have	  been	  utilized	  in	  metabolomics	  without	  necessarily	  taking	  
into	  consideration	  some	  of	  the	  problems	  of	  metabolomic	  data.	  While	  microarrays	  
present	  a	  data	  set	  where	  all	  the	  discrete	  features	  are	  labeled	  unambiguously	  at	  the	  
outset	  and	  all	  discrete	  features	  have	  an	  assigned	  value,	  in	  the	  case	  of	  metabolomic	  
data,	  due	  to	  the	  nature	  of	  the	  technology,	  no	  experiment	  can	  possibly	  identify	  a	  
complete	  set	  of	  metabolites;	  of	  those	  identified	  as	  discrete,	  not	  all	  can	  be	  assigned	  
an	  identity	  precisely.	  Of	  those	  assigned	  an	  identity,	  relatively	  few	  are	  annotated	  with	  
pathway	  information.	  Moreover,	  the	  missing	  metabolites	  may	  not	  be	  missing	  at	  
random,	  but	  may	  reflect	  a	  chemical	  class.	  As	  a	  consequence,	  at	  the	  same	  time	  ORA	  
and	  QEA	  have	  a	  substantial	  loss	  of	  information	  (because	  of	  the	  non-­‐mapped	  
pathways),	  they	  also	  have	  the	  potential	  to	  be	  inaccurate	  due	  to	  a	  small	  number	  of	  
misidentified	  metabolites.	  
	   Additionally,	  all	  annotation-­‐based	  statistical	  tests	  are	  predicated	  on	  an	  
accurate	  assumption	  of	  the	  “background”—that	  is,	  the	  total	  number	  of	  pathways	  
and	  metabolites	  possible.	  Generally,	  the	  assumed	  background	  is	  the	  number	  of	  total	  
metabolites	  in	  pathways;	  restricting	  it	  to	  the	  background	  of	  all	  metabolites	  
identified	  in	  the	  experiment	  (945)	  diminishes	  or	  eliminates	  the	  statistical	  
significance.	  It	  is	  difficult	  to	  know	  which	  contributes	  more	  to	  the	  error—non-­‐
random,	  missing	  data	  or	  an	  incorrect	  assumption	  about	  background	  size.	  
	   Furthermore,	  analyzing	  the	  pathways	  over-­‐represented	  in	  the	  total	  number	  
of	  metabolites	  identified	  in	  the	  experiment	  pointed	  to	  some	  other	  causes	  for	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concern.	  One,	  when	  analyzed	  via	  IMPaLA	  (a	  platform	  which	  can	  combined	  multiple	  
metabolite	  pathway	  databases	  for	  ORA),	  there	  appeared	  to	  be	  a	  significant	  pathway	  
bias	  in	  the	  identification	  process,	  and	  of	  the	  top	  three	  pathways	  identified	  as	  over-­‐
represented,	  two	  pathways	  (“Butirosin	  and	  neomycin	  biosynthesis”	  and	  “Drug	  
metabolism”)	  were	  not	  pathways	  that	  should	  have	  been	  seen	  in	  this	  sample	  and	  
likely	  indicate	  misidentified	  metabolites.	  Furthermore,	  of	  the	  945	  metabolites	  
identified,	  only	  468	  were	  mapped	  via	  IMPaLA	  to	  pathways.	  A	  small	  sample	  taken	  at	  
random	  of	  the	  remaining	  477	  non-­‐mapped	  metabolites	  were	  manually	  checked	  for	  
biological	  significance,	  and	  the	  non-­‐mapped	  metabolites	  in	  the	  sample	  consisted	  of	  
either	  plant	  of	  bacterial	  metabolites	  that	  were	  not	  likely	  candidates	  to	  be	  present	  in	  
MCF-­‐7	  cells.	  A	  manual	  inspection	  of	  the	  468	  mapped	  metabolites	  confirmed	  the	  
results	  of	  the	  over-­‐representation	  analysis—there	  were	  several	  compounds	  (e.g.	  
chlorophyll)	  that	  were	  misidentified	  metabolites;	  based	  on	  a	  small	  subsample,	  the	  
error	  rate	  was	  estimated	  to	  be	  at	  least	  10	  percent.	  Notably,	  of	  the	  library	  used	  to	  
identify	  the	  metabolites,	  of	  the	  4,128,	  only	  2,573	  were	  mapped	  to	  pathways	  via	  
IMPaLA.	  Given	  the	  likely	  error	  rate	  that	  this	  indicates	  in	  metabolite	  identification,	  
this	  makes	  the	  results	  of	  QEA	  highly	  suspect.	  	  
	  
Pathway	   Source	   #	  Metabolites	   Pathway	  
(Background)	  
p-­‐value	   q-­‐value	  
Transport	  of	  vitamins,	  
nucleosides,	  and	  related	  molecules	  
Reactome	   25	   63	  (64)	   1.52E-­‐07	   0.000525	  
Butirosin	  and	  neomycin	  
biosynthesis	  -­‐	  Homo	  sapiens	  
(human)	  
KEGG	   15	   29	  (29)	   8.57E-­‐07	   0.00148	  
Drug	  metabolism	  -­‐	  cytochrome	   KEGG	   29	   88	  (88)	   1.59E-­‐06	   0.00183	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P450	  -­‐	  Homo	  sapiens	  (human)	  
Chapter	  IV,	  Table	  6:	  Pathways	  Returned	  by	  IMPaLA	  for	  All	  Metabolites	  
Identified	  in	  Sample	  
	  
In	  order	  to	  investigate	  the	  depedency	  of	  the	  results	  on	  the	  library	  and	  
improve	  the	  number	  of	  human	  specific	  results,	  the	  library	  used	  to	  identify	  the	  
metabolites,	  we	  created	  an	  alternative	  library	  based	  on	  all	  metabolites	  marked	  as	  
endogenous	  in	  HMDB—2,415	  metabolites	  total.	  Some	  obvious	  errors	  were	  removed	  
(recognizable	  drug	  and	  pesticide	  names),	  and	  the	  library	  was	  checked	  for	  
completeness	  against	  the	  SMPD	  database;	  any	  non-­‐disease	  related	  pathways	  with	  
more	  than	  15	  metabolites	  but	  only	  50	  percent	  pathway	  coverage	  were	  manually	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improved	  plausibility	  (see	  Figures	  7	  and	  8).	  In	  the	  pathways	  identified	  as	  significant,	  
all	  but	  one	  pathway	  (biotin,	  which	  has	  only	  four	  metabolites	  for	  the	  entire	  pathway)	  
had	  more	  than	  two	  metabolites	  in	  the	  pathways.	  (See	  Table	  7).	  The	  results	  were	  
therefore	  far	  less	  sensitive	  to	  a	  single	  misidentification.	  
	  
	   Total	  
Cmpd	  
Hits	   Statistic	  Q	   Expected	  
Q	  
Raw	  p	   Holm	  p	   FDR	  
LYSINE	  DEGRADATION	   13	   2	   40.375	   5.8824	   9.32E-­‐06	   0.00058718	   0.00031832	  
STEROID	  BIOSYNTHESIS	   31	   5	   35.658	   5.8824	   1.01E-­‐05	   0.00062654	   0.00031832	  
RETINOL	  METABOLISM	   18	   3	   38.127	   5.8824	   8.16E-­‐05	   0.0049748	   0.0017126	  
ANDROGEN	  AND	  ESTROGEN	  
METABOLISM	  
17	   6	   20.182	   5.8824	   0.00064549	   0.038729	   0.010166	  
SELENOAMINO	  ACID	  
METABOLISM	  
15	   7	   21.137	   5.8824	   0.00086838	   0.051235	   0.010942	  
PANTOTHENATE	  AND	  COA	  
BIOSYNTHESIS	  
10	   5	   23.82	   5.8824	   0.0011924	   0.069162	   0.012521	  
BIOTIN	  METABOLISM	   4	   1	   47.505	   5.8824	   0.0015558	   0.088682	   0.014002	  
RIBOFLAVIN	  METABOLISM	   9	   3	   26.836	   5.8824	   0.0018759	   0.10505	   0.014773	  
TYROSINE	  METABOLISM	   38	   7	   19.31	   5.8824	   0.0031746	   0.1746	   0.020541	  
NICOTINATE	  AND	  
NICOTINAMIDE	  METABOLISM	  
13	   6	   21.818	   5.8824	   0.0032889	   0.1776	   0.020541	  
BILE	  ACID	  BIOSYNTHESIS	   49	   15	   23.017	   5.8824	   0.0035864	   0.19008	   0.020541	  
ARGININE	  AND	  PROLINE	  
METABOLISM	  
26	   4	   26.519	   5.8824	   0.0042354	   0.22024	   0.022236	  
BETA	  OXIDATION	  OF	  VERY	  
LONG	  CHAIN	  FATTY	  ACIDS	  
14	   1	   36.141	   5.8824	   0.0083187	   0.42425	   0.040314	  
GLYCEROLIPID	  METABOLISM	   13	   5	   19.304	   5.8824	   0.0093868	   0.46934	   0.04224	  
PURINE	  METABOLISM	   45	   12	   14.601	   5.8824	   0.010473	   0.51319	   0.043988	  
GLUTATHIONE	  METABOLISM	   10	   3	   22.619	   5.8824	   0.011318	   0.54328	   0.044566	  
UREA	  CYCLE	   20	   3	   19.682	   5.8824	   0.01216	   0.57152	   0.045064	  
PYRIMIDINE	  METABOLISM	   36	   14	   12.577	   5.8824	   0.012887	   0.59279	   0.045104	  
Chapter	  IV,	  Table	  7:	  Experiment	  1,	  8-­‐Hour	  Time	  Point,	  HMDB	  Library	  QEA	  
	  
On	  the	  other	  hand,	  of	  the	  1,025	  metabolites	  identified	  in	  the	  sample,	  only	  484	  
were	  mapped	  to	  pathways	  in	  IMPaLA—so	  while	  the	  improved	  library	  may	  have	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increased	  the	  likelihood	  of	  identifying	  valid	  metabolites,	  it	  did	  not	  substantially	  
increase	  the	  ability	  to	  use	  pathway-­‐based	  annotations	  for	  data	  analysis.	  
Furthermore,	  while	  the	  second	  library	  likely	  eliminated	  some	  misidentifications,	  
there	  is	  no	  certainty	  that	  it	  produced	  more	  accurate	  metabolite	  identification,	  as	  
that	  would	  require	  the	  verification	  of	  metabolite	  identity	  with	  another	  technology	  
(such	  as	  MS/MS,	  which	  allows	  a	  more	  precise	  identification	  based	  on	  
fragmentation).	  	  
3.2	  Correlation	  Approach:	  Because	  of	  the	  concern	  about	  annotation-­‐
dependent	  approaches,	  an	  unsupervised,	  non-­‐annotation	  based	  approach	  was	  used	  
to	  cluster	  the	  metabolites	  identified	  in	  experiment	  1	  via	  the	  HMDB	  library.	  The	  
WGCNA	  package	  appeared	  to	  cluster	  the	  metabolites	  into	  distinct	  modules	  (Figure	  
9).	  However,	  the	  network	  (based	  on	  topological	  overlap	  metric)	  was	  much	  more	  
dense	  than	  is	  typically	  seen	  with	  microarray	  data,	  which	  typically	  produces	  a	  
network	  with	  more	  distinct,	  non-­‐overlapping	  modules.	  This	  likely	  reflects	  the	  
difficulty	  of	  clustering	  metabolomics	  data	  compared	  to	  microarray	  data	  as	  
metabolites	  are	  intrinsically	  more	  correlated	  (Figure	  10).	  Five	  of	  the	  modules	  were	  
correlated	  with	  time	  or	  dose	  with	  a	  p-­‐value	  of	  less	  than	  .01,	  once	  again	  indicating	  
the	  presence	  of	  a	  dose-­‐response.	  However,	  the	  module	  with	  the	  highest	  correlation	  
for	  time	  and	  dose	  (the	  Red	  module)	  was	  not	  significantly	  over-­‐represented	  for	  
metabolites	  in	  a	  pathway;	  in	  fact,	  only	  two	  of	  the	  20	  metabolites	  could	  be	  mapped	  to	  
a	  pathway,	  and	  all	  modules	  had	  fewer	  than	  50	  percent	  of	  the	  metabolites	  mapped	  to	  
a	  pathway.	  Despite	  this,	  the	  Blue	  and	  Black	  modules	  did	  have	  a	  statistically	  
significant	  over-­‐representation,	  indicating	  that	  the	  method	  does	  appear	  to	  group	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similar	  metabolites	  together.	  However,	  attempts	  to	  characterize	  the	  identity	  of	  the	  
unmapped	  metabolites	  were	  not	  successful,	  as	  many	  of	  them	  were	  dipeptides	  or	  
seemed	  unlikely	  candidates,	  and	  clustering	  the	  modules	  by	  chemical	  similarity	  did	  
not	  indicate	  that	  similar	  chemicals	  were	  clustering	  together.	  For	  this	  application,	  
there	  did	  not	  appear	  to	  be	  enough	  information	  for	  the	  modules	  to	  be	  characterized,	  
the	  identity	  of	  the	  members	  verified,	  or	  the	  biological	  significance	  understood.	  	  	  
	  	  
Chapter	  IV,	  Figure	  9:	  Dendrogram	  based	  on	  WGCNA	  
	  
Legend,	  Figure	  9:	  WGCNA	  appeared	  to	  cluster	  the	  metabolites	  into	  distinct	  
branches;	  modules	  indicated	  by	  color.	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Chapter	  IV,	  Figure	  10:	  Metabolites	  clustered	  by	  Topological	  Overlap	  Metric	  
and	  colored	  by	  module.	  	  
Legend,	  Figure	  10:	  Metabolites	  formed	  a	  fairly	  dense	  network;	  metabolites	  not	  
assigned	  to	  a	  module	  are	  in	  grey.	  	  
	  
Module	   R	   p-­‐value	   R	   p-­‐value	  
Red	   0.377	   0.0000936	   0.44	   0.000357	  
Black	   0.006	   0.947	   0.23	   0.0153	  
Blue	   0.21	   0.031	   0.19	   0.0455	  
Brown	   0.18	   0.006	   0.24	   0.00148	  
Pink	   0.23	   0.00186	   0.05	   0.549	  
Green	   0.1	   0.281	   0.07	   0.475	  
Turquoise	   0.005	   0.964	   0.23	   0.0177	  
Chapter	  IV,	  Table	  8:	  Modules	  Correlated	  with	  Time	  and	  Dose	  
	  
Module	   p-­‐value	   adjusted	  
p-­‐value	  
Blue	   	   	  
Bile	  Acid	  Biosynthesis	   2.24E-­‐06	   3.39E-­‐05	  
Steroidogenesis	   2.24E-­‐03	   1.05E-­‐02	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Arachidonic	  Acid	  Metabolism	   9.41E-­‐04	   6.59E-­‐03	  
Black	  	   	  
Riboflavin	   2.23E-­‐03	   1.12E-­‐02	  
Red	   	   	  
Tauraine	  and	  Hypotaurine	  
Metabolism	  
1.56E-­‐02	   1.87E-­‐01	  
Brown	   	   	  
Vitamin	  B6	  Metabolism	   4.35E-­‐02	   2.60E-­‐01	  
Arginine	  and	  Proline	  Metabolism	   4.35E-­‐03	   2.60E-­‐01	  
Glutathione	  Metabolism	   3.25E-­‐02	   2.60E-­‐01	  
Chapter	  IV,	  Table	  9:	  Modules	  annotated	  via	  MBRole	  
	  
3.3	  Variability	  and	  Reproducibility:	  Some	  insight	  into	  the	  possible	  source	  
of	  difficulty	  came	  to	  light	  when	  analyzing	  two	  studies	  that	  had	  been	  done	  under	  
identical	  conditions	  two	  weeks	  apart	  in	  the	  same	  laboratory	  (Experiments	  4	  and	  5)	  
and	  two	  studies	  done	  to	  examine	  inter-­‐laboratory	  reproducibility	  (Experiments	  2	  
and	  3).	  	  
The	  studies	  initially	  showed	  no	  overlap	  when	  analyzed	  by	  inferential	  
statistics	  at	  each	  time-­‐point’s	  dose	  response	  when	  analyzed	  by	  ANOVA.	  
Furthermore,	  there	  was	  no	  overlap	  when	  QEA	  was	  performed	  on	  the	  dose–response	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the	  X	  variables	  and	  the	  Y	  labels.	  	  
	   	  
Chapter	  VI,	  Figure	  13:	  Experiments	  4	  and	  5	  (0	  and	  1	  nm	  estrogen,	  24	  Hours)	  
PLS,	  2-­‐D	  plot	  
	   	  
Chapter	  IV,	  Figure	  14:	  Experiments	  2	  and	  3	  (Dose–Response	  Curve,	  24	  Hours),	  
3-­‐D	  plot	  
	  
In	  both	  cases,	  PLS	  appeared	  to	  offer	  some	  separation	  of	  the	  samples.	  PLS	  
models	  can	  be	  affected	  by	  systematic	  variation	  between	  two	  samples,	  and	  one	  
caveat	  of	  PLS	  is	  that	  it	  is	  prone	  to	  over-­‐fitting;	  the	  dose–response	  separation	  
observed	  cannot	  be	  taken	  ipso	  facto	  as	  evidence	  of	  a	  robust	  dose–response	  effect.	  
Compared)to)Agilent))PLSDA))09)
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The	  key	  finding,	  however,	  was	  when	  examining	  the	  variable	  importance—the	  
metabolites	  that	  contributed	  to	  dose	  separation.	  In	  each	  case,	  there	  was	  minimal	  
overlap	  of	  the	  top	  100	  metabolites	  that	  contributed	  to	  dose	  separation:	  only	  35	  
metabolites	  were	  present	  in	  both	  samples;	  several	  of	  the	  top	  metabolites	  that	  
contributed	  to	  the	  dose-­‐separation	  were	  plant	  metabolites	  or	  drugs.	  In	  other	  words,	  
despite	  being	  the	  same	  cells	  with	  the	  same	  treatment,	  even	  a	  fairly	  sensitive	  
exploratory	  data	  technique	  could	  only	  find	  minimal	  indications	  of	  similarity	  
between	  the	  two	  experiments.	  	  
	   This	  suggests	  that	  the	  failure	  to	  find	  consistent	  pathways	  and	  overlap	  based	  
on	  inferential	  statistics	  was	  not	  due	  completely	  to	  biological	  variability,	  but	  instead	  
that	  there	  were	  consistent	  problems	  with	  accurate	  metabolite	  identification	  that	  
were	  skewing	  the	  results.	  There	  are	  several	  possible	  explanations	  for	  this,	  including,	  
but	  not	  limited	  to:	  (1)	  peak	  identification	  may	  have	  been	  incorrect	  or	  incomplete,	  
(2)	  ions	  may	  have	  been	  incorrectly	  identified,	  and	  (3)	  the	  metabolite	  may	  be	  
incorrectly	  identified	  because	  of	  compounds	  with	  similar	  weight.	  While	  all	  three	  
sources	  of	  error	  will	  potentially	  cause	  problems	  for	  data	  analysis,	  the	  first	  two	  will	  
result	  in	  an	  incorrect	  molecular	  weight	  and	  incorrect	  concentration,	  while	  the	  third	  
will	  result	  in	  a	  correct	  molecular	  weight	  and	  concentration,	  but	  simply	  an	  incorrect	  
label.	  Unfortunately,	  attempts	  to	  match	  the	  molecular	  weights	  of	  some	  of	  the	  non-­‐
endogenous	  or	  implausible	  metabolites	  with	  more	  likely	  candidates	  in	  the	  Metlin	  
database	  were	  not	  successful,	  and	  this	  would	  indicate	  that	  the	  problems	  were	  more	  
than	  mere	  labels.	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   One	  possible	  cause	  of	  the	  misidentification	  was	  the	  recursive	  algorithm	  used	  
in	  the	  Agilent	  workflow	  to	  identify	  compounds.	  To	  explore	  this	  possibility,	  we	  tried	  
an	  alternative	  data	  analysis	  using	  XCMS,	  which	  does	  not	  identify	  metabolites	  but	  
extracts	  a	  fold-­‐change	  difference	  between	  features	  (m/z)	  for	  a	  two-­‐class	  
comparison—avoiding	  the	  recursive	  algorithm	  used	  by	  Masshunter.	  This	  allowed	  us	  
to	  attempt	  an	  alternative	  means	  of	  metabolite	  identification,	  Mummichog	  (Li	  et	  al.,	  
2013).	  While	  most	  metabolomics	  platforms	  attempt	  to	  assign	  metabolite	  
identification	  based	  on	  formula,	  Mummichog	  maps	  all	  possible	  metabolites	  to	  the	  
feature	  list	  and	  then	  attempts	  to	  deduce	  the	  likely	  correct	  assignments	  by	  looking	  
for	  plausible	  biological	  pathways.	  In	  other	  words,	  it	  tries	  to	  leverage	  the	  intrinsic	  
inter-­‐connectedness	  of	  metabolites	  to	  correctly	  assign	  metabolite	  identification.	  
Pathway	  significance	  is	  determined	  by	  a	  permutation	  test	  based	  on	  all	  possible	  
pathways.	  In	  this	  analysis,	  Experiment	  4	  and	  Experiment	  5	  each	  had	  significant	  
pathways	  identified	  as	  being	  differentially	  regulated	  by	  estradiol	  treatment,	  and	  
there	  was	  overlap	  for	  12	  of	  the	  pathways	  (see	  Table	  12).	  
	  






28	   58	   0.00034	   0.01013	  
Urea	  cycle/amino	  
group	  metabolism	  
24	   53	   0.00273	   0.01033	  
Caffeine	  metabolism	   8	   11	   0.00197	   0.01052	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Tryptophan	  
metabolism	  
29	   74	   0.01293	   0.01098	  
Ascorbate	  (Vitamin	  
C)	  and	  Aldarate	  
Metabolism	  
12	   23	   0.0085	   0.01103	  
Histidine	  
metabolism	  
13	   26	   0.00976	   0.0111	  
Beta-­‐Alanine	  
metabolism	  
9	   17	   0.01992	   0.01247	  
Valine,	  leucine	  and	  
isoleucine	  
degradation	  




26	   71	   0.04403	   0.01309	  
Butanoate	  
metabolism	  
12	   28	   0.04923	   0.01466	  
Pyruvate	  
Metabolism	  
9	   19	   0.04459	   0.01497	  
Pyrimidine	  
metabolism	  
20	   56	   0.09121	   0.01711	  
Tyrosine	  
metabolism	  
32	   97	   0.10521	   0.0173	  
Pentose	  phosphate	  
pathway	  




10	   25	   0.10769	   0.02131	  
Arginine	  and	  Proline	  
Metabolism	  
15	   42	   0.13275	   0.02206	  
	  
	   97	  
Hexose	  
phosphorylation	  
8	   20	   0.14328	   0.02759	  
Nitrogen	  
metabolism	  
3	   4	   0.06235	   0.02943	  
Glycerophospholipid	  
metabolism	  
15	   46	   0.23639	   0.03557	  
Vitamin	  H	  (biotin)	  
metabolism	  
3	   5	   0.12502	   0.04508	  
Glutamate	  
metabolism	  
5	   12	   0.20011	   0.04566	  
Chapter	  IV,	  Table	  10:	  Pathways	  identified	  as	  significant	  by	  Mummichog	  for	  











12	   19	   0.00026	   0.00761	  
Valine,	  leucine	  and	  
isoleucine	  
degradation	  
18	   37	   0.0007	   0.00764	  
Arginine	  and	  
Proline	  Metabolism	  
18	   40	   0.00219	   0.00776	  




21	   57	   0.01606	   0.00869	  
	  




12	   28	   0.01861	   0.00926	  
Glycolysis	  and	  
Gluconeogenesis	  
16	   43	   0.03071	   0.00991	  
Ascorbate	  (Vitamin	  
C)	  and	  Aldarate	  
Metabolism	  
10	   23	   0.02776	   0.0103	  
Tyrosine	  
metabolism	  




11	   28	   0.04653	   0.01181	  
TCA	  cycle	   10	   26	   0.06501	   0.01387	  
Vitamin	  E	  
metabolism	  
13	   37	   0.07577	   0.01408	  
Beta-­‐Alanine	  
metabolism	  
7	   16	   0.06074	   0.01494	  
Hexose	  
phosphorylation	  




11	   32	   0.11224	   0.01865	  
Urea	  cycle/amino	  
group	  metabolism	  




5	   11	   0.09381	   0.02283	  
Aspartate	  and	   20	   69	   0.17897	   0.02369	  
	  





20	   72	   0.23987	   0.03269	  
Galactose	  
metabolism	  
12	   40	   0.21858	   0.03377	  
Biopterin	  
metabolism	  




8	   25	   0.22157	   0.04019	  
	  
Chapter	  IV,	  Table	  11:	  Pathways	  Identified	  by	  Mummichog,	  Experiment	  5,	  24	  
Hours	  
Box	  1:	  Common	  Pathways,	  Experiments	  4	  and	  5,	  Mummichog	  
	  
Alanine	  and	  Aspartate	  Metabolism	  
Arginine	  and	  Proline	  Metabolism	  
Ascorbate	  (Vitamin	  C)	  and	  Aldarate	  Metabolism;	  	  
Aspartate	  and	  asparagine	  metabolism;	  	  
Beta-­‐Alanine	  metabolism;	  	  
Butanoate	  metabolism	  




Urea	  cycle/amino	  group	  metabolism	  
Valine,	  leucine	  and	  isoleucine	  degradation	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However,	  it	  is	  difficult	  to	  determine	  if	  the	  concordance	  between	  the	  two	  
samples	  is	  dependent	  on	  the	  methodology,	  since	  Mummichog	  presumes	  there	  are	  
pathways.	  This	  is	  a	  supervised	  approach,	  and	  it	  may	  simply	  be	  structuring	  the	  data	  
rather	  than	  deriving	  a	  structure	  from	  the	  data.	  Although	  the	  common	  pathways	  
between	  the	  two	  identical	  experiments	  are	  encouraging,	  and	  the	  pathways	  
suggested	  are	  plausible,	  in	  the	  absence	  of	  authenticated	  standards,	  it	  is	  difficult	  to	  
know	  if	  this	  approach	  is	  superior.	  	  
While	  the	  above	  outlined	  approach	  offers	  at	  least	  some	  reproducibility	  and	  
plausibility,	  there	  are	  several	  drawbacks	  too:	  Mummichog	  cannot	  integrate	  positive	  
and	  negative	  mode	  and	  is	  therefore	  restricted	  to	  analyzing	  a	  subset	  of	  the	  
experimental	  results.	  Because	  of	  its	  methodology	  and	  the	  statistical	  stringency	  
required	  when	  testing	  for	  significantly	  impacted	  pathways,	  it	  most	  likely	  misses	  
smaller	  pathways	  and	  is	  disadvantaged	  when	  looking	  for	  pathways	  that	  may	  consist	  
of	  many	  compounds	  missed	  by	  a	  given	  analytical	  methodology—this	  most	  likely	  
accounts	  for	  its	  failure	  to	  find	  estrogen	  metabolites.	  Furthermore,	  errors	  in	  the	  
pathway	  database	  used	  likely	  contributed	  to	  the	  misidentification	  of	  several	  
compounds	  (e.g.	  benzo-­‐a-­‐pyrene,	  acetyl	  isoniazid,	  compounds	  with	  fluorine),	  so	  
while	  the	  error	  rate	  is	  at	  least	  one	  percent	  –	  based	  solely	  on	  compounds	  that	  were	  
not	  relevant	  for	  this	  biological	  system	  -­‐	  the	  actual	  error	  rate	  cannot	  effectively	  be	  
estimated.	  One	  other	  key	  disadvantage	  of	  Mummichog	  is	  that	  it	  can	  only	  be	  used	  to	  
do	  a	  two-­‐class	  comparison,	  as	  it	  depends	  on	  relative	  fold-­‐changes	  to	  assess	  
consistent	  pathway	  impact	  and	  therefore	  cannot	  analyze	  a	  dose–response	  curve	  or	  a	  
time-­‐course.	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   Going	  forward,	  it	  is	  clear	  that	  adequate	  peak	  identification	  and	  high	  accuracy	  
in	  determining	  the	  accurate	  parent	  compound	  from	  adducts	  is	  key	  for	  an	  untargeted	  
approach,	  as	  any	  failure	  in	  those	  stages	  will	  likely	  lead	  to	  an	  inaccurate	  molecular	  
weight	  and	  concentration,	  and	  that	  cannot	  be	  easily	  remedied	  with	  a	  bioinformatics	  
approach.	  One	  potential	  solution	  involves	  ProbMetab	  (Silva	  et	  al.,	  2014),	  an	  R	  
package	  for	  Bayesian	  inference	  of	  identification.	  ProbMetab,	  like	  Mummichog,	  
presumes	  metabolites	  in	  a	  sample	  are	  related	  in	  pathways	  and	  uses	  that	  information	  
as	  part	  of	  the	  metabolite	  identification.	  However,	  unlike	  Mummichog,	  it	  takes	  
advantage	  of	  several	  other	  sources	  of	  information—namely,	  retention	  time	  and	  
isotope	  abundance—and	  therefore	  is	  not	  uniquely	  dependent	  on	  pathway	  
annotations	  and	  structure.	  More	  importantly,	  it	  assigns	  a	  probability	  to	  the	  
identification,	  so	  a	  measure	  of	  the	  underlying	  uncertainty	  is	  preserved.	  Lastly,	  it	  
retains	  features	  that	  could	  not	  be	  assigned	  identifications,	  so	  that	  this	  information	  is	  
not	  lost	  and	  can	  be	  mined	  later.	  Another	  possibility	  is	  to	  attempt	  to	  leverage	  
transcriptomic	  data	  to	  identify	  pathways	  that	  are	  up-­‐	  or	  down-­‐	  regulated,	  which	  
could	  be	  used	  by	  a	  pathway-­‐based	  algorithm	  to	  weigh	  likely	  pathways	  against	  less	  
likely	  pathways.	  Metabolite	  identification	  at	  this	  stage	  remains	  a	  data-­‐mining	  puzzle	  
of	  using	  multiple	  clues	  as	  to	  the	  identity	  of	  a	  metabolite,	  and	  assembling	  them	  in	  a	  
way	  that	  respects	  the	  underlying	  uncertainty.	  
	   Despite	   the	   challenges,	   metabolomics—and	   specifically,	   the	   ability	   to	   do	  
untargeted	   metabolomics—is	   key	   to	   understanding	   disease,	   drug	   effects,	   and	  
toxicity.	  With	  every	  drug	  studied,	  there	  are	  always	  surprises	  at	  how	  complicated	  the	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effects	   of	   drugs	   are;	   inhibition	   of	   an	   individual	   pathway	   can	   have	   unpredictable	  
results,	  since	  all	  pathways	  are	  connected.	  	  
	   As	  with	  any	  "-­‐omics"	  discipline,	  the	  interpretation	  of	  the	  data	  is	  heavily	  
dependent	  on	  the	  quality	  of	  the	  annotations	  used	  for	  data	  analysis.	  Even	  older,	  more	  
established	  annotations	  such	  as	  GO	  have	  known	  biases	  that	  can	  distort	  data	  analysis	  
(Gene	  Ontology	  et	  al.,	  2013).	  Large-­‐scale,	  integrated	  pathway	  databases	  of	  
metabolites	  are	  relatively	  new	  (the	  most	  extensive,	  the	  Human	  Metabolome	  
Database	  (Wishart	  et	  al.,	  2013),	  began	  in	  2004)	  and	  are	  likely	  to	  have	  uneven	  
coverage	  of	  metabolites.	  This	  is	  particularly	  true	  for	  toxicological	  applications,	  as	  
the	  existing	  annotated	  pathways	  are	  likely	  canonical	  pathways	  focusing	  on	  
endogenous	  metabolites.	  The	  HMDB	  includes	  ethanol	  and	  caffeine	  metabolism	  
pathways,	  but	  has	  no	  other	  pathway-­‐level	  annotations	  for	  other	  exogenous	  
compounds.	  And	  while	  another	  database,	  the	  Toxin	  and	  Toxin-­‐Target	  Database	  
(T3DB)	  (Lim	  et	  al.,	  2010),	  contains	  2,900	  toxins	  and	  over	  1,300	  targets,	  it	  does	  not	  
integrate	  this	  information	  into	  relevant	  pathways,	  nor	  does	  it	  provide	  an	  easy	  way	  
to	  interpret	  the	  target	  in	  terms	  of	  biologic	  networks.	  
	   Any	  future	  metabolomics	  studies	  should	  start	  by	  demonstrating	  
reproducibility—in	  terms	  of	  quantifying	  and	  identifying	  known	  compounds—so	  
that	  analytical	  issues	  can	  be	  solved	  before	  attempting	  to	  tackle	  complicated	  
biological	  problems.	  It	  is	  also	  essential	  to	  explore	  a	  data	  set	  via	  several	  methods	  
(ORA,	  QEA,	  correlation	  analysis,	  and	  perhaps	  in	  future	  genome-­‐scale	  network	  
reconstruction	  based	  on	  parallel	  microarray	  experiments).	  Lastly,	  results	  that	  are	  
radically	  dependent	  on	  the	  methodology	  should	  cause	  concern.	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   Currently,	  the	  most	  significant	  bottleneck	  is	  metabolite	  identification:	  while	  
some	  of	  the	  challenges	  for	  metabolite	  identification	  are	  largely	  analytical,	  a	  well-­‐
characterized,	  biochemically	  complete	  network	  would	  significantly	  aid	  the	  task.	  In	  
addition	  to	  reducing	  (if	  not	  eliminating)	  uncertainty	  in	  metabolite	  identification,	  it	  
would	  also	  help	  go	  beyond	  pathway	  identification	  to	  an	  analysis	  that	  is	  systems	  
oriented,	  such	  as	  flux	  analysis	  or	  systems	  control	  theory.	  As	  it	  stands,	  however,	  
bioinformatics	  can	  help	  fill-­‐in	  gaps	  in	  incomplete	  data,	  but	  it	  cannot	  repair	  
extremely	  noisy	  data.	  	  	  
	   In	  conclusion,	  scientists	  embarking	  on	  metabolomics	  as	  a	  part	  of	  systems	  
biology	  should	  remember	  the	  effort	  of	  an	  early	  pioneer:	  the	  16th	  century,	  Italian	  
physician	  Sanctorius,	  whose	  30-­‐year	  experiment	  (which	  involved	  meticulously	  
weighing	  everything	  he	  ate	  and	  excreted)	  laid	  the	  foundation	  for	  the	  quantitative	  
study	  of	  metabolism	  (Ben-­‐Menahem,	  2009).	  Metabolomics	  has	  always	  required	  a	  
very	  long-­‐term	  commitment;	  it	  is	  not	  for	  the	  scientist	  looking	  for	  a	  quick	  payoff.	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CHAPTER	  V	  –	  Conclusion	  	  
	  
"Truth	  is	  much	  too	  complicated	  to	  allow	  anything	  but	  approximations."	  —John	  von	  
Neumann	  
	  
Transforming	  toxicology	  from	  a	  reductionist	  paradigm	  to	  a	  more	  systems-­‐
based	  approach	  will	  require	  a	  profound	  change	  in	  both	  practical	  hazard	  assessment	  
and	  the	  basic	  research	  that	  underpins	  our	  understanding	  of	  toxic	  mechanisms.	  
	   	  As	  outlined	  in	  Chapter	  II	  and	  demonstrated	  in	  Chapter	  III,	  both	  the	  
proliferation	  of	  alternative	  assays	  and	  the	  increasing	  sophistication	  of	  
chemoinformatics	  requires	  new	  ways	  to	  think	  about	  chemical	  assessments,	  and	  a	  
move	  towards	  a	  more	  formal	  and	  quantified	  paradigm	  and	  away	  from	  a	  weight-­‐of-­‐
evidence	  approach.	  Small	  improvements	  from	  the	  perspective	  of	  machine	  learning	  
can	  yield	  large	  improvements	  for	  practical	  hazard	  assessment—establishing	  with	  90	  
percent	  certainty	  that	  a	  chemical	  is	  not	  a	  strong	  sensitizer	  with	  a	  few	  in	  vitro	  assays	  
can	  help	  immensely	  when	  prioritizing	  chemicals	  in	  the	  R&D	  chain.	  Data	  mining	  and	  
machine	  learning	  approaches	  are	  no	  longer	  optional	  in	  the	  modern	  era—they	  are	  a	  
toolkit	  that	  every	  discipline	  will	  need	  to	  take	  advantage	  of,	  and	  toxicology	  is	  no	  
exception.	  
	   Secondly,	  toxicology	  must	  move	  away	  from	  simplistic	  mechanisms	  towards	  a	  
more	  pathway	  and/or	  network-­‐oriented	  approach.	  While	  a	  toxic	  process	  may	  start	  
with	  interference	  at	  a	  discrete	  point	  in	  the	  cell—for	  example,	  inhibiting	  one	  specific	  
enzyme—rarely	  does	  that	  tell	  the	  whole	  story.	  While	  at	  some	  level	  attempting	  to	  
capture	  the	  complexity	  may	  seem	  daunting,	  network	  abstractions	  allow	  one	  to	  see	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the	  higher-­‐level	  simplicity—protein	  interaction	  networks,	  whether	  in	  yeast	  or	  
humans,	  share	  a	  similar	  topology	  (Bork	  et	  al.,	  2004).	  The	  seemingly	  bewildering	  
array	  of	  regulatory	  interactions	  in	  a	  cell,	  in	  fact,	  demonstrate	  a	  few	  simple	  motifs	  
(Alon,	  2007).	  
	  In	  Chapter	  V,	  it	  was	  shown	  that	  MPTP	  toxicity	  involves	  a	  mechanism	  that	  is	  
known	  (mitochondrial	  disruption)	  but	  has	  consequences	  that	  have	  yet	  to	  be	  fully	  
described,	  and	  suggested	  a	  methodology	  to	  look	  for	  new	  candidates	  to	  extend	  the	  
pathway	  past	  “the	  usual	  suspects”.	  –	  an	  approach	  that	  took	  advantage	  of	  the	  high-­‐
dimensional	  data	  in	  part	  by	  reducing	  its	  dimensionality	  to	  look	  not	  at	  individual	  
genes	  but	  at	  modules	  of	  genes	  that	  were	  related	  from	  both	  a	  functional	  and	  
regulatory	  perspective.	  In	  Chapter	  VI,	  the	  potential	  and	  pitfalls	  of	  another	  high-­‐
dimensional	  field,	  metabolomics,	  were	  explored.	  	  	  
	   Pathway	  mapping	  approaches	  have	  many	  advantages	  over	  more	  vague	  and	  
merely	  predictive	  “signatures	  of	  toxicity”	  approaches	  or	  black-­‐box	  animal	  models.	  
However,	  a	  fully	  specified	  Pathway	  of	  Toxicity	  requires	  a	  very	  fine-­‐grained	  
understanding	  of	  a	  biological	  system.	  From	  a	  bioinformatics	  perspective,	  this	  means	  
that	  instead	  of	  stopping	  at	  the	  level	  of	  an	  abstract	  connectivity	  map	  (as	  is	  typically	  
produced	  from	  correlation	  networks)	  or	  a	  truncated,	  simplified	  pathway	  of	  a	  
complex	  disease	  (as	  is	  common	  in	  many	  pathway	  databases),	  a	  complete	  “molecules	  
to	  phenotype”	  functional	  characterization	  will	  be	  required.	  While	  this	  may	  seem	  
daunting,	  small	  improvements	  in	  our	  understanding	  of	  a	  Pathway	  of	  Toxicity	  can	  
provide	  for	  large	  improvements	  in	  hazard	  assessment.	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In	  our	  machine-­‐learning	  approach	  to	  skin	  sensitization,	  the	  modest	  
improvement	  in	  balanced	  accuracy	  could	  likely	  be	  improved	  by	  adopting	  an	  
approach	  that	  is	  structured	  by	  the	  known	  mechanisms	  of	  toxicity;	  previous	  machine	  
learning	  predictive	  models	  for	  skin	  sensitization	  have	  generally	  approached	  the	  
problem	  more	  or	  less	  blind	  to	  the	  known	  mechanistic	  steps.	  However,	  as	  skin	  
sensitization	  has	  a	  well-­‐characterized	  Adverse	  Outcome	  Pathway,	  it	  should	  be	  
possible	  to	  build	  a	  model	  that	  takes	  advantage	  of	  this.	  The	  steps	  involved	  in	  skin	  
sensitization—skin	  penetration,	  electrophilic	  activity,	  covalent	  protein	  binding,	  
cytokine	  induction	  &	  T-­‐cell	  proliferation,	  and	  the	  processes	  that	  determine	  tissue	  	  
inflammation,	  damage	  and	  repair	  —can	  each	  be	  predicted	  with	  some	  degree	  of	  
accuracy	  with	  either	  chemical	  descriptors	  or	  in	  vitro	  assays.	  Therefore,	  one	  obvious	  
extension	  of	  this	  methodology	  is	  to	  adapt	  a	  Hidden	  Markov	  model	  that	  combines	  
chemical	  descriptors	  and	  in	  vitro	  assays	  and	  essentially	  progresses	  along	  each	  
critical	  step	  of	  the	  pathway—that	  is	  to	  say,	  the	  transition	  probability	  between	  one	  
state	  and	  the	  next	  would	  be	  determined	  by	  the	  probability	  that	  a	  chemical	  was	  
positive	  or	  negative	  for	  each	  step	  of	  the	  Adverse	  Outcome	  Pathway.	  This	  has	  the	  
advantage	  of	  simplifying	  the	  problem—there	  is	  no	  point	  in	  predicting	  
electrophilicity	  for	  compounds	  that	  will	  not	  penetrate	  the	  skin—and	  could	  serve	  as	  
a	  proof-­‐of-­‐concept	  on	  how	  to	  optimally	  incorporate	  chemoinformatics,	  in	  vitro	  
assays,	  and	  a	  known	  Adverse	  Outcome	  Pathway	  to	  assess	  the	  probability	  of	  hazard.	  
Additionally,	  the	  basic	  insight	  of	  the	  approach—to	  incorporate	  a	  dose-­‐based	  
structure	  for	  the	  data—could	  be	  used	  for	  the	  concentration–response	  information	  
from	  the	  assays	  themselves.	  Currently,	  information	  from	  the	  in	  vitro	  assays	  is	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summarized	  as	  an	  EC50,	  but	  in	  some	  respect	  this	  represents	  a	  loss	  of	  information.	  
Including	  a	  dose–response	  based	  model	  for	  the	  descriptors	  as	  well	  as	  the	  end-­‐point	  
should	  both	  capture	  more	  data	  and	  eliminate	  some	  of	  the	  noise	  (caused	  by	  
cytotoxicity	  or	  non-­‐specific	  responses)	  that	  is	  intrinsic	  to	  in	  vitro	  assays.	  	  
Lastly,	  existing	  skin	  sensitization	  classifications	  are	  built	  around	  LLNA	  
testing	  results,	  and	  while	  this	  provides	  an	  acceptable	  accuracy	  for	  hazard	  
identification,	  the	  ultimate	  goal	  is	  to	  predict	  hazard	  in	  humans.	  A	  recent	  publication	  
(Basketter	  et	  al.,	  2014)	  has	  identified	  131	  chemicals,	  which	  can	  be	  classified	  with	  
confidence	  into	  six	  categories,	  ranked	  1	  to	  5	  based	  on	  potency	  and	  class	  6	  as	  true	  
non-­‐sensitizers.	  These	  categories	  reflect	  more	  accurately	  the	  range	  of	  hazards	  faced	  
occupationally,	  since	  it	  considers	  both	  potency	  and	  length	  of	  exposure.	  Compared	  to	  
other	  data	  sets	  used	  for	  machine	  learning	  approaches,	  it	  offers	  the	  additional	  
advantage	  of	  being	  balanced	  equally	  among	  the	  classes,	  as	  opposed	  to	  other	  data	  
sets,	  which	  are	  typically	  weighted	  towards	  non-­‐sensitizers.	  A	  six-­‐class	  model	  would	  
likely	  be	  extremely	  difficult	  for	  most	  standard	  machine	  learning	  approaches,	  but	  a	  
dose-­‐based	  Hidden	  Markov	  model	  would	  likely	  be	  better	  able	  to	  make	  meaningful	  
predictions	  in	  a	  six-­‐class	  model.	  
Even	  for	  a	  well-­‐understood	  Pathway	  of	  Toxicity,	  neither	  chemical	  descriptors	  
alone	  nor	  any	  individual	  in	  vitro	  test	  will	  work	  adequately	  as	  a	  stand-­‐alone	  
replacement	  for	  assessing	  hazard;	  it	  is	  necessary	  to	  combine	  assays	  that	  address	  
multiple	  points	  on	  the	  Pathway	  of	  Toxicity.	  In	  instances	  where	  the	  Pathway	  of	  
Toxicity	  is	  unknown,	  it	  requires	  methodologies	  that	  can	  better	  delineate	  critical	  
points	  at	  a	  molecular	  level—in	  essence,	  a	  methodology	  that	  can	  locate	  where,	  within	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the	  regulatory	  circuitry	  of	  the	  cell,	  a	  toxicant	  is	  causing	  a	  malfunction	  that	  results	  in	  
an	  altered	  phenotype.	  
While	  we	  demonstrated	  that	  a	  relatively	  small	  data	  set	  can	  provide	  novel	  
insights	  even	  for	  a	  comparatively	  well-­‐characterized	  toxin	  such	  as	  MPTP,	  it	  also	  
demonstrated	  the	  limitations	  of	  depending	  on	  existing	  annotations.	  Although	  
ontologies	  and	  annotations	  have	  certainly	  proven	  their	  worth	  vis-­‐à-­‐vis	  microarray	  
data,	  an	  approach	  overly	  dependent	  on	  annotations	  will	  be	  limited	  to	  “looking	  under	  
the	  lamp	  post	  for	  your	  key,	  because	  that’s	  where	  the	  light	  is”—it	  allows	  you	  to	  see	  
known	  biology,	  but	  limits	  the	  ability	  to	  find	  novel	  connections.	  It	  will	  certainly	  be	  
too	  limiting	  for	  newer	  technologies,	  such	  as	  metabolomics.	  
While	  text-­‐mining	  is	  key	  to	  extending	  annotations,	  it	  typically	  works	  best	  
when	  used	  to	  answer	  a	  targeted	  question.	  A	  question	  such	  as	  “Which	  transcription	  
factors	  are	  involved	  in	  Parkinson’s?”	  is	  not	  easy	  for	  text-­‐mining	  to	  answer.	  On	  the	  
other	  hand,	  text-­‐mining	  can	  well	  prioritize	  a	  small	  list	  of	  candidate	  transcription	  
factors	  likely	  to	  be	  involved	  in	  Parkinson’s.	  While	  the	  approach	  taken	  here	  was	  fairly	  
simplistic,	  the	  existence	  of	  text-­‐mining	  engines	  such	  as	  Textpresso	  (Muller,	  
Rangarajan,	  Teal,	  &	  Sternberg,	  2008)—which	  both	  tokenizes	  the	  data	  and	  resolves	  
synonyms,	  and	  structures	  the	  data	  by	  looking	  for	  parts	  of	  speech	  that	  indicate	  
interactions	  among	  entities—can	  answer	  fairly	  specific	  questions	  more	  efficiently	  
than	  a	  literature	  review,	  an	  approach	  that	  was	  used	  to	  add	  substantially	  to	  the	  
number	  of	  known	  histone	  acetylation	  positions	  (Huang	  et	  al.,	  2009)	  (see	  Appendix).	  
While	  there	  are	  a	  few	  text-­‐mining	  solutions	  that	  look	  for	  associations	  between	  a	  
short	  list	  of	  genes—e.g.	  Chilibot	  (Chen	  &	  Sharp,	  2004)—there	  are	  no	  robust	  text-­‐
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mining	  solutions	  that	  can	  find	  associations	  between	  several	  hundred	  genes	  and	  
suggest	  functional	  characterizations.	  	  	  
	  In	  the	  case	  of	  genes,	  the	  problem	  of	  resolving	  synonyms	  has	  been	  largely	  
addressed.	  For	  metabolomics,	  only	  the	  most	  rudimentary	  solutions	  are	  available,	  
and	  effectively	  incorporating	  the	  extensive	  literature-­‐base	  into	  a	  useful	  framework	  
for	  a	  systems	  biology	  approach	  will	  be	  key	  to	  moving	  the	  discipline	  forward.	  	  
Moreover,	  mere	  functional	  characterization	  provides	  little	  information	  about	  
regulatory	  mechanisms.	  WGCNA	  (Weighted	  Gene	  Correlation	  Network	  Analysis)	  
combined	  with	  other	  high-­‐throughput	  techniques	  offers	  one	  methodology	  to	  make	  
an	  educated	  guess	  about	  mechanisms—in	  other	  words,	  to	  assign	  arrows	  to	  the	  
connectivity	  map.	  While	  this	  methodology	  appears	  to	  work	  well	  for	  time-­‐course	  
studies,	  it	  may	  work	  less	  well	  for	  dose–response	  curves,	  and	  will	  likely	  need	  to	  be	  
adjusted	  slightly	  to	  capture	  dose-­‐dependent	  effects.	  In	  particular,	  a	  time-­‐course	  
network	  will	  capture	  largely	  linear	  effects,	  while	  a	  dose–response	  tends	  to	  have	  
more	  non-­‐linear	  effects.	  Put	  another	  way,	  somewhere	  on	  the	  dose–response	  curve	  
there	  is	  a	  threshold	  that	  triggers	  a	  key	  change	  in	  biology.	  It	  may	  be	  necessary,	  then,	  
to	  use	  correlation	  networks	  and	  graph	  theoretical	  approaches	  in	  order	  to	  focus	  
more	  specifically	  on	  changes	  in	  network	  topology.	  However,	  this	  may	  require	  
rethinking	  experimental	  design,	  as	  determining	  a	  network	  at	  each	  dose	  point	  will	  
require	  comparatively	  more	  microarrays	  than	  are	  currently	  used.	  	  	  
In	  order	  to	  truly	  take	  a	  systems	  level	  view,	  a	  “molecules	  to	  phenotype”	  
functional	  characterization	  requires	  substantially	  more	  information	  than	  a	  
correlative	  approach	  can	  provide,	  and	  since	  it	  is	  largely	  a	  method	  of	  hypothesis	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generation,	  it	  requires	  other	  means—typically	  in	  vitro	  or	  in	  vivo	  studies—to	  confirm	  
the	  regulatory	  mechanisms	  proposed.	  However,	  as	  bioinformatics	  methods	  generate	  
more	  and	  more	  testable	  hypotheses,	  a	  smarter	  approach	  to	  exploring	  such	  proposed	  
regulatory	  mechanisms	  is	  required.	  
One	  possibility	  is	  to	  transform	  the	  genetic	  regulatory	  networks	  produced	  by	  
data	  mining	  into	  an	  SBML	  model	  (Systems	  Biology	  Markup	  Language)	  (Finney	  &	  
Hucka,	  2003).	  SBML	  is	  a	  system	  designed	  to	  formally	  describe	  any	  biological	  entities	  
that	  are	  linked	  by	  interactions	  or	  processes	  in	  a	  machine-­‐readable	  format	  and	  
(through	  graphical	  interpretation)	  human-­‐readable	  diagrams.	  It	  is	  sufficiently	  
flexible	  to	  specify	  genetic	  regulatory	  circuits,	  metabolic	  pathways,	  or	  cell-­‐signaling	  
pathways	  and	  can	  describe	  a	  system	  in	  as	  much	  or	  as	  little	  detail	  as	  necessary	  to	  
capture	  the	  essential	  features	  (Chaouiya	  et	  al.,	  2013).	  An	  additional	  benefit	  is	  that	  
there	  are	  several	  SBML-­‐compatible	  curated	  pathways	  (e.g.	  PANTHER	  Pathways)	  to	  
help	  structure	  the	  data;	  therefore,	  SBML	  models	  often	  do	  not	  require	  starting	  from	  
scratch,	  but	  usually	  only	  the	  far	  simpler	  task	  of	  adding	  the	  relevant	  information	  
suggested	  by	  the	  high-­‐throughput	  approach	  along	  with	  existing	  pathways.	  	  
Because	  SBML	  requires	  explicit,	  formally	  specified	  interactions,	  it	  often	  
shows	  areas	  in	  proposed	  pathways	  that	  are	  poorly	  understood	  or	  characterized	  and,	  
in	  some	  cases,	  conflicting.	  The	  standard	  diagrams	  employed	  by	  cell	  biologists	  to	  
describe	  mechanisms	  in	  molecular	  biology	  generally	  involve	  a	  bunch	  of	  arrows	  and	  
symbols.	  The	  arrows	  could	  mean	  anything—transcription,	  activation,	  
phosphorylation,	  or	  merely	  a	  vague	  and	  unspecified	  interaction—and	  the	  symbols	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could	  be	  genes,	  proteins,	  small	  molecules,	  or,	  worse	  still,	  vague	  concepts	  such	  as	  
“oxidative	  stress.”	  	  
Therefore,	  structuring	  proposed	  pathways	  using	  SBML	  or	  other	  
standardized,	  controlled	  formats	  would	  not	  only	  help	  both	  prune	  and	  extend	  the	  
network	  generated	  by	  “-­‐omics”	  technologies,	  it	  would	  help	  make	  the	  leap	  from	  basic	  
pathway	  identification	  and	  hypothesis	  generation	  to	  models	  than	  can	  be	  used	  for	  
more	  complex	  simulations,	  which	  can	  both	  weed	  out	  false	  positives	  and	  point	  to	  
areas	  where	  proposed	  regulatory	  mechanisms	  are	  clearly	  inadequate	  to	  describe	  
the	  data.	  	  	  
	   Meeting	  this	  challenge	  will	  involve	  both	  larger,	  more	  integrated	  data	  sets,	  
novel	  bioinformatics	  approaches	  that	  look	  for	  dose–response	  curves,	  and	  an	  ability	  
to	  incorporate	  legacy	  data	  to	  allow	  for	  better	  interpretation	  of	  “-­‐omics”	  results.	  
Transcriptomics	  has	  been	  in	  use	  for	  over	  two	  decades	  and	  has	  well-­‐established	  
analysis	  tools	  and	  standards	  for	  best	  practices	  and	  documentation,	  and	  
transcriptomics	  will	  likely	  play	  a	  key	  role	  in	  discerning	  Pathways	  of	  Toxicity.	  As	  
demonstrated	  here,	  much	  information	  can	  be	  gleaned	  from	  even	  a	  small	  study.	  	  	  
	   Metabolomics,	  on	  the	  other	  hand,	  is	  a	  nascent	  field.	  Measuring	  the	  abundance	  
of	  metabolites	  has	  technical	  challenges	  as	  well	  as	  data	  analysis	  bottlenecks	  due	  to	  a	  
relatively	  under-­‐developed	  data	  infrastructure	  and	  a	  process	  that	  is	  acutely	  
dependent	  on	  a	  fairly	  complex	  data	  analysis	  workflow.	  From	  the	  bioinformatics	  
perspective,	  the	  relatively	  sparse	  annotation	  data	  available	  for	  metabolites	  
compared	  to	  genes	  will	  require	  an	  approach	  that	  can	  learn	  networks	  from	  data	  
rather	  than	  depend	  on	  existing	  pathway	  maps.	  While	  correlation	  of	  co-­‐expression	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(commonly	  called	  the	  "guilt-­‐by-­‐association”	  method)	  has	  been	  a	  powerful	  method	  to	  
predict	  gene	  networks	  ab	  initio	  from	  microarray	  data	  (Quackenbush,	  2003;	  Stuart,	  
Segal,	  Koller,	  &	  Kim,	  2003)	  its	  application	  to	  metabolomics	  is	  less	  straightforward.	  
While	  genes	  that	  show	  similar	  expression	  patterns	  likely	  share	  some	  level	  of	  
transcriptional	  control,	  this	  is	  not	  the	  case	  for	  correlation	  of	  co-­‐expression	  in	  
metabolomics,	  as	  metabolites	  are	  intrinsically	  interdependent	  in	  a	  way	  that	  genes	  
are	  not.	  Nonetheless,	  such	  correlations	  that	  are	  consistent	  over	  conditions	  (such	  as	  
time-­‐course	  analysis	  or	  different	  treatments)	  are	  not	  necessarily	  close	  by	  on	  a	  
metabolic	  map,	  but	  do	  probably	  have	  some	  sort	  of	  linkage:	  they	  may	  be	  in	  chemical	  
equilibrium,	  have	  a	  mass	  conservation	  relationship,	  are	  under	  asymmetric	  control,	  
or	  are	  under	  the	  tight	  control	  of	  a	  specific	  gene	  which	  varies	  amongst	  the	  data	  sets	  
(Steuer,	  Kurths,	  Fiehn,	  &	  Weckwerth,	  2003).	  Correlative	  based	  approaches	  have	  
been	  used	  to	  deduce	  novel	  pathways	  (Fukushima,	  Kusano,	  Redestig,	  Arita,	  &	  Saito,	  
2011)	  in	  previous	  metabolomics	  studies.	  	  
	   However,	  while	  bioinformatics	  approaches	  can	  solve	  metabolite	  identities	  if	  
some	  of	  the	  network	  is	  accurately	  identified	  and	  quantified,	  it	  can	  do	  little	  to	  solve	  
deeper	  analytical	  problems.	  	  One	  way	  forward	  for	  both	  the	  analytic	  and	  
bioinformatics	  problems	  presented	  by	  metabolomics	  involves	  the	  use	  of	  stable	  
isotope	  labeling.	  Such	  isotopes	  can	  be	  used	  as	  standards	  for	  metabolite	  
identification,	  which	  provides	  a	  needed	  check	  on	  whether	  data	  analysis	  workflows	  
are	  performing	  adequately.	  Furthermore,	  stable	  isotopes	  can	  used	  for	  fluxomics	  –	  
that	  is,	  studying	  the	  reaction	  rates	  in	  cells	  –	  which	  can	  be	  considered	  the	  most	  direct	  
read	  –out	  of	  the	  metabolic	  phenotype	  (Klein	  &	  Heinzle,	  2012).	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However,	  as	  it	  is,	  the	  learning	  curve	  for	  metabolomics	  is	  incredibly	  steep,	  and	  
metabolomics	  will	  likely	  require	  greater	  maturation	  as	  a	  field	  before	  it	  becomes	  an	  
equal	  partner	  to	  transcriptomics	  for	  Pathway	  of	  Toxicity	  identification	  and	  certainly	  
has	  a	  long	  way	  to	  go	  before	  it	  becomes	  an	  everyday	  tool	  for	  hazard	  assessment.	  
	   This	  does,	  however,	  indicate	  that	  one	  key	  goal	  of	  any	  project	  to	  provide	  
effective	  in	  vitro	  assays	  to	  discern	  Pathways	  of	  Toxicity	  will	  be	  establishing	  an	  
effective	  dimensionality	  reduction	  of	  the	  data	  so	  that	  the	  noise	  from	  both	  the	  
biological	  variability	  and	  technical	  aspects	  does	  not	  overwhelm	  the	  signal,	  and	  that	  
the	  derived	  Pathways	  of	  Toxicity	  are	  not	  the	  result	  of	  over-­‐fitting	  to	  one	  limited	  set	  
of	  data	  and	  are	  robust	  when	  compared	  with	  existing	  data.	  	  
	   Mapping	  the	  Human	  Toxome	  will	  involve	  a	  degree	  of	  integration	  of	  multiple	  
levels	  of	  molecular	  data	  with	  cellular	  responses	  that	  has	  not	  as	  of	  yet	  been	  carried	  
out—and	  because,	  ultimately,	  toxicity	  is	  the	  study	  of	  dose,	  it	  will	  require	  a	  
mechanistic	  understanding	  of	  phenotypic	  changes	  at	  a	  low-­‐dose	  level	  and	  
bioinformatics	  approaches	  that	  can	  tease	  out	  dose	  response.	  Theoretically,	  an	  
estrogenic	  compound	  can	  begin	  affecting	  cells	  at	  concentrations	  as	  low	  as	  a	  single	  
molecule	  per	  cell.	  Understanding	  how	  a	  Pathway	  of	  Toxicity	  responds	  to	  stimuli,	  
especially	  at	  low	  doses	  typical	  of	  environmental	  exposures,	  will	  be	  a	  substantial	  
bioinformatics	  challenge,	  yet	  it	  is	  essential	  for	  this	  approach	  to	  be	  effective	  	  
At	  the	  same	  time,	  it	  is	  necessary	  to	  be	  realistic	  about	  the	  limitations	  of	  in	  
vitro	  approaches:	  cells	  are	  often	  misidentified,	  often	  the	  standard	  cell	  lines	  which	  
form	  the	  foundation	  of	  much	  of	  basic	  science	  are	  radically	  genetically	  different—as	  
an	  example,	  HeLa	  cells	  are	  radically	  genetically	  different	  between	  groups,	  and	  cells	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of	  tumor	  origin	  may	  have	  up	  to	  20,000	  mutations	  (Hartung,	  2013).	  Tissue	  culture	  
cells	  often	  exist	  in	  a	  micro-­‐environment	  that	  is	  profoundly	  abnormal	  and	  may	  lack	  
metabolism	  or	  cell	  defenses	  (Hartung,	  2007).	  	  
	   Finally,	  many,	  if	  not	  most,	  toxic	  processes	  involve	  interplay	  between	  tissue	  
types.	  As	  an	  example,	  any	  attempt	  to	  examine	  MPTP	  toxicity	  that	  assumed	  
astrocytes	  only	  metabolized	  MPTP	  to	  MPP+	  may	  miss	  critical	  processes	  in	  
astrocytes	  that	  contribute	  to	  the	  adverse	  outcome.	  While	  this	  may	  seem	  an	  intrinsic	  
limitation	  for	  in	  vitro	  approaches,	  this	  is	  not	  necessarily	  so.	  More	  complex	  organ-­‐on-­‐
a-­‐chip	  in	  vitro	  systems	  offer	  one	  solution	  (van	  der	  Meer	  &	  van	  den	  Berg,	  2012).	  As	  
another,	  it	  is	  necessary	  to	  accept	  that	  a	  stand-­‐alone	  replacement	  for	  an	  animal	  test	  is	  
unlikely—skin	  sensitization	  is	  a	  fairly	  easy	  target	  compared	  to	  neurotoxicity	  or	  
endocrine	  disruption.	  Any	  attempt	  to	  use	  in	  vitro	  assays	  will	  likely	  require	  an	  
intelligent	  way	  to	  combine	  multiple	  sources	  of	  information.	  	  	  
	   Additionally,	  the	  limitations	  of	  high-­‐throughput/high-­‐dimensional	  
approaches	  must	  be	  kept	  in	  mind.	  To	  begin	  with,	  such	  approaches	  often	  fail—
especially	  when	  the	  technology	  is	  new—to	  conduct	  adequate	  quality	  assurance.	  
Quality	  assurance	  is	  an	  essential	  component	  of	  science;	  however,	  in	  the	  past,	  much	  
of	  basic	  science	  and	  preclinical	  research	  paid	  minimal	  attention	  to	  quality	  assurance	  
and	  reproducibility,	  but	  this	  attitude	  must	  be	  changed,	  given	  the	  growth	  of	  studies	  
that	  are	  not	  reproducible	  (Begley	  &	  Ellis,	  2012)	  (Hartung,	  2013).	  Both	  the	  
temptation	  (and,	  owing	  to	  the	  complexity	  of	  interpretation,	  the	  comparative	  ease)	  of	  
spinning	  high-­‐throughput/high-­‐dimensional	  data	  into	  a	  “good	  story”	  means	  that	  
quality	  assurance	  is	  of	  critical	  importance	  to	  any	  alternative	  method	  based	  on	  such	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techniques.	  This	  will	  be	  of	  particular	  importance	  to	  metabolomics,	  owing	  to	  the	  
sensitivity	  of	  the	  technique,	  the	  ambiguity	  of	  metabolite	  identification,	  and	  the	  high	  
probability	  of	  artifacts—the	  temptation	  will	  always	  be	  there	  for	  researchers	  to	  treat	  
a	  fluke	  as	  a	  profound	  finding,	  and	  the	  only	  guard	  against	  this	  is	  a	  culture	  of	  quality	  
assurance	  and	  reproducibility.	  	  
	   Lastly,	  all	  technologies	  offer	  only	  a	  narrow	  glimpse	  of	  the	  biological	  
complexity	  underneath,	  and	  just	  as	  important	  as	  it	  is	  to	  adequately	  interpret	  the	  
data	  presented,	  it	  is	  equally	  important	  to	  keep	  in	  mind	  what	  a	  given	  technology	  is	  
simply	  incapable	  of	  seeing.	  	  
As	  useful	  as	  transcriptomics	  has	  been,	  much	  of	  cell	  signaling	  is	  either	  reflected	  in	  the	  
phospho-­‐proteome,	  the	  metabolome,	  or	  the	  complex	  dynamics	  of	  microRNA	  
regulation.	  Each	  of	  these	  represent	  analytical	  and	  bioinformatics	  challenges	  to	  scale-­‐
up	  to	  the	  extent	  that	  they	  can	  be	  an	  equal	  partner	  to	  transcriptomics,	  but	  a	  more	  
complete	  understanding	  of	  the	  Human	  Toxome	  will	  require	  the	  different	  
perspectives.	  Nonetheless,	  a	  microarray	  study	  which	  provides	  a	  plausible	  genetic	  
regulatory	  network	  is	  a	  far	  more	  efficient	  and	  informative	  use	  of	  animals	  than	  a	  
study	  which	  provides	  only	  a	  NOAEL/LOAEL;	  going	  forward,	  any	  use	  of	  animals	  
should	  aim	  to	  do	  so	  in	  as	  data-­‐rich	  a	  way	  as	  possible,	  both	  as	  more	  humane	  science	  
but	  also	  as	  simply	  better	  science.	  
	   As	  the	  Human	  Toxome	  is	  finite,	  it	  can	  certainly	  be	  mapped,	  but	  currently	  we	  
have	  only	  a	  few	  well-­‐characterized	  islands	  and	  a	  vast	  ocean	  of	  unknowns.	  In	  many	  
instances	  (e.g.	  endocrine	  disruptors),	  the	  unknowns	  might	  as	  well	  be	  mapped	  “Here	  
Be	  Dragons,”	  as	  they	  become	  a	  locus	  onto	  which	  nebulous	  fears	  are	  projected.	  At	  the	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same	  time,	  the	  finiteness	  of	  the	  Human	  Toxome	  will	  never	  allow	  us	  the	  luxury	  of	  
certainty	  about	  toxicity	  mechanisms.	  A	  useful	  cautionary	  tale	  comes	  from	  the	  early	  
history	  of	  x-­‐ray	  technology.	  It	  was	  a	  commonly	  understood	  occupational	  hazard	  that	  
individuals	  who	  worked	  with	  x-­‐rays	  would	  often	  have	  skin	  burns,	  but	  the	  results	  
were	  consistently	  attributed	  to	  things	  other	  than	  the	  x-­‐ray	  (perhaps	  the	  chemicals	  
used	  to	  develop	  it?)	  simply	  because	  no	  one	  could	  imagine	  light	  that	  was	  neither	  seen	  
nor	  felt	  could	  possibly	  produce	  injury	  (Kevles,	  1998).	  No	  doubt	  there	  are	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APPENDIX	  I	  Green	  Toxicology	  
(Originally	  published	  as:	  Maertens,	  A.,	  Anastas,	  N.,	  Spencer,	  P.	  J.,	  Stephens,	  M.,	  
Goldberg,	  A.,	  &	  Hartung,	  T.	  (2013).	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  Toxicology.	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  243-­‐249.)	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Abstract	  
Historically,	  early	  identification	  and	  characterization	  of	  adverse	  effects	  of	  industrial	  
chemicals	  was	  difficult	  because	  conventional	  toxicological	  test	  methods	  did	  not	  
meet	  R&D	  needs	  (e.g.	  methods	  that	  are	  rapid,	  relatively	  inexpensive	  and	  amenable	  
to	  small	  amounts	  of	  test	  material).	  The	  pharmaceutical	  industry	  has	  moved	  to	  front-­‐
loading	  toxicity	  testing,	  i.e.	  into	  using	  some	  in	  silico,	  in	  vitro	  and	  less	  demanding	  
animal	  tests	  at	  earlier	  stages	  of	  product	  development	  to	  identify	  and	  anticipate	  
undesirable	  toxicological	  effects	  and	  optimize	  product	  development.	  The	  Green	  
Chemistry	  movement	  embraces	  similar	  ideas	  to	  result	  in	  less	  toxic	  products,	  safer	  
processes	  and	  less	  waste	  and	  exposure.	  Going	  even	  a	  step	  further,	  the	  concept	  of	  
“benign	  design”	  suggests	  ways	  to	  consider	  possible	  toxicities	  before	  the	  actual	  
synthesis	  and	  to	  apply	  some	  structure/activity	  rules	  (SAR)	  and	  in	  silico	  methods.	  
This	  requires	  not	  only	  scientific	  development	  but	  a	  change	  in	  corporate	  culture,	  
where	  synthetic	  chemists	  work	  with	  toxicologists.	  An	  emerging	  discipline	  called	  
Green	  Toxicology	  (Anastas,	  2012)	  provides	  a	  framework	  for	  integrating	  the	  
principles	  of	  toxicology	  into	  the	  enterprise	  of	  designing	  safer	  chemicals,	  thereby	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minimizing	  potential	  toxicity	  as	  early	  in	  production	  as	  possible.	  Green	  toxicology’s	  
novel	  utility	  lies	  in	  driving	  innovation	  by	  moving	  safety	  considerations	  to	  the	  
earliest	  stage	  in	  a	  chemical’s	  lifecycle,	  i.e.,	  to	  molecular	  design.	  In	  principle	  this	  field	  
is	  no	  different	  than	  other	  sub-­‐disciplines	  of	  toxicology	  that	  endeavor	  to	  focus	  the	  
tools	  of	  toxicology	  on	  a	  specific	  area,	  for	  example,	  clinical,	  environmental	  or	  forensic	  
toxicology.	  We	  use	  the	  same	  principles	  and	  tools	  of	  toxicology	  to	  evaluate	  an	  
existing	  substance	  or	  to	  design	  a	  new	  one.	  The	  unique	  emphasis	  is	  in	  using	  21st	  
century	  toxicology	  tools	  as	  a	  preventative	  strategy	  to	  design	  out	  undesired	  human	  
health	  and	  environmental	  effects	  thereby	  increasing	  the	  likelihood	  of	  launch	  of	  a	  
successful,	  sustainable	  product.	  Starting	  with	  the	  formation	  of	  a	  steering	  group	  and	  
a	  series	  of	  workshops,	  the	  Green	  Toxicology	  concept	  is	  currently	  spread	  
internationally	  and	  refined	  as	  an	  iterative	  process.	  	  
	  
Introduction	  
Over	  the	  past	  few	  decades,	  there	  has	  been	  an	  increase	  in	  consumer	  demand	  for	  less	  
toxic,	  more	  environmentally	  friendly	  products,	  as	  well	  as	  increasing	  regulatory	  and	  
economic	  pressure	  for	  more	  sustainable	  products,	  less	  wasteful	  manufacturing,	  and	  
a	  switch	  to	  renewable	  resources	  as	  source	  materials—in	  essence,	  a	  “Green	  
Chemistry”	  approach	  (Paul	  &	  John,	  1998)	  which	  puts	  environmental	  and	  sustainable	  
principles	  at	  the	  forefront	  of	  chemical	  design.	  	  
However,	  in	  order	  for	  Green	  Chemistry	  to	  flourish,	  there	  must	  be	  a	  parallel	  
paradigm	  change	  in	  toxicology:	  less	  toxic	  chemicals	  cannot	  be	  effectively	  designed	  
unless	  scientists	  have	  the	  necessary	  tools	  to	  quickly	  and	  accurately	  assess	  chemical	  
hazards.	  Toxicology	  has	  hitherto	  been	  little	  concerned	  with	  developing	  tools	  to	  help	  
chemists	  better	  understand	  toxicity	  and	  design	  better	  alternatives.	  The	  principle	  of	  
“benign	  design”	  has	  been	  part	  of	  the	  12	  founding	  principles	  of	  Green	  Chemistry	  from	  
the	  beginning,	  as	  principles	  3	  and	  4	  directly	  address	  this	  (Box	  1).	  Other	  principles	  
aim	  to	  reduce	  waste	  and	  use	  of	  chemicals	  and	  thus	  limit	  exposure	  in	  the	  
environment	  and	  the	  workplace.	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Box	  1	  
The	  12	  principles	  of	  Green	  Chemistry	  .	  (Paul	  &	  John,	  1998)	  
1. It	  is	  better	  to	  prevent	  waste	  than	  to	  treat	  or	  clean	  up	  waste	  after	  it	  is	  formed.	  
2. Synthetic	  methods	  should	  be	  designed	  to	  maximize	  the	  incorporation	  of	  all	  
materials	  use	  in	  the	  process	  into	  the	  final	  product.	  
3. Wherever	  practicable,	  synthetic	  methodologies	  should	  be	  designed	  to	  use	  
and	  generate	  substances	  that	  possess	  little	  or	  no	  toxicity	  to	  human	  health	  
and	  the	  environment.	  
4. Chemical	  products	  should	  be	  designed	  to	  preserve	  efficacy	  of	  function	  while	  
reducing	  toxicity.	  
5. The	  use	  of	  auxiliary	  substances	  (e.g.	  solvents,	  separation	  agents,	  etc.)	  should	  
be	  made	  unnecessary	  wherever	  possible	  and	  innocuous	  when	  used.	  
6. Energy	  requirements	  should	  be	  recognized	  for	  their	  environmental	  and	  
economic	  impacts	  and	  should	  be	  minimized.	  Synthetic	  methods	  should	  be	  
conducted	  at	  ambient	  temperature	  and	  pressure.	  
7. A	  raw	  material	  or	  feedstock	  should	  be	  renewable	  rather	  than	  depleting	  
wherever	  technically	  and	  economically	  practicable.	  
8. Reduce	  derivatives:	  Unnecessary	  derivatization	  (blocking	  group,	  
protection/deprotection,	  temporary	  modification)	  should	  be	  avoided	  
whenever	  possible.	  
9. Catalytic	  reagents	  (as	  selective	  as	  possible)	  are	  superior	  to	  stoichiometric	  
reagents.	  
10. Chemical	  products	  should	  be	  designed	  so	  that	  at	  the	  end	  of	  their	  function	  
they	  do	  not	  persist	  in	  the	  environment	  and	  break	  down	  into	  innocuous	  
degradation	  products.	  
11. Analytical	  methodologies	  need	  to	  be	  further	  developed	  to	  allow	  for	  real-­‐time,	  
in-­‐process	  monitoring	  and	  control	  prior	  to	  the	  formation	  of	  hazardous	  
substances.	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12. Substances	  and	  the	  form	  of	  a	  substance	  used	  in	  a	  chemical	  process	  should	  be	  
chosen	  to	  minimize	  potential	  for	  chemical	  accidents,	  including	  releases,	  
explosions,	  and	  fires.	  
	  
The	  current	  industrial	  product	  development	  paradigm	  relies	  on	  time-­‐consuming,	  
expensive	  animal	  studies	  and	  is	  too	  slow	  to	  keep	  pace	  with	  technological	  change	  
(Hartung,	  2010b;	  Hartung	  &	  Rovida,	  2009).	  	  For	  example,	  a	  typical	  2-­‐generation	  
reproductive	  study	  costs	  more	  than	  $500,000,	  uses	  more	  than	  3000	  rats	  and	  takes	  
15	  months	  to	  complete.	  For	  this	  reason,	  toxicity	  testing	  is	  typically	  reserved	  for	  the	  
latter	  stages	  of	  chemical/product	  development	  after	  it’s	  determined	  to	  be	  
commercially	  viable.	  Consequently,	  toxic	  effects	  are	  identified	  closer	  to	  
commercialization	  when	  little	  options	  for	  design	  changes	  exist	  and	  after	  significant	  
investment	  of	  time,	  resources	  and	  money.	  Today,	  rapidly	  evolving,	  21st	  century	  
safety	  assessment	  methodologies	  have	  the	  potential	  to	  transform	  how	  companies	  
develop	  and	  commercialize	  new	  products	  and	  chemicals	  
This	  rapid,	  high-­‐throughput,	  high-­‐content	  “Green	  Toxicology”	  paradigm	  can	  work	  in	  
tandem	  with	  R&D	  by	  providing	  answers	  about	  mechanism	  of	  toxicity	  quickly,	  
inexpensively,	  and	  with	  the	  small	  quantities	  of	  material	  typically	  available	  for	  R&D.	  
“Green	  Toxicology”	  combines	  the	  in	  vitro	  and	  in	  silico	  tools	  of	  predictive	  toxicology	  
with	  the	  principles	  of	  chemical	  design	  to	  develop	  chemicals	  that	  have	  negligible	  
toxicity,	  and	  early	  elimination	  of	  candidates	  possessing	  undesirable	  traits	  by	  “failing	  
early	  and	  failing	  cheaply”,	  or	  to	  put	  it	  more	  positively,	  to	  enable	  innovation	  through	  
early	  and	  inexpensive	  evaluation	  of	  hazard.	  	  
	  
Consideration	  1:	  The	  first	  principle	  of	  Green	  Toxicology—“Benign	  design”	  
The	  idea	  is	  simple:	  toxicologists	  partner	  with	  synthetic	  chemists	  to	  understand	  what	  
chemical	  moiety	  may	  impart	  undesired	  hazard	  traits	  as	  early	  as	  feasible	  in	  product	  
development.	  Toxicology	  is	  in	  the	  midst	  of	  a	  major	  transition	  from	  animal-­‐based	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methods	  that	  are	  slow,	  expensive	  and	  suffer	  from	  low-­‐throughput,	  to	  more	  modern	  
approaches	  utilizing	  cheminformatics,	  cell	  cultures,	  genomics	  and	  computational	  
biology	  to	  achieve	  greater	  speed	  and	  throughput,	  lower	  cost,	  and	  ultimately,	  more	  
accurate	  predictions	  of	  safety	  in	  humans	  and	  the	  environment.	  	  	  	  
For	  example,	  programs	  based	  on	  structure	  activity	  relationships	  (SAR)	  can	  be	  useful	  
in	  guiding	  early	  selection	  of	  low	  hazard	  candidates	  to	  continue	  in	  product	  
development.	  A	  nice	  illustration	  is	  the	  “ultimate	  rat	  carcinogen”	  drawn	  by	  Tennant	  
and	  Ashby	  (Ashby	  &	  Tennant,	  1991)	  showing	  the	  chemical	  features	  associated	  with	  
mutagenicity	  in	  one	  theoretical	  molecule	  (Figure	  1).	  However,	  when	  challenged	  to	  
prospectively	  predict	  the	  outcome	  for	  30	  chemicals	  to	  be	  tested	  in	  the	  US	  National	  
Toxicology	  Program,	  the	  authors	  achieved	  only	  50-­‐60%	  prediction	  of	  the	  
carcinogenic	  substances	  and	  wrongly	  predicted	  40-­‐50%	  of	  non-­‐carcinogens	  to	  be	  
positive	  in	  the	  animal	  test	  (Benigni	  &	  Zito,	  2004).	  This	  illustrates	  the	  limitations	  of	  
SARs	  for	  such	  complex	  endpoints	  (D.	  Basketter	  et	  al.,	  2012)	  and	  	  
	  
Chapter	  I,	  Figure	  15:	  Ultimate	  Rat	  Carcinogen	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therefore,	  as	  much	  as	  read-­‐across	  and	  QSARs	  have	  helped	  to	  make	  testing	  more	  
targeted	  and	  efficient,	  their	  utility	  lies	  as	  low	  cost,	  rapid	  “Tier	  1”	  assessments	  of	  new	  
candidate	  chemistries	  and	  sustainable	  alternatives.	  	  	  
It	  is	  worth	  pondering	  whether	  the	  existing	  QSARs	  will	  have	  adequate	  applicability	  
for	  the	  more	  novel	  chemicals	  that	  emerge	  from	  green	  chemistry	  research—e.g.	  
QSARs	  developed	  for	  industrial	  synthetic	  chemicals	  may	  not	  be	  applicable	  for	  bio-­‐
based	  materials.	  Some	  positive	  examples	  exist	  especially	  in	  the	  field	  of	  aquatic	  
toxicity	  (Voutchkova,	  Ferris,	  Zimmerman,	  &	  Anastas,	  2010;	  Voutchkova	  et	  al.,	  2011;	  
Voutchkova,	  Osimitz,	  &	  Anastas,	  2010)	  	  but	  this	  is	  arguably	  an	  easy	  case,	  where	  
lipophilicity	  is	  key	  to	  uptake	  and	  thus	  hazard.	  However,	  this	  does	  not	  mean	  that	  
helpful	  estimates	  for	  more	  complex	  hazards	  such	  as	  immunotoxicity	  (Hartung	  and	  
Corsini,	  2013),	  developmental	  neurotoxicity	  (Smirnova,	  Hogberg,	  Leist,	  &	  Hartung,	  
2014)	  or	  endocrine	  disruption	  (Juberg	  et	  al.,	  2013)	  could	  not	  be	  done.	  	  
Additionally,	  while	  QSARs	  have	  certainly	  proven	  their	  merit	  in	  the	  pharmaceutical	  
industry,	  this	  success	  is	  unlikely	  to	  be	  repeated	  for	  industrial	  chemicals	  for	  a	  variety	  
of	  reasons.	  Industrial	  chemicals	  may	  consist	  of	  polymers	  with	  a	  wide	  range	  of	  
molecular	  weights,	  various	  impurities,	  left	  over	  reagents	  etc.,	  while	  the	  large	  
majority	  of	  drugs	  fall	  into	  a	  more	  narrow	  chemical	  space,	  often	  referred	  to	  as	  the	  
Lipinsky	  rules	  (Lipinski,	  2004):	  
• No	  more	  than	  5	  hydrogen	  bond	  donors	  (the	  total	  number	  of	  nitrogen–
hydrogen	  and	  oxygen–hydrogen	  bonds)	  
• Not	  more	  than	  10	  hydrogen	  bond	  acceptors	  (all	  nitrogen	  or	  oxygen	  atoms)	  
• A	  molecular	  mass	  less	  than	  500	  daltons	  
• An	  octanol-­‐water	  partition	  coefficient	  log	  P	  not	  greater	  than	  5	  
This	  is	  a	  nice	  example,	  though	  not	  for	  safety	  but	  efficacy,	  how	  structure	  
considerations	  can	  help	  designing	  substances.	  
More	  fundamentally,	  QSARs	  developed	  for	  the	  pharmaceutical	  industry	  have	  a	  
domain	  defined	  by	  suspected	  biological	  activity;	  QSARs	  may	  simply	  lack	  the	  
accuracy	  necessary	  when	  the	  overwhelming	  number	  of	  chemicals	  are	  in	  fact	  lacking	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toxicity,	  as	  is	  the	  case	  for	  many	  industrial	  chemicals	  (Box	  2);	  the	  respective	  
estimates	  reflect	  internal	  ECVAM	  analyses	  of	  the	  European	  New	  Chemical	  Database,	  
which	  includes	  new	  industrial	  chemicals	  registered	  since	  1981	  under	  the	  Dangerous	  
Substance	  Directive,	  around	  2005(Hoffmann,	  Cole,	  &	  Hartung,	  2005;	  Hoffmann	  &	  
Hartung,	  2005).	  Therefore,	  while	  QSARS	  likely	  will	  have	  a	  role	  to	  play	  in	  the	  
development	  of	  benign	  alternatives,	  it	  is	  equally	  important	  that	  toxicology	  develop	  
other	  techniques	  and	  approaches	  that	  link	  molecular	  structure	  with	  toxic	  outcomes	  
in	  a	  way	  that	  can	  be	  useful	  to	  synthetic	  chemists.	  
	  
	  
Consideration	  2:	  The	  second	  principle	  of	  Green	  Toxicology—“Test	  early,	  
produce	  safe”	  
The	  pharmaceutical	  industry	  has	  developed	  concepts	  of	  “fail	  early,	  fail	  cheap”	  as	  a	  
consequence	  of	  the	  cost	  explosion	  in	  the	  late	  clinical	  part	  of	  development	  and	  the	  
high	  failure	  rates	  observed	  there	  (Hartung,	  2013;	  Hartung	  &	  Zurlo,	  2012).	  For	  
Box	  2	  	  
Most	  chemicals	  are	  not	  toxic:	  
90%	  not	  acutely	  toxic	  (EU	  New	  Chemical	  Database)	  
97%	  not	  skin	  corrosive	  (EU	  New	  Chemical	  Database)	  
93%	  not	  skin	  irritant	  (EU	  New	  Chemical	  Database)	  
97%	  not	  teratogenic	  (expert	  estimate,	  about	  60%	  not	  positive	  in	  single	  species	  
two-­‐generation	  studies)	  
80-­‐95%	  not	  carcinogenic	  (expert	  estimates,	  47%	  not	  positive	  in	  rodent	  bioassay)	  
80%	  not	  eye	  irritating	  (EU	  New	  Chemical	  Database)	  
65%	  not	  skin	  sensitizing	  (EU	  New	  Chemical	  Database)	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example	  it	  was	  noted	  that	  in	  the	  1990s,	  a	  large	  number	  of	  drugs	  failed	  because	  of	  
pharmacokinetic	  problems,	  i.e.	  the	  active	  agent	  did	  not	  reach	  sufficient	  
concentrations	  in	  the	  targeted	  organ	  in	  patients.	  Addressing	  this	  early	  and	  with	  
human	  relevant	  methods	  markedly	  reduced	  this	  type	  of	  failure	  (Singh,	  2006;	  
Tsaioun	  &	  Jacewicz,	  2009).	  
This	  approach	  can	  also	  be	  adapted	  to	  the	  front-­‐loading	  of	  toxicity	  testing	  of	  
industrial	  chemicals.	  In	  the	  short	  term,	  predictive	  safety	  assessment	  offers	  a	  way	  to	  
enrich	  the	  R&D	  pipeline	  for	  chemicals	  that	  are	  most	  likely	  to	  clear	  challenging	  
regulatory	  hurdles.	  Because	  predictive	  methods	  focus	  on	  the	  root	  causes	  of	  toxicity	  
at	  the	  cellular	  and	  molecular	  levels,	  they	  also	  generate	  new	  knowledge	  to	  inform	  the	  
design	  of	  safer	  and	  more	  sustainable	  products.	  Traditional	  toxicity	  tests	  total	  several	  
million	  dollars	  for	  a	  product	  to	  go	  to	  the	  market.	  These	  studies	  also	  take	  a	  lot	  of	  
time,	  in	  some	  cases	  taking	  years	  to	  complete,	  e.g.,	  the	  rat	  cancer	  bioassay	  entails	  two	  
years	  of	  treatment	  plus	  time	  for	  planning,	  histopathology	  and	  reporting.	  And	  often,	  
at	  the	  end	  of	  this	  process,	  the	  results	  are	  equivocal	  and	  may	  be	  of	  questionable	  
relevance	  to	  humans.	  If	  the	  results	  are	  positive,	  such	  bioassays	  typically	  provide	  no	  
mechanistic	  information	  for	  the	  synthetic	  chemist	  to	  design	  a	  less	  toxic	  alternative.	  
Clearly,	  under	  the	  pressure	  of	  “time	  to	  market”	  and	  the	  running	  clock	  of	  the	  patents	  
and	  competitive	  economic	  pressures,	  these	  are	  not	  the	  best	  tools	  for	  early	  decision	  
taking.	  	  
Front-­‐loading	  thus	  requires	  screening	  level	  tests	  that	  are	  both	  less	  costly	  and	  much	  
faster,	  and	  a	  movement	  to	  a	  smarter	  approach	  that	  begins	  with	  in	  silico	  screening	  to	  
predict	  possible	  targets	  and	  progresses	  to	  targeted	  in	  vitro	  tests	  that	  can	  examine	  
suspected	  Pathways	  of	  Toxicity	  (Hartung	  and	  McBride,	  2011;	  Kleensang	  et	  al.,	  
2014).	  For	  those	  candidates	  that	  do	  move	  on	  to	  whole	  animal	  tests,	  a	  smarter	  
testing	  approach	  might	  allow	  for	  reduced	  reliance	  on	  high-­‐dose	  testing	  that	  causes	  
gross	  pathological	  change	  as	  an	  indication	  of	  toxicity	  and	  focuses	  more	  precisely	  on	  
the	  molecular	  initiating	  event	  at	  doses	  that	  can	  meaningfully	  be	  related	  to	  possible	  
human	  exposures.	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Another	  advantage	  of	  front-­‐loading	  toxicity	  in	  the	  R&D	  process	  would	  be	  to	  reduce	  
cases	  of	  “out	  of	  the	  frying	  pan,	  into	  the	  fire”—in	  other	  words,	  often	  replacements	  that	  
are	  promoted	  as	  alternatives	  to	  known	  “bad	  actors”	  turn	  out	  to	  be	  not	  necessarily	  
less	  toxic,	  but	  in	  fact	  simply	  have	  less	  data.	  This	  was	  the	  case	  with	  flame	  retardants	  
(Lakind	  &	  Birnbaum,	  2010).	  This	  creates	  a	  somewhat	  perverse	  incentive	  not	  to	  
gather	  toxicity	  data,	  which	  is	  compounded	  by	  the	  fact	  that	  consumer	  preference	  can	  
be	  markedly	  influenced	  by	  the	  results	  of	  toxicity	  tests	  that	  are	  taken	  out	  of	  context.	  
More	  rigorous	  toxicity	  testing	  as	  an	  essential	  part	  of	  the	  R&D	  process	  would	  likely	  
produce	  a	  more	  rational	  selection	  of	  benign	  replacements.	  	  
	  
Consideration	  3:	  The	  third	  principle	  of	  Green	  Toxicology—“Avoid	  exposure	  
and	  thus	  testing	  needs”	  
Traditionally,	  toxicologists	  are	  trained	  to	  think	  in	  terms	  of	  molecules	  and	  not	  in	  
terms	  of	  the	  production	  processes	  behind	  them.	  However,	  within	  the	  many	  steps	  
involved	  in	  the	  production	  of	  industrial	  chemicals,	  there	  are	  often	  small	  alterations	  
that	  can	  achieve	  significant	  reductions	  in	  terms	  of	  exposure	  and	  therefore	  minimize	  
risk—e.g.	  toxicity	  may	  reside	  in	  a	  catalytic	  agent	  that	  can	  be	  eliminated	  with	  
alternative	  routes	  of	  synthesis.	  For	  many	  polymers,	  the	  final	  product	  has	  a	  
sufficiently	  large	  molecular	  weight	  so	  as	  to	  preclude	  bioavailability,	  and	  any	  hazard	  
is	  likely	  because	  of	  residual	  monomer.	  Consequently,	  small	  changes	  in	  the	  efficiency	  
of	  the	  reaction	  or	  the	  purification	  step	  can	  drastically	  reduce	  the	  hazard	  while	  
conserving	  resources.	  Similarly,	  a	  change	  to	  “one-­‐pot	  synthesis”	  (meaning	  that	  all	  
reactions	  take	  place	  in	  the	  same	  vessel)	  can	  decrease	  the	  number	  of	  exposed	  
workers.	  In	  this	  respect,	  the	  goals	  of	  Green	  Toxicology	  dovetail	  with	  the	  Green	  
Chemistry	  goal	  of	  improved	  efficiency	  and	  emphasize	  the	  importance	  of	  close	  
collaboration	  between	  the	  chemist	  and	  the	  toxicologist.	  Together	  their	  measures	  
directly	  affect	  occupational	  health	  and	  then	  via	  reduced	  exposure	  also	  influence	  risk	  
assessment	  and	  management.	  Such	  scenarios	  are	  ripe	  for	  exposure-­‐driven	  testing	  
strategies,	  which	  can	  result	  in	  reduced	  testing	  demands.	  Reduced	  exposure	  also	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makes	  it	  more	  likely	  that	  Thresholds	  of	  Toxicological	  Concern	  (TTC)	  (R	  Kroes,	  
Kleiner,	  &	  Renwick,	  2005),	  (Munro,	  Renwick,	  &	  Danielewska-­‐Nikiel,	  2008)	  are	  not	  
exceeded,	  an	  example	  of	  a	  formalized	  exposure-­‐driven	  assessment.	  The	  idea	  is	  
simple:	  we	  can	  assess	  how	  much	  of	  the	  known	  toxicants	  is	  necessary	  to	  exert	  a	  
certain	  effect	  (which	  will	  give	  a	  distribution	  of	  doses)	  and	  then	  define	  a	  point	  of	  
departure	  dose.	  With	  an	  appropriate	  safety	  factor,	  it	  is	  unlikely	  that	  an	  unknown	  
agent	  will	  exert	  this	  toxicity.	  The	  concept	  has	  been	  pioneered	  for	  food	  (Robert	  Kroes	  
et	  al.,	  2004)	  and	  cosmetics	  (Blackburn	  et	  al.,	  2005;	  R	  Kroes	  et	  al.,	  2007)	  but	  also	  
adapted	  to	  pharmaceuticals,	  especially	  for	  genotoxic	  impurities.	  Noteworthy,	  the	  
World	  Health	  Organization	  is	  currently	  reviewing	  the	  approach1.	  TTCs	  have	  first	  
been	  used	  for	  carcinogens,	  but	  the	  concept	  was	  also	  adapted	  for	  example	  to	  
reproductive	  toxicity	  testing	  (Van	  Ravenzwaay,	  Dammann,	  Buesen,	  &	  Schneider,	  
2011).	  We	  argued	  in	  a	  similar	  way	  in	  the	  context	  of	  immunotoxicity	  (Hartung	  &	  
Corsini,	  2013),	  showing	  that	  clinical	  immunosuppressants	  require	  mg/kg	  quantities	  
to	  exert	  their	  effects	  and	  that	  this	  could	  be	  used	  for	  establishing	  TTC	  for	  substances	  
not	  optimized	  for	  this	  purpose.	  	  
In	  conclusion,	  Green	  Chemistry—by	  reducing	  exposure	  and	  thus	  testing	  demands—
has	  more	  to	  offer	  to	  toxicology,	  safety	  testing	  and	  risk	  management	  than	  just	  Benign	  
Design	  and	  Early	  Testing	  (figure	  2).	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  http://www.who.int/foodsafety/chem/ttc/en/	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Chapter	  I,	  Figure	  16:	  Green	  Toxicology	  Paradigm	  
	  
Consideration	  4:	  The	  fourth	  principle	  of	  Green	  Toxicology—“Make	  testing	  
sustainable”	  
Animal	  testing	  is	  not	  just	  costly	  in	  terms	  of	  time	  and	  money,	  but	  is	  inefficient	  with	  
regards	  to	  resources,	  requiring	  energy	  and	  producing	  a	  great	  deal	  of	  biohazard	  
waste.	  Consequently,	  we	  argue	  that	  the	  long-­‐term	  use	  of	  animals	  is	  fundamentally	  
not	  sustainable.	  It	  has	  been	  estimated	  that	  regulatory	  requirements	  in	  Europe	  
require	  approximately	  300	  animals	  to	  test	  new	  chemical	  compounds	  up	  to	  10,000	  
for	  a	  pesticide	  (A.	  Bottini	  &	  Hartung,	  2010).	  Notably,	  the	  10.000	  animals	  per	  
pesticide	  do	  not	  include	  abandoned	  products.	  Before	  REACH	  in	  Europe	  90	  to	  140	  
thousand	  animals	  were	  used	  for	  chemical	  testing	  of	  roughly	  200	  new	  chemicals	  per	  
year,	  but	  this	  does	  not	  include	  testing	  outside	  of	  Europe.	  In	  the	  US,	  discrepancies	  in	  
testing	  demands	  between	  are	  even	  stronger	  between	  different	  products	  with	  7	  out	  
of	  8	  new	  industrial	  chemicals	  having	  no	  toxicity	  data	  at	  pre-­‐marketing	  notification	  
under	  the	  Toxic	  Substance	  Control	  Act	  (Hartung,	  2010)	  and	  similar	  requests	  of	  more	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than	  30	  animal	  tests	  for	  pesticides.	  With	  40,000	  animals	  tested	  for	  safety	  per	  new	  
substance	  entering	  the	  market	  and	  350,000	  for	  R&D	  (factoring	  in	  the	  animals	  used	  
for	  candidate	  drugs	  that	  do	  not	  succeed),	  the	  pharmaceutical	  sector	  still	  has	  very	  
high	  animal	  use	  despite	  the	  impressive	  reductions	  in	  recent	  years.	  This	  is	  not	  only	  
unsustainable	  but	  may	  impose	  an	  economic	  barrier	  that	  is	  prohibitive	  for	  niche	  
chemicals	  that	  may	  have	  limited	  profitability.	  A	  smarter,	  in	  vitro	  testing	  strategy	  can	  
reduce	  the	  use	  of	  resources	  for	  testing	  by	  better	  prioritization	  and	  more	  efficient	  
screening-­‐level	  tests.	  Longer	  term	  we	  hope	  agencies	  will	  find	  greater	  application	  of	  
predictive	  methods	  to	  address	  some	  requirements	  of	  their	  programs.	  
	  
Consideration	  5:	  “Early	  testing	  can	  use	  methods	  not	  yet	  mature	  for	  
regulating”.	  
Regulation	  tends	  to	  take	  a	  precautionary	  approach	  that	  is	  oriented	  towards	  
minimizing	  mistakes	  rather	  than	  optimizing	  the	  cost/benefit	  analysis.	  This	  makes	  it	  
profoundly	  difficult	  to	  change	  traditional	  approaches.	  Furthermore,	  a	  traditional	  
validation	  study	  takes	  about	  one	  decade.	  Consequently,	  a	  validated	  test	  is	  “frozen	  in	  
time,”	  and	  it	  is	  simply	  impossible	  for	  regulatory	  mechanisms	  to	  keep	  up-­‐to-­‐date	  
with	  the	  current	  rate	  of	  change	  in	  science	  (Hartung,	  2007;(Leist,	  Hasiwa,	  Daneshian,	  
&	  Hartung,	  2012).	  	  
Frontloading	  toxicity	  at	  the	  research	  and	  development	  stage,	  however,	  allows	  a	  
more	  flexible	  approach.	  Prioritization	  of	  substances	  as	  lead	  for	  development	  can	  be	  
based	  on	  methods,	  which	  still	  have	  some	  margins	  of	  error.	  Early	  testing	  allows	  the	  
use	  of	  methods	  not	  yet	  validated.	  In	  silico	  and	  in	  vitro	  tests	  that	  are	  individually	  too	  
inaccurate	  for	  regulatory	  purposes	  will	  likely	  have	  a	  useful	  place	  in	  an	  integrated	  
testing	  strategy	  (Hartung	  et	  al.,	  2013).	  Such	  strategies	  allow	  uncertainty	  in	  results	  
and	  seek	  to	  combine	  data	  from	  multiple	  tests	  in	  a	  flexible	  manner	  that	  maximizes	  
predictive	  power	  while	  also	  providing	  an	  estimate	  of	  the	  uncertainty	  in	  the	  data.	  
This	  helps	  to	  build	  capacity	  and	  capability	  to	  perform	  these	  assays	  also	  for	  later	  
regulatory	  use,	  if	  validated	  and	  accepted.	  In	  the	  meantime,	  these	  front-­‐loaded	  
methods	  will	  be	  generating	  data,	  and	  thereby	  facilitating	  an	  assessment	  of	  the	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predictive	  value	  of	  these	  methods	  and	  thus	  contributing	  to	  the	  validation	  and	  
acceptance	  process.	  	  	  
This	  opens	  up	  also	  a	  role	  for	  new	  risk	  assessments	  based	  on	  toxicity	  “pathways”	  
(cell/molecular	  level	  changes)	  and	  data-­‐driven	  uncertainty	  factors	  (e.g.,	  intra-­‐
human	  variability	  factors	  based	  on	  genetic	  analysis).	  It	  will	  take	  tremendous	  time	  to	  
base	  regulatory	  testing	  on	  pathways	  of	  toxicity	  (PoT),	  as	  the	  respective	  database	  
first	  would	  need	  to	  be	  sufficiently	  comprehensive	  and	  validated	  (Hartung	  and	  
McBride,	  2011).	  However,	  with	  each	  and	  every	  PoT	  identified	  the	  respective	  assays	  
can	  be	  included	  in	  integrated	  testing	  strategies.	  A	  pathway-­‐based	  approach	  can	  also	  
allow	  for	  more	  precise	  understanding	  of	  individual	  variation	  in	  response	  to	  toxicity	  
as	  well	  as	  susceptible	  populations	  by	  illuminating	  more	  precisely	  the	  differences	  in	  
PoT.	  Similarly,	  default	  safety	  and	  assessment	  factors	  might	  be	  replaced	  by	  
knowledge	  on	  intra-­‐species	  and	  inter-­‐individual	  differences	  in	  PoT.	  
	  
Consideration	  6:	  Green	  Toxicology	  as	  a	  Driver	  of	  21st	  Century	  Toxicology	  
Biology	  has	  been	  transformed	  over	  the	  last	  decade	  from	  a	  reductionist	  and	  largely	  
qualitative	  science	  to	  a	  more	  quantitative	  approach	  that	  requires	  systems-­‐level	  
thinking,	  large-­‐scale	  data	  analysis,	  and	  multi-­‐scale	  modeling.	  Although	  certain	  areas	  
of	  toxicology	  (such	  as	  PBPK	  modeling)	  have	  long	  embraced	  mathematical	  models	  
and	  certain	  elements	  of	  systems-­‐level	  thinking,	  the	  insights	  gained	  from	  systems	  
biology	  have	  not	  generally	  been	  reflected	  in	  regulatory	  toxicology	  or	  hazard	  
assessment.	  Furthermore,	  the	  field	  of	  toxicology	  is	  only	  beginning	  to	  assemble	  the	  
type	  of	  large-­‐scale	  data	  sets	  that	  have	  been	  transformative	  for	  molecular	  biology.	  As	  
the	  green	  toxicology	  paradigm	  of	  high-­‐throughput,	  -­‐omics	  based	  approaches	  for	  
screening	  many	  compounds	  gathers	  data,	  this	  can	  act	  as	  a	  driver	  towards	  
transforming	  toxicology	  from	  a	  reductionist	  approach	  based	  on	  “feet-­‐up/feet-­‐down”	  
assays	  (i.e.	  the	  LD50)	  towards	  an	  approach	  that	  uses	  the	  insights	  of	  systems	  biology,	  
computational	  modeling,	  and	  exploratory	  data	  mining	  to	  locate	  the	  mechanism	  of	  
toxicity	  in	  perturbed	  networks.	  Green	  toxicology	  can	  serve	  as	  a	  bridge	  between	  21st	  
century	  toxicology	  methods	  and	  the	  development	  of	  safer,	  sustainable	  products.	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This	  paradigm	  shift	  and	  transformation	  is	  necessarily	  a	  slow	  and	  long	  process	  as	  
safety	  of	  workers	  and	  consumers	  is	  at	  stake.	  This	  delay	  makes	  regulatory	  science	  
less	  attractive	  for	  academic	  research	  and	  even	  more	  for	  the	  commercialization	  of	  
test	  methods.	  If	  companies	  have	  to	  wait	  a	  decade	  for	  the	  regulatory	  acceptance	  of	  a	  
test	  with	  unclear	  prospects	  for	  the	  validation	  phase,	  the	  return	  of	  investment	  is	  
rather	  unlikely.	  Early	  non-­‐regulatory	  testing	  creates	  an	  immediate	  market	  for	  new	  
test	  methods.	  It	  therefore	  liberates	  the	  market	  forces	  necessary	  to	  standardize	  and	  
disseminate	  tests	  also	  internationally	  (A.	  A.	  Bottini,	  Amcoff,	  &	  Hartung,	  2007),	  






Consideration	  7:	  The	  Green	  Toxicology	  Program	  
Following	  on	  the	  initial	  success	  of	  our	  Green	  Toxicology	  Day	  in	  November	  of	  2013	  
and	  its	  forerunner	  at	  University	  of	  Connecticut	  in	  December	  20122,	  a	  follow-­‐up	  
series	  of	  webinars	  is	  planned.	  In	  addition,	  a	  proposal	  for	  a	  session	  at	  the	  2015	  SOT	  
meeting	  has	  been	  accepted.	  Information	  sessions	  at	  the	  GlobalChem	  conference	  and	  
the	  ACS	  Green	  Chemistry	  Conference	  are	  planned.	  A	  multi-­‐day	  “Green	  Toxicology	  
Workshop”	  is	  planned	  for	  the	  spring	  of	  2015	  in	  Washington	  State.	  Curricula	  for	  
students	  especially	  of	  synthetic	  chemistry—who	  typically	  are	  given	  minimal	  
training	  in	  toxicology—are	  a	  further	  goal.	  Development	  of	  dedicated	  scientific	  
articles	  and	  a	  textbook	  on	  “Green	  Toxicology”	  as	  well	  as	  a	  compendium	  of	  Design	  
Rules	  for	  Reduced	  Hazard	  aimed	  at	  synthetic	  chemists	  (‘the	  green	  toolbox”),	  will	  be	  
significant	  products	  of	  the	  effort.	  Furthermore,	  the	  CAAT	  policy	  program	  will	  inform	  
policy	  makers	  about	  the	  opportunities	  of	  a	  Green	  Toxicology	  approach.	  Key	  to	  this	  
outreach	  will	  be	  bringing	  together	  two	  communities—toxicologists	  and	  chemists—
that	  have	  long	  worked	  in	  parallel	  but	  have	  heretofore	  rarely	  worked	  collaboratively.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2	  http://caat.jhsph.edu/programs/workshops/greenTox.html	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Conclusions	  
Alternative	  methods	  in	  toxicology	  increasingly	  represent	  themselves	  as	  enabling	  
technologies,	  i.e.	  they	  can	  do	  more	  than	  optimize	  and	  replace	  current	  regulatory	  
testing:	  The	  pharmaceutical	  field	  has	  for	  a	  while	  been	  taking	  advantage	  of	  front-­‐
loading	  of	  testing	  and	  mechanistic	  understanding	  for	  early	  determination	  of	  
possible	  toxic	  liabilities.	  The	  chemical	  industry	  has	  started	  to	  embrace	  similar	  
concepts	  in	  the	  Green	  Chemistry	  movement.	  A	  Green	  Toxicology	  is	  emerging,	  which	  
uses	  structure-­‐activity	  relationships	  for	  the	  design	  of	  less	  harmful	  substances,	  tests	  
early	  in	  the	  development	  process	  to	  prioritize	  less	  dangerous	  chemicals	  and	  reduces	  
exposures	  thus	  reducing	  risk	  and	  testing	  demands.	  These	  approaches	  promise	  to	  
create	  opportunities	  for	  the	  development	  and	  use	  of	  alternative	  test	  methods	  and	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APPENDIX	  II	  Integrated	  Testing	  Strategy	  
	  
(Originally	  publishes	  as:	  Hartung,	  T.,	  Luechtefeld,	  T.,	  Maertens,	  A.,	  &	  Kleensang,	  A.	  
(2013).	  Food	  for	  Thought…	  Integrated	  Testing	  Strategies	  for	  Safety	  Assessments.	  




“Playing	  safe	  is	  probably	  the	  most	  
unsafe	  thing	  in	  the	  world.	  
	  You	  cannot	  stand	  still.	  
	  You	  must	  go	  forward”	  
Robert	  Collier	  (1885-­‐1950)	  
	  
Food	  for	  thought…	  
Integrated	  Testing	  Strategies	  for	  Safety	  Assessments	  
	  
Thomas	  Hartung1,2,	  Tom	  Luechtefeld1,	  Alexandra	  Maertens1	  and	  Andre	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1Johns	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  Public	  Health,	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Abstract	  
Despite	  the	  fact	  that	  toxicology	  uses	  many	  stand-­‐alone	  tests,	  very	  often	  a	  systematic	  
combination	  of	  several	  information	  sources	  is	  required:	  Examples	  include,	  when	  not	  
all	  possible	  outcomes	  of	  interest	  (e.g.	  modes	  of	  action),	  classes	  of	  test	  substances	  
(applicability	  domains)	  or	  severity	  classes	  of	  effect	  are	  covered	  in	  a	  single	  test;	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furthermore,	  sometimes	  the	  positive	  test	  result	  is	  rare	  (low	  prevalence	  leading	  to	  
excessive	  false-­‐positive	  results)	  or	  the	  gold	  standard	  test	  is	  too	  costly	  /	  uses	  too	  
many	  animals	  creating	  a	  need	  for	  prioritization	  by	  screening.	  Similarly,	  tests	  are	  
combined	  when	  the	  human	  predictivity	  of	  a	  single	  test	  is	  not	  satisfying	  or	  existing	  
data	  and	  evidences	  from	  various	  tests	  shall	  be	  integrated.	  Increasingly,	  also	  kinetic	  
information	  shall	  be	  integrated	  to	  make	  an	  in	  vivo	  extrapolation	  from	  in	  vitro	  data.	  
The	  solution	  to	  these	  problems	  is	  Integrated	  Testing	  Strategies	  (ITS).	  They	  have	  
been	  discussed	  for	  more	  than	  a	  decade	  and	  some	  attempts	  have	  been	  made	  in	  test	  
guidance	  for	  regulations.	  But	  despite	  their	  obvious	  potential	  to	  revamp	  regulatory	  
toxicology,	  we	  still	  have	  little	  guidance	  on	  the	  composition,	  validation	  and	  
adaptation	  of	  ITS	  for	  different	  purposes.	  Similarly	  to	  approaches	  of	  Weight	  of	  
Evidence	  and	  Evidence-­‐based	  Toxicology,	  different	  pieces	  of	  evidence	  and	  test	  data	  
need	  to	  be	  weighed	  and	  combined.	  ITS	  represent	  also	  the	  logical	  way	  of	  combining	  
pathway-­‐based	  tests	  as	  suggested	  in	  Toxicology	  for	  the	  21st	  Century.	  Here,	  the	  state	  
of	  the	  art	  of	  ITS	  is	  described	  and	  suggestions	  as	  to	  definition,	  systematic	  
combination	  and	  quality	  assurance	  of	  ITS	  are	  made.	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Introduction	  
Replacing	  a	  test	  on	  a	  living	  organism	  with	  a	  cellular,	  chemico-­‐analytical	  or	  
computational	  approach	  is	  obviously	  reductionistic.	  Sometimes	  this	  might	  work	  
well,	  e.g.	  when	  an	  extreme	  pH	  is	  a	  clear	  indication	  of	  corrosivity.	  However,	  in	  
general	  it	  is	  quite	  naïve	  to	  expect	  a	  single,	  system	  to	  substitute	  for	  all	  mechanisms,	  
the	  entire	  applicability	  domain	  (substance	  classes)	  and	  degrees	  of	  severity.	  Still	  
toxicology	  has	  long	  neglected	  this	  when	  requesting	  a	  replacement	  to	  substitute	  one	  
by	  one	  the	  traditional	  animal	  test.	  We	  might	  even	  extend	  this	  to	  say	  it	  is	  similarly	  
naïve	  to	  address	  an	  entire	  human	  health	  effect	  with	  a	  single	  animal	  experiment	  
using	  inbred,	  young	  rodents…	  The	  only	  way	  to	  approximate	  human	  relevance	  is	  to	  
mimic	  the	  complexity	  and	  responsiveness	  of	  the	  organ	  situation	  and	  model	  the	  
respective	  kinetics,	  i.e.	  what	  the	  human-­‐on-­‐a-­‐chip	  approach	  targets	  (Hartung	  and	  
Zurlo,	  2012).	  Everything	  else	  requires	  making	  use	  of	  several	  information	  sources	  if	  
not	  compromising	  the	  coverage	  of	  the	  test.	  Genotoxicity	  is	  a	  nice	  example,	  where	  
patches	  have	  continuously	  been	  added	  to	  cover	  the	  various	  mechanisms.	  However,	  
here	  the	  simplest	  possible	  strategy,	  i.e.	  a	  battery	  of	  tests,	  where	  every	  positive	  result	  
is	  considered	  a	  liability,	  causes	  problem.	  We	  have	  seen	  where	  the	  inevitable	  
accumulation	  of	  false-­‐positives	  leads	  (Kirkland	  et	  al.,	  2005),	  ultimately	  undermining	  
the	  credibility	  of	  in	  vitro	  approaches.	  
The	  solution	  is	  the	  “intelligent”	  or	  “integrated”	  use	  of	  several	  information	  sources	  in	  
a	  testing	  strategy	  (ITS).	  There	  is	  a	  lot	  of	  confusion	  around	  this	  term	  and	  even	  more,	  
how	  to	  design,	  validate	  and	  use	  ITS.	  	  
This	  article	  aims	  to	  elaborate	  on	  these	  aspects	  with	  examples	  and	  outline	  the	  
prospects	  of	  ITS	  in	  toxicology.	  It	  thereby	  expands	  the	  thoughts	  elaborated	  for	  the	  
introduction	  to	  the	  roadmap	  for	  animal-­‐free	  systemic	  toxicity	  testing	  (Basketter	  et	  
al.,	  2012).	  The	  underlying	  problems	  and	  the	  approach	  is	  actually	  not	  unique	  to	  
toxicology.	  The	  most	  evident	  similarity	  is	  to	  diagnostic	  testing	  strategies	  in	  clinical	  
medicine,	  where	  similarly	  several	  sources	  of	  information	  are	  used	  for	  differential	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diagnosis;	  we	  have	  discussed	  earlier	  these	  similarities	  (Hoffmann	  and	  Hartung,	  
2005).	  
	  
Consideration	  1:	  The	  two	  origins	  of	  ITS	  in	  safety	  assessments	  
When	  do	  we	  need	  a	  test	  and	  when	  do	  we	  need	  a	  testing	  strategy?	  We	  need	  more	  
than	  one	  test,	  if:	  
-­‐ not	  all	  possible	  outcomes	  of	  interest	  (e.g.	  modes	  of	  action)	  are	  covered	  in	  a	  
single	  test	  
-­‐ not	  all	  classes	  of	  test	  substances	  are	  covered	  (applicability	  domains)	  
-­‐ not	  all	  severity	  classes	  of	  effect	  are	  covered	  
-­‐ when	  the	  positive	  test	  result	  is	  rare	  (low	  prevalence)	  and	  the	  number	  of	  
false-­‐positive	  results	  becomes	  excessive	  (Hoffmann	  and	  Hartung,	  2005)	  
-­‐ when	  the	  gold	  standard	  test	  is	  too	  costly	  or	  uses	  too	  many	  animals	  and	  
substances	  need	  to	  be	  prioritized	  	  
-­‐ when	  the	  accuracy	  (human	  predictivity)	  is	  not	  satisfying	  and	  predictivity	  can	  
be	  improved	  
-­‐ existing	  data	  and	  evidences	  from	  various	  tests	  shall	  be	  integrated	  
-­‐ kinetic	  information	  shall	  be	  integrated	  to	  make	  an	  in	  vivo	  extrapolation	  from	  
in	  vitro	  data	  (Basketter	  et	  al.,	  2012)	  
All	  together,	  it	  is	  difficult	  to	  imagine	  a	  case,	  where	  we	  should	  not	  apply	  a	  testing	  
strategy.	  It	  is	  astonishing	  how	  long	  we	  have	  still	  pursued	  “one	  test	  suits	  all”	  solutions	  
in	  toxicology.	  If	  at	  all,	  a	  restricted	  usefulness	  (applicability	  domain)	  was	  stated,	  but	  
it	  was	  only	  with	  the	  discussion	  on	  Integrated	  Testing	  of	  in	  vitro,	  in	  silico	  and	  
toxicokinetics	  (adsorption,	  distribution,	  metabolism,	  excretion,	  i.e.	  ADME)	  
information	  that	  such	  integration	  was	  attempted.	  Bas	  Blaauboer	  and	  colleagues	  was	  
for	  long	  spearheading	  this	  (Blaauboer,	  2010;	  Blaauboer,	  Barratt,	  &	  Houston,	  1999;	  
DeJongh,	  Nordin-­‐Andersson,	  Ploeger,	  &	  Forsby,	  1999;	  Forsby	  &	  Blaauboer,	  2007).	  
The	  first	  ITS	  were	  accepted	  as	  OECD	  test	  guidelines	  in	  2002	  for	  eye	  and	  skin	  
irritation	  (OECD	  TG	  404,	  2002;	  OECD	  TG	  405,	  2002).	  A	  major	  driving	  force	  was	  then	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the	  emerging	  REACH	  legislation,	  which	  sought	  to	  make	  use	  of	  all	  available	  
information	  for	  registration	  of	  chemicals	  (especially	  existing	  chemicals)	  in	  order	  to	  
limit	  costs	  and	  animal	  use,	  prompted	  the	  call	  for	  Intelligent	  TS	  	  (Ahlers,	  Stock,	  &	  
Werschkun,	  2008;	  Anon,	  2005;	  Combes	  &	  Balls,	  2011;	  Gabbert	  &	  Benighaus,	  2012;	  
Leist	  et	  al.,	  2012;	  Schaafsma,	  Kroese,	  Tielemans,	  Van	  de	  Sandt,	  &	  Van	  Leeuwen,	  
2009;	  van	  Leeuwen,	  Patlewicz,	  &	  Worth,	  2007;	  Vonk	  et	  al.,	  2009)..	  	  
The	  two	  differ	  to	  some	  extent	  as	  the	  REACH-­‐ITS	  include	  also	  in	  vivo	  data	  and	  are	  
somewhat	  restricted	  to	  the	  tools	  prescribed	  in	  legislation.	  This	  excludes	  largely	  the	  
21st	  century	  methodologies	  (van	  Vliet,	  2011)	  i.e.	  omics,	  high-­‐throughput	  and	  high-­‐
content	  imaging	  techniques,	  which	  are	  not	  mentioned	  in	  the	  legislative	  text.	  The	  
very	  narrow	  interpretation	  of	  the	  legislative	  text	  in	  administrating	  REACH	  does	  not	  
encourage	  such	  additional	  approaches.	  This	  represents	  a	  tremendous	  opportunity	  
lost	  and	  some	  more	  flexibility	  and	  “learning	  on	  the	  road”	  would	  benefit	  one	  of	  the	  
largest	  investments	  in	  consumer	  safety	  ever	  attempted.	  
Astonishingly,	  despite	  these	  prospects	  and	  billions	  of	  Euros	  spent	  for	  REACH	  the	  
literature	  on	  ITS	  for	  safety	  assessments	  is	  still	  poor	  and	  little	  progress	  toward	  
consensus	  and	  guidance	  have	  been	  made.	  For	  example,	  two	  In	  Vitro	  Testing	  
Industrial	  Platform	  workshops	  were	  summarized	  stating	  (De	  Wever	  et	  al.,	  2012):	  
“As	  yet,	  there	  is	  great	  dispute	  among	  experts	  on	  how	  to	  represent	  ITS	  for	  classification,	  
labelling	  or	  risk	  assessments	  of	  chemicals,	  and	  whether	  or	  not	  to	  focus	  on	  the	  whole	  
chemical	  domain	  or	  on	  a	  specific	  application.	  The	  absence	  of	  accepted	  Weight	  of	  
Evidence	  (WoE)	  tools	  allowing	  for	  objective	  judgements	  was	  identified	  as	  an	  
important	  issue	  blocking	  any	  significant	  progress	  in	  the	  area.”	  Similarly,	  the	  
ECVAM/EPAA	  workshop	  concluded	  (Kinsner-­‐Ovaskainen	  et	  al.,	  2012):	  “Despite	  the	  
fact	  that	  some	  useful	  insights	  and	  preliminary	  conclusions	  could	  be	  extracted	  from	  the	  
dynamic	  discussions	  at	  the	  workshop,	  regretfully,	  true	  consensus	  could	  not	  be	  reached	  
on	  all	  aspects.”	  
We	  have	  earlier	  commissioned	  a	  whiter	  paper	  on	  ITS	  (Jaworska	  &	  Hoffmann,	  2010)	  
in	  the	  context	  of	  our	  transatlantic	  think	  tank	  for	  toxicology	  (t4)	  and	  a	  2010	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conference	  on	  21st	  century	  validation	  for	  21st	  century	  tools.	  It	  similarly	  concluded:	  
“Although	  a	  pressing	  concern,	  the	  topic	  of	  ITS	  has	  drawn	  mostly	  general	  reviews,	  
broad	  concepts,	  and	  the	  expression	  of	  a	  clear	  need	  for	  more	  research	  on	  ITS	  
(Benfenati,	  Gini,	  Hoffmann,	  &	  Luttik,	  2010;	  J.	  Hengstler	  et	  al.,	  2006;	  Worth	  et	  al.,	  2007).	  
Published	  research	  in	  the	  field	  remains	  scarce	  (Gubbels-­‐van	  Hal	  et	  al.,	  2005;	  Hoffmann	  
et	  al.,	  2008;	  Jaworska,	  Gabbert,	  &	  Aldenberg,	  2010).”	  
Noteworthy,	  testing	  strategies	  from	  pharmaceutical	  industry	  do	  not	  help	  a	  lot.	  They	  
try	  to	  identify	  an	  active	  compound	  (the	  future	  drug)	  out	  of	  thousands	  of	  substances,	  
without	  regard	  to	  what	  they	  miss—but	  this	  approach	  is	  unacceptable	  in	  a	  safety	  ITS.	  
Pharmacology	  screening	  also	  typically	  starts	  with	  a	  target,	  i.e.	  a	  mode	  of	  action,	  
while	  toxicological	  assessments	  need	  to	  be	  open	  to	  various	  mechanisms,	  some	  as	  yet	  
uncharacterized,	  until	  we	  have	  a	  comprehensive	  list	  of	  relevant	  pathways	  of	  toxicity	  
(Hartung	  and	  McBride,	  2011).	  
Due	  to	  its	  origin	  from	  alternative	  methods	  and	  REACH,	  ITS	  discussions	  are	  much	  
more	  predominant	  in	  Europe	  (Hartung,	  2010b).	  However,	  they	  resonate	  in	  principle	  
very	  strongly	  with	  the	  US	  approach	  of	  toxicity	  testing	  in	  the	  21st	  century	  (Tox-­‐21c)	  
(Hartung,	  2009).	  The	  latter	  suggests	  moving	  regulatory	  toxicology	  to	  mechanisms	  
(the	  pathways	  of	  toxicity,	  PoT).	  This	  means	  breaking	  the	  hazard	  down	  to	  its	  modes	  
of	  action	  and	  combining	  it	  with	  chemico-­‐physical	  properties	  (including	  QSAR)	  and	  
PBPK	  models.	  This	  implies	  in	  similar	  ways	  that	  different	  pieces	  of	  evidence	  and	  tests	  
are	  strategically	  combined.	  	  
	  
Consideration	  2:	  The	  need	  for	  a	  definition	  of	  ITS	  
The	  currently	  best	  reference	  for	  definitions	  of	  terminology	  is	  provided	  by	  OECD	  
guidance	  document	  34	  on	  validation	  (OECD,	  2005).	  An	  extract	  of	  the	  most	  relevant	  
definitions	  is	  given	  in	  box	  1.	  Notably,	  (integrated)	  test	  strategy	  is	  not	  defined.	  	  
Following	  a	  series	  of	  ECVAM	  internal	  meetings,	  an	  ECVAM/EPAA	  workshop	  was	  
held	  to	  address	  this	  (Kinsner-­‐Ovaskainen	  et	  al.,	  2009)	  and	  came	  up	  with	  a	  working	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definition:	  “As	  previously	  defined	  within	  the	  literature,	  an	  ITS	  is	  essentially	  an	  
information-­‐gathering	  and	  generating	  strategy,	  which	  in	  itself	  does	  not	  have	  to	  
provide	  means	  of	  using	  the	  information	  to	  address	  a	  specific	  regulatory	  question.	  
However,	  it	  is	  generally	  assumed	  that	  some	  decision	  criteria	  will	  be	  applied	  to	  the	  
information	  obtained,	  in	  order	  to	  reach	  a	  regulatory	  conclusion.	  Normally,	  the	  totality	  
of	  information	  would	  be	  used	  in	  a	  weight-­‐of-­‐evidence	  (WoE)	  approach.”	  WoE	  had	  
been	  addressed	  in	  an	  earlier	  ECVAM	  workshop	  (Balls	  et	  al.,	  2006):	  “Weight	  of	  
evidence	  (WoE)	  is	  a	  phrase	  used	  to	  describe	  the	  type	  of	  consideration	  made	  in	  a	  
situation	  where	  there	  is	  uncertainty,	  and	  which	  is	  used	  to	  ascertain	  whether	  the	  
evidence	  or	  information	  supporting	  one	  side	  of	  a	  cause	  or	  argument	  is	  greater	  than	  
that	  supporting	  the	  other	  side.”	  It	  is	  of	  critical	  importance	  to	  understand	  that	  WoE	  
and	  ITS	  are	  two	  different	  things	  though	  they	  combine	  the	  same	  types	  of	  
information!	  In	  WoE	  there	  is	  no	  formal	  integration,	  usually	  no	  strategy	  and	  often	  no	  
testing.	  WoE	  is	  much	  more	  a	  “poly-­‐pragmatic	  shortcut”	  to	  come	  to	  a	  preliminary	  
decision,	  where	  there	  is	  no	  or	  limited	  certainty.	  As	  proponents	  of	  evidence-­‐based	  
toxicology	  (EBT)	  (Hoffman	  and	  Hartung,	  2006),	  we	  have	  to	  admit	  that	  the	  term	  EBT	  
further	  contributes	  to	  this	  confusion	  (Hartung,	  2009b).	  However,	  there	  is	  obvious	  
cross-­‐talk	  between	  these	  approaches,	  when	  for	  example	  the	  quality	  scoring	  of	  
studies	  developed	  for	  EBT	  (Schneider	  et	  al.,	  2009)	  helps	  to	  filter	  their	  use	  in	  WoE	  
and	  ITS	  approaches.	  
	  The	  following	  definition	  was	  put	  forward	  by	  the	  ECVAM/EPAA	  workshops	  
(Kinsner-­‐Ovaskainen	  et	  al.,	  2009):	  “In	  the	  context	  of	  safety	  assessment,	  an	  
Integrated	  Testing	  Strategy	  is	  a	  methodology	  which	  integrates	  information	  for	  
toxicological	  evaluation	  from	  more	  than	  one	  source,	  thus	  facilitating	  decision-­‐
making.	  This	  should	  be	  achieved	  whilst	  taking	  into	  consideration	  the	  principles	  
of	  the	  Three	  Rs	  (reduction,	  refinement	  and	  replacement)”.	  In	  line	  with	  the	  
proposal	  put	  forward	  in	  the	  2007	  OECD	  Workshop	  on	  Integrated	  Approaches	  to	  
Testing	  and	  Assessment,	  they	  reiterated,	  “a	  good	  ITS	  should	  be	  structured,	  
transparent	  and	  hypothesis	  driven”	  (OECD,	  2008).	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Jaworska	  and	  Hoffmann	  (Jaworska	  and	  Hoffmann,	  2010)	  defined	  ITS	  somewhat	  
differently:	  “In	  narrative	  terms,	  ITS	  can	  be	  described	  as	  combinations	  of	  test	  
batteries	  covering	  relevant	  mechanistic	  steps	  and	  organized	  in	  a	  logical,	  
hypothesis-­‐driven	  decision	  scheme,	  which	  is	  required	  to	  make	  efficient	  use	  of	  
generated	  data	  and	  to	  gain	  a	  comprehensive	  information	  basis	  for	  making	  
decisions	  regarding	  hazard	  or	  risk.	  We	  approach	  ITS	  from	  a	  system	  analysis	  
perspective	  and	  understand	  them	  as	  decision	  support	  tools	  that	  synthesize	  information	  
in	  a	  cumulative	  manner	  and	  that	  guide	  testing	  in	  such	  a	  way	  that	  information	  gain	  in	  
a	  testing	  sequence	  is	  maximized.	  This	  definition	  clearly	  separates	  ITS	  from	  tiered	  
approaches	  in	  two	  ways.	  First,	  tiered	  approaches	  consider	  only	  the	  information	  
generated	  in	  the	  last	  step	  for	  a	  decision	  as,	  for	  example,	  in	  current	  regulated	  
sequential	  testing	  strategy	  for	  skin	  irritation	  (OECD	  TG	  405,	  2002)	  or	  the	  recently	  
proposed	  in	  vitro	  testing	  strategy	  for	  eye	  irritation	  (Laurie	  Scott	  et	  al.,	  2010).	  
Secondly,	  in	  tiered	  testing	  strategies	  the	  sequence	  of	  tests	  is	  prescribed,	  albeit	  loosely,	  
based	  on	  average	  biological	  relevance	  and	  is	  left	  to	  expert	  judgment.	  In	  contrast,	  our	  
definition	  enables	  an	  integrated	  and	  systematic	  approach	  to	  guide	  testing	  such	  that	  
the	  sequence	  is	  not	  necessarily	  prescribed	  ahead	  of	  time	  but	  is	  tailored	  to	  the	  
chemical-­‐specific	  situation.	  Depending	  on	  the	  already	  available	  information	  on	  a	  
specific	  chemical	  the	  sequence	  might	  be	  adapted	  and	  optimized	  for	  meeting	  specific	  
information	  targets.”	  
It	  might	  be	  useful	  to	  start	  from	  the	  scratch	  with	  our	  definitions	  to	  get	  around	  some	  
glitches.	  	  
• The	  leading	  principle	  should	  be	  that	  a	  test	  gives	  one	  result,	  and	  it	  does	  not	  
matter	  how	  many	  endpoints	  (measurements)	  the	  test	  requires.	  Figure	  1	  
shows	  these	  different	  scenarios.	  A	  test	  /	  assay	  thus	  consists	  of	  a	  test	  system	  
(biological	  in	  vivo	  or	  in	  vitro	  model)	  and	  a	  Standard	  Operation	  Protocol	  (SOP)	  
including	  endpoint(s)	  to	  measure,	  reference	  substance(s),	  data	  
interpretation	  procedure	  (a	  way	  to	  express	  the	  result),	  information	  on	  
reproducibility	  /	  uncertainty,	  applicability	  domain	  /	  information	  on	  
limitations	  and	  favorably	  performance	  standards.	  Note,	  that	  tests	  can	  include	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multiple	  test	  systems	  and/or	  multiple	  endpoints	  as	  long	  as	  they	  lead	  to	  one	  
result.	  
	  
Figure	  1:	  Three	  prototypic	  tests	  
Three	  prototypic	  tests,	  i.e.	  (a)	  a	  simple	  test	  with	  one	  endpoint,	  (b)	  two	  test	  
systems	  giving	  a	  joint	  result	  and	  (c)	  multiple	  endpoints	  (including	  omics	  and	  other	  
high-­‐content	  analysis)	  
• An	  integrated	  test	  strategy	  is	  an	  algorithm	  to	  combine	  (different)	  test	  
result(s)	  and	  possibly	  non-­‐test	  information	  (existing	  data,	  in	  silico	  
extrapolations	  from	  existing	  data	  or	  modeling)	  to	  give	  a	  combined	  test	  result.	  
They	  often	  will	  have	  interim	  decision	  points	  on	  which	  further	  building	  blocks	  
to	  consider.	  
• A	  battery	  of	  tests	  is	  a	  group	  of	  tests,	  which	  complement	  each	  other	  but	  are	  
not	  integrated	  in	  a	  strategy.	  A	  classical	  example	  is	  the	  genotoxicity	  testing	  
battery.	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• Tiered	  testing	  describes	  the	  simplest	  ITS,	  where	  a	  sequence	  of	  tests	  is	  
defined	  without	  formal	  integration	  of	  results.	  
• A	  probabilistic	  TS	  describes	  an	  ITS,	  where	  the	  different	  building	  blocks	  
change	  the	  probability	  for	  a	  test	  result.	  
• Validation	  of	  a	  test	  or	  an	  ITS	  requires	  a	  prediction	  model	  (a	  way	  to	  
translate	  it	  to	  the	  point	  of	  reference)	  and	  the	  point	  of	  reference	  itself,	  which	  
can	  be	  correlative	  on	  the	  basis	  of	  results	  or	  mechanistic.	  
Some	  of	  these	  aspects	  are	  shown	  in	  Figure	  2.	  
	  
Figure	  2:	  Components	  of	  a	  test	  (strategy)	  and	  its	  traditional	  (correlative)	  or	  
mechanistic	  validation	  
Consideration	  3:	  Composition	  of	  ITS	  –	  no	  GOBSATT!	   	  
The	  ITS	  in	  use	  to	  date	  is	  based	  on	  consensus	  processes	  often	  called	  “weight	  of	  
evidence”	  (WoE)	  approaches.	  Such	  “Good	  old	  boys	  sitting	  around	  the	  table”	  
(GOBSATT)	  is	  not	  really	  a	  way	  forward	  to	  compose	  ITS.	  The	  complexity	  of	  data	  and	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the	  multiplicity	  of	  performance	  aspects	  to	  consider	  (costs,	  animal	  use,	  time,	  
predictivity	  etc.)	  (Gabbert	  &	  Benighaus,	  2012;	  Nordberg,	  Rudén,	  &	  Hansson,	  
2008)call	  for	  simulation	  based	  on	  test	  data.	  Shortcomings	  of	  existing	  ITS	  were	  
recently	  analyzed	  in	  detail	  by	  (Jaworska	  et	  al.,	  2010):	  “Though	  both	  current	  ITS	  and	  
WoE	  approaches	  are	  undoubtedly	  useful	  tools	  for	  systemizing	  chemical	  hazard	  and	  
risk	  assessment,	  they	  lack	  a	  consistent	  methodological	  basis	  for	  making	  inferences	  
based	  on	  existing	  information,	  for	  coupling	  existing	  information	  with	  new	  data	  from	  
different	  sources,	  and	  for	  analyzing	  test	  results	  within	  and	  across	  testing	  stages	  in	  
order	  to	  meet	  target	  information	  requirements”	  and	  in	  more	  detail	  in	  (Jaworska	  &	  
Hoffmann,	  2010):	  “The	  use	  of	  flow	  charts	  as	  the	  ITS’	  underlying	  structure	  may	  lead	  to	  
inconsistent	  decisions.	  There	  is	  no	  guidance	  on	  how	  to	  conduct	  consistent	  and	  
transparent	  inference	  about	  the	  information	  target,	  taking	  into	  account	  all	  relevant	  
evidence	  and	  its	  interdependence.	  Moreover,	  there	  is	  no	  guidance,	  other	  than	  purely	  
expert-­‐driven,	  regarding	  the	  choice	  of	  the	  subsequent	  tests	  that	  would	  maximize	  
information	  gain.”	  A	  pioneering	  example	  of	  ITS	  evaluation,	  focused	  on	  skin	  irritation,	  
has	  been	  provided	  by	  Hoffmann	  et	  al.	  (Hoffmann	  et	  al.,	  2008).	  They	  compiled	  a	  
database	  of	  100	  chemicals.	  A	  number	  of	  strategies,	  both	  animal-­‐free	  and	  inclusive	  of	  
animal	  data	  were	  constructed	  and	  subsequently	  evaluated	  considering	  predictive	  
capacities,	  severity	  of	  misclassifications	  and	  testing	  costs.	  Noteworthy,	  the	  different	  
ITS	  to	  be	  compared	  where	  “hand-­‐made”,	  i.e.	  based	  on	  scientific	  reasoning	  and	  
intuition,	  but	  not	  any	  construction	  principles.	  They	  correctly	  conclude:	  “To	  promote	  
ITS,	  further	  guidance	  on	  construction	  and	  multi-­‐parameter	  evaluation	  need	  to	  be	  
developed.”	  Similarly,	  the	  ECVAM/EPAA	  workshop	  only	  stated	  needs	  (Kinsner-­‐
Ovaskainen	  et	  al.,	  2009):	  “So	  far,	  there	  is	  also	  a	  lack	  of	  scientific	  knowledge	  and	  
guidance	  on	  how	  to	  develop	  an	  ITS,	  and	  in	  particular,	  on	  how	  to	  combine	  the	  different	  
building	  blocks	  for	  an	  efficient	  and	  effective	  decision-­‐making	  process.	  Several	  aspects	  
should	  be	  taken	  into	  account	  in	  this	  regard,	  including:	  
—	  the	  extent	  of	  flexibility	  in	  combining	  the	  ITS	  components;	  
—	  the	  optimal	  combination	  of	  ITS	  components	  (including	  the	  minimal	  number	  of	  
components	  and/or	  combinations	  that	  have	  a	  desired	  predictive	  capacity);	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—	  the	  applicability	  domain	  of	  single	  components	  and	  the	  whole	  ITS;	  and	  
—	  the	  efficiency	  of	  the	  ITS	  (cost,	  time,	  technical	  difficulties)”	  
Using	  this	  “wish	  list”	  as	  guidance	  some	  aspects	  shall	  be	  discussed.	  
Extent	  of	  flexibility	  in	  combining	  the	  ITS	  components:	  This	  is	  a	  key	  dilemma—any	  
validation	  “puts	  tests	  into	  stone”	  and	  “freezes	  them	  in	  time”	  (Hartung,	  2007).	  An	  ITS	  
is,	  however,	  so	  much	  larger	  than	  individual	  tests	  that	  there	  is	  even	  more	  reasons	  for	  
change	  (technical	  advances,	  limitations	  of	  individual	  ITS	  components	  for	  the	  given	  
substance	  to	  study,	  availability	  of	  all	  tests	  in	  a	  given	  setting	  etc.).	  What	  is	  needed	  
here	  is	  a	  measure	  of	  similarity	  of	  tests	  and	  performance	  standards.	  The	  latter	  
concept	  was	  introduced	  in	  the	  modular	  approach	  to	  validation	  (Hartung	  et	  al.,	  2004)	  
and	  is	  now	  broadly	  used	  for	  the	  new	  validations.	  It	  defines	  what	  criteria	  a	  “me-­‐too”	  
development	  (a	  term	  borrowed	  from	  pharmaceutical	  industry,	  where	  a	  competitor	  
follows	  the	  innovative,	  pioneering	  work	  of	  another	  company	  introducing	  a	  
compound	  with	  the	  same	  work	  principle)	  has	  to	  fulfill	  to	  be	  considered	  equivalent	  
to	  the	  original	  one.	  The	  idea	  is	  that	  this	  meant	  to	  avoid	  undertaking	  again	  a	  full-­‐
blown	  validation	  ring	  trial	  with	  its	  enormous	  resources.	  There	  is	  some	  difference	  in	  
interpretation,	  whether	  this	  still	  needs	  to	  be	  multi-­‐laboratory	  exercise	  to	  establish	  
also	  inter-­‐laboratory	  reproducibility	  and	  transferability.	  Noteworthy,	  this	  requires	  
demonstrating	  the	  similarity	  of	  tests,	  for	  which	  we	  have	  no	  real	  guidance.	  However,	  
it	  also	  implies	  that	  any	  superiority	  of	  the	  new	  test	  compared	  to	  the	  originally	  
validated	  one	  cannot	  be	  shown.	  For	  ITS	  components,	  in	  the	  same	  way	  similarity	  and	  
performance	  criteria	  need	  to	  be	  established	  to	  allow	  exchange	  for	  something	  
different	  without	  a	  complete	  reevaluation	  of	  the	  ITS.	  This	  can	  first	  be	  based	  on	  the	  
scientific	  relevance	  and	  the	  PoT	  covered	  as	  argued	  earlier	  (Hartung,	  2010b).	  This	  
means	  that	  two	  assays,	  which	  cover	  the	  same	  mechanism	  can	  substitute	  for	  each	  
other.	  Alternatively,	  it	  can	  be	  based	  on	  correlation	  of	  results.	  Two	  assays,	  which	  
agree	  (concordance)	  to	  a	  sufficient	  degree,	  can	  be	  considered	  similar.	  We	  might	  call	  
these	  two	  options	  “mechanistic	  similarity”	  and	  “correlative	  similarity”.	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The	  optimal	  combination	  of	  ITS	  components:	  The	  typical	  combination	  of	  building	  
blocks	  so	  far	  is	  following	  a	  Boolean	  logic,	  i.e.,	  the	  logical	  combinations	  are	  AND,	  OR	  
and	  NOT.	  Table	  1	  gives	  the	  different	  examples	  for	  combining	  two	  tests	  with	  
dichotomous	  (plus/minus)	  outcome	  with	  such	  logic	  and	  the	  consequences	  for	  the	  
joint	  applicability	  domain	  and	  the	  validation	  need.	  Noteworthy,	  in	  most	  cases	  the	  
validation	  of	  the	  building	  blocks	  will	  suffice,	  but	  the	  joint	  applicability	  domain	  will	  
just	  be	  the	  overlap	  of	  the	  two	  tests’	  applicability	  domains.	  This	  is	  a	  simple	  
application	  of	  set	  theory.	  Only	  if	  the	  two	  tests	  measure	  the	  same	  but	  for	  different	  
substances	  /	  substance	  severity	  classes,	  the	  logical	  combination	  OR	  results	  in	  the	  
combined	  applicability	  domain.	  If	  the	  result	  requires	  that	  both	  tests	  are	  positive,	  e.g.	  
when	  a	  screening	  tests	  and	  a	  confirmatory	  test	  are	  combined,	  it	  is	  necessary	  to	  
validate	  the	  overall	  ITS	  outcome.	  
The	  principal	  opportunities	  in	  combining	  tests	  into	  the	  best	  ITS	  lie,	  however,	  in	  
interim	  decision	  points	  (Figure	  3	  is	  showing	  a	  simple	  example,	  where	  the	  positive	  or	  
negative	  outcome	  is	  confirmed).	  Here,	  the	  consequences	  for	  the	  joint	  applicability	  
domain	  are	  more	  complex	  and	  typically	  only	  the	  overall	  outcome	  can	  be	  validated.	  
The	  other	  opportunity	  is	  combining	  tests	  not	  with	  Boolean	  logic	  but	  with	  fuzzy	  /	  
probabilistic	  logic.	  This	  means	  that	  the	  result	  is	  not	  dichotomous	  (toxic	  or	  not)	  but	  a	  
probability	  or	  score	  is	  assigned.	  We	  could	  say	  that	  a	  value	  in-­‐between	  0	  (non-­‐toxic)	  
and	  1	  (toxic)	  is	  assigned.	  Such	  combinations	  will	  typically	  only	  allow	  use	  in	  the	  
overlapping	  applicability	  domains.	  It	  also	  implies	  that	  only	  the	  overall	  ITS	  can	  be	  
validated.	  The	  challenge	  lies	  here	  mostly	  in	  the	  point	  of	  reference,	  which	  normally	  
needs	  to	  be	  graded	  and	  not	  dichotomous	  as	  well.	  	  
The	  advantages	  of	  a	  probabilistic	  approach	  were	  recently	  summarized	  by	  Jaworska	  
and	  Hoffmann	  (2010):	  “Further,	  probabilistic	  methods	  are	  based	  on	  fundamental	  
principles	  of	  logic	  and	  rationality.	  In	  rational	  reasoning	  every	  piece	  of	  evidence	  is	  
consistently	  valued,	  assessed	  and,	  coherently	  used	  in	  combination	  with	  other	  pieces	  of	  
evidence.	  While	  knowledge-­‐	  and	  rule-­‐based	  systems,	  as	  manifested	  in	  current	  testing	  
strategy	  schemes,	  typically	  model	  the	  expert’s	  way	  of	  reasoning,	  probabilistic	  systems	  
describe	  dependencies	  between	  pieces	  of	  evidence	  (towards	  an	  information	  target)	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within	  the	  domain	  of	  interest.	  This	  ensures	  the	  objectivity	  of	  the	  knowledge	  
representation.	  Probabilistic	  methods	  allow	  for	  consistent	  reasoning	  when	  handling	  
conflicting	  data,	  incomplete	  evidence,	  and	  heterogeneous	  pieces	  of	  evidence.”	  
	  
	  
Test	  combinations	  and	  consequences	  for	  applicability	  domain	  and	  validation	  
needs	  




A	  AND	  B	   Screening	  plus	  
confirmatory	  test	  
Overlap	   Total	  ITS	  
A	  OR	  B	   Different	  Mode	  of	  
Action	  





Combined	   Building	  Blocks	  
A	  NOT	  B	   Exclusion	  of	  a	  
property	  (such	  as	  
cytotoxicity)	  
Overlap	   Total	  ITS	  
IF	  A	  positive:	  B	  
IF	  A	  negative:	  C	  




result	  in	  a	  second	  
test	  
Combined	  
overlap	  A/B	  and	  
overlap	  A/C	  
Total	  ITS	  
Fuzzy	  /	  Probabilistic	  
p(A,	  B)	  
i.e.	  probability	  as	  
function	  of	  A	  and	  
B	  
Combined	  change	  
of	  probability,	  e.g.	  
priority	  score	  
Overlap	   Building	  Blocks	  
Appendix	  II,	  Table	  12:	  Boolean	  versus	  Fuzzy	  Logic	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Chapter	  II,	  Figure	  3:	  Illustration	  of	  a	  simple	  decision	  tree,	  where	  outcomes	  of	  
test	  A	  are	  confirmed	  by	  different	  second	  tests	  B	  or	  C	  
The	  applicability	  domain	  of	  single	  components	  and	  the	  whole	  ITS:	  Simple	  logic	  
shows	  as	  discussed	  above	  that	  in	  most	  instances	  an	  ITS	  can	  only	  be	  applied	  where	  
all	  building	  blocks	  applied	  to	  a	  substance	  allow	  so.	  Only	  if	  the	  combination	  serves	  
exactly	  the	  purpose	  of	  expanding	  the	  applicability	  domain	  (by	  combining	  two	  tests	  
with	  OR)	  the	  picture	  changes.	  However,	  this	  implies	  that	  essentially	  the	  same	  thing	  
is	  measured	  (i.e.	  similarity	  of	  tests);	  if	  tests	  differ	  in	  applicability	  domain	  and	  what	  
they	  measure,	  a	  hierarchy	  needs	  to	  be	  established	  first.	  This	  is	  one	  of	  the	  key	  
arguments	  for	  flexibility	  of	  ITS	  as	  we	  need	  to	  exchange	  building	  blocks	  for	  others	  to	  
meet	  the	  applicability	  domain	  for	  a	  given	  substance.	  
The	  efficiency	  of	  the	  ITS:	  Typically,	  here	  resources	  such	  as	  cost	  and	  labor	  are	  
referred	  to.	  However,	  animal	  use	  and	  suffering	  is	  outside	  of	  this	  equation.	  It	  is	  a	  
societal	  decision	  how	  to	  value	  the	  replacement	  of	  an	  animal	  test.	  In	  the	  EU	  
legislation,	  the	  term	  “reasonably	  available”	  is	  used	  to	  mandate	  the	  use	  of	  an	  
alternative	  (Hartung,	  2010a).	  This	  leaves	  room	  for	  interpretation	  but	  there	  are	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certainly	  limits:	  How	  much	  more	  costly	  can	  an	  alternative	  method	  be	  to	  be	  
reasonably	  available?	  And	  the	  cost/benefit	  calculation	  needs	  to	  include	  also	  societal	  
acceptability.	  However,	  this	  is	  missing	  the	  point:	  Especially	  for	  safety	  assessments	  it	  
centers	  in	  the	  end	  around	  predicting	  human	  health	  and	  environmental	  effects.	  What	  
are	  the	  costs	  of	  a	  test	  versus	  the	  risk	  of	  a	  scandal?	  However,	  if	  we	  only	  attempt	  to	  be	  
as	  good	  as	  the	  animal	  test,	  this	  argument	  has	  no	  leverage.	  We	  thus	  need	  to	  advance	  
to	  human	  relevance	  if	  we	  really	  want	  to	  impact.	  This	  is	  difficult	  on	  the	  level	  of	  
correlation,	  because	  we	  typically	  do	  not	  have	  the	  human	  data	  for	  a	  statistically	  
sufficient	  number	  of	  substances.	  However,	  we	  have	  more	  and	  more	  the	  mechanisms	  
relevant	  to	  human	  health	  effects.	  Thus,	  the	  efficacy	  to	  cover	  relevant	  mechanisms	  
for	  human	  health	  and	  environmental	  effects	  is	  becoming	  increasingly	  important.	  I	  
have	  called	  this	  “mechanistic	  validation”	  (Hartung,	  2007).	  This	  does	  require	  that	  we	  
establish	  causality	  for	  a	  given	  mechanism	  to	  create	  a	  health	  or	  environmental	  effect.	  
The	  classical	  frameworks	  of	  the	  Koch-­‐Dale	  (Dale,	  1929)	  and	  Bradford	  Hill	  (Hill,	  
1965)	  principles	  for	  assessing	  evidence	  of	  causation	  come	  to	  mind	  first.	  Dale	  
translated	  the	  Koch	  postulates	  for	  a	  pathogen	  to	  cause	  a	  certain	  disease	  to	  a	  
mediator	  (at	  the	  time	  histamine	  and	  neurotransitter)	  of	  a	  physiological	  effect.	  We	  
have	  recently	  applied	  this	  to	  systematically	  evaluate	  the	  nature	  of	  the	  Gram-­‐positive	  
bacterial	  endotoxin	  (Hartung,	  2012).	  We	  can	  similarly	  translate	  to	  a	  PoT	  being	  
responsible	  for	  the	  manifestation	  of	  an	  adverse	  cellular	  outcome	  of	  substance	  X:	  
• Evidence	  for	  presence	  of	  the	  PoT	  in	  affected	  cells	  
• Perturbation	  /	  activation	  of	  the	  PoT	  leads	  to	  or	  amplifies	  the	  adverse	  
outcome	  
• Hindering	  PoT	  perturbation	  /	  activation	  diminishes	  manifestation	  of	  the	  
adverse	  outcome	  
• Blocking	  the	  PoT	  once	  perturbed	  /	  activated	  PoT	  diminishes	  manifestation	  of	  
the	  adverse	  outcome	  
Please	  note	  that	  the	  current	  debate	  whether	  a	  PoT	  represents	  a	  chemico-­‐biological	  
interaction	  impacting	  on	  the	  biological	  system	  or	  the	  perturbed	  normal	  physiology	  
is	  reflected	  in	  using	  both	  terminologies.	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Similarly,	  the	  Bradford-­‐Hill	  criteria	  can	  be	  applied:	  
• Strength:	  The	  stronger	  an	  association	  between	  cause	  and	  effect	  the	  more	  
likely	  a	  causal	  interpretation,	  but	  a	  small	  association	  does	  not	  mean	  that	  
there	  is	  not	  a	  causal	  effect.	  	  
• Consistency:	  Consistent	  findings	  of	  different	  persons	  in	  different	  places	  with	  
different	  samples	  increase	  the	  causal	  role	  of	  a	  factor	  and	  its	  effect.	  
• Specificity:	  The	  more	  specific	  an	  association	  is	  between	  factor	  and	  effect,	  the	  
bigger	  the	  probability	  of	  a	  causal	  relationship.	  
• Temporality:	  The	  effect	  has	  to	  occur	  after	  the	  cause.	  
• Biological	  gradient:	  Greater	  exposure	  should	  lead	  to	  greater	  incidence	  of	  the	  
effect	  with	  the	  exception	  that	  it	  can	  also	  be	  inverse,	  meaning	  greater	  
exposure	  leads	  to	  lower	  incidence	  of	  the	  effect.	  
• Plausibility:	  A	  possible	  mechanism	  between	  factor	  and	  effect	  increases	  the	  
causal	  relationship,	  with	  the	  limitation	  that	  knowledge	  of	  the	  mechanism	  is	  
limited	  by	  best	  available	  current	  knowledge.	  
• Coherence:	  A	  coherence	  between	  epidemiological	  and	  laboratory	  findings	  
leads	  to	  an	  increase	  in	  the	  likelihood	  of	  this	  effect.	  However,	  the	  lack	  of	  
laboratory	  evidence	  cannot	  nullify	  the	  epidemiological	  effect	  on	  the	  
associations.	  
• Experiment:	  Similar	  factors	  that	  lead	  to	  similar	  effects	  increase	  the	  causal	  
relationship	  of	  factor	  and	  effect.	  
Most	  recently,	  a	  new	  approach	  to	  causation	  was	  proposed	  originating	  from	  
ecological	  modeling	  (Sugihara	  et	  al.,	  2012;	  Marshall,	  2012).	  Whether	  this	  offers	  an	  
avenue	  for	  systematically	  testing	  causality	  in	  large	  datasets	  from	  omics	  and/or	  high-­‐
throughput	  testing	  needs	  to	  be	  explored.	  It	  might	  represent	  an	  alternative	  to	  
choosing	  meaningful	  biomarkers	  (Blaauboer	  et	  al.,	  2012),	  being	  always	  limited	  to	  
the	  current	  state	  of	  knowledge.	  
As	  a	  more	  pragmatic	  approach,	  DeWever	  et	  al.	  (De	  Wever	  et	  al.,	  2012)	  suggested	  key	  
elements	  of	  an	  ITS:	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“(1)	  Exposure	  modelling	  to	  achieve	  fast	  prioritisation	  of	  chemicals	  for	  testing,	  as	  well	  
as	  the	  tests	  which	  are	  most	  relevant	  for	  the	  purpose.	  Physiologically	  based	  
pharmacokinetic	  modelling	  (PBPK)	  should	  be	  employed	  to	  determine	  internal	  doses	  in	  
blood	  and	  tissue	  concentrations	  of	  chemicals	  and	  metabolites	  that	  result	  from	  the	  
administered	  doses.	  Normally,	  in	  such	  PBPK	  models,	  default	  values	  are	  used.	  However,	  
the	  inclusion	  of	  values	  or	  results	  form	  in	  vitro	  data	  on	  metabolism	  or	  exposure	  may	  
contribute	  to	  a	  more	  robust	  out-­‐come	  of	  such	  modelling	  systems.	  
(2)	  Data	  gathering,	  sharing	  and	  read-­‐across	  for	  testing	  a	  class	  of	  chemicals	  expected	  
to	  have	  a	  similar	  toxicity	  profile	  as	  the	  class	  of	  chemicals	  providing	  the	  data.	  In	  vitro	  
results	  can	  be	  used	  to	  demonstrate	  differences	  or	  similarities	  in	  potency	  across	  a	  
category	  or	  to	  investigate	  differences	  or	  similarities	  in	  bioavailability	  across	  a	  
category	  (e.g.	  data	  from	  skin	  penetration	  or	  intestinal	  uptake).	  
(3)	  A	  battery	  of	  tests	  to	  collect	  a	  broad	  spectrum	  of	  data	  focussing	  on	  different	  
mechanisms	  and	  mode	  of	  actions.	  For	  instance	  changes	  in	  gene	  expression,	  signalling	  
pathway	  alterations	  could	  be	  used	  to	  predict	  toxic	  events	  which	  are	  meaningful	  for	  the	  
compound	  under	  investigation.	  
(4)	  Applicability	  of	  the	  individual	  tests	  and	  the	  ITS	  itself	  has	  to	  be	  assured.	  The	  
acceptance	  of	  a	  new	  method	  depends	  on	  whether	  it	  can	  be	  easily	  transferred	  from	  the	  
developer	  to	  other	  labs,	  whether	  it	  requires	  sophisticated	  equipment	  and	  models,	  or	  if	  
intellectual	  property	  issues	  and	  the	  costs	  involved	  are	  important.	  In	  addition,	  an	  
accurate	  description	  of	  the	  compounds	  that	  can	  and	  cannot	  be	  tested	  is	  essential	  in	  
this	  context.	  
(5)	  Flexibility	  allowing	  for	  adjustment	  of	  the	  ITS	  to	  the	  target	  molecule,	  exposure	  
regime	  or	  application.	  
(6)	  Human-­‐specific	  methods	  should	  be	  prioritised	  whenever	  possible	  to	  avoid	  species	  
differences	  and	  to	  eliminate	  ‘low	  dose’	  extrapolation.	  Thus,	  the	  in	  vitro	  methods	  of	  
choice	  are	  based	  upon	  human	  tissues,	  human	  tissue	  slices	  or	  human	  primary	  cells	  and	  
cell	  lines	  for	  in	  vitro	  testing.	  If	  in	  vivo	  studies	  be	  unavoidable,	  transgenic	  animals	  
should	  be	  the	  preferred	  choice	  if	  available.	  If	  not,	  comparative	  genomics	  (animal	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versus	  human)	  and	  computational	  models	  of	  kinetics	  and	  dynamics	  in	  animals	  and	  
humans	  may	  help	  to	  overcome	  species	  differences.”	  
This	  “shopping	  list”	  extends	  ITS	  from	  hazard	  identification	  to	  exposure	  
considerations	  and	  the	  inclusion	  of	  existing	  data	  beyond	  de	  novo	  testing	  (including	  
some	  quite	  questionable	  approaches	  of	  read-­‐across	  and	  forming	  of	  chemical	  classes,	  
for	  which	  no	  guidance	  and	  quality	  assurance	  is	  yet	  available).	  It	  similarly	  calls	  for	  
flexibility,	  a	  key	  difference	  to	  current	  guidance	  document	  from	  ECHA	  or	  OECD.	  
Compared	  to	  REACH	  it	  calls	  for	  human	  predictivity	  and	  mode-­‐of-­‐action	  information	  
in	  the	  sense	  of	  Toxicity	  Testing	  for	  the	  21st	  Century.	  Similarly,	  an	  earlier	  report	  also	  
based	  on	  an	  IVTP	  symposium,	  to	  which	  the	  author	  contributed,	  made	  further	  
recommendations	  more	  along	  a	  concept	  based	  on	  pathways	  of	  toxicity	  (Berg	  et	  al.,	  
2011):	  “When	  selecting	  the	  battery	  of	  in	  vitro	  and	  in	  silico	  methods	  addressing	  key	  
steps	  in	  the	  relevant	  biological	  pathways	  (the	  building	  blocks	  of	  the	  ITS)	  it	  is	  
important	  to	  employ	  standardized	  and	  internationally	  accepted	  tests.	  Each	  block	  
should	  be	  producing	  data	  that	  are	  reliable,	  robust	  and	  relevant	  (the	  alternative	  3R	  
elements)	  for	  assessing	  the	  specific	  aspect	  (e.g.	  biological	  pathway)	  it	  is	  supposed	  to	  
address.	  If	  they	  comply	  with	  these	  elements	  they	  can	  be	  used	  in	  an	  ITS.”	  
An	  important	  additional	  consideration	  was	  made	  by	  Hoffmann	  et	  al.	  (Hoffmann	  et	  
al.,	  2008):	  “Furthermore,	  the	  study	  underlined	  the	  need	  for	  databases	  of	  chemicals	  
with	  testing	  information	  to	  facilitate	  the	  construction	  of	  practical	  testing	  strategies.	  
Such	  databases	  must	  comprise	  a	  good	  spread	  of	  chemicals	  and	  test	  data	  in	  order	  that	  
the	  applicability	  of	  approaches	  may	  be	  effectively	  evaluated.	  Therefore,	  the	  (non-­‐)	  
availability	  of	  data	  is	  a	  caveat	  at	  the	  start	  of	  any	  ITS	  construction.	  Whilst	  in	  silico	  and	  
in	  vitro	  data	  may	  be	  readily	  generated,	  in	  vivo	  data	  of	  sufficient	  quality	  are	  often	  
difficult	  to	  obtain.”	  This	  comes	  back	  again	  to	  both	  the	  need	  for	  data-­‐sharing	  (D.	  
Basketter	  et	  al.,	  2012)	  and	  the	  construction	  of	  a	  point	  of	  reference	  for	  validation	  
exercises(Hoffmann	  et	  al.,	  2008).	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The	  most	  comprehensive	  framework	  for	  ITS	  composition	  so	  far	  was	  produced	  by	  
Jaworska	  and	  Hoffmann	  as	  a	  t4	  commissioned	  white-­‐paper	  	  see	  (Jaworska	  &	  
Hoffmann,	  2010)	  also	  (Jaworska	  et	  al.,	  2010):	  	  
“ITS	  should	  be:	  
	  a)	  Transparent	  and	  consistent	  
–	  As	  a	  new	  and	  complex	  development,	  key	  to	  ITS,	  as	  to	  any	  methodology,	  is	  the	  
property	  that	  they	  are	  comprehensible	  to	  the	  maximum	  extent	  possible.	  In	  addition	  to	  
ensuring	  credibility	  and	  acceptance,	  this	  may	  ultimately	  attract	  the	  interest	  needed	  to	  
gather	  the	  necessary	  momentum	  required	  for	  their	  development.	  The	  only	  way	  to	  
achieve	  this	  is	  a	  fundamental	  transparency.	  
–	  Consistency	  is	  of	  similar	  importance.	  While	  difficult	  to	  achieve	  for	  weight	  of	  evidence	  
approaches,	  a	  well-­‐defined	  and	  transparent	  ITS	  can	  and	  should,	  when	  fed	  with	  the	  
same,	  potentially	  even	  conflicting	  and/or	  incomplete	  information,	  always	  (re-­‐)produce	  
the	  same	  results,	  irrespective	  of	  who,	  when,	  where,	  and	  how	  it	  is	  applied.	  In	  case	  of	  
inconsistent	  results,	  reasons	  should	  be	  identified	  and	  used	  to	  further	  optimize	  the	  ITS	  
consistency.	  
–	  In	  particular,	  transparency	  and	  consistency	  are	  of	  utmost	  importance	  in	  the	  
handling	  of	  variability	  and	  uncertainty.	  While	  transparency	  could	  be	  achieved	  
qualitatively,	  e.g.	  by	  appropriate	  documentation	  of	  how	  variability	  and	  uncertainty	  
were	  considered,	  consistency	  in	  this	  regard	  may	  only	  be	  achievable	  when	  handled	  
quantitatively.	  
b)	  Rational	  
–	  Rationality	  of	  ITS	  is	  essential	  to	  ensure	  that	  information	  is	  fully	  exploited	  and	  used	  in	  
an	  optimized	  way.	  Furthermore,	  generation	  of	  new	  information,	  usually	  by	  testing,	  
needs	  to	  be	  rational	  in	  the	  sense	  that	  it	  is	  focused	  on	  providing	  the	  most	  informative	  
evidence	  in	  an	  efficient	  way.	  
c)	  Hypothesis-­‐driven	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–	  ITS	  should	  be	  driven	  by	  a	  hypothesis,	  which	  will	  usually	  be	  closely	  linked	  to	  the	  
information	  target	  of	  the	  ITS,	  a	  concept	  detailed	  below.	  In	  this	  way	  the	  efficiency	  of	  an	  
ITS	  can	  be	  ensured,	  as	  a	  hypothesis-­‐driven	  approach	  offers	  the	  flexibility	  to	  adjust	  the	  
hypothesis	  whenever	  new	  information	  is	  obtained	  or	  generated.	  
…	  Having	  defined	  and	  described	  the	  framework	  of	  ITS,	  we	  propose	  to	  fill	  it	  with	  the	  
following	  five	  elements:	  
1.	  Information	  target	  identification;	  
2.	  Systematic	  exploration	  of	  knowledge;	  
3.	  Choice	  of	  relevant	  inputs;	  
4.	  Methodology	  to	  evidence	  synthesis;	  	  
5.	  Methodology	  to	  guide	  testing”	  
The	  reader	  is	  referred	  to	  the	  original	  article	  (Jaworska	  and	  Hoffmann,	  2010)	  and	  its	  
implementation	  for	  skin	  sensitization	  (Jaworska	  et	  al.,	  2011).	  
	  
Consideration	  4:	  Guidance	  from	  testing	  strategies	  in	  clinical	  diagnostics	  
We	  have	  earlier	  stressed	  the	  principal	  similarities	  of	  a	  diagnostic	  and	  a	  toxicological	  
test	  strategy	  (Hoffmann	  and	  Hartung,	  2005).	  In	  both	  cases,	  different	  sources	  of	  
information	  have	  to	  be	  combined	  to	  come	  to	  an	  overall	  result.	  Vecchio	  pointed	  out	  
already	  in	  1966	  the	  problem	  of	  single	  tests	  in	  unselected	  populations	  (Vecchio,	  
1966)	  leading	  to	  unbearable	  false-­‐positive	  rates.	  Systematic	  reviews	  of	  an	  evidence-­‐
based	  toxicology	  (EBT)	  approach	  (Hoffman	  and	  Hartung,	  2006;	  Hartung	  2009b)	  and	  
meta-­‐analysis	  could	  serve	  the	  evaluation	  and	  quality	  assurance	  of	  toxicological	  tests.	  
The	  frameworks	  for	  evaluation	  of	  clinical	  diagnostic	  tests	  are	  well	  developed	  
(Deeks,	  2001)	  (Devillé	  et	  al.,	  2002;	  Leeflang	  et	  al.,	  2008)	  and	  led	  to	  the	  Cochrane	  
Handbook	  for	  Diagnostic	  Test	  Accuracy	  Reviews	  (Anon,	  2011).	  Deville	  et	  al.	  (Devillé	  
et	  al.,	  2002)	  give	  very	  concise	  guidance	  how	  to	  evaluate	  diagnostic	  methods.	  This	  is	  
closely	  linked	  to	  efforts	  to	  improve	  reporting	  on	  diagnostic	  tests;	  a	  set	  of	  minimal	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reporting	  standards	  for	  diagnostic	  research	  has	  been	  proposed:	  Standards	  for	  
Reporting	  of	  Diagnostic	  Accuracy	  statement	  (STARD)	  [http://www.consort-­‐
statement.org/].	  We	  have	  argued	  earlier	  that	  this	  represents	  an	  interesting	  
approach	  to	  complement	  or	  substitute	  for	  traditional	  method	  validation	  (Hartung,	  
2010b).	  Deeks	  et	  al.	  (Deeks,	  2001)	  summarize	  their	  experience	  as	  follows	  [with	  
translation	  to	  toxicology	  inserted	  in	  brackets]:	  “Systematic	  reviews	  of	  studies	  of	  
diagnostic	  [hazard	  assessment]	  accuracy	  differ	  from	  other	  systematic	  reviews	  in	  the	  
assessment	  of	  study	  quality	  and	  the	  statistical	  methods	  used	  to	  combine	  results.	  
Important	  aspects	  of	  study	  quality	  include	  the	  selection	  of	  a	  clinically	  relevant	  cohort	  
[relevant	  test	  set	  of	  substances],	  the	  consistent	  use	  of	  a	  single	  good	  reference	  
standard	  [reference	  data],	  and	  the	  blinding	  of	  results	  of	  experimental	  and	  reference	  
tests.	  The	  choice	  of	  statistical	  method	  for	  pooling	  results	  depends	  on	  the	  summary	  
statistic	  and	  sources	  of	  heterogeneity,	  notably	  variation	  in	  diagnostic	  thresholds	  
[thresholds	  of	  adversity].	  Sensitivities,	  specificities,	  and	  likelihood	  ratios	  may	  be	  
combined	  directly	  if	  study	  results	  are	  reasonably	  homogeneous.	  When	  a	  threshold	  
effect	  exists,	  study	  results	  may	  be	  best	  summarised	  as	  a	  summary	  receiver	  operating	  
characteristic	  curve,	  which	  is	  difficult	  to	  interpret	  and	  apply	  to	  practice.”	  
Interestingly,	  Schunemann	  et	  al.	  (Holger	  J	  Schünemann,	  2008)	  developed	  GRADE	  for	  
grading	  quality	  of	  evidence	  and	  strength	  of	  recommendations	  for	  diagnostic	  tests	  
and	  strategies.	  This	  framework	  uses	  “patient-­‐important	  outcomes”	  as	  measures,	  in	  
addition	  to	  test	  accuracy.	  A	  less	  invasive	  test	  can	  be	  better	  for	  a	  patient	  even	  if	  it	  
does	  not	  give	  the	  same	  certainty.	  Similarly,	  we	  might	  frame	  our	  choices	  by	  aspects	  
such	  as	  throughput,	  costs	  or	  animal	  use.	  
	  
Consideration	  5:	  The	  many	  faces	  of	  (I)TS	  for	  safety	  assessments	  
As	  defined	  earlier,	  any	  systematic	  combination	  of	  different	  (test)	  results	  represents	  
a	  testing	  strategy.	  It	  does	  not	  really	  matter	  of	  these	  results	  already	  exist,	  are	  
estimated	  from	  structures	  or	  related	  substances,	  measured	  by	  chemico-­‐physical	  
methods	  or	  stem	  from	  testing	  in	  a	  biological	  system	  or	  from	  human	  observations	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and	  studies.	  Jaworska	  et	  al.	  (Jaworska	  et	  al.,	  2010)and	  Basketter	  et	  al.	  (D.	  Basketter	  
et	  al.,	  2012)	  list	  many	  of	  the	  more	  recently	  proposed	  ITS.	  One	  of	  the	  authors	  (THA)	  
had	  the	  privilege	  to	  coordinate	  from	  the	  side	  of	  the	  European	  Commission	  the	  ITS	  
development	  within	  the	  guidance	  for	  REACH	  implementation	  for	  industry,	  which	  
formed	  the	  basis	  for	  current	  ECHA	  guidance	  (http://echa.europa.eu/guidance-­‐
documents/guidance-­‐on-­‐information-­‐requirements-­‐and-­‐chemical-­‐safety-­‐
assessment).	  Classical	  examples,	  some	  of	  them	  commonly	  used	  without	  the	  label	  
ITS,	  in	  toxicology	  are:	  
Test	  battery	  of	  genotoxicity	  assays:	  Several	  assays	  (3-­‐6)	  depending	  on	  the	  field	  of	  
use	  (Hartung,	  2008)	  are	  carried	  out	  and	  typically	  any	  positive	  result	  is	  taken	  as	  an	  
alert.	  They	  are	  often	  combined	  with	  further	  mutagenicity	  testing	  in	  vivo	  (Hartung,	  
2010a).	  The	  latter	  is	  necessary	  to	  reduce	  the	  tremendous	  rate	  of	  false-­‐positive	  
classifications	  of	  the	  battery	  as	  discussed	  earlier	  (Basketter	  et	  al.,	  2012).	  
Interestingly,	  Aldenberg	  and	  Jaworska	  (Aldenberg	  &	  Jaworska,	  2010)	  applied	  a	  
Bayesian	  network	  to	  the	  dataset	  assembled	  by	  Kirkland	  et	  al.	  showing	  the	  potential	  
of	  a	  probabilistic	  network	  to	  analyze	  such	  datasets.	  
ITS	  for	  eye	  and	  skin	  irritation:	  As	  already	  mentioned,	  these	  were	  the	  first	  areas	  to	  
introduce	  internationally	  accepted	  ITS,	  though	  relatively	  simple,	  e.g.	  suggesting	  a	  pH	  
test	  before	  progressing	  to	  corrosivity	  testing.	  The	  rich	  data	  available	  from	  six	  
International	  validation	  studies,	  eight	  retrospective	  assessments	  and	  three	  recently	  
completed	  validation	  studies	  of	  new	  tests	  (Adler	  et	  al.,	  2011;	  Zuang,	  Eskes,	  
Griesinger,	  &	  Hartung,	  2007)	  makes	  it	  an	  ideal	  test	  case	  for	  ITS	  development.	  For	  
ocular	  toxicity,	  since	  2002	  the	  OECD	  TG	  405	  has	  provided	  an	  ITS	  approach	  for	  eye	  
irritation	  and	  corrosion.	  In	  spite	  of	  this	  TG,	  the	  Office	  of	  Pesticide	  Programs	  (OPPs)	  
of	  the	  US	  EPA,	  requested	  the	  development	  of	  an	  in	  vitro	  eye	  irritation	  strategy	  to	  
register	  anti-­‐microbial	  cleaning	  products.	  The	  Institute	  for	  In-­‐Vitro	  Sciences	  in	  
collaboration	  with	  industry	  partners	  developed	  such	  an	  ITS	  of	  three	  in	  vitro	  
approaches,	  which	  was	  then	  accepted	  by	  regulators	  (De	  Wever	  et	  al.,	  2012).	  ITS	  
development	  has	  very	  much	  advanced	  around	  this	  test	  case	  (McNamee	  et	  al.,	  2009;	  
L.	  Scott	  et	  al.,	  2010).	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For	  skin	  irritation,	  we	  already	  referred	  to	  the	  work	  by	  Hoffmann	  et	  al.	  (Hoffmann	  et	  
al.,	  2008),	  which	  was	  based	  on	  an	  evaluation	  of	  the	  prevalence	  of	  this	  hazard	  among	  
new	  chemicals	  (HOFFMANN	  et	  al.,	  2005).	  The	  study	  showed	  the	  potential	  of	  
simulations	  to	  guide	  ITS	  construction.	  
Embryonic	  Stem	  Cell	  test	  (EST)	  –	  an	  ITS?	  The	  EST	  	  (Marx-­‐Stoelting	  et	  al.,	  2009;	  
Seiler	  &	  Spielmann,	  2011;	  Spielmann	  et	  al.,	  2006)	  is	  an	  interesting	  test	  case	  for	  our	  
definition	  of	  an	  ITS.	  It	  consists	  of	  two	  test	  systems	  (mouse	  embryonic	  stem	  cells	  and	  
3T3	  fibroblasts)	  and	  two	  endpoints	  (cell	  differentiation	  into	  beating	  cardiomyocytes	  
and	  cytotoxicity	  in	  both	  cell	  systems).	  The	  result	  (embryotoxicity),	  however,	  is	  only	  
deduced	  from	  all	  this	  information.	  According	  to	  the	  suggested	  definition	  of	  tests	  and	  
ITS,	  therefore,	  this	  represents	  a	  test	  and	  not	  an	  ITS.	  Noteworthy,	  the	  EST	  formed	  a	  
key	  element	  of	  the	  ITS	  developed	  at	  the	  end	  of	  the	  Integrated	  Project	  ReProTect	  
(Hareng,	  Pellizzer,	  Bremer,	  Schwarz,	  &	  Hartung,	  2005);	  a	  final	  feasibility	  study	  
showed	  the	  tremendous	  potential	  of	  this	  approach	  (Schenk	  et	  al.,	  2010).	  
Skin	  sensitization:	  The	  area	  has	  been	  subject	  to	  intense	  work	  over	  the	  last	  decade,	  
which	  resulted	  in	  about	  20	  test	  systems.	  As	  outlined	  in	  the	  roadmap	  process	  
(Basketter	  et	  al.,	  2012),	  the	  area	  now	  requires	  the	  creation	  of	  an	  ITS.	  It	  seems	  that	  
only	  the	  gridlock	  of	  the	  political	  decision	  process	  on	  the	  2013	  deadline,	  which	  
includes	  skin	  sensitization	  as	  an	  endpoint,	  hinders	  the	  finalization	  of	  this	  important	  
work.	  Since	  at	  the	  same	  time	  this	  represents	  a	  critical	  endpoint	  for	  REACH	  (notably	  
all	  chemicals	  under	  REACH	  require	  at	  the	  moment	  a	  local	  lymph	  node	  assay	  for	  skin	  
sensitization),	  such	  delays	  are	  hardly	  acceptable.	  It	  is	  very	  important	  that	  BASF	  has	  
pushed	  the	  area	  by	  submitting	  their	  ITS	  (Mehling	  et	  al.,	  2012)	  for	  ECVAM	  evaluation	  
already.	  Pioneering	  work	  to	  develop	  a	  Bayesian	  ITS	  for	  this	  hazard	  was	  referred	  to	  
earlier	  (Jaworska	  et	  al.,	  2011).	  
In	  silico	  ITS:	  There	  are	  also	  attempts	  to	  combine	  only	  various	  in	  silico	  (QSAR)	  
approaches.	  We	  have	  discussed	  some	  of	  the	  limitations	  of	  the	  in	  silico	  approaches	  in	  
isolation	  earlier	  (Hartung	  and	  Hoffmann,	  2009).	  Since	  they	  are	  referred	  to	  in	  REACH	  
as	  “non-­‐testing	  methods”	  they	  might	  actually	  be	  called	  “Integrated	  Non-­‐Testing	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Strategies”	  (INTS).	  An	  example	  for	  bioaccumulation,	  already	  earlier	  proposed	  to	  suit	  
ITS	  (De	  Wolf	  et	  al.,	  2007;	  Ahlers	  et	  al.,	  2008),	  was	  reported	  recently	  (Fernández	  et	  
al.,	  2012)	  showing	  improved	  prediction	  by	  combining	  several	  QSAR.	  	  	  	  
	  
Consideration	  6:	  Validation	  of	  ITS	  
Concepts	  for	  the	  validation	  of	  ITS	  are	  only	  emerging.	  The	  ECVAM/EPAA	  workshop	  
(Kinsner-­‐Ovaskainen	  et	  al.,	  2009)	  noted	  only:	  “There	  is	  a	  need	  to	  further	  discuss	  and	  
to	  develop	  the	  ITS	  validation	  principles.	  A	  balance	  in	  the	  requirements	  for	  validation	  of	  
the	  individual	  ITS	  components	  versus	  the	  requirements	  for	  the	  validation	  of	  a	  whole	  
ITS	  should	  be	  considered.”	  Later	  in	  the	  text,	  the	  only	  statement	  made	  was:	  “It	  was	  
concluded	  that	  a	  formal	  validation	  should	  not	  be	  required,	  unless	  the	  strategy	  could	  
serve	  as	  full	  replacement	  of	  an	  in	  vivo	  study	  used	  for	  regulatory	  purposes.”	  The	  
workshop	  stated	  that	  for	  screening,	  hazard	  classification	  &	  labeling	  and	  risk	  
assessment	  neither	  a	  formal	  validation	  of	  the	  ITS	  components	  nor	  the	  entire	  ITS	  is	  
required.	  We	  would	  kindly	  disagree,	  as	  validation	  is	  certainly	  desirable	  also	  for	  
other	  uses,	  but	  should	  be	  tailored	  to	  the	  use	  scenario	  and	  the	  available	  resources.	  
The	  follow-­‐up	  workshop	  (Kinsner-­‐Ovaskainen	  et	  al.,	  2012)	  did	  not	  go	  much	  further	  
with	  regard	  to	  recommendations	  for	  validation:	  “	  Firstly,	  it	  was	  agreed	  that	  the	  
validation	  of	  a	  partial	  replacement	  test	  method	  (for	  application	  as	  part	  of	  a	  testing	  
strategy)	  should	  be	  differentiated	  from	  the	  validation	  of	  an	  in	  vitro	  test	  method	  for	  
application	  as	  a	  stand-­‐alone	  replacement.	  It	  was	  also	  agreed	  that	  any	  partial	  
replacement	  test	  method	  should	  not	  be	  any	  less	  robust,	  reliable	  or	  mechanistically	  
relevant	  than	  stand-­‐alone	  replacement	  methods.	  However,	  an	  evaluation	  of	  predictive	  
capacity	  (as	  defined	  by	  its	  accuracy	  when	  predicting	  the	  toxicological	  effects	  observed	  
in	  vivo)	  of	  each	  of	  these	  test	  methods	  would	  not	  necessarily	  be	  as	  important	  when	  
placed	  in	  a	  testing	  strategy,	  as	  long	  as	  the	  predictive	  capacity	  of	  the	  whole	  testing	  
strategy	  could	  be	  demonstrated.	  This	  is	  especially	  the	  case	  for	  test	  methods	  for	  which	  
the	  relevant	  prediction	  relates	  to	  the	  impact	  of	  the	  tested	  chemical	  on	  the	  biological	  
pathway	  of	  interest	  (i.e.	  biological	  relevance).	  The	  extent	  to	  which	  (or	  indeed	  how)	  this	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biological	  relevance	  of	  test	  methods	  could,	  and	  should,	  be	  validated,	  if	  reference	  data	  
(a	  ‘gold	  standard’)	  were	  not	  available,	  remained	  unclear.	  
Consequently,	  a	  recommendation	  of	  the	  workshop	  was	  for	  ECVAM	  to	  consider	  how	  the	  
current	  modular	  approach	  to	  validation	  could	  be	  pragmatically	  adapted	  for	  
application	  to	  test	  methods,	  which	  are	  only	  used	  in	  the	  context	  of	  a	  testing	  strategy,	  
with	  a	  view	  to	  making	  them	  acceptable	  for	  regulatory	  purposes.	  
Secondly,	  it	  was	  agreed	  that	  ITS	  allowing	  for	  flexible	  and	  ad	  hoc	  approaches	  cannot	  be	  
validated,	  whereas	  the	  validation	  of	  clearly	  defined	  ITS	  would	  be	  feasible.	  However,	  
even	  then,	  current	  formal	  validation	  procedures	  might	  not	  be	  applicable,	  due	  to	  
practical	  limitations	  (including	  the	  number	  of	  chemicals	  needed,	  cost,	  time,	  etc).	  
Thirdly,	  concerning	  the	  added	  value	  of	  a	  formal	  validation	  of	  testing	  strategies,	  the	  
views	  of	  the	  group	  members	  differed	  strongly,	  and	  a	  variety	  of	  perspectives	  were	  
discussed,	  clearly	  indicating	  the	  need	  for	  further	  informed	  debate.	  Consequently,	  the	  
workshop	  recommended	  the	  use	  of	  EPAA	  as	  a	  forum	  for	  industry	  to	  share	  case	  studies	  
demonstrating	  where,	  and	  how,	  in	  vitro	  and/or	  integrated	  testing	  strategies	  have	  
been	  successfully	  applied	  for	  safety	  decision-­‐making	  purposes.	  Based	  on	  these	  case	  
studies,	  a	  pragmatic	  way	  to	  evaluate	  the	  suitability	  of	  partial	  replacement	  test	  
methods	  could	  be	  discussed,	  with	  a	  view	  to	  establishing	  conditions	  for	  regulatory	  
acceptance	  and	  to	  reflect	  on	  the	  cost/benefit	  of	  formal	  validation,	  i.e.	  the	  confirmation	  
of	  scientific	  validity	  of	  a	  strategy	  by	  a	  validation	  body	  and	  in	  line	  with	  generally	  
accepted	  validation	  principles,	  as	  provided	  in	  OECD	  Guidance	  Document	  34	  (OECD,	  
2005).	  
Finally,	  the	  group	  agreed	  that	  test	  method	  developers	  should	  be	  encouraged	  to	  develop	  
and	  submit	  to	  ECVAM,	  not	  only	  tests	  designed	  as	  full	  replacements	  of	  animal	  methods,	  
but	  also	  partial	  replacements	  in	  the	  context	  of	  a	  testing	  strategy.”	  
Somewhat	  going	  further,	  De	  Wever	  et	  al.	  2012	  noted:	  “In	  some	  cases,	  the	  assessment	  
of	  predictive	  capacity	  of	  a	  single	  building	  block	  may	  not	  be	  as	  important,	  as	  long	  as	  the	  
predictive	  capacity	  of	  the	  whole	  testing	  strategy	  is	  demonstrated.	  However,	  …	  the	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predictive	  capacity	  of	  each	  single	  element	  of	  an	  ITS	  and	  that	  of	  the	  ITS	  as	  a	  whole	  
needs	  to	  be	  evaluated”.	  
Berg	  et	  al.	  go	  further	  challenging	  validation	  need	  and	  suggesting	  a	  more	  hands-­‐on	  
approach	  to	  gain	  experiences	  (Berg	  et	  al.,	  2011):	  “Does	  it	  make	  sense	  to	  validate	  a	  
strategy	  that	  builds	  upon	  tests	  for	  hazard	  identification	  which	  change	  over	  time,	  but	  is	  
to	  be	  used	  for	  risk	  assessment?	  One	  needs	  to	  incorporate	  new	  thinking	  into	  risk	  
assessment.	  Regulators	  are	  receptive	  to	  new	  technologies	  but	  concrete	  data	  are	  
needed	  to	  support	  their	  use.	  Data	  documentation	  should	  be	  comprehensive,	  traceable	  
and	  make	  it	  possible	  for	  other	  investigators	  to	  retrieve	  information	  as	  well	  as	  reliably	  
repeat	  the	  studies	  in	  question	  regardless	  of	  whether	  the	  original	  work	  was	  performed	  
to	  GLP	  standards.”	  
What	  is	  the	  problem?	  If	  we	  follow	  the	  traditional	  approach	  of	  correlating	  results,	  we	  
need	  a	  good	  coverage	  of	  each	  branch	  of	  the	  ITS	  with	  suitable	  reference	  substances	  
to	  establish	  correct	  classification.	  However,	  even	  for	  these	  very	  simple	  stand-­‐alone	  
tests	  we	  are	  often	  limited	  by	  the	  low	  number	  of	  available	  well	  characterized	  
reference	  compounds	  and	  how	  much	  testing	  we	  can	  afford.	  However,	  such	  an	  
approach	  would	  only	  be	  valid	  for	  static	  ITS	  anyway	  and	  would	  lose	  all	  the	  flexibility	  
of	  exchanging	  building	  blocks.	  The	  opportunity	  lies	  in	  the	  earlier	  suggested	  
“mechanistic	  validation”.	  If	  we	  can	  agree	  that	  a	  certain	  building	  block	  covers	  a	  
certain	  relevant	  mechanism,	  we	  might	  relax	  our	  validation	  requirements	  and	  also	  
accept	  as	  equivalent	  another	  test	  covering	  the	  same	  mechanism.	  This	  does	  not	  blunt	  
the	  need	  for	  reproducibility	  assessments,	  but	  a	  few	  pertinent	  toxicants	  relevant	  to	  
humans	  should	  suffice	  to	  show	  that	  we	  at	  least	  identify	  the	  liabilities	  of	  the	  past.	  The	  
second	  way	  forward	  is	  to	  stop	  making	  any	  test	  a	  “game-­‐changer”:	  If	  we	  accept	  that	  
each	  and	  every	  test	  only	  changes	  probabilities	  of	  hazard,	  we	  can	  relax	  and	  fine-­‐tune	  
the	  weight	  added	  with	  each	  piece	  of	  evidence	  “on	  the	  road”.	  It	  appears	  that	  such	  
probabilistic	  hazard	  assessment	  also	  should	  be	  ideally	  compatible	  with	  probabilistic	  
PBPK	  modeling	  and	  probabilistic	  exposure	  modeling	  	  (Van	  Der	  Voet	  &	  Slob,	  2007).	  
This	  is	  the	  tremendous	  opportunity	  of	  probabilistic	  hazard	  and	  risk	  assessment	  
(Thompson	  &	  Graham,	  1996)	  (Hartung	  et	  al.,	  2012a).	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Consideration	  7:	  Challenges	  ahead	  
Regulatory	  acceptance:	  A	  key	  recommendation	  from	  the	  ECVAM/EPAA	  workshop	  
(Kinsner-­‐Ovaskainen	  et	  al.,	  2009)	  was:	  “It	  is	  necessary	  to	  initiate,	  as	  early	  as	  possible,	  
a	  dialogue	  with	  regulators	  and	  to	  include	  them	  in	  the	  development	  of	  the	  principles	  for	  
the	  construction	  and	  validation	  of	  ITS.”	  An	  earlier	  OECD	  workshop	  in	  2008	  (OECD,	  
2008)	  made	  some	  first	  steps	  and	  posed	  some	  of	  the	  most	  challenging	  questions:	  
• how	  these	  tools	  and	  methods	  can	  be	  used	  in	  an	  integrated	  approach	  to	  fulfil	  the	  
regulatory	  endpoint,	  independent	  of	  current	  legislative	  requirements;	  	  
• how	  the	  results	  gathered	  using	  these	  tools	  and	  methods	  can	  be	  transparently	  
documented;	  and	  	  
• how	  the	  degree	  of	  confidence	  of	  using	  them	  can	  be	  communicated	  throughout	  
the	  decision	  making	  process.	  	  
With	  impressive	  crowd-­‐sourcing	  of	  about	  60	  nominated	  experts	  and	  three	  case	  
studies,	  a	  number	  of	  conclusions	  were	  reached:	  
• There	  is	  limited	  acceptability	  for	  use	  of	  structural	  alerts	  to	  identify	  effects.	  
Acceptability	  can	  be	  improved	  by	  confirming	  the	  mode	  of	  action	  (e.g.	  in	  vitro	  
testing,	  in	  vivo	  information	  from	  an	  analogue	  or	  category).	  
• There	  is	  a	  higher	  acceptability	  for	  positive	  (Q)SAR	  results	  compared	  to	  negative	  
(Q)SAR	  results	  (except	  for	  aquatic	  toxicity).	  
• The	  communication	  on	  how	  the	  decision	  to	  accept	  or	  reject	  a	  (Q)SAR	  result	  can	  
be	  based	  on	  the	  applicability	  domain	  of	  a	  (Q)SAR	  model	  and/or	  the	  lack	  of	  
transparency	  of	  the	  (Q)SAR	  model.	  
• The	  acceptability	  of	  a	  (Q)SAR	  result	  can	  be	  improved	  by	  confirming	  the	  
mechanism/mode	  of	  action	  of	  a	  chemical	  and	  using	  a	  (Q)SAR	  model	  applicable	  
for	  that	  specific	  mechanism/mode	  of	  action.	  
• Read-­‐across	  from	  analogues	  can	  be	  used	  for	  priority	  setting,	  classification	  &	  
labelling	  and	  risk	  assessment.	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• The	  combination	  of	  analogue	  information	  and	  (Q)SAR	  results	  for	  both	  target	  
chemical	  and	  analogue	  can	  be	  used	  for	  classification	  &	  labelling	  and	  risk	  
assessment	  for	  acute	  aquatic	  toxicity	  if	  the	  target	  chemical	  and	  the	  analogue	  
share	  the	  same	  mode	  of	  action	  and	  if	  the	  target	  chemical	  and	  analogue	  are	  in	  
the	  applicability	  domain	  of	  the	  QSAR.	  
• Confidence	  in	  read-­‐across	  from	  a	  single	  analogue	  improves	  if	  it	  can	  be	  
demonstrated	  that	  the	  analogue	  is	  likely	  to	  be	  more	  toxic	  than	  the	  target	  
chemical	  or	  if	  it	  can	  be	  demonstrated	  that	  the	  target	  chemical	  and	  the	  
analogue	  have	  similar	  metabolisation	  pathways.	  
• Confidence	  in	  read-­‐across	  improves	  if	  experimental	  data	  is	  available	  on	  
structural	  analogues	  ”bracketing”	  the	  target	  substance.	  The	  confidence	  is	  
increased	  with	  an	  increased	  number	  of	  ”good”	  analogues	  that	  provide	  
concordant	  data.	  
• Lower	  quality	  data	  on	  a	  target	  chemical	  can	  be	  used	  for	  classification	  &	  
labelling	  and	  risk	  assessment	  if	  it	  confirms	  an	  overall	  trend	  over	  analogues	  and	  
target.	  
• Confidence	  is	  reduced	  in	  cases	  where	  robust	  study	  summaries	  for	  analogues	  are	  
incomplete	  or	  inadequate.	  
• It	  is	  difficult	  to	  judge	  analogues	  with	  missing	  functional	  groups	  compared	  to	  
the	  target;	  good	  analogues	  have	  no	  functional	  group	  compared	  to	  the	  target	  
and	  when	  choosing	  analogues,	  other	  information	  on	  similarity	  than	  functional	  
groups	  is	  requested.	  
Taken	  together,	  these	  conclusions	  address	  more	  a	  WoE	  approach	  and	  the	  use	  of	  
non-­‐testing	  information	  than	  actually	  ITS.	  They	  still	  present	  important	  information	  
on	  the	  comfort	  zone	  of	  regulators	  and	  how	  to	  handle	  such	  information	  for	  inclusion	  
into	  ITS.	  Noteworthy,	  the	  questions	  of	  documentation	  and	  expressing	  confidence	  
were	  not	  tackled.	  
Flexibility	  by	  determining	  the	  Most	  Valuable	  (next)	  Test:	  A	  key	  problem	  is	  to	  
break	  out	  of	  the	  rigid	  test	  guideline	  principles	  of	  the	  past.	  ITS	  must	  not	  be	  forced	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into	  a	  scheme	  with	  yearlong	  debate	  of	  expert	  consensus	  and	  committees.	  Too	  often,	  
technological	  changes	  to	  components,	  difficulties	  with	  availability	  and	  applicability	  
of	  building	  blocks	  and	  case-­‐by-­‐case	  adaptations	  for	  the	  given	  test	  sample	  will	  be	  
necessary.	  For	  example,	  the	  integration	  of	  existing	  data,	  obviously	  at	  the	  beginning	  
of	  an	  ITS,	  already	  creates	  a	  very	  different	  starting	  point.	  Chemico-­‐physical,	  
structural	  properties	  (including	  read-­‐across	  or	  chemical	  category	  assignments)	  and	  
prevalence	  will	  also	  change	  the	  probability	  of	  risk	  even	  before	  the	  first	  tests	  are	  
applied.	  In	  order	  to	  maintain	  the	  desired	  flexibility	  in	  applying	  an	  ITS,	  at	  each	  
moment	  the	  MVT	  (most	  valuable	  test)	  to	  follow	  needs	  to	  be	  determined.	  Such	  an	  
approach	  should	  have	  the	  following	  features:	  
1.	  Assess	  finally	  the	  probability	  of	  toxicity	  from	  the	  different	  test	  results.	  
2.	  Determine	  most	  valuable	  next	  test	  given	  from	  previous	  test	  results	  and	  other	  
information.	  	  
3.	  Have	  a	  measure	  of	  model	  stability	  (e.g.	  confidence	  intervals)	  and	  robustness.	  
Assessing	  the	  probability	  of	  toxicity	  for	  given	  tests	  can	  be	  done	  by	  a	  machine	  
learning	  tools.	  Generative	  models	  work	  best	  for	  providing	  the	  values	  needed	  to	  find	  
a	  most	  valuable	  test	  given	  prior	  tests.	  One	  simple	  generative	  model	  would	  predict	  
probability	  of	  toxicity	  using	  a	  discriminative	  model	  (e.g.	  Random	  Forest),	  and	  test	  
probability	  via	  a	  generative	  model	  (e.g.	  Naive	  Bayes).	  A	  classifier	  for	  determining	  
risk	  of	  chemical	  toxicity	  must	  have	  the	  following	  traits:	  
• Outputs	  unbiased	  and	  consistent	  probability	  estimates	  for	  toxicity	  (e.g.	  by	  
cross-­‐validation).	  	  
• Outputs	  probability	  estimates	  even	  when	  missing	  certain	  results	  (both	  
Random	  Forests	  and	  Naive	  Bayes	  can	  handle	  missing	  values).	  
• Reliable	  and	  stable	  results	  based	  on	  cross-­‐validation	  measures.	  
The	  MVT	  identification	  based	  on	  previous	  tests	  is	  not	  a	  direct	  consequence	  of	  
building	  a	  toxicity	  probability	  estimator.	  To	  find	  MVTs	  we	  need	  a	  generative	  model	  
capable	  of	  determining	  test	  probabilities.	  One	  simple	  and	  effective	  way	  to	  determine	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the	  MVT	  is	  via	  the	  same	  method	  that	  decision	  trees	  use,	  i.e.	  an	  iterative	  process	  of	  
determining,	  which	  tests	  gives	  the	  most	  'information'	  on	  the	  endpoint.	  Information	  
gain	  can	  be	  calculated	  given	  a	  generative	  model.	  To	  determine	  the	  test,	  which	  gives	  
the	  most	  information,	  we	  can	  find	  the	  test	  that	  yields	  the	  greatest	  reduction	  in	  
Shannon	  entropy.	  This	  is	  basically	  a	  measure	  that	  quantifies	  information	  as	  a	  
function	  of	  the	  probability	  of	  different	  values	  for	  a	  test	  and	  the	  impact	  those	  values	  
have	  on	  the	  endpoint	  category	  (toxic	  vs.	  non-­‐toxic).	  The	  mathematical	  formula	  is:	  
	  
Where	  T	  is	  the	  test	  in	  question	  and	  p(Ti)	  signifies	  the	  probability	  of	  a	  test	  taking	  on	  
one	  of	  its	  values	  (enumerated	  by	  i).	  To	  determine	  the	  most	  valuable	  test	  we	  need	  
not	  only	  the	  toxicity	  classifier,	  but	  we	  need	  probability	  estimates	  for	  every	  test	  as	  a	  
function	  of	  all	  other	  tests.	  To	  determine	  these	  transition	  probabilities	  we	  need	  to	  
discretize	  every	  test	  into	  the	  n	  buckets	  shown	  in	  the	  above	  equation.	  	  
We	  can	  expect	  that	  users	  applying	  this	  model	  would	  want	  to	  determine	  probabilities	  
of	  toxicity	  for	  their	  test	  item	  within	  some	  risk	  threshold	  in	  the	  fewest	  number	  of	  test	  
steps	  or	  minimizing	  the	  costs.	  When	  we	  start	  testing	  for	  toxicity	  we	  may	  want	  to	  
check	  on	  the	  current	  level	  of	  risk	  before	  deciding	  on	  more	  testing.	  For	  example	  we	  
might	  decide	  to	  stop	  testing	  if	  a	  test	  item	  has	  less	  than	  10%	  chance	  of	  being	  toxic	  or	  
a	  greater	  than	  90%	  chance.	  Finding	  MVTs	  from	  a	  generative	  model	  has	  an	  advantage	  
over	  directly	  using	  decision	  trees.	  Unfortunately,	  decision	  trees	  cannot	  handle	  
sparse	  data	  effectively.	  The	  amount	  of	  data	  needed	  to	  determine	  n	  tests	  increases	  
exponentially	  with	  the	  number	  of	  tests.	  By	  calculating	  MVTs	  on	  top	  of	  a	  generative	  
model	  we	  can	  leverage	  a	  simple	  calculation	  from	  a	  complex	  model	  that	  is	  not	  as	  
heavily	  constrained	  by	  data	  size.	  
Combining	  the	  ITS	  concept	  with	  Tox-­‐21c:	  As	  discussed	  above,	  Tox-­‐21c	  relies	  on	  
breaking	  risk	  assessment	  down	  in	  many	  components.	  These	  need	  to	  be	  put	  together	  
again	  in	  a	  way	  to	  allow	  decision-­‐taking,	  ultimately	  envisioned	  as	  Systems	  Toxicology	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metabolomics	  lacks	  the	  large-­‐scale,	  integrated	  databases	  that	  have	  been	  crucial	  to	  
the	  analysis	  of	  transcriptomic	  and	  proteomic	  data.	  Like	  the	  early	  years	  of	  
microarrays,	  there	  are	  still	  no	  established	  methods	  to	  interpret	  data.	  Exploring	  data	  
sets	  via	  several	  methods	  (Sugimoto,	  Kawakami,	  Robert,	  Soga,	  &	  Tomita,	  2012)	  (ORA,	  
QEA,	  correlation	  analysis,	  and	  genome-­‐scale	  network	  reconstruction)	  will	  hopefully	  
provide	  some	  guidance	  for	  future	  toxicological	  applications	  for	  metabolomics	  and	  
help	  better	  understand	  the	  puzzle	  as	  well	  as	  develop	  and	  provide	  new	  perspectives	  
on	  how	  to	  integrate	  several	  ‘-­‐omics’	  technologies.	  At	  some	  level,	  metabolomics	  
remains	  at	  this	  stage	  one	  of	  hypothesis	  generation	  and	  potentially,	  biomarker	  
discovery,	  and	  as	  such	  will	  be	  dependent	  on	  validation	  by	  other	  means.	  	  
One	  critical	  problem	  for	  metabolomics	  is	  that	  while	  a	  more-­‐or-­‐less	  complete	  "parts	  
list"	  and	  wiring	  diagrams	  exist	  for	  genomic	  and	  proteomic	  networks,	  knowledge	  of	  
metabolic	  networks	  is	  still	  relatively	  incomplete.	  Currently,	  there	  are	  three	  non-­‐
tissue	  specific	  genome-­‐scale	  human	  metabolic	  networks:	  Recon	  1	  (Rolfsson,	  
Palsson,	  &	  Thiele,	  2011)	  (Rolfsson	  et	  al.,	  2011),	  the	  Edinburgh	  Human	  Metabolic	  
Network	  (EHMN)	  (Ma	  et	  al.,	  2007),	  and	  HumanCyc	  (Romero	  et	  al.,	  2004).	  	  These	  
reconstructions	  are	  "first-­‐drafts":	  in	  addition	  to	  genes	  and	  proteins	  of	  unknown	  
function	  as	  well	  as	  "dead-­‐end”	  or	  "orphaned"	  metabolites	  which	  are	  not	  associated	  
with	  specific	  anabolic	  or	  catabolic	  pathways.	  Furthermore,	  the	  networks	  are	  not	  
tissue-­‐specific.	  Many	  toxicants,	  including	  endocrine	  disruptors,	  exhibit	  tissue-­‐
specific	  toxicity,	  and	  a	  cell	  or	  tissue-­‐specific	  metabolic	  network	  (Hao,	  Ma,	  Zhao,	  &	  
Goryanin,	  2012)	  should	  provide	  a	  more	  accurate	  model	  of	  pathology	  than	  a	  generic,	  
global	  human	  metabolic	  network.	  Longer-­‐term,	  a	  well-­‐characterized,	  biochemically	  
complete	  network	  will	  help	  make	  the	  leap	  from	  pathway	  identification	  to	  a	  
parameterized	  model	  than	  can	  be	  used	  for	  more	  complex	  simulations	  such	  as	  
metabolic	  control	  analysis,	  flux	  analysis,	  and	  systems	  control	  theory	  to	  understand	  
the	  wiring	  diagram	  that	  allows	  the	  cell	  to	  maintain	  homeostasis	  and	  where,	  within	  
that	  wiring	  diagram,	  there	  are	  vulnerabilities.	  
Steering	  the	  new	  developments:	  At	  this	  stage,	  no	  strategic	  planning	  and	  
coordination	  for	  the	  challenge	  of	  ITS	  implementation	  exists.	  This	  was	  noticed	  in	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most	  of	  the	  meetings	  do	  far,	  e.g.,	  (Berg	  et	  al.,	  2011):	  “…there	  was	  a	  clear	  call	  from	  the	  
audience	  for	  a	  credible	  leadership	  with	  the	  capacity	  to	  assure	  alignment	  of	  ongoing	  
activities	  and	  initiation	  of	  concerted	  actions,	  e.g.	  a	  global	  human	  toxicology	  project.”	  
The	  Human	  Toxicology	  Project	  Consortium	  (http://htpconsortium.wordpress.com)	  
is	  one	  of	  the	  advocates	  for	  such	  steering	  (Seidle	  and	  Stephens,	  2009).	  There	  is	  still	  
quite	  a	  road	  to	  go	  (Hartung,	  2009a).	  While	  we	  aim	  to	  establish	  some	  type	  of	  
coordinating	  center	  in	  the	  US	  at	  Johns	  Hopkins	  (working	  title	  PoToMaC—Pathway	  
of	  Toxicity	  Mapping	  Center),	  no	  such	  effort	  is	  yet	  in	  place	  in	  Europe.	  We	  have	  been	  
suggesting	  the	  creation	  of	  a	  European	  Safety	  Sciences	  Institute	  (ESSI)	  in	  our	  policy	  
program,	  but	  this	  discussion	  is	  only	  starting.	  It	  is,	  however,	  evident	  that	  we	  need	  
such	  structures	  for	  developing	  the	  new	  toxicological	  toolbox	  and	  a	  global	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Box	  1	  
RELEVANT	  DEFINITIONS	  FROM	  OECD	  SERIES	  ON	  TESTING	  AND	  ASSESSMENT	  
OECD	  SERIES	  ON	  TESTING	  AND	  ASSESSMENT	  Number	  34	  
GUIDANCE	  DOCUMENT	  ON	  THE	  VALIDATION	  AND	  INTERNATIONAL	  ACCEPTANCE	  
OF	  NEW	  OR	  UPDATED	  TEST	  METHODS	  FOR	  HAZARD	  ASSESSMENT	  
Adjunct	  test:	  Test	  that	  provides	  data	  that	  add	  to	  or	  help	  interpret	  the	  results	  of	  
other	  tests	  and	  provide	  information	  useful	  for	  the	  risk	  assessment	  process	  
Assay:	  Uses	  interchangeably	  with	  Test.	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Data	  interpretation	  procedure	  (DIP):	  An	  interpretation	  procedure	  used	  to	  
determine	  how	  well	  the	  results	  from	  the	  test	  predict	  or	  model	  the	  biological	  effect	  of	  
interest.	  See	  Prediction	  Model.	  
Decision	  Criteria:	  The	  criteria	  in	  a	  test	  method	  protocol	  that	  describe	  how	  the	  test	  
method	  results	  are	  used	  for	  decisions	  on	  classification	  or	  other	  effects	  measured	  or	  
predicted	  by	  the	  test	  method.	  
Definitive	  test:	  A	  test	  that	  is	  considered	  to	  generate	  sufficient	  data	  to	  determine	  the	  
specific	  hazard	  or	  lack	  of	  hazard	  of	  the	  substance	  without	  the	  need	  for	  further	  
testing,	  and	  which	  may	  therefore	  be	  used	  to	  make	  decisions	  pertaining	  to	  hazard	  or	  
safety	  of	  the	  substance.	  
Hierarchical	  (tiered)	  testing	  approach:	  An	  approach	  where	  a	  series	  of	  tests	  to	  
measure	  or	  elucidate	  a	  particular	  effect	  are	  used	  in	  an	  ordered	  sequence.	  In	  a	  typical	  
hierarchical	  testing	  approach,	  one	  or	  a	  few	  tests	  are	  initially	  used;	  the	  results	  from	  
these	  tests	  determine	  which	  (if	  any)	  subsequent	  tests	  are	  to	  be	  used.	  For	  a	  
particular	  chemical,	  a	  weigh-­‐of-­‐evidence	  decision	  regarding	  hazard	  could	  be	  made	  
at	  any	  stage	  (tier)	  in	  the	  testing	  strategy,	  in	  which	  case	  there	  would	  be	  no	  need	  to	  
proceed	  to	  subsequent	  tiers.	  
In	  silico	  models:	  Approaches	  for	  the	  assessment	  of	  chemicals	  based	  on	  the	  use	  
computer-­‐based	  estimations	  or	  simulations.	  Examples	  include	  structure-­‐activity	  
relationships	  (SAR),	  quantitative	  structure-­‐activity	  relationships	  (QSARs),	  and	  
expert	  systems.	  
(Q)SARs	  (Quantitative	  Structure-­‐Activity	  Relationships):	  Theoretical	  models	  for	  
making	  predictions	  of	  physicochemical	  properties,	  environmental	  fate	  parameters,	  
or	  biological	  effects	  (including	  toxic	  effects	  in	  environmental	  and	  mammalian	  
species).	  They	  can	  be	  divided	  into	  two	  major	  types,	  QSARs	  and	  SARs.	  QSARs	  are	  
quantitative	  models	  yielding	  a	  continuous	  or	  categorical	  result	  while	  SARs	  are	  
qualitative	  relationships	  in	  the	  form	  of	  structural	  alerts	  that	  incorporate	  molecular	  
substructures	  or	  fragments	  related	  to	  the	  presence	  or	  absence	  of	  activity.	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A	  screen/screening	  test	  is	  often	  a	  rapid,	  simple	  test	  method	  conducted	  for	  the	  
purpose	  of	  classifying	  substances	  into	  a	  general	  category	  of	  hazard.	  The	  results	  of	  a	  
screening	  test	  generally	  are	  used	  for	  preliminary	  decision	  making	  in	  the	  context	  of	  a	  
testing	  strategy	  (i.e.,	  to	  assess	  the	  need	  for	  additional	  and	  more	  definitive	  tests).	  
Screening	  tests	  often	  have	  a	  truncated	  response	  range	  in	  that	  positive	  results	  may	  
be	  considered	  adequate	  to	  determine	  if	  a	  substance	  is	  in	  the	  highest	  category	  of	  a	  
hazard	  classification	  system	  without	  the	  need	  for	  further	  testing,	  but	  are	  not	  usually	  
adequate	  without	  additional	  information/tests	  to	  make	  decisions	  pertaining	  to	  
lower	  levels	  of	  hazard	  or	  safety	  of	  the	  substance	  	  
Test	  (or	  assay):	  An	  experimental	  system	  used	  to	  obtain	  information	  on	  the	  adverse	  
effects	  of	  a	  substance.	  Used	  interchangeably	  with	  assay.	  
Test	  battery:	  A	  series	  of	  tests	  usually	  performed	  at	  the	  same	  time	  or	  in	  close	  
sequence.	  Each	  test	  within	  the	  battery	  is	  designed	  to	  complement	  the	  other	  tests	  
and	  generally	  to	  measure	  a	  different	  component	  of	  a	  multi-­‐factorial	  toxic	  effect.	  Also	  
called	  base	  set	  or	  minimum	  data	  set	  in	  ecotoxicological	  testing.	  
Test	  method:	  A	  process	  or	  procedure	  used	  to	  obtain	  information	  on	  the	  
characteristics	  of	  a	  substance	  or	  agent.	  Toxicological	  test	  methods	  generate	  
information	  regarding	  the	  ability	  of	  a	  substance	  or	  agent	  to	  produce	  a	  specified	  
biological	  effect	  under	  specified	  conditions.	  Used	  interchangeably	  with	  “test”	  and	  
“assay”.	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APPENDIX	  III	  Pathways	  of	  Toxicity	  Workshop	  Report	  
	  
(Originally	  published	  as:	  Kleensang,	  A.,	  Maertens,	  A.,	  Rosenberg,	  M.,	  Fitzpatrick,	  S.,	  
Lamb,	  J.,	  Auerbach,	  S.,	  ...	  &	  Hartung,	  T.	  (2014).	  t4	  workshop	  report:	  pathways	  of	  
toxicity.	  Altex,	  31(1),	  53)	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There	  is	  a	  goal,	  
but	  no	  way;	  









Despite	  wide-­‐spread	  consensus	  on	  the	  need	  to	  transform	  toxicology	  and	  risk	  
assessment	  in	  order	  to	  keep	  pace	  with	  technological	  and	  computational	  changes	  that	  
have	  revolutionized	  the	  life	  sciences,	  there	  remains	  much	  work	  to	  be	  done	  to	  achieve	  
the	  vision	  of	  toxicology	  based	  on	  a	  mechanistic	  foundation.	  To	  this	  end,	  a	  workshop	  
was	  organized	  to	  explore	  one	  key	  aspect	  of	  this	  transformation—the	  development	  of	  
Pathways	  of	  Toxicity	  as	  a	  key	  tool	  for	  hazard	  identification	  based	  on	  systems	  biology.	  
Several	  issues	  were	  discussed	  in	  depth	  in	  the	  workshop:	  
	  The	  first	  was	  the	  challenge	  of	  formally	  defining	  the	  concept	  of	  a	  Pathway	  of	  Toxicity	  
(PoT),	  as	  distinct	  from,	  but	  complementary	  to,	  other	  toxicological	  pathway	  concepts	  
such	  as	  mode	  of	  action	  (MoA).	  The	  workshop	  came	  up	  with	  a	  preliminary	  definition	  of	  
PoT	  as	  “A	  molecular	  definition	  of	  cellular	  processes	  shown	  to	  mediate	  adverse	  
outcomes	  of	  toxicants”.	  It	  is	  further	  recognized	  that	  normal	  physiological	  pathways	  
exist	  that	  maintain	  homeostasis	  and	  these,	  sufficiently	  perturbed,	  can	  become	  PoT.	  
Second,	  the	  workshop	  sought	  to	  define	  the	  adequate	  public	  and	  commercial	  resources	  
for	  PoT	  information,	  including	  data,	  visualization,	  analyses,	  tools,	  and	  use-­‐cases,	  as	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well	  as	  the	  kinds	  of	  efforts	  that	  will	  be	  necessary	  to	  enable	  the	  creation	  of	  such	  a	  
resource.	  
Third,	  the	  workshop	  explored	  ways	  in	  which	  systems	  biology	  approaches	  could	  inform	  
pathway	  annotation,	  and	  which	  resources	  are	  needed	  and	  available	  that	  can	  provide	  
relevant	  PoT	  information	  to	  the	  diverse	  user	  communities.	  
	   	  
	  




1.	   Introduction	  
	  
The	  “Toxicology	  in	  the	  21st	  Century”	  (Tox-­‐21c)	  movement,	  initiated	  with	  the	  2007	  
NRC	  report	  (Krewski	  et	  al.,	  2010;	  National	  Research	  Council,	  2007),	  has	  stirred	  the	  
toxicological	  community	  (T.	  Hartung,	  2008;	  Hartung,	  2009,	  2011;	  Hartung	  &	  Leist,	  
2008)	  and	  initiated	  a	  far-­‐reaching	  discussion	  about	  current	  practices	  in	  risk	  
assessment	  and	  possible	  avenues	  for	  advancement.	  A	  critical	  overview	  of	  the	  
extensive	  dialog	  that	  ensued	  after	  the	  publication	  of	  the	  report	  has	  been	  
summarized	  by	  Andersen	  and	  Krewski	  (Andersen	  &	  Krewski,	  2010).	  Within	  a	  few	  
years	  the	  discussion	  has	  moved	  from	  whether	  the	  field	  of	  toxicology	  should	  change	  
to	  discussions	  on	  how	  and	  when	  to	  do	  so—from	  the	  call	  for	  a	  Human	  Toxicology	  
Project	  (Seidle	  &	  Stephens,	  2009;	  http://www.humantoxicologyproject.org)	  to	  the	  
ongoing	  programs	  by	  the	  US	  federal	  agencies	  (R.	  S.	  Judson	  et	  al.,	  2010;	  Knudsen	  et	  
al.,	  2011)	  and	  the	  redefinition	  of	  the	  EPA	  toxicity-­‐testing	  paradigm	  (Firestone,	  
Kavlock,	  Zenick,	  Kramer,	  &	  Testing,	  2010).	  
The	  United	  States	  Food	  and	  Drug	  Administration	  (FDA)	  has	  recently	  
embraced	  this	  strategy	  (Hamburg,	  2011):	  	  
“We	  must	  bring	  21st	  century	  approaches	  to	  21st	  century	  products	  and	  problems.	  
Toxicology	  is	  a	  prime	  example.	  Most	  of	  the	  toxicology	  tools	  used	  for	  regulatory	  
assessment	  rely	  on	  high-­‐dose	  animal	  studies	  and	  default	  extrapolation	  procedures	  
and	  have	  remained	  relatively	  unchanged	  for	  decades,	  despite	  the	  scientific	  
revolutions	  of	  the	  past	  half-­‐century.	  We	  need	  better	  predictive	  models	  to	  identify	  
concerns	  earlier	  in	  the	  product	  development	  process	  to	  reduce	  time	  and	  costs.	  We	  
also	  need	  to	  modernize	  the	  tools	  used	  to	  assess	  emerging	  concerns	  about	  potential	  
risks	  from	  food	  and	  other	  product	  exposures.	  …	  With	  an	  advanced	  field	  of	  
regulatory	  science,	  new	  tools,	  including	  functional	  genomics,	  proteomics,	  
metabolomics,	  high-­‐throughput	  screening,	  and	  systems	  biology,	  can	  replace	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current	  toxicology	  assays	  with	  tests	  that	  incorporate	  the	  mechanistic	  
underpinnings	  of	  disease	  and	  of	  underlying	  toxic	  side	  effects.	  This	  should	  allow	  the	  
development,	  validation,	  and	  qualification	  of	  preclinical	  and	  clinical	  models	  that	  
accelerate	  the	  evaluation	  of	  toxicities	  during	  drug	  development.	  …	  Ultimately,	  
investments	  in	  regulatory	  science	  can	  lead	  to	  a	  new	  era	  of	  progress	  and	  safety.	  
Because	  such	  investments	  will	  promote	  not	  only	  public	  health	  but	  also	  the	  
economy,	  job	  creation,	  and	  global	  economic	  competitiveness,	  they	  have	  major	  
implications	  for	  the	  nation’s	  future.”	  	  
We	  could	  not	  summarize	  it	  better.	  
The	  key	  proposal	  of	  Tox-­‐21c	  is	  straightforward:	  we	  have	  to	  base	  regulatory	  
toxicology	  (for	  environmental	  chemicals,	  because	  this	  was	  the	  mandate	  of	  the	  
National	  Academy	  of	  Sciences	  panel)	  on	  mechanism	  and	  mode	  of	  action.	  The	  term	  
“toxicity	  pathways”	  was	  coined	  in	  the	  NRC	  report	  and	  later	  the	  term	  “Pathway	  of	  
Toxicity”	  (PoT)	  was	  created	  by	  Hartung	  and	  colleagues	  (Hartung,	  2009,	  2011).	  OECD	  
uses	  adverse	  outcome	  pathway	  in	  the	  context	  of	  their	  QSAR	  Toolbox	  and	  
ecotoxicology	  (Ankley	  et	  al.,	  2006)	  and	  recently	  published	  a	  proposal	  for	  a	  template,	  
and	  guidance	  on	  developing	  and	  assessing	  the	  completeness	  of	  adverse	  outcome	  
pathways	  as	  a	  draft	  document	  (OECD,	  2012).	  This	  is	  in	  line	  with	  the	  science	  of	  
toxicology	  moving	  toward	  a	  more	  complete	  mechanistic	  understanding.	  There	  have	  
already	  been	  some	  tentative	  efforts	  to	  identify	  and	  describe	  PoT.	  One	  component	  of	  
the	  Tox-­‐21	  alliance	  formed	  by	  US	  EPA	  (ToxCast),	  the	  NIEHS	  (within	  the	  National	  
Toxicology	  Program),	  NIH	  Chemical	  Genomics	  Center	  (the	  high-­‐throughput	  testing	  
program)	  and	  FDA	  (the	  Critical	  Path	  Initiative),	  is	  focused	  on	  use	  of	  HTS	  data	  to	  
facilitate	  and	  test	  PoT3.	  
The	  limitations	  of	  the	  existing	  paradigm	  are	  well	  known.	  Hazard	  assessment	  
based	  on	  animal	  testing	  has	  limited	  throughput	  achieved	  at	  a	  high	  cost;	  if	  traditional	  
tests	  are	  applied	  to	  the	  backlog	  of	  existing	  chemicals	  of	  concern	  for	  which	  there	  is	  
limited	  safety	  data,	  the	  costs	  would	  be	  enormous	  and,	  even	  if	  that	  were	  not	  an	  
obstacle,	  the	  capacity	  is	  simply	  not	  there	  (see	  e.g.	  Hartung	  &	  Rovida,	  2009;	  Rovida	  &	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3	  http://epa.gov/ncct/Tox21	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Hartung,	  2009;	  Seok	  et	  al.,	  2013).	  Furthermore,	  while	  the	  continued	  or	  expanded	  
use	  of	  animal	  testing	  has	  become	  more	  and	  more	  objectionable	  to	  the	  general	  
public,	  as	  well	  as	  to	  many	  in	  the	  toxicology	  community,	  there	  is	  at	  the	  same	  time	  a	  
public	  mandate	  to	  perform	  more	  thorough	  hazard	  assessment	  and	  testing	  for	  
industrial	  chemicals	  (e.g.,	  European	  REACH	  legislation),	  not	  to	  mention	  the	  demands	  
of	  the	  drug	  and	  consumer	  industry.	  New	  types	  of	  products—such	  as	  
nanomaterials—that	  will	  likely	  play	  a	  large	  role	  in	  our	  economic	  future	  require	  a	  
more	  sophisticated	  hazard	  assessment	  paradigm	  (Hartung,	  2010b).	  The	  necessary	  
practice	  of	  high-­‐dose	  to	  low-­‐dose	  extrapolation	  is	  both	  imprecise	  and	  often	  results	  
in	  an	  overly	  cautious	  approach.	  	  
To	  foster	  the	  ideas	  of	  the	  NRC	  report,	  in	  Oct	  2012	  the	  Center	  for	  Alternatives	  
to	  Animal	  Testing	  supported	  by	  the	  Doerenkamp-­‐Zbinden	  Foundation,	  Zurich,	  
Switzerland,	  and	  Unilever	  held	  a	  workshop	  on	  “Pathways	  of	  Toxicity”	  that	  discussed	  
the	  concept	  of	  PoT	  as	  well	  as	  defining	  the	  necessary	  associated	  tools,	  standards,	  and	  
core	  competencies.	  The	  three-­‐day	  workshop	  brought	  together	  a	  diverse	  group	  of	  
more	  than	  30	  front-­‐line	  researchers	  and	  experts	  from	  academia	  (e.g.,	  Universities	  in	  
Boston,	  Alberta,	  Tel-­‐Aviv	  and	  Johns	  Hopkins	  University	  in	  Baltimore),	  independent	  
research	  institutes	  (TNO	  Netherlands	  and	  The	  Hamner	  Institutes	  for	  Health	  
Sciences),	  industry	  (e.g.,	  Agilent	  and	  Unilever),	  non-­‐governmental	  organizations	  
(e.g.,	  The	  Humane	  Society	  of	  the	  US),	  systems	  biology/toxicology	  content	  and	  tool	  
providers	  (e.g.,	  KEGG,	  Thomson	  Reuters,	  WikiPathways,	  Reactome,	  Ingenuity	  
Systems,	  Genometry),	  and	  the	  regulatory	  professionals	  that	  employ	  toxicology	  
studies	  and	  data	  analysis	  tools	  to	  protect	  public	  health	  (e.g.,	  NIH	  &	  NIEHS,	  US	  EPA,	  
US	  FDA,	  European	  Commission).	  This	  report	  presents	  the	  conclusions	  and	  
perspectives	  from	  that	  conference.	  We	  outline	  the	  possible	  benefits	  of	  mapping	  PoT,	  
clarify	  the	  meaning	  and	  definition	  of	  PoT,	  complemented	  by	  a	  thorough	  discussion	  
of	  the	  usefulness	  and	  validation	  of	  a	  public	  PoT	  database.	  Finally,	  we	  discuss	  the	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2.	   What	  are	  the	  benefits	  of	  mapping	  PoT?	  	  
	  
Toxicology,	  like	  the	  rest	  of	  biology,	  is	  undergoing	  a	  shift	  from	  a	  reductionist	  
approach	  to	  a	  more	  system-­‐oriented	  view	  that	  takes	  advantage	  of	  the	  newer,	  high-­‐
content	  and	  high-­‐throughput	  technologies	  (van	  Vliet,	  2011).	  The	  opportunity	  to	  
move	  away	  from	  the	  limited	  mechanistic	  information	  provided	  by	  traditional	  animal	  
tests	  to	  a	  pathway-­‐based	  approach	  that	  provides	  detailed,	  specific	  mechanistic	  
understanding	  at	  a	  cellular	  level,	  predictive	  for	  target	  organ	  toxicities	  in	  a	  causal	  
(ideally	  dose	  dependent)	  manner,	  presents	  both	  challenges	  and	  opportunities	  
(Hartung	  &	  McBride,	  2011;	  Hartung	  et	  al.,	  2012b).	  As	  part	  of	  this	  challenge,	  the	  
production	  of	  a	  comprehensive	  list	  of	  all	  PoT—that	  is,	  the	  “Human	  Toxome”—	  
would	  be	  of	  great	  benefit.	  This	  concept	  is	  based	  on	  the	  assumption	  that	  the	  number	  
of	  PoT	  is	  finite,	  and	  that,	  once	  mapped,	  toxicology	  can	  move	  towards	  more	  certainty	  
while	  sharply	  reducing	  and	  eventually	  eliminating	  the	  need	  for	  animal	  testing	  [see	  
also	  section	  IV].	  	  
Pathway-­‐based	  approaches	  for	  toxicity	  testing	  require	  different	  methods	  for	  
extrapolations.	  With	  animal	  testing,	  an	  expensive,	  two-­‐year	  animal	  assay	  may	  
establish,	  for	  example,	  that	  a	  6	  ppm	  dose	  exposure	  concentration	  is	  a	  point-­‐of-­‐
departure	  for	  specific	  adverse	  responses.	  For	  non-­‐cancer	  effects,	  this	  in-­‐life	  point-­‐of-­‐
departure	  would	  be	  divided	  by	  various	  uncertainty	  factors	  to	  arrive	  at	  a	  “safe”	  dose.	  
Linear	  low-­‐dose	  modeling	  would	  be	  used	  with	  carcinogens	  to	  estimate	  a	  dose	  
associated	  with	  some	  level	  of	  risk	  (e.g.,	  1/100,000	  or	  1/1,000,000).	  With	  a	  PoT	  
approach,	  the	  point-­‐of-­‐departure	  will	  arise	  from	  observations	  in	  the	  in	  vitro	  test	  
batteries	  that	  provide	  greater	  multi-­‐dose	  concentration	  response	  curves.	  These	  in	  
vitro	  PoDs	  will	  be	  adjusted	  using	  in	  vitro-­‐in	  vivo	  extrapolation	  (Rotroff	  et	  al.,	  2010;	  
Wetmore	  et	  al.,	  2012)	  and	  there	  will	  be	  a	  need	  for	  computational	  pathway	  models	  
(Bhattacharya,	  Zhang,	  Carmichael,	  Boekelheide,	  &	  Andersen,	  2011)	  to	  derive	  
proposed	  “safe	  doses”	  depending	  on	  characteristics	  of	  the	  pathway	  architecture.	  
These	  pathway	  approaches	  will	  link	  dose	  and	  dynamics—especially	  at	  low	  doses—
	  
	   177	  
and	  will	  show	  a	  clear	  causal	  linkage	  between	  initiating	  event	  and	  adverse	  outcome	  
that	  should	  be	  useful	  both	  for	  setting	  safe	  doses	  as	  well	  as	  identifying	  biomarkers.	  	  
Lastly,	  it	  is	  necessary	  to	  move	  toxicology	  away	  from	  an	  approach	  that	  
extrapolates	  from	  rodents,	  and	  instead	  uses	  a	  human-­‐tissue	  based	  approach;	  this	  
necessitates	  by	  definition	  understanding	  toxicological	  mechanisms	  at	  the	  cellular	  
and	  pathway	  level,	  jointly	  with	  in	  vitro	  to	  in	  vivo	  extrapolations	  of	  dose	  levels.	  
Ultimately,	  a	  pathway-­‐based	  approach	  that	  uses	  human	  tissue	  informed	  by	  a	  deeper	  
mechanistic	  understanding	  of	  toxicity,	  as	  well	  as	  mechanistic	  understanding	  of	  
human	  disease	  decreases	  uncertainty	  in	  decision-­‐making.	  
As	  an	  example	  of	  the	  existing	  problems	  that	  face	  regulators	  when	  testing	  a	  
substance	  with	  current	  approaches,	  consider	  the	  dilemma	  posed	  by	  negative	  
results:	  there	  is	  always	  the	  possibility	  that	  a	  different	  dosing	  scheme,	  different	  
species	  or	  other	  experimental	  variation	  might	  yield	  very	  different	  results.	  The	  
uncertainty	  only	  increases	  when	  we	  consider	  that	  animals	  might	  have	  a	  defense	  
mechanism	  not	  present	  in	  humans	  or	  in	  sensitive	  populations,	  like	  newborns,	  who,	  
for	  instance,	  lack	  a	  functional	  blood-­‐brain	  barrier	  for	  chemicals.	  Conventionally	  
however,	  we	  assume	  that	  with	  some	  additional	  measures	  (high	  dose,	  species	  
selection,	  more	  than	  one	  species,	  structural	  alerts,	  etc.)	  we	  can	  overcome	  this	  
problem.	  However,	  a	  more	  definitive	  answer	  could	  be	  given	  if	  we	  had	  a	  complete	  list	  
of	  human	  relevant	  PoT	  and	  a	  corresponding	  validated	  test	  battery.	  Then	  we	  could,	  
for	  the	  first	  time,	  be	  reasonably	  confident	  that	  a	  substance	  does	  not	  trigger/perturb	  
relevant	  PoT.	  Similarly,	  we	  can	  establish	  concentrations	  of	  substances	  (in	  vitro	  no-­‐
effect	  levels—NOELin	  vit)	  where	  no	  PoT	  is	  triggered.	  It	  is	  important	  to	  note	  that	  the	  
triggering	  of	  a	  PoT	  does	  not	  necessarily	  indicate	  harm,	  but	  a	  potential	  for	  harm.	  
	  







• Box	  1:	  How	  should	  a	  PoT	  database	  be	  designed?	  
	  




• PoT	  should	  be	  grounded	  at	  the	  molecular	  and	  cellular	  level	  
	  
• It	  should	  include:	  
	  
structured	  and	  hierarchal	  vocabulary	  of	  adverse	  events,	  
MoA	  and	  pathway	  description,	  
	  
spatial	  and	  temporal	  effects,	  
	  
dose-­‐response:	  thresholds	  of	  adversity	  are	  essential,	  
	  
links	  to	  evidence	  and	  raw	  data	  needed	  	  
	  
both	  machine	  and	  human	  readable,	  
	  
quality	  assurance/validation	  summaries	  based	  on	  
evidence-­‐based	  toxicology	  principles,	  and	  
	  
interfaces	  with	  other	  databases	  (e.g.,	  WikiPathways)	  for	  
import/export	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Chapter	  IV,	  Figure	  1:	  Possible	  Structure	  of	  a	  PoT	  Database	  
	  




As	  -­‐omics	  technologies	  have	  increasingly	  added	  to	  our	  knowledge	  of	  biology,	  there	  
has	  been	  a	  proliferation	  of	  pathway	  oriented	  databases	  such	  as	  KEGG,	  
WikiPathways,	  Reactome	  etc.,	  so	  the	  question	  might	  be	  asked,	  is	  there	  really	  a	  need	  
for	  another	  pathway	  database?	  
Participants	  identified	  several	  needs	  unmet	  by	  currently	  available	  resources	  
[see	  also	  Figure	  1	  and	  Box	  1]:	  
Firstly,	  existing	  databases	  do	  not	  focus	  on	  toxicology-­‐related	  pathways—any	  
approach	  that	  uses	  “off-­‐the-­‐shelf”	  pathway	  annotations	  such	  as	  KEGG	  focuses	  on	  
highly	  conserved	  pathways	  and	  may	  be	  missing	  much	  that	  is	  of	  interest	  to	  
toxicologists.	  
Secondly,	  many	  toxicology	  related	  databases,	  such	  as	  the	  T3	  (Toxin	  and	  Toxin	  
Targets)	  database	  (Lim	  et	  al.,	  2010),	  have	  extensive	  documentation	  on	  various	  
toxins	  and	  their	  biological	  targets,	  but	  the	  information	  is	  not	  available	  in	  a	  manner	  
that	  facilitates	  a	  systems-­‐based	  approach.	  For	  example,	  informative	  descriptions	  are	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often	  provided	  as	  free-­‐text	  which	  is	  not	  machine	  readable,	  and	  does	  not	  use	  a	  
structured	  vocabulary	  or	  ontology	  that	  describes	  mechanism	  and	  targets.	  While	  
ontologies	  exist	  for	  certain	  outcomes	  (for	  example,	  the	  commercial	  CCNet’s	  ToxWiz	  
ontology	  for	  histopathology4),	  no	  comprehensive,	  agreed	  upon,	  open-­‐access	  
ontology	  currently	  exists	  for	  toxicology	  especially	  at	  the	  molecular	  level,	  although	  a	  
few	  are	  in	  development	  (for	  example,	  eTox,	  Cases,	  Pastor,	  &	  Sanz,	  2013)5.	  An	  
ontology	  is	  defined	  as	  a	  “formal,	  explicit	  specification	  of	  a	  shared	  conceptualization”	  
(Gruber,	  1993,	  p	  199-­‐200).	  An	  ontology	  provides	  both	  a	  shared	  controlled	  
vocabulary—a	  collection	  of	  precisely	  defined	  terms—and	  an	  explicit	  model	  of	  the	  
properties	  and	  relations	  between	  those	  terms	  (Hardy	  et	  al.,	  2012a,	  2012b).	  
Although	  ontologies	  may	  seem	  somewhat	  academic,	  most	  people	  use	  them	  
everyday—whether	  as	  a	  library	  card	  catalog	  or	  the	  more	  specialized	  ontologies,	  
such	  as	  GO	  (Gene	  Ontology),	  SNOMED-­‐CT	  (Systemized	  Nomenclature	  of	  Medicine	  –	  
Clinical	  Terms)	  or	  MeSH	  (Medical	  Subject	  Headings,	  US	  National	  Library	  of	  
Medicine).	  Although	  toxicology	  has,	  in	  recent	  years,	  seen	  a	  vast	  increase	  in	  the	  
availability	  of	  databases	  (e.g.,	  ToxRefDB,	  Chemical	  Effects	  in	  Biological	  Systems,	  
Comparative	  Toxicogenomics	  Database)	  and	  datasets	  (e.g.,	  ToxCast),	  the	  lack	  of	  
commonly	  agreed	  upon	  ontology	  and	  structured	  vocabulary	  has	  held	  back	  both	  
data-­‐sharing	  and	  data-­‐mining.	  One	  key	  to	  transforming	  data	  into	  knowledge	  is	  the	  
use	  of	  an	  ontology	  to	  provide	  structure	  and	  access	  to	  the	  data.	  Fortunately	  the	  
toxicology	  community	  need	  not	  start	  from	  scratch	  but	  can	  build	  on	  existing	  
ontologies	  such	  as	  SNOMED,	  MeDRA	  (the	  Medical	  Dictionary	  for	  Regulatory	  
Activities),	  ChEBI	  (for	  chemicals)	  and	  GO.	  	  
Thirdly,	  existing	  databases	  do	  not	  “connect	  the	  head	  to	  the	  tail”—that	  is	  to	  
say,	  they	  are	  not	  comprehensive	  from	  initiating	  event	  to	  adverse	  outcome.	  Lastly,	  
one	  of	  the	  concerns	  unique	  to	  toxicology	  (and	  specifically,	  regulatory	  toxicology)	  is	  
having	  certainty	  with	  respect	  to	  negative	  results;	  absence	  of	  evidence	  is	  not	  the	  
same	  as	  evidence	  of	  absence,	  and	  the	  database	  user	  must	  be	  able	  to	  distinguish	  “no	  
effect”	  from	  “no	  evidence”.	  Unlike	  databases	  such	  as	  KEGG	  that	  focus	  on	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4	  ToxWiz,	  http://toxwiz.com/	  (accessed	  12	  June	  2013)	  
5	  eTOX,	  http://www.etoxproject.eu/	  (accessed	  12	  June	  2013)	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comprehensive	  coverage	  of	  biological	  processes,	  a	  PoT	  database	  does	  not	  have	  to	  
offer	  global	  coverage.	  Instead,	  it	  can	  focus	  on	  relevant	  pathways	  that	  are	  both	  
curated	  and	  quality-­‐controlled	  for	  the	  specific	  needs	  of	  the	  regulatory	  community	  
and	  toxicology	  researchers.	  Having	  a	  strong	  emphasis	  on	  quality-­‐control	  does	  not	  
preclude	  acting	  as	  a	  more	  general	  repository	  of	  data	  useful	  for	  data-­‐mining—a	  PoT	  
can	  be	  low	  confidence,	  but	  depending	  on	  the	  consequences	  of	  the	  decision	  for	  the	  
regulator	  (or	  the	  interest	  of	  a	  researcher)	  could	  still	  offer	  useful	  information.	  
Ultimately,	  it	  is	  hoped	  that	  a	  PoT	  database	  will	  function	  both	  as	  a	  data	  repository	  for	  
the	  research	  community	  and	  a	  knowledge-­‐base	  that	  regulators	  can	  rely	  upon.	  
Participants	  agreed	  as	  well	  that,	  ideally,	  the	  database	  should	  be	  constructed	  
to	  allow	  easy	  answers	  to	  inquiries	  that	  might	  come	  from	  researchers—(e.g.,	  What	  
nodes	  with	  a	  signaling	  network	  are	  suspected	  of	  being	  involved	  in	  endocrine	  
disruption?)	  as	  well	  as	  from	  regulatory	  scientists	  looking	  to	  de-­‐risk	  chemicals	  early	  
in	  the	  R&D	  process	  (e.g.,	  What	  nodes	  in	  a	  PoT	  have	  assays?).	  And	  lastly,	  it	  should	  be	  





4.	   What	  is	  a	  Pathway	  of	  Toxicity;	  how	  many	  PoT	  are	  there	  and	  is	  the	  
number	  finite?	  
	  
After	  extensive	  discussion,	  the	  workshop	  participants	  came	  up	  with	  a	  formal	  
definition	  of	  a	  Pathway	  of	  Toxicity:	  
A	  Pathway	  of	  Toxicity	  is	  
a	  molecular	  definition	  
of	  the	  cellular	  processes	  
shown	  to	  mediate	  adverse	  outcomes	  
of	  toxicants.	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This	  definition	  focuses	  our	  attention	  on	  understanding	  thoroughly	  the	  molecular	  
mechanisms	  of	  toxicity	  while	  maintaining	  the	  emphasis	  on	  the	  cellular	  context.	  PoT	  
are	  relevant	  to	  regulators,	  if	  and	  only	  if,	  we	  can	  define	  necessary	  and	  sufficient	  
pathways	  for	  adverse	  outcomes	  and	  establish	  their	  relevance	  by	  evaluating	  the	  
scientific	  evidence.	  Evidence-­‐Based	  Toxicology	  (EBT)	  could	  serve	  as	  a	  framework	  to	  
establish	  the	  tools	  necessary	  for	  validating	  the	  PoT	  [see	  also	  section	  V]	  (Hartung,	  
2010a).	  
It	  is	  important	  to	  keep	  in	  mind	  that	  a	  linear	  pathway	  is	  an	  artificial	  
construct—all	  pathways	  are	  abstracted	  from	  a	  broader,	  global	  cellular	  network	  and	  
therefore	  are,	  at	  some	  level,	  an	  oversimplification	  (Figure	  2	  and	  for	  an	  overview	  see	  
e.g.	  Kholodenko,	  Yaffe,	  &	  Kolch,	  2012).	  Nonetheless,	  the	  complexity	  of	  a	  network	  is	  
both	  difficult	  to	  represent	  on	  a	  map	  and	  distracts	  from	  focusing	  on	  key-­‐events.	  
Nonetheless,	  it	  may	  be	  necessary	  not	  to	  think	  of	  the	  pathways	  as	  sharply	  and	  
precisely	  delineated	  from	  the	  broader	  cellular	  network,	  but	  rather	  to	  keep	  in	  mind	  
that	  a	  pathway	  representation	  may	  always	  be	  a	  “warm,	  fuzzy,	  cloud”:	  that	  is	  to	  say,	  
warm	  since	  the	  answer	  is	  close	  but	  not	  necessarily	  exact;	  fuzzy,	  since	  the	  
membership	  of	  components	  in	  a	  pathway	  is	  graded;	  and	  a	  cloud,	  since	  the	  
boundaries	  are	  not	  sharply	  defined.	  	  
There	  will	  be	  several	  challenges	  to	  refining	  the	  definition	  of	  PoT	  into	  a	  useful	  
working	  definition—how	  does	  one	  choose	  where	  a	  pathway	  ends?	  How	  does	  a	  
pathway-­‐based	  approach	  refine	  our	  understanding	  of	  a	  dose-­‐response	  dependency?	  
Toxicological	  processes	  are	  both	  spatially	  and	  temporally	  dynamic—how	  will	  this	  
be	  represented	  in	  a	  pathway-­‐based	  approach?	  
There	  are	  other	  questions	  that	  will	  need	  to	  be	  addressed	  as	  evidence	  
accumulates:	  are	  PoT	  perturbations	  of	  known	  physiological	  pathways?	  For	  example,	  
proliferation	  is	  a	  normal	  process—when	  does	  one	  re-­‐label	  it	  as	  a	  Pathway	  of	  
Toxicity?	  Is	  it	  possible	  that	  certain	  PoT	  are	  novel	  pathways	  active	  only	  in	  the	  
presence	  of	  a	  toxicant?	  Are	  there	  any	  PoT	  that	  are	  distinct	  pathways	  altogether?	  
How	  many	  PoT	  can	  we	  expect	  to	  find?	  “132”	  Mel	  Andersen,	  one	  of	  the	  proponents	  of	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Tox-­‐21c	  and	  workshop	  organizer,	  often	  answers	  adding,	  after	  a	  pause,	  “As	  a	  
toxicologist/risk	  assessor,	  I	  am	  accustomed	  to	  false	  accuracy.”	  	  
At	  this	  moment,	  any	  such	  questions	  about	  the	  number	  and	  nature	  of	  PoT	  is	  a	  
pure	  speculation	  and	  will	  have	  to	  wait	  for	  more	  experimental	  evidence.	  Nonetheless,	  
the	  number	  of	  cellular	  targets	  and	  metabolic	  pathways	  is	  finite,	  and	  thus	  the	  number	  
of	  PoT	  should	  thus	  be,	  too.	  Evolution	  cannot	  have	  left	  too	  many	  vulnerable	  points	  
given	  the	  number	  of	  xenobiotics	  we	  are	  exposed	  to,	  and	  the	  astonishingly	  large	  
number	  of	  healthy	  years	  we	  enjoy	  on	  average.	  We	  see	  the	  enormous	  redundancy	  
and	  buffering	  provided	  via	  biological	  networks	  when	  you	  consider	  the	  surprising	  
number	  of	  viable	  homozygous	  knockout	  mice,	  which	  often	  have	  only	  subtle	  
phenotypic	  changes,	  despite	  lacking	  an	  entire	  gene.	  The	  recent	  finding	  that	  each	  
human	  individual	  is	  null	  for	  both	  alleles	  of	  in	  excess	  of	  twenty	  genes,	  also	  attests	  to	  
the	  genomes’	  redundancy	  (MacArthur	  et	  al.,	  2012).	  
One	  unique	  challenge	  for	  the	  PoT	  database	  will	  be	  the	  requirement	  not	  only	  
to	  represent	  the	  PoT	  or	  their	  network	  but	  also	  the	  kinetics	  and	  cellular	  or	  tissue	  
location	  of	  these	  events,	  as	  a	  PoT	  represents	  a	  spatio-­‐temporal	  event	  in	  the	  cell.	  In	  
this	  respect,	  it	  may	  be	  necessary	  to	  extend	  the	  definition	  of	  PoT	  to	  include	  a	  more	  
quantitative	  model,	  similar	  to	  those	  discussed	  in	  Uri	  Alon’s	  Introduction	  to	  Systems	  
Biology	  (Uri	  Alon,	  2007).	  From	  this	  perspective,	  a	  pathway	  represents	  not	  just	  a	  link	  
between	  a	  series	  of	  nodes	  but	  instead	  might	  be	  thought	  of	  as	  a	  wiring	  diagram	  with	  
components	  such	  as	  positive	  and	  negative	  feedback	  loops,	  along	  with	  quantitative	  
information	  about	  inputs,	  thresholds,	  and	  outputs.	  
	  
	  
5.	   How	  to	  identify	  and	  validate	  a	  PoT?	  
	  
Most	  importantly,	  toxicology	  is	  not	  alone	  in	  identifying	  pathways—all	  the	  life	  
sciences	  are	  on	  the	  same	  quest	  under	  the	  label	  of	  systems	  biology.	  It	  is	  the	  logical	  
next	  step	  stemming	  from	  the	  advent	  of	  high-­‐content	  technologies	  (-­‐omics),	  
attempting	  to	  create	  order	  by	  identifying	  the	  underlying	  pathways.	  Therefore,	  we	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will	  not	  have	  to	  reinvent	  the	  wheel	  as	  pathway	  mapping,	  visualization	  and	  database	  
tools	  are	  increasingly	  developed	  in	  other	  areas	  of	  the	  life	  sciences	  [e.g.,	  Cytoscape	  
(Cline	  et	  al.,	  2007),	  PathVisio	  (van	  Iersel	  et	  al.,	  2008),	  iPath	  (Letunic,	  Yamada,	  
Kanehisa,	  &	  Bork,	  2008),	  CellDesigner	  (Funahashi,	  Morohashi,	  Kitano,	  &	  Tanimura,	  
2003),	  VANTED	  (Junker,	  Klukas,	  &	  Schreiber,	  2006),	  IPA	  from	  Ingenuity	  Systems,	  
Agilent	  Genespring,	  or	  MetaCore	  from	  Thomson	  Reuters].	  	  
As	  an	  example	  for	  primary	  data	  analysis,	  identification	  of	  statistically	  
significant	  signatures	  and	  mapping	  cross-­‐technology	  datasets	  on	  known	  pathways,	  
the	  Human	  Toxome	  Consortium—which	  initiated	  this	  PoT	  workshop—is	  largely	  
relying	  on	  Agilent	  GeneSpring	  software.	  GeneSpring	  is	  a	  comprehensive	  package	  
that	  combines	  advanced	  bioinformatics	  tools	  for	  analysis	  of	  gene	  expression	  
microarrays,	  NGS,	  LC/MS	  and	  GC/MS	  data	  with	  unique	  ability	  to	  conduct	  joint	  
analysis	  in	  the	  context	  of	  curated	  or	  customized	  pathways.	  At	  the	  time	  of	  this	  
writing,	  GeneSpring	  supports	  WikiPathways,	  Biocyc,	  Ingenuity	  and	  Metacore	  
content,	  KEGG	  will	  become	  available	  later	  this	  year.	  Besides	  data	  normalization,	  QC,	  
clustering,	  and	  statistical	  analyses	  of	  their	  primary	  gene	  expression	  and	  metabolite	  
abundance	  data	  users	  can	  perform	  pathway	  enrichment	  computations	  that	  leverage	  
multiple	  data	  types	  and	  seamlessly	  explore	  and	  co-­‐analyze	  the	  results	  overlaid	  on	  
pathway	  diagrams	  in	  the	  Pathway	  Architect	  module.	  Additional	  analysis	  and	  
visualization	  methods	  tailored	  to	  specific	  needs	  of	  PoT	  projects,	  such	  as	  multi-­‐omics	  
correlation	  tools,	  will	  be	  developed	  soon	  in	  collaboration	  with	  members	  of	  the	  NIH	  
transformative	  research	  project	  on	  “Mapping	  the	  Human	  Toxome	  by	  Systems	  
Toxicology”	  (http://humantoxome.com).	  
WikiPathways	  (Kelder	  et	  al.,	  2012;	  Pico	  et	  al.,	  2008)	  facilitates	  the	  
contribution	  and	  maintenance	  of	  pathway	  information	  by	  the	  biology	  community.	  It	  
is	  an	  open,	  collaborative	  platform	  dedicated	  to	  online	  pathway	  curation.	  
WikiPathways	  thus	  complements	  ongoing	  efforts,	  such	  as	  KEGG,	  and	  Reactome	  (see	  
next	  paragraph).	  Building	  on	  the	  same	  MediaWiki	  software	  that	  powers	  Wikipedia,	  
custom	  graphical	  pathway	  editing	  tool	  and	  integrated	  databases	  are	  included	  
covering	  major	  small-­‐(bio)molecule	  systems.	  The	  web-­‐based	  format	  of	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WikiPathways	  reduces	  the	  barrier	  for	  biologists	  (e.g.,	  toxicologists)	  to	  participate	  in	  
pathway	  curation.	  More	  importantly,	  the	  open,	  public	  approach	  of	  WikiPathways	  
allows	  for	  wider	  participation	  by	  the	  entire	  toxicological	  community.	  This	  approach	  
also	  shifts	  the	  bulk	  of	  peer	  review,	  editorial	  curation,	  and	  maintenance	  to	  the	  
toxicological	  community,	  and	  as	  such	  can	  represent	  content	  for	  more	  peer-­‐reviewed	  
efforts	  such	  as	  Reactome	  or	  the	  creation	  of	  a	  PoT	  database.	  Efforts	  to	  use	  
WikiPathway	  content/tools	  in	  the	  context	  of	  in	  vitro	  toxicology,	  specifically	  to	  
address	  the	  use	  of	  human	  disease	  mechanisms	  in	  silico	  in	  the	  interpretation	  of	  in	  
vitro	  toxicological	  data	  have	  started	  under	  the	  Assuring	  Safety	  Without	  Animal	  
testing	  (ASAT)	  initiative	  for	  allergic	  contact	  dermatitis,	  hepatocellular	  cancer	  and	  
soon	  to	  be	  extended	  with	  models	  for	  cholestasis.	  
Reactome,	  another	  valuable	  resource,	  is	  a	  freely	  accessible,	  open-­‐source,	  
curated	  and	  peer-­‐reviewed	  biological	  knowledgebase	  of	  human	  bioreactions,	  
pathways	  and	  processes,	  which	  serves	  as	  a	  platform	  for	  pathway	  visualization	  and	  
analysis	  of	  complex	  experimental	  data	  sets	  (Croft	  et	  al.,	  2010).	  A	  recent	  extension	  of	  
the	  Reactome	  data	  model	  permits	  the	  capture	  of	  normal	  biological	  pathway	  
behavior	  and	  predicts	  its	  response	  to	  a	  stress	  like	  a	  mutational	  change	  in	  a	  protein’s	  
function	  or	  the	  presence	  of	  a	  novel	  small	  molecule	  in	  the	  environment,	  in	  a	  
comprehensive	  and	  internally	  consistent	  format	  (Milacic	  et	  al.,	  2012).	  The	  Reactome	  
data	  model	  allows	  for	  annotation	  of	  small	  molecules,	  toxicological	  agents,	  and	  their	  
specific	  mode	  of	  action.	  Pathway	  data	  visualization	  is	  facilitated	  by	  the	  Reactome	  
Pathway	  Browser,	  a	  Systems	  Biology	  Graphical	  Notation	  (SBGN)-­‐based	  interface	  (Le	  
Novere	  et	  al.,	  2009),	  which	  exploits	  the	  Proteomics	  Standard	  Initiative	  Common	  
QUery	  InterfaCe	  (PSICQUIC)	  web	  services	  (Aranda	  et	  al.,	  2011)	  to	  overlay	  molecular	  
interaction	  data	  from	  external	  interaction	  databases.	  Overlaying	  interaction	  data	  
from	  ChEMBL	  or	  Drugbank	  (Gaulton	  et	  al.,	  2012;	  Knox	  et	  al.,	  2011)	  databases	  of	  
bioactive	  drug-­‐like	  compounds	  provides	  an	  opportunity	  to	  identify	  protein	  variant-­‐
drug	  interactions,	  identify	  novel	  small	  molecule	  targets,	  off-­‐target	  effects,	  or	  
pharmaceuticals	  that	  can	  perturb	  or	  moderate	  reactions	  or	  pathways	  of	  toxicity.	  
Reactome	  also	  provides	  the	  Functional	  Interaction	  (FI)	  network	  plug-­‐in	  for	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Cytoscape,	  which	  can	  identify	  gene	  network	  patterns	  related	  to	  diseases,	  including	  
cancer	  (Wu	  &	  Stein,	  2012).	  Future	  expansion	  of	  the	  Reactome	  pathway	  database	  and	  
the	  FI	  network	  with	  interactions	  based	  upon	  Pathways	  of	  Toxicity	  should	  
significantly	  improve	  coverage,	  enrich	  the	  functional	  annotations	  supported,	  and	  
enhance	  the	  functionality	  of	  the	  pathway	  and	  network	  analyses.	  
MetaCore™	  from	  Thomson	  Reuters	  (formerly	  GeneGo)	  is	  a	  commercial	  
systems	  biology	  platform	  for	  network	  and	  pathway	  analysis.	  MetaCore	  includes	  a	  
large	  manually-­‐curated	  database	  of	  molecular	  interactions	  (protein-­‐protein,	  
compound-­‐protein,	  enzyme-­‐reaction,	  reaction-­‐substrate,	  miRNA,	  etc.),	  and	  tools	  to	  
flexibly	  reconstruct	  and	  analyze	  biological	  networks.	  MetaCore	  also	  contains	  over	  
800	  Canonical	  Pathway	  Maps—interactive	  visual	  representations	  of	  precise	  
molecular	  pathways	  for	  well-­‐characterized	  and	  annotated	  biological,	  metabolic,	  
disease	  and	  toxicological	  processes.	  At	  this	  time,	  260	  of	  these	  maps,	  covering	  a	  wide	  
range	  of	  pathways	  relevant	  to	  toxicological	  and	  disease	  processes	  have	  been	  made	  
freely	  available	  at	  http://pathwaymaps.com.	  
However,	  many	  of	  these	  existing	  pathway	  and	  network	  mapping	  tools	  are	  
more	  suited	  to	  hypothesis	  generation	  and	  do	  not	  provide	  the	  necessary	  precision	  
and	  reproducibility	  for	  predicting	  full	  dose-­‐dependent	  in	  vivo	  toxicity	  in	  man	  that	  
will	  be	  required	  for	  PoT	  to	  become	  a	  useful	  tool	  for	  regulators.	  Validating	  PoT	  will	  
likely	  require	  a	  sustained,	  coordinated	  effort	  to	  generate	  the	  necessary	  datasets	  to	  
benchmark	  and	  provide	  context	  to	  the	  scoring	  of	  PoT.	  	  
Furthermore,	  we	  will	  need	  to	  develop	  tools	  which	  are	  suitable	  for	  looking	  at	  
systems	  toxicology	  with	  the	  aim	  of	  validating	  them	  for	  regulatory	  purposes.	  As	  part	  
of	  this	  effort,	  an	  evidence-­‐based	  toxicology	  collaboration	  (EBTC,	  
http://www.ebtox.com)	  has	  been	  established,	  which	  promises	  to	  generate	  a	  
partnership	  between	  agency	  representatives,	  individuals	  from	  the	  corporate	  sector,	  
and	  those	  promoting	  the	  paradigm	  shift	  in	  toxicology	  (Zurlo,	  2011).	  Evidence-­‐based	  
toxicology	  uses	  concepts	  learned	  from	  evidence-­‐based	  medicine,	  
mechanistic/molecular	  toxicology,	  biostatistics,	  and	  validation	  to	  bring	  the	  
necessary	  consistency	  and	  objectivity	  to	  the	  process.	  Moreover,	  evidence-­‐based	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toxicology	  can	  help	  concisely	  summarize	  existing	  evidence	  on	  a	  specific	  topic	  so	  that	  
experts	  and	  non-­‐experts	  can	  use	  an	  EBT-­‐assessed	  PoT	  database	  for	  decision-­‐making	  
in	  a	  regulatory	  context.	  Noteworthy,	  EBT	  has	  embarked	  on	  developing	  the	  
validation	  concepts	  for	  21st	  century	  tools	  (Hartung,	  2010a;	  Hartung,	  Hoffmann,	  &	  
Stephens,	  2013;	  R.	  Judson	  et	  al.,	  2013).	  
	  
	  
6.	   Future	  challenges	  and	  directions;	  creation	  of	  a	  PoT	  consortium	  
	  
There	  are	  many	  obstacles	  that	  remain	  before	  a	  comprehensive,	  PoT-­‐based	  
toxicology	  can	  be	  realized.	  Some	  of	  them	  are	  technological.	  While	  transcriptomics	  is	  
a	  mature	  technology,	  metabolomics	  is	  just	  beginning	  to	  contribute	  to	  systems-­‐
toxicology	  (Bouhifd	  et	  al.,	  2014),	  and	  some	  technologies—such	  as	  
phosphoproteomics—remain	  in	  their	  infancy	  (van	  Vliet,	  2011).	  Furthermore,	  even	  
though	  gene	  and	  protein	  networks	  are	  relatively	  complete	  for	  humans	  (Tang,	  Zhong,	  
&	  Xie,	  2012;	  Taylor	  &	  Wrana,	  2012),	  such	  “hairball”	  networks	  tell	  only	  a	  limited	  
story—it	  is	  difficult	  to	  extract	  complete	  concise	  pathways	  or	  to	  take	  into	  account	  
dose,	  and	  spatial	  and	  temporal	  effects.	  In	  particular,	  causality	  with	  respect	  to	  
predicting	  target	  organ	  specificity	  needs	  to	  be	  addressed	  (Hartung,	  Hoffmann,	  et	  al.,	  
2013).	  It	  will	  be	  necessary	  to	  analyze	  new	  methodologies	  for	  determining	  dose-­‐
response	  with	  high-­‐throughput,	  high-­‐content	  data	  and	  a	  PoT-­‐based	  approach.	  It	  may	  
be	  necessary	  then,	  to	  bootstrap	  our	  way	  from	  what	  we	  know	  to	  what	  we	  don’t	  know	  
in	  an	  iterative	  process.	  The	  workshop	  participants	  agreed,	  however,	  that	  we	  do	  not	  
need	  to	  know	  every	  detail	  of	  a	  pathway	  to	  use	  it	  in	  the	  context	  of	  a	  PoT,	  but	  we	  need	  
to	  establish	  fit-­‐for-­‐purpose	  principles.	  
Depending	  on	  the	  specific	  PoT,	  it	  may	  also	  be	  necessary	  to	  address	  the	  
question	  of	  what	  types	  of	  data	  will	  be	  included	  and	  how	  the	  data	  will	  be	  integrated.	  
Combining	  datasets	  of	  transcriptomics,	  metabolomics	  and	  other	  -­‐omics	  still	  
represents	  a	  challenge,	  although	  some	  progress	  in	  the	  application	  of	  systems	  
biology	  approaches	  to	  such	  cross-­‐domain	  data	  integration	  in	  toxicology	  has	  already	  
	  
	   188	  
been	  made	  (e.g.	  Xu	  et	  al.,	  2008).	  Integrating	  biomarker	  and	  epidemiology	  data	  will	  
require	  new	  ways	  to	  turn	  the	  surfeit	  of	  existing	  data	  into	  useful	  information.	  
Other	  challenges	  will	  involve	  a	  dedicated	  process	  of	  consensus	  building	  in	  the	  
toxicology	  community	  to	  develop	  a	  useful	  ontology	  and	  structured	  vocabulary	  to	  
facilitate	  sharing	  information.	  And	  lastly,	  it	  will	  require	  new	  tools	  and	  concepts	  
within	  the	  risk	  assessment	  community	  as	  toxicology	  moves	  away	  from	  older	  
paradigms	  into	  a	  more	  probabilistic	  approach	  (Hartung,	  Luechtefeld,	  et	  al.,	  2013;	  
Hartung	  et	  al.,	  2012a).	  
The	  creation	  of	  a	  PoT	  database	  will	  make	  it	  necessary	  to	  form	  and	  coordinate	  
a	  larger	  consortium	  and	  linking	  it	  to	  the	  development	  of	  the	  necessary	  concepts.	  
Central	  steering	  needs	  to	  be	  established,	  incorporating	  the	  ideas	  of	  opinion	  leaders	  
and	  the	  needs	  of	  stakeholders,	  especially	  regulators	  who	  ultimately	  have	  to	  accept	  
the	  changes	  derived	  from	  novel	  approaches	  (Hartung,	  2009).	  Regulators,	  therefore,	  
need	  a	  seat	  at	  the	  table	  to	  provide	  input	  into	  the	  processes	  from	  the	  very	  beginning.	  
The	  governance	  of	  such	  a	  consortium	  effort	  needs	  to	  be	  established,	  as	  does	  the	  
quality	  assurance	  (validation),	  comparison	  to	  the	  current	  approaches,	  and	  possible	  
transition.	  CAAT	  with	  its	  partners	  is	  at	  the	  moment	  trying	  to	  form	  such	  a	  consortium	  
to	  define	  and	  set	  up	  a	  public	  resource	  for	  PoT	  information.	  
The	  vision	  represented	  here	  takes	  advantage	  of	  new	  innovations	  afforded	  by	  
our	  rapidly	  evolving	  understanding	  of	  systems	  biology	  and	  a	  host	  of	  molecular,	  
informational,	  and	  computational	  tools.	  Toxicity	  testing	  today	  is	  much	  like	  
cartography	  before	  the	  development	  of	  satellites—islands	  of	  well-­‐described	  
territory	  alongside	  vast	  oceans	  about	  which	  little	  is	  known;	  it	  could	  be	  said	  that	  
even	  the	  extent	  of	  the	  unmapped	  territory	  is	  unknown.	  A	  mapped	  Human	  Toxome	  
available	  in	  a	  PoT-­‐database	  would	  provide	  the	  necessary	  perspective	  to	  bring	  
toxicology	  into	  the	  21st	  century.	  
Freeman	  Dyson	  (Princeton),	  and	  his	  1995	  book,	  The	  Scientist	  as	  Rebel	  said:	  
“The	  great	  advances	  in	  science	  usually	  result	  from	  new	  tools	  rather	  than	  from	  new	  
doctrines”	  (Dyson,	  2006,	  p	  805).	  The	  map	  of	  the	  Human	  Toxome	  available	  in	  a	  PoT	  
database	  promises	  to	  be	  such	  a	  new	  tool.	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  Adjunct	  Faculty	  	  
• Courses	  taught:	  	  Introduction	  to	  Biology	  (Lecture	  and	  Lab),	  Introduction	  to	  
Chemistry	  (Lecture	  and	  Lab)	  
	  	  University	  of	  Maryland	  University	  College,	  Adelphi,	  MD.	  2002-­‐2006.	  Teaching	  Assistant	  
• Courses	  TA’d:	  Introduction	  to	  Bioinformatics,	  Regulatory	  Issues	  in	  
Biotechnology,	  Societal	  Issues	  in	  Biotechnology	  
Posters:	  	  
“Using	  Weighted	  Gene	  Correlation	  Network	  Analysis	  to	  Derive	  Networks	  from	  
Microarrays:	  MPTP	  at	  day	  1	  and	  7	  post-­‐lesion	  compared	  to	  controls	  ”	  Maertens	  
A,	  	  Kleensang	  A,	  Hartung,	  T.	  Developmental	  Neurotoxicity	  Conference	  2014.	  	  
“Probabilistic	  Hazard	  Assessment	  for	  Skin	  Sensitization	  Potency	  using	  Machine	  
Learning	  to	  Design	  Integrated	  Testing	  Strategies.”.	  Luechtefeld,	  T,	  Maertens,	  A,	  
Kleensang	  A,	  Hartung,	  T.	  Sarocha,	  V.	  Society	  of	  Toxicology	  2014.	  
“Using	  Weighted	  Gene	  Correlation	  Network	  Analysis	  for	  Microarray	  Meta-­‐Analysis”	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